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This research aimed to investigate the molecular regulation of odontoblast behaviour 
during primary, secondary and tertiary (reactionary and reparative) dentinogenesis.  
Using gene microarray analysis and sq-RT-PCR, evidence is presented that the changes 
in secretory activity of odontoblasts reflect differential transcriptional control and 
that common regulatory processes may exist between dentine and bone. The p38 gene 
was shown to be highly expressed in odontoblasts during active primary 
dentinogenesis, but was drastically down-regulated as cells become quiescent in 
secondary dentinogenesis. Based on the hypothesis that parallels between 
development and healing processes in teeth exist, the results suggested that the p38-
MAPKinase pathway may be activated during odontoblast stimulation in tertiary 
dentinogenesis by both p38 phosphorylation and enhanced nuclear translocation, 
supporting a recapitulation of events from primary dentinogenesis during tertiary 
dentinogenesis. The feasibility of use of the mouse as an in vivo model for studying 
pulpal healing in response to restorative procedures was also assessed. This approach 
provides a novel opportunity to exploit use of genetically modified animals to explore 
cellular and molecular processes during reparative events. Lastly, a transgenic mouse 
model was used to analyse the possible role of Msx2 transcription factor in odontoblast 
differentiation. The nature of the tooth phenotype in Msx2 null mutant animals was 
subsequently analysed.   
This study has increased our understanding of the regulation of dentinogenic events, 
which may allow translation into new therapies aimed at maintenance of the vitality 
of the pulp. 
 
 
Key Words : 






L’objectif de ce travail a été d’explorer les régulations moléculaires au sein de 
l’odontoblaste au cours des dentinogénèses primaire, secondaire et tertiaire. 
Les résultats obtenus à partir de  micro-puces et de PCR semi quantitative ont permis 
de mettre en évidence un contrôle différentiel transcriptionnel de l’activité sécrétrice 
de l’odontoblaste. Des processus de régulation commun entre la dentine et l’os sont 
également discutés. La forte expression du gène p38 au cours de la dentinogénèse 
primaire, est drastiquement diminuée dans l’odontoblaste mature.  
Les résultats suggèrent également que la voie de signalisation p38-MAPKinase pourrait 
être activée pendant la dentinogénèse tertiaire, par la phosphorylation de la protéine 
p38 et sa translocation nucléaire, confirmant ainsi la récapitulation d’un processus du 
développement initiale de la dent dans celui de la cicatrisation pulpaire. L’utilisation 
de la souris comme nouveau modèle de laboratoire pour étudier la cicatrisation 
pulpaire est également décrite. Ce nouveau modèle constitue une opportunité réelle 
car il permet d’utiliser les animaux génétiquement modifiés pour explorer les 
processus cellulaires et moléculaires impliqués dans la réparation pulpaire. Enfin, un 
modèle de souris transgénique a été utilisé afin d’analyser l’éventuel rôle du facteur 
de transcription Msx2 dans le processus de différentiation odontoblastique. Le 
phénotype dentaire du mutant nul Msx2 -/- est analysé en détail. 
Ce travail permet de compléter les connaissances sur la régulation moléculaire de la 
dentinogénèse, étape importante pour le développement de nouvelles thérapeutiques 
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Significant progress in the field of carious disease management has led to much 
research into the mineralisation of teeth and the biological behaviour of the dentine-
pulp complex. It is apparent that the dentine-pulp complex is able to adapt to a 
multitude of stimuli invoking defence responses to maintain pulp vitality. The main 
role of the pulp is to secrete dentine. When tooth development is completed, the 
pulp maintains the dentine through homeostatic and self-protective mechanisms. The 
dental pulp is also able to reinitiate dentinogenesis at any time to protect itself from 
external injuries. However, advances in understanding the basic biology of this tissue 
have not yet been fully translated into better treatments in day-to-day dental 
practice beyond only minor carious lesions. When caries has progressed through most 
of the depth of the dentine, it is generally assumed that it is too late to use 
regenerative techniques to intervene. When the caries extends to the pulp, a 
pulpectomy is usually considered in order to prevent painful, infectious 
complications. However, so far no guidelines clearly define the indications for 
pulpectomy versus pulp vitality conservation. 
Many researchers have been investigating the pulp healing process over several 
years and recent advances in biotechnology have opened opportunities for 
development of applications in pulp vitality maintenance, reactionary dentinogenesis 







1.1 Towards a biological approach 
The concept of vital pulp therapy is one that focuses on using biological principles 
to maintain pulp vitality. This requires an understanding of the many patho-
physiological processes of the dentine-pulp complex and the development of new 
materials for clinical use, which exploit the pulpal healing processes and better 
mimic the physiological tissues being restored. However, this evolution of new 
therapeutic principles within conservative dentistry dictates that techniques should 
be developed in which new materials are used in the context of minimising damage 
to the dental tissues during restorative preparation.    
The gradual replacement of amalgams by composites, which are considered to have 
better aesthetic properties in coronal restorations, has been justified in part by the 
toxicity of the former both to the patient and environment, although resins are far 
from being inert themselves. However, adhesive restorations have a biological 
advantage in minimising the amount of dental tissue needing to be removed during 
preparation. Apart from the biomechanical advantages of maximal retention of 
dental tissue, injury to the tissues is minimised and diffusion pathways to the pulp 
are reduced with the decreased number of open tubules. The improvement in the 
long-term prognosis offered by these approaches is evident (Murray, About et al. 
2000). Therefore, minimalist dentistry, also called “non-invasive” dentistry or 
Minimal Intervention Therapy, has significant potential (Pashley 1996; Banerjee, Kidd 
et al. 2003; Ericson, Kidd et al. 2003; Kidd, Banerjee et al. 2003; Kidd 2004; Pashley 
2002). 
 
1.2 The dentine-pulp complex 
Dentine provides protection to the pulp, a soft connective tissue, which ensures the 






called because of the intimate relationship of the two tissues that makes it difficult 
to separate their functional behaviours.  
Dentine is a mineralised connective tissue that constitutes the main component of 
the tooth; it ensures support for the organ and confers elasticity. Seventy percent of 
dentine is mineralised by hydroxyapatite crystals; it is also composed of 20% organic 
matrix and 10% water. The organic component is mostly composed of proteins, which 
play various structural, formative, signalling and homeostatic roles as well as being 
important in the pulp healing process.  
Predentine, present on the formative surface, represents the unmineralised precursor 
of the dentine matrix. While the composition is similar to that of dentine, changes in 
some matrix components occur as the mineralisation front is approached (Linde 
1984). The dentine is made of various types of collagen such as collagen type I (the 
major collagenous constituent), V and VI, and of non-collagenous proteins 
(proteoglycans, glycoproteins, dentin phosphoprotein, etc). Among these molecules, 
Dentin Sialo-protein (DSP) and Dentin Phospho-protein v are considered to be more 
specific to dental tissues. Nevertheless, these proteins have also been found in other 
mineralised tissues such as bone but at significant lower concentrations than in 
dentine (Goldberg and Smith 2004). 
The non-collagenous proteins, secreted from the distal part of the odontoblast 
process, ensure the transformation of the predentine into dentine, by initiating and 
controlling the mineralisation of the extracellular matrix (ECM) in the area of the 
“mineralisation front” (Butler 1998). 
Dentine is a permeable tissue that is traversed by tubular structures called dentinal 
tubules, which extend from the enamel-dentine junction (EDJ) (or the cemental-
dentine junction (CDJ) at the root level) to the pulp cavity (chamber or canal). These 






odontoblast processes in the tubules remains controversial with some authors 
claiming that the processes extend from the pulp chamber to the EDJ or CDJ 
(Maniatopoulos and Smith 1983; Sigal, Aubin et al. 1984; Sigal, Aubin et al. 1985). 
Others, however, suggest that the odontoblast processes are limited to the internal 
third of the tubules only (Garberoglio and Brannstrom 1976; Thomas and Carella 
1983; Thomas and Carella 1984; Pashley 2002). This structural distinction is 
important because the presence of cellular extensions in the tubules can influence 
therapeutic approaches during disease management. Tubules that have been partially 
occluded by cellular activity will confer different permeability properties on the 
tissue than those whose dimensions have been increased by carious processes and this 
will affect treatment planning accordingly. 
The circumpulpal dentine is composed of inter-tubular dentine (between tubules) and 
peri- or intra-tubular dentine (deposited within/around the tubule, which reduces 
the diameter of the tubule; (Figure 1). 
 
Figure 1: Schematic of the structure of circumpulpal dentine (also called orthodentine). 






The secretion of intra-tubular dentine is continuous throughout the life of the tooth 
and can be accelerated in certain patho-physiological conditions (such as caries and 
tooth wear), leading to dentinal sclerosis (Senawongse, Otsuki et al. 2008). 
The chemical compositions of inter-tubular and peritubular dentine are different, 
particularly in terms of their collagen content and responses to etching procedures. 
These structural differences must be taken into account clinically because, for 
example, they can cause difficulties for bonding procedures. Protocols must differ 
between bonding on sclerotic dentine and filling a deep cavity in a relatively young 
tooth. This structural difference is also important in Endodontics with the 
introduction of resin-based adhesive systems. Since the dentine structure in the 
apical region is closer to a fibro-dentine structure than to a tubular one (Mjor, Sveen 
et al. 2001) questions remain regarding the sealing effectiveness of these systems in 
the short-, medium- and longer-term where the use of a protocol directly inspired by 
coronal bonding may not be optimal for endodontic use. 
1.2.1 Three types of dentine 
Confusion remains regarding the terminology of the different types of dentine, i.e.  
primary, secondary and tertiary dentines. Many definitions have been proposed in the 
literature with several of which being contradictory. Although these definitions have 
not reached a consensus, they have been collated by Goldberg and Smith (Goldberg 
and Smith 2004) who supported the following definitions: 
Primary dentine: this is the earliest dentine formed during tooth development giving 
rise to the crown and root structure of the tooth. It “patterns” the tooth organ. The 
most external, relatively thin, layer adjacent to the amelo-dentinal junction is 
formed as the odontoblasts are completing differentiation resulting in a variable 






Secondary dentine: this is physiologically secreted either after the tooth has erupted 
into the oral cavity, or following apical closure. This dentine is generally responsible 
for the progressively decreasing space of the canal, which is improperly called 
“calcification”. It is a physiological dentine rather than being pathological in nature; 
its continuing secretion is responsible for the asymmetrical loss of endodontic 
volume. This biological process explains the differences in canal volume between a 
young and an older tooth. The secondary dentine secretion is not uniform, but 
appears to occur predominantly on the roof and lateral walls of the pulp chamber 
and not on its floor. The chemical composition and the histological structure of the 
primary and secondary types of dentine are considered to be identical, although the 
published evidence for this is limited. Only the rate of secretion differs: 4 µm/day for 
primary dentine and 0.4 µm/day for secondary dentine (Schour and Poncher 1937; 
Ziskin, Applebaum et al. 1949; Nanci 2003). The interface between primary and 
secondary dentine is sometimes demarcated by a subtle calciotraumatic line. 
However, since both dentines are secreted by the same odontoblasts there will be 
tubular continuity and thus, there does not appear to be any obvious clinical 
consequence as to whether primary or secondary dentine is present (Figure 2) 
 
Figure 2: The histological localisation of the two types of physiological







In summary, primary dentinogenesis occurs during development leading to formation 
of the crown and root of the tooth, whereas secondary dentine is secreted 
throughout the life of the tooth, and is responsible for reduction in the size of the 
pulp chamber, root canals and continued deposition of peritubular dentine (Baume 
1980). 
Tertiary dentine: is secreted in response to external stimuli, such as caries or 
abrasion, in order to protect the underlying pulp. In the case of moderate stress, 
which does not result in destruction of odontoblasts, the secreted dentine is termed 
“reactionary dentine”; when the stress is more intense and odontoblast survival is 
compromised (i.e., dentine bridge formation at sites of exposure), it is termed 
“reparative dentine” (Figure 3). 
 . 
 







Understanding the distinction between the three types of dentine is important, and 
above all the distinction between secondary (physiological) and tertiary (healing) 
dentine must be clear, as they are often confused when reported in the literature. 
1.2.2 Dentine and bone 
Notably, dentine and bone are very similar in their composition, but show some 
structural differences. Many studies have shown that the compositions of these 
tissues are more similar than previously appreciated. Indeed, certain molecules that 
were originally considered to be specific to dentine (such as Dentine sialoprotein; 
DSP) have been shown to be present in alveolar bone (Butler, Brunn et al. 2003; 
Huang, Sun et al. 2008). It is therefore more difficult to find specific markers to 
characterise these tissues. Nevertheless, the profiles of the SIBLINGS protein for 
example, show differences between the two tissues (Huang, Sun et al. 2008). 
On a structural level, bone and dentine exhibit several common features. Cells of 
both bone and dentine are of a similar mesodermal embryonic origin, which may 
explain some of the similarities found in their formation and structures. In bone, 
secretion of the matrix is performed by osteoblasts; once embedded in the 
mineralised matrix, they appear to change into quiescent cells called osteocytes 
which communicate with each other through an extensive network of cell processes 
embedded in canuliculi. In the dentine-pulp complex, odontoblasts remain on the 
formative surface of the dentine matrix but have a cell process extending through 
the dentine with many lateral processes. The similarities between the morphologies 
of dentinal tubules and osteocyte canuliculi have recently been highlighted (Lu, Xie 
et al. 2007) and recent molecular data demonstrate striking similarities in the 
behaviour of odontoblasts and bone cells at different stages of their life cycles 






1.2.3 Dentinal tubules - a means of communication. 
1.2.3.1 The tubular structure  
The tubular density of dentine is high (~30,000/mm² on average), and these tubules 
are approximately 1 to 3 micrometers in diameter on average in humans depending 
on the intratubular dentine thickness; their distribution is unequal throughout the 
dentine and their density increases near the pulp cavity reflecting the crowding of 
odontoblasts as they move pulpally during dentinogenesis (Figure 4). 
 
Figure 4 : The density of the dentinal tubules varies according to the depth of the dentine and 
the proximity to the pulp. Surface area occupied by tubules is 2/3% near the Enamel, but 20-
25% near the pulp. (Pashley 1996) (according to (Olgart and Bergenholtz 2003) – D=Dentine, 
P=Pulp, B=Bone. Bar=500µm 
 
The tubules course in a sinusoidal manner in the crown rather than a rectilinear way, 
due to a change in the radius of curvature from the outer to the inner aspect of the 
dentine and each has numerous lateral extensions, which provide a means of 
communication between them. Thus, much of the area of the dentine matrix is in 
direct communication with the odontoblasts on its formative surface through their 







terms of the communication between the inner and outer regions of the tooth and 
how disease or surgical intervention can impact. 
The tubular density differs significantly at outer and inner areas of the dentine. It is 
estimated that the surface occupied by these tubules represents 1% of the dentinal 
surface in the periphery of the dentine (under the enamel) and 22% near the pulp 
(Fosse, Saele et al. 1992). This variable distribution underlines the importance of 
location when drilling a cavity or making a coronal preparation, due to the opening of 
a diffusion pathway into the pulp tissue and potentially allowing the ingress of 
bacteria, toxins, and other adverse agents.  
The entire length of the tubules will contain dentinal fluid, which probably 
represents a cellular transudate from the pulp parenchyma together with any local 
odontoblast secretions. Two different phenomena are encountered from the moment 
when open tubules are exposed: 
Diffusion (Figure 5): When two biological environments (i.e., the pulp and the 
external environment of the oral cavity) are separated by a filter (i.e., the tubular 
dentine), a concentration gradient is established for agents within these two 
environments. Diffusion occurs from the most concentrated to the least concentrated 
milieu in order to equilibrate the concentrations. In the case of teeth, the presence 
of bacteria at high concentration in the saliva will lead to their passive diffusion to 
the sterile pulp parenchyma if the permeability barrier of the enamel is absent from 
the outside of the tooth. Nevertheless, the relatively large diameter of bacteria 
relative to the diameters of tubules is an obstacle to their movement through the 
tubules, although toxins and other molecules can still readily pass through. 
The phenomenon of intra-pulpal pressure, is greater than that external to the 
tooth: physiologically, the pressure in the pulp relative to that external to the tooth 






and thus limits the risk of pulpal contamination from inward diffusion (Figure 6). 
Fluid mechanics represents a complex science, especially in the context of the 
irregular architecture within a dentinal tubule, but this outward pressure in the 
tubule ensures that the tubular dentine matrix does not act as a simple permeable 
sieve. 
 
1.2.3.2 Dentine permeability and clinical implications 
The greater pressure intra-pulpally is directly relevant to clinical procedures in 
restorative dentistry. In the bonding process, it is recommended to “dry but not 
dessicate” the dentinal surface. It is worth noting that a few seconds after drying, 
the dentinal surface is wet again. At this stage, it is not recommended to further dry 
the surface, otherwise dessication of the dentine may occur causing unnecessary 
damage to the pulp, which would inevitably lead to post-surgical pain. New 
generations of adhesives take this into account and tolerate the presence of moisture 
in the dentine to ensure optimal adhesion. 
Dentinal permeability is an unavoidable factor necessary to consider during 
therapeutic procedures in dentistry. Surgical intervention of teeth will inevitably 
cause some damage to the pulp; the responding defence processes are numerous and 
complex and their interplay is not yet fully understood. Nevertheless, they are the 
basis of the healing process, and post-surgical pain is sometimes encountered after 
even conservative treatment. It is necessary to recognise the defence processes 









The pulpal hydrodynamic theory (Brannstrom 1963) probably provides our best 
explanation for pulpal pain. This theory helps explain how one tooth can become 
very sensitive to cold after dentinal exposure, whereas other teeth in the same 
Figure 5 : There is a differential concentration of bacteria/toxins, between the
carious dentine and the pulp tissue. Bacteria and toxins tend to diffuse from the
highest concentration area to the lowest one through the dentinal tubules. This 
phenomenon is termed diffusion. 
 
Figure 6 : The difference in the pressure between the intra-pulpal cavity and the 
outside area is protective of the pulp parenchyma. The external direction of this 







mouth remain painless or why for experimental purposes, application of a few drops 
of sugar solution can provoke violent pain whereas patients can tolerate much more 
aggressive stimuli to other teeth? On the basis of histological and physiological 
observations, Brannström (1963) proposed that dentinal sensitivity is closely 
associated with very fast and brief movements of dentinal fluid inside the tubules, 
which may trigger responses within the vascular and neural structures at the pulpal 
level (Figure 7). 
Since Brannström’s (1963) seminal publication, new theories have been proposed to 
extend our understanding of dentinal sensitivity, such as the possibility of partial 
innervation of the tubules (Carda and Peydro 2006). Recent findings suggest the 
possible existence of sensory properties for the odontoblast and its role in sensory 
transmission of stimuli to the tooth (Okumura, Shima et al. 2005; Allard, Magloire et 
al. 2006). 
Although the precise mechanisms of pain transmission in teeth remain to be fully 
elucidated, our present knowledge already allows understanding of some of the 
clinical responses encountered in day-to-day practice. It is quite common to find 
patients complaining of pain after they have received a bonded inlay using an 
indirect technique. Sensitivity is mainly encountered while chewing and can be 
explained by the hydrodynamic theory. When chewing, some resin-bonded 
restorations exhibit a “shock absorber” effect owing to their visco-elastic properties. 
During each micro-movement, fluid movements in the tubules and in the hybrid layer 
are triggered and may be responsible for the extra external pressure being exerted 






Movement of the dentinal fluid may explain the unusual pain described by patients 
presenting with a root crack or fracture. This pain is considered as peculiar since it is 
not a reaction to pressure, but it is felt during relaxation (opening). In the case of a 
crack or fissure, the pressure within the tooth during occlusion causes micro-
movements and tends to separate the two edges of the crack; therefore, the pulpal 
interstitial fluid tends to invade the space created. When pressure is released, the 
two dentinal edges will close up, thus creating increased intra-pulpal pressure 
resulting in very sharp and transient pain. Therefore, the appropriate treatment for 
such pathology is to retain the edge gap and provide a tooth covering (for example, 













Figure 7 : The principle of Brannström’s hydrodynamic theory: (A) The application of forces 
on the filling can lead to a displacement of the dentinal fluid into the tubules, and create an 







1.2.3.3 Consequences of new technological developments. 
Our knowledge of the dentine-pulp complex provides an important foundation on 
which to underpin a new era for dentistry with a biological focus. For example, the 
concept of cavity disinfection is of primary importance to prevent bacterial 
penetration and diffusion of toxins beneath restorations and this is being exploited in 
the development of new restorative products.  Bonding systems have now been 
developed, which aim to complement the adhesive properties with antibacterial 
molecules to control residual and recurrent caries. Protect Bond® (Kuraray®, 
Germany), in which 12-methacryloyloxy-dodecyl-pyridinium-bromide (MDPB) has been 
added to the bonding agent, is a relevant example of this new generation of 
products. New research is underway to consider addition of other molecules which 
would play a role in stimulating pulpal healing. 
1.3 Histological content of the Pulpal tissue 
The pulp contains many different cell types several of which show specialisation for 
particular functions (Figure 8). 
1.3.1 Odontoblasts.  
These are highly differentiated, post-mitotic cells, and are organised at the periphery 
of the pulp as a unicellular palisade. The presence of all the elements of the 
secretory/mineralisation machinery in the cells confirms their intense activity, 
notably during primary dentinogenesis. At a later stage during secondary 
dentinogenesis, the cells return to a quiescent state, with a reduced number of 
cytoplasmic organelles (Jones and Boyde 1984). Odontoblasts are joined by cellular 
junctions, such as gap junctions, thereby making a palisade of cells that provide a 






communication, which may be involved in regulating the pulp healing process 




Unlike osteocytes, odontoblasts do not become incorporated in the matrix, except for 
their processes that are embedded in the tubules. This is why dentine must not be 
considered as an individual tissue but rather as the dentine-pulp complex. The 
odontoblast processes contain limited organelles (which are believed to be 
responsible for the later secretion of intra-tubular dentine), but are mostly filled by a 
dense network of micro-filaments and other micro-tubules.  
Increasingly, coronal odontoblasts are regarded as being different from those found 
in the root (Nanci 2003). The coronal odontoblasts are elongated and pyramidal with 
Figure 8: Histology of first upper bovine molar. 7µm section, Haematoxylin and eosin 






an apical nucleus, whereas radicular odontoblasts are more cuboidal, which is 
potentially an indication of significantly lower cellular activity. This fact is seldom 
taken into account, but would explain why therapeutic interventions that have been 
validated at a coronal level (pulp capping, for instance) will often fail when applied 
to the radicular pulp (pulpotomy). 
1.3.2 Final differentiation process of odontoblasts during 
development. 
Odontoblasts synthesise the components of the predentine (collagen, glycoproteins 
and other non-collagenous proteins) and are responsible for its mineralisation. As for 
the other cells of the dental pulp, the odontoblasts are derived from neural crest 
mesenchymal cells and their differentiation is under the control of the internal 
dental epithelium (IDE). Differentiation is initiated at each cusp tip and is carried out 
according to a specific temporo-spatial pattern. In the mouse, the first differentiated 
odontoblasts appear on the 18th day of embryonic development, on the top of the 
main cusp of the first lower molar. The differentiation process gradually extends to 
the apical area and leads to the formation of a gradient of differentiation (Ruch, 
Lesot et al. 1995). 
1.3.2.1 From preodontoblast to functional odontoblast 
In the early stages of development, undifferentiated cells derived from the cranial 
neural crest migrate to the first branchial arch. The oral epithelium plays a key role 
in the initial pattern of the tooth, by controlling cellular commitment as well as the 
morphology of the tooth germs (incisor, molar, etc). 
Final differentiation of preodontoblasts into odontoblast occurs after a specific 
number of cell divisions (Ruch, Lesot et al. 1995). All of the cells of the dental papilla 
have the potential to differentiate into odontoblasts, however, only those in contact 






undergo terminal differentiation. This consideration has implications in the healing 
process, in which other signalling processes are responsible for induction of 
odontoblast-like cell differentiation.  
In mice, the pre-odontoblasts, located near the basal membrane (BM), undergo 14 to 
15 mitoses before leaving the cell division cycle; the number of cell divisions 
necessary for this process in humans, however, has not yet been demonstrated. 
During the last division, the mitotic spindle, originally parallel to the basal 
membrane, realigns to be perpendicular to this membrane (Osman and Ruch 1976). 
After the last mitosis, only the cell in contact with the BM is able to enter into the 
terminal differentiation process, while the other daughter cell (not in contact with 
the BM), becomes a part of Höhl’s cell layer.  
1.3.2.2 Cytological modifications and odontoblast differentiation 
Differentiation induces nuclear polarisation and cell elongation, implying important 
cytological changes. The rough reticulum cisternae and the Golgi apparatus are 
orientated parallel to the long axis of the cell and are localised in its distal area 
where the process will develop. The cell body of the differentiated secretory 
odontoblast is approximately 50 to 60 µm long. 
Functional odontoblasts are connected by many intercellular junctions; gap junctions 
ensure rapid transport of ions and small molecules between cells. These junctions are 
present along the cytoplasmic membrane of the body of the cell, creating cell 
contact between odontoblasts themselves and between odontoblasts and cells in the 
sub-odontoblast layer (Sasaki, Nakagawa et al. 1982). Other intercellular junctions, 
such as desmosomes, enable a mechanical cohesion between the odontoblasts 
creating a true histological barrier. These junctions are located in the area of the cell 






creates a physical barrier between the compartment of the predentine, and the 
odontoblast cell-body. 
Immature odontoblasts are small and ovoid in shape, having a high nuclear/ 
cytoplasmic ratio, a rudimentary granular endoplasmic reticulum and a few Golgi 
cisternae. Cellular modifications appear when cells reach the secretory phase 
(Goldberg and Smith 2004). Matrix vesicles were initially identified in cartilage of 
long bone (Bernard 1969), and then later were described in the dentine-pulp complex 
(Katchburian and Severs 1982). Theses vesicles are located in the extracellular matrix 
adjacent to the odontoblasts during mantle dentine formation. They disappear once 
mantle dentine formation is completed and the distal process has started to 
elongate. 
At the ultrastructural level, these vesicles appear as extracellular spherical 
structures, contain amorphous material more or less electron-dense and surrounded 
by a membrane. As in bone and cartilage, the membrane of these vesicles is made of 
3 layers, and contains various enzymes, especially phosphatases, involved in the 
mineralisation process. The vesicles are the initial sites of mineralisation in the 
mantle dentine and are also found in cartilage and bone.  
Ultrastructural modifications have also been shown in the secretory cells during 
primary, secondary and tertiary dentinogenesis related to their functional activity 
(Couve 1986). Active cell appears elongated, with basal nuclei. They contain many 
organelles with numerous vesicles, extensive rough endoplasmic reticulum and a well 
developed Golgi complex located between the nucleus and distal region of the cell. 
Morphologically the quiescent cell is stubby, cuboidal, and shows only limited 
cytoplasm. Organelle numbers decrease and this is related to the lower activity of 






1.3.2.3 Regulation of odontoblast differentiation  
During development, odontoblast differentiation is controlled by reciprocal 
interactions between the inner dental epithelium and the dental papilla. The 
extracellular matrix (ECM) and the basal membrane (BM) play a critical role in this 
regulation, serving as a reservoir of paracrine and autocrine factors. 
Only a specific dental BM is able to induce the differentiation of odontoblasts; the 
preodontoblasts can respond to epigenetic signals only after having carried out a 
fixed number of cell cycle divisions. Moreover, to play its role, the BM is subject to 
modifications, regulated by the inner dental epithelium. These changes are 
fundamental for the regulation of dental development.  
The main components of the BM are collagen IV, fibronectin, laminin (Lesot, Osman 
et al. 1981), nidogen, tenascin, hyaluronic acid and proteoglycans including heparan 
sulfate (Thesleff, Barrach et al. 1981). 
1.3.2.4 Growth factors 
Various growth factors and their receptors have been shown to be present at the 
enamel organ-dental papilla interface by immunohistochemistry and in situ 
hybridisation during tooth development and have been implicated in odontobalst 
differentiation: 
- GH (growth hormone) plays a paracrine and/or autocrine role in dental 
development (Zhang, Li et al. 1997), 
- IGF-1 and -2 (of the family of IGF: Insulin-like Growth Factor) (Begue-Kirn, 
Smith et al. 1994; Joseph, Savage et al. 1996; Cassidy, Fahey et al. 1997), 
- TGFβ-1, - 2 & - 3 (D'Souza, Happonen et al. 1990; Thesleff and Vaahtokari 






polarisation and the differentiation of odontoblasts (Begue-Kirn, Smith et al. 1994). 
Notably in adult pulp, TGFβ-1 plays an important role in the regulation of the 
inflammatory response and tissue regenerative processes. 
The sequestration of these growth factors in the dentine matrix and their subsequent 
fossilisation during the mineralisation process appears key to the pulp healing process 
where their release from the matrix may be responsible for various signalling events. 
Their precise localisation in the dentine (Smith, Matthews et al. 1998) and the full 
scope of their roles, however, remain to be  elucidated.  
1.3.2.5 Transcription factors :  
A second level of regulation exists during dental development through transcription 
factors. Notably, Msx1 is expressed in polarised preodontoblasts and Msx2 is present 
in mature odontoblasts (Begue-Kirn, Smith et al. 1994). Msx1 protein and transcripts 
have been identified in the pulp mesenchyme at early stages of tooth development 
and their concentrations decreased at the bell stage (Coudert, Pibouin et al. 2005). 
Msx1 sense RNA is mainly expressed in the dental pulp of the mouse at 15th day of 
tooth development. 
Expression of these transcription factors is under the control of growth factors and 
they can ultimately have broad ranging effects. Significantly, BMP4 up-regulates Msx1 
and Msx2 expression. In turn, transcription factors regulate further growth factor 
expression; for example, Msx1 up regulates BMP4 synthesis in the mesenchyme and 
Msx2 regulates Runx2 and Osteocalcin gene expression during odontogenesis (Bidder, 
Latifi et al. 1998; Blin-Wakkach, Lezot et al. 2001). 
Growth factors and transcription factors are thus central to the cascade of molecular 
and cellular events during tooth development and are responsible for many of the 






The second layer of the pulp is a dense zone of cells (the “cell rich layer of Höhl”, 
separated from the odontoblasts by an acellular layer called the “cell free zone of 
Weil”). During tooth development, the cellular differentiation process requires a 
minimum number of mitoses of the odontoblast progenitor cells before they are 
competent to differentiate to the final cellular phenotype of the odontoblast. The 
last mitosis has important spatial implications because it occurs perpendicular to the 
dental basement membrane resulting in two daughter cells : the one adjacent to the 
basement membrane receives the inductive signal to differentiate to an odontoblast 
while the other does not and contributes to the Höhl layer (Ruch, Lesot et al. 1995). 
This layer has long been considered as a potential reservoir of cells, containing 
incompletely differentiated cells that could be involved in the healing process for 
reparative dentinogenesis and dentine bridge formation if the odontoblast layer is 
damaged (Fitzgerald 1979). 
The capillary and nerve plexi that exist between both layers are significant; only a 
few nerve fibres accompany the cytoplasmic extensions into the dentinal tubules and 
then only for a short distance (Carda and Peydro 2006). Capillaries are closely 
associated with the odontoblast palisade and provide these cells with the necessary 
nutrients for their mineralising/synthetic activities. 
 
1.3.3 Pulp fibroblasts  
Similar to other connective tissues, the major cell of pulp tissue is the fibroblast. 
These cells are responsible for the formation and renewal of the extracellular matrix, 
but at the same time they mediate its controlled remodelling. The extracellular 
matrix plays an important role in this connective tissue. Its viscosity changes with 
time (fibrosis increases with the age of the tissue) and during pathophysiological 






variations in pressure, inherent in the inflammatory process. Due to this adaptability, 
most episodes of pulp inflammation are clinically silent. Pain increases when the 
intra-pulpal pressure, connected with the vasodilatation inherent in inflammation, 
can no longer be compensated for. 
1.3.4 Immune cells 
Dendritic cells have been identified in the pulp tissue (Jontell, Gunraj et al. 1987), 
even under physiological conditions (Jontell, Okiji et al. 1998). Macrophages are 
frequently found in healthy pulp (Trowbridge 2002). These phagocytic cells 
participate in the immune surveillance of the pulp, and enable a rapid response to 
occur to invading bacteria (Okiji, Kawashima et al. 1992; Okiji, Morita et al. 1992). 
Products of bacterial origin (such as toxins) diffuse via the tubules, and when in 
contact with pulp cells, they can behave like antigens; therefore, the immune system 
of the pulpal parenchyma plays an important role (Heyeraas, Sveen et al. 2001). 
Recent studies have demonstrated that human dental pulp cells, and particularly 
odontoblasts, may constitute the first line of defence to cariogenic bacteria entering 
dentine after enamel disruption (Staquet, Durand et al. 2008). Odontoblasts are 
proposed to initiate immune/inflammatory events within the dental pulp in response 
to cariogenic bacteria, by being stimulated by pathogens through Toll-like receptors 
(TLRs), production of chemokines upon cell stimulation with microbial by-products 
and induction of dendritic cell migration (Keller, Carrouel et al. 2009). TLR genes are 
expressed in the healthy human dental pulp that is thus well equipped to combat 
pathogens entering the tissue. Notably TLR2, CCL2 and CXCL1 are upregulated in 
odontoblasts both under carious lesions and upon stimulation with pathogen by-
products. These molecules are now targets for the design of therapeutic agents able 
to reduce the immune/inflammatory response to cariogenic bacteria and favour pulp 






Dendritic cells capture antigens and move these to the lymphatic nodes, where they 
are presented to T-lymphocytes. Then, these activated T lymphocytes return to the 
damaged pulp. In this way, the host is immunised and will automatically respond to 
the future presence of these antigens. Other molecules, such as those of the TGF-β 
super-family, which have been liberated from the dentine during the mineralisation 
process, are able to regulate the immune system of the pulp (Farges, Romeas et al. 
2003). 
Dendritic cells also interact with nerve fibres and blood vessels within the pulp. The 
neuro-immunological response of the pulp is presumed to be one of the first 
inflammatory reactions of the dentine-pulp complex (Jontell, Okiji et al. 1998; 
Farges, Keller et al. 2009). 
1.3.5 Dental pulp stem cells 
The growing interest in stem cells by the scientific community is a key area in dental 
research. The description of dental pulp stem cells (DPSC) (Gronthos, Mankani et al. 
2000) inside the pulp parenchyma demonstrated that the dental organ provides a 
“niche” environment for replacement cells. Another population of stem cells has also 
been reported in the pulp of deciduous teeth. These cells, or SHED (stem cells from 
human exfoliated deciduous teeth) (Miura, Gronthos et al. 2003), are singularly 
interesting because they are relatively easy to collect when the deciduous tooth is 
shed and replaced by the permanent successor.   
More recently, a further group of mesenchymal stem cells has been reported in the 
apical papilla of human immature teeth. These pluripotent cells have been termed 
Stem Cells of Apical Papilla (SCAP) (Huang, Sonoyama et al. 2008). Since they may be 
bone marrow-derived cells, SCAPS have potential for osteogenic and dentinogenic 






also express neurogenic factors, such as nestin and neurofilament M when stimulated 
with neurogenic medium (Sonoyama, Liu et al. 2008). 
The role of these cells in induced apexogenesis in necrotic immature teeth has been 
hypothesized. Many investigations have studied the revascularization process to treat 
immature necrotic teeth. The possibility of canal colonization by SCAPs, which could 
be introduced to the canal by induction of a blood clot and stimulating and 
disorganising the apical papilla cells with the file has been investigated by several 
authors. New therapeutics for necrotic teeth should arise in the future as more 
understanding of the processes involved become available (Iwaya, Ikawa et al. 2001; 
Banchs and Trope 2004; Thibodeau, Teixeira et al. 2007; Thibodeau and Trope 2007). 
The presence of stem cells in the dental pulp offers exciting possibilities for their 
exploitation in regenerative medicine both for dental and other diseases.  These cells 
are easier to collect than bone marrow cells, which is currently one of the main 
sources of post-natal stem cells. Also, they appear to be a promising reservoir of 
multipotent cells, and as such offer significant potential for use in various non-dental 
biotechnological applications. The presence of a population of stem/progenitor cells 
in the dental pulp provides a local source of cells for generating new “odontoblast-
like” cells for both natural pulp wound healing or regeneration and direct pulp 
capping after injury to the tooth. It is still unclear whether these stem cells have a 
developmental derivation from the dental papilla or if they migrate to the pulp 
through the vasculature. An important focus of future studies will be a more precise 
characterisation of these stem cells and their potentiality to allow their most 
effective application in new regenerative therapies.  
The discovery of stem cells in the dental pulp represents a significant advancement 






“post-natal stem cells” in the tooth provides a new platform for development of 
exciting biological approaches for vital pulp therapy. 
 
1.4 Pulpal responses to injury 
Progress in tissue regeneration has enabled researchers to understand better how the 
odontoblasts and, more generally, the pulp react after injury. The tertiary dentine 
secreted in the absence of pulpal exposure is commonly reactionary in nature and 
helps to both restore the structural integrity of the tooth and increase the distance 
between the injurious agent and the pulp. After the initial secretion and 
development of the primary dentine, the secretory odontoblast appears to fall into a 
semi-quiescent, semi-inactive state during which it continues its secretory activity 
but at a much slower rate. This process of secondary dentinogenesis is responsible for 
the gradual reduction in size of the pulp chamber, although the molecular control of 
the odontoblasts responsible for the decrease in activity remains to be elucidated. 
During injury to the tooth (caries, trauma or wear), a cascade of pulpal responses will 
be initiated. The exquisite regenerative or healing potential of the pulp though 
means that transient histological changes do not necessarily lead to clinically 
significant manifestations (Seltzer, Bender et al. 1963). Depending on the nature of 
the injury (whether it is brief or prolonged, or low- or high-intensity), the scope of 
the pulpal responses will likely differ. Injury of weak or moderate intensity will often 
be resolved by a brief inflammatory response followed by reactionary dentinogenesis. 
With injury of a greater intensity, odontoblast death will occur (e.g., deep caries or 
severe trauma), and as long as inflammation does not become uncontrolled, 
differentiation of a new generation of odontoblast-like cells may occur leading to 







1.4.1 Reactionary dentinogenesis 
Following injury, odontoblasts are released from their quiescent state and their 
secretory activity is subsequently up-regulated resulting in deposition of reactionary 
dentine. Histologically, the calico-traumatic line demarcates this new activity in the 
dentine matrix (Figure 9). Importantly, because the same cells are responsible for 
secretion of the reactionary dentine, tubular continuity is seen together with 
consequent maintenance of dentine permeability. This clearly has consequences with 





Figure 9 : Longitudinal histological section of a mouse molar which has been treated with a 







 Although still poorly understood, it can be postulated that the molecular control 
processes that are responsible for down-regulating odontoblast activity during the 
change from primary to secondary dentinogenesis may be reversed to stimulate the 
odontoblasts again during tertiary dentinogenesis. Decryption of the phenomenon of 
cell reactivation is necessary, and should facilitate development of new therapeutics 
that control cell activity. 
It is also important to consider the nature of the signalling process between the 
injurious agent and the odontoblasts. Bacteria and their toxins are key candidates in 
the direct stimulation of odontoblasts during caries (Durand, Flacher et al. 2006). 
Also, lipopolysaccharides and other bacterial toxins initiate intra-pulpal inflammatory 
processes, but other signalling processes may also be critical in the overall balance of 
pulpal cell responses leading to healing and tissue regeneration (Magloire, Bouvier et 
al. 1992; Tziafas, Smith et al. 2000; Botero, Shelburne et al. 2006; Smith, Lumley et 
al. 2008; Choi, Jeong et al. 2009). For example, authors reported recently that TNF-α 
stimulates differentiation of dental pulp cells toward an odontoblastic phenotype via 
p38 phosphorylation of the MAP Kinase Pathway (Paula-Silva, Ghosh et al. 2009) 
Whilst dentine is a mineralised connective tissue rich in collagen, it is also contains 
trace amounts of very potent bio-active molecules including cytokines and growth 
factors, which are sequestrated within the matrix during the mineralisation process 
and become essentially fossilised therein. During the decay process, demineralisation 
of the tissue is accompanied by the release of these molecules, which were initially 
fossilised (Smith 2003). In this pool of substances, many growth factors can be found, 
especially those of the TGF-β family (Cassidy, Fahey et al. 1997) (Smith, Matthews et 
al. 1998). These growth factors are extremely potent and have a variety of cell 
signalling properties which enable them to act at very low concentrations. Once 






responses, including activation of the odontoblasts (Smith, Tobias et al. 1995). Once 
stimulated, these formerly quiescent cells enter an active state, and secrete a 
tertiary reactionary dentine (Figure 10).  
 
 
Although the rate of dentine secretion is clearly decreased in the adult, the 
metabolic activity of the odontoblasts can be up-regulated in response to injury. The 
members of the TGF-β family present in the dentine may be solubilised by plaque 
bacterial acids during caries (Smith, Tobias et al. 1995; Smith, Matthews et al. 1998) 
or by restorative treatments. These molecules could be responsible for the 
stimulation of odontoblast activity. The organic components secreted in response to 
injury give rise to the dentine matrix termed “reactionary”, corresponding to an 
increase in matrix secretion by the stimulated odontoblasts. 
From this concept, it is possible to imagine opportunities for therapeutic stimulation, 
inducing a targeted release of these proteins. For example, cleaning the cavity with 
EDTA solution, which is well known for its ability to dissolve the mineral phase, would 
be a potential way to liberate growth factors and to induce the stimulation of 
Figure 10 : Numerous matrix proteins (represented by multicoloured dots) are fossilised 
in the collagen matrix of the dentine during the mineralization process: (a) these factors
are released by the dissolution of the mineral matrix (whether pathological or
therapeutic); (b) they encounter the odontoblast layer via the tubules; (c) these
molecules are considered to be important regulators of signalling pathways in the dentine






odontoblasts (Smith, Tobias et al. 1990; Smith, Tobias et al. 1994; Smith, Tobias et 
al. 2001). Etching with orthophosphoric acid, used for conditioning the dentine in 
bonding procedures, also promotes demineralisation of the dentine and liberation of 
biological factors. Other products that are presently in the dentist’s therapeutic 
arsenal might come back into favour with new indications. For a long time, calcium 
hydroxide has been used as a protective lining, especially beneath amalgams fillings, 
but has more recently fallen out of favour. Nevertheless, this material certainly has 
the ability to release components from the dentine, including growth factors 
(Graham, Cooper et al. 2006).  Unlike the chelating agents which only have brief 
contact with the dentine, calcium hydroxide remains in place beneath restorations 
and favours a gentle and continued dissolution, thus releasing growth factors; its 
action is prolonged and potentially controllable depending on the form of the 
product.  
More recently, the action of Mineral Trioxide Aggregate (MTA® - Dentsply Maillefer) 
in releasing growth factors has been demonstrated (Tomson, Grover et al. 2007), 
although the amounts released differ from those liberated by calcium hydroxide. 
These differences are interesting because they might explain the differential 
behaviour observed in response to both materials. If the processes underlying this 
action were better understood, then the use of such linings under coronal 
restorations might readily find favour again thereby providing a new focus for 
research in bioactive materials. 
1.4.2 Reparative dentinogenesis 
Odontoblasts are the only cells that secrete dentine. If they suffer injury, the 
formation of a dentine bridge at sites of pulpal exposure is still possible, providing 
that new odontoblast-like cells are “available” in the area. Conventionally, wound 






superficial cells move to the centre of the injury regenerating and repairing the 
tissue and allowing its reorganisation. 
Odontoblasts are differentiated post-mitotic cells and are unable to divide to 
produce new secretory cells. When these cells are lost, cellular replacement occurs 
which involves stem or progenitor cells resident in the pulp (Fitzgerald 1979; 
Fitzgerald, Chiego et al. 1990) (Figure 11). Following pulp exposure, and after 
placement of an appropriate material, a dentine bridge is formed in a few weeks 
(Figure 12) by new odontoblast-like cells. The origin of these odontoblast-like cells in 
the dentine pulp healing process is not clearly established. Several authors believe 
that these processes are likely to be the same as those involved in tooth development 
(Smith and Lesot 2001; Mitsiadis and Rahiotis 2004), however, the derivation of these 
cells is still unclear with an origin from outside the tooth via the vasculature cannot 
be excluded.  
                   
 
Figure 11 : Dentine bridge formation five weeks after pulp capping with MTA® in a
mouse first molar (frontal semi-thin section, x50 magnification, methylene blue –






Various clinical procedures for repair of a pulp exposure have been proposed and 
calcium hydroxide has long been considered as the material of choice. However, the 
poor quality of the dentinal bridge and its lack of hermetic seal are potential sources 
of failure with this material.  
(a)    (b)  




Currently, a lack of trust in pulp capping due to the inability to predict its prognosis 
exists and practitioners will frequently therefore remove the pulp of the tooth rather 
than try to maintain its viability. Although several authors have proposed capping the 
pulp with the filling material itself, there is no histological evidence that this can 
 Figure 12 : Reparative dentinogenesis. Contrary to conventional connective tissues, the
healing process in the odontoblastic layer does not occur by cell division of other 
odontoblasts at the edge of the injury (a and b). The attraction of new cells and their 
differentiation into dentine secreting cells (c) induce the formation of a dentinal bridge in






induce dentine bridge formation. Even if, clinically, the results seem to be 
satisfactory, this approach cannot be considered to be reliable in the long term. This 
example perhaps illustrates what distinguishes the clinician from the scientist. 
Whereas clinicians focus on the sealing properties of materials and the prevention of 
any bacterial or fluid leakage, scientists are more interested in the bio-activity of 
these materials and their ability to induce a wound healing response. Both are 
complementary, and it is essential that these two stances are brought together. For 
the future, existing materials will provide an important stepping stone towards the 
development of more specific bio-molecules as dentistry develops a biotechnological 
direction and may encourage greater practitioner uptake of such approaches. 
 
1.4.3 Pulp capping 
Following pulp exposure, direct capping using a suitable material can induce a 
protective response by reparative dentinogenesis resulting in dentine bridge 
formation.  As pulp exposure results in odontoblast loss, the healing process is 
consequently more complex requiring the recruitment and subsequent differentiation 
of new dentine secreting odontoblast-like cells. It is therefore probable that the 
processes involved in pulp repair (reactionary and reparative dentinogenesis) 
recapitulate those of physiological dentinogenesis, although physiological regulation 
of odontoblast secretory behaviour may differ in tertiary dentinogenesis (Tziafas, 
Smith et al. 2000; Smith and Lesot 2001). 
Many factors intervene in the prognosis of a pulp capping treatment (Murray, Hafez 
et al. 2002; Murray, Hafez et al. 2003); lack of inflammation, infection control, and 
biocompatibility of the used material are reported to be the  key factors for 






As it has also been established that an inflammatory response occurs in pulp tissue as 
soon as caries reaches the dentine (even at a superficial layer), it appears to be 
difficult to treat a non-inflamed dental pulp except after a trauma with pulp 
exposure. Pulp exposure often occurs after trauma and as the pulp is generally free 
of inflammation, pulp capping in such situations, represents a good approach for 
treatment. However, it is important to consider management of such cases in the 
context of the biological behaviour of the pulp, especially in immature teeth which 
are still developing. 
The ultimate goal of pulp capping with a dedicated material is to induce the 
formation of a barrier of reparative dentine between the pulp and the material of 
obturation, by allowing the pulp cells to express their dentinogenic potential 
(Schroder 1985). In 1965, Kakehashi demonstrated the systematic formation of a 
dentine bridge after pulp exposure in laboratory “germ-free” animals (Kakehashi, 
Stanley et al. 1965). This study highlights the ability of the pulp to heal depends on 
its environment, and can occur in the absence of bacterial infection (Cotton 1974).  
Over the years, many materials have been used for pulp capping with calcium 
hydroxide having long been considered the gold standard.  Indeed, a search of 
PubMed (search keywords: calcium hydroxide and pulp capping) currently reveals 
more than 650 references (July 2009).  Characterised by a very basic pH (Faraco and 
Holland 2001), calcium hydroxide no longer seems to be the ideal material for the 
following reasons: 
− The induced dentine bridge is inconsistent and porous (Cox, Subay et al. 1996) 
− Calcium hydroxide does not adhere to the dentinal walls 
− Sealing ability of Calcium Hydroxide is quite poor. 






Because of its highly basic pH, calcium hydroxide in direct contact with the pulp 
locally destroys a layer of pulp tissue, and thus creates an uncontrolled necrotic 
zone; this necrotic layer induces an inflammatory reaction which persists in time, or 
formation of intra pulpal calcification.  
Currently, there is considerable research focus directed towards identification of 
other materials able to induce the formation of a well formed dentine bridge (Tarim, 
Hafez et al. 1998), however, thus far results remain inconsistent. Other approaches 
including protection of the pulp with the hybrid layer from new adhesive systems 
have also been studied (Cox, Hafez et al. 1998). 
The introduction of Mineral Trioxide Aggregate (MTA) (Abedi, Torabinejad et al. 
1996; Pitt Ford, Torabinejad et al. 1996; Torabinejad and Chivian 1999) has perhaps 
challenged the position of calcium hydroxide as the gold standard pulp capping 
material. Although our understanding of its composition and biological effects is 
limited, recent data suggest the better quality of the dentine bridge compared to 
that obtained with calcium hydroxide (Nair, Duncan et al. 2008). Moreover, cells in 
direct contact with the dentine bridge express protein markers of odontoblasts 
(Simon, Cooper et al. 2008). In a recent randomized prospective study on human 
teeth, Nair et al. concluded that clinically MTA was more appropriate than calcium 
hydroxide and should be considered as the new gold standard (Nair, Duncan et al. 
2008). 
Several in vivo studies have shown that MTA induces the creation of a dentine bridge 
of good quality, with an effective hermetic seal, which can merge with the dentinal 
walls at the edge of the defect (Simon, Cooper et al. 2008). The advantage of the 
quality of the dentine bridge obtained with MTA versus calcium hydroxide as a pulp 
capping agent has been recently demonstrated in a randomised clinical trial (Nair, 






In spite of the unpublished composition of the material by the manufacturer, recent 
data suggest that Portland cement resembles the active ingredient of this material 
and exhibits similar properties (Estrela, Bammann et al. 2000; Holland, de Souza et 
al. 2001; Abdullah, Ford et al. 2002; Funteas, Wallace et al. 2003; Saidon, He et al. 
2003). 
1.4.3.1 Pulp Capping and pulp repair: 
In most injury situations, pulp exposure is inevitably associated with an inflammatory 
response and the following steps ensue: 
- Haemostasis and formation of a blood clot 
- Inflammatory response 
- Cell proliferation and/or recruitment 
- Tissue remodelling 
The healing process in connective tissues is always characterised by these successive 
steps. Failure to resolve the inflammatory process leads to chronic inflammation, and 
eventually to pulp necrosis. Pulp tissue adjacent to an exposure is characterised by 
the presence of necrotic debris, of blood clot formation, and a cellular response 
involving significant infiltration of neutrophils. Yamamura characterised the 
chronology of the healing process in the dog after pulp capping with calcium 
hydroxide (Yamamura 1985) as follows: exudative phase (3 to 5 days), proliferative 
phase (3 to 7 days), formation of osteodentine (5 to 14 days), formation of tubular 
dentine (14 days and more). After 3 to 6 days, the inflammatory layer is replaced by 
granulation tissue. This tissue is arranged along the wound, and contains many 
fibroblasts and newly formed blood capillaries (Fitzgerald 1979). New extracellular 
matrix and nodules of mineralisation are seen during healing (Schroder and Granath 
1972). The first mineral deposits are found in matrix vesicles, indicating significant 






(Hayashi 1982). At 11 days, the newly formed matrix surrounds cuboidal cells, and a 
few cells present the first features of odontoblast differentiation (Mjor, Dahl et al. 
1991). At 14 days, cells are reorganised in a palisade of cells similar to that seen in 
primary or secondary dentine (Mjor, Dahl et al. 1991). At 1 month, the dentine bridge 
and a necrotic layer associated with an inflammatory response in the adjacent pulp 
tissue can be seen (Fitzgerald 1979). At the ultrastructural level, “tunnel defects” 
are clearly visible in the dentine bridges of 89% of the cases studied (Cox, Subay et 
al. 1996). 
Reparative dentinogenesis is a complex process comprising a cascade of biological 
processes;  
Interactions of pulpal cells with growth factors, cytokines and other molecular 
mediators during the healing process are at the origin of each of the three steps of 
reparative process: 
1- Progenitor cells recruitment 
2- Cellular differentiation 
3- Up regulation of cell synthetic and secretory activity. 
1.4.3.2 Progenitor cells of the “second generation” odontoblasts: 
Many cellular processes initially observed during embryonic development appear to 
be recapitulated in situ during wound healing and particularly for pulp repair. These 
phenomena lead to the production of reactionary or reparative dentine depending on 
whether the pulp has been exposed or not  (Smith, Cassidy et al. 1995)  
Reparative dentinogenesis during pulp healing requires progenitor cell recruitment 
and subsequently, the differentiation of these cells into odontoblast-like cells. The 
newly formed odontoblast-like cells result from the proliferation and differentiation 
of a population of stem/progenitor cells, probably residing within dental pulp (Ruch 






the pulp after capping with calcium hydroxide in the monkey. They stressed that the 
migration of cells occurred from the central pulp tissue to the pulp/material 
interface.  They also showed that two DNA replications were necessary before the 
migration of these cells and their differentiation. 
Despite our knowledge of tooth development, our understanding of these 
stem/progenitor cells is still limited. Pulp cells cultured under certain conditions can 
differentiate into cells with an odontoblast-like phenotype and have the capacity to 
form nodules of mineralisation in vitro (Couble, Farges et al. 2000), although it is 
unclear whether a sub-population of cells or all pulp cells can exhibit this behaviour. 
More is known of the multipotent cells of bone marrow (BMSCs), and their potential 
to differentiate into osteoblasts, chondrocytes, adipocytes, myocytes and neuronal 
cells (Bennett, Joyner et al. 1991; Krebsbach, Kuznetsov et al. 1997; Azizi, Stokes et 
al. 1998; Ferrari, Cusella-De Angelis et al. 1998; Pittenger, Mackay et al. 1999). In 
the pulp, the origin of replacement odontoblast-like cells has not yet been clearly 
identified. For a long time, the cell rich layer of Höhl was regarded as a reservoir of 
progenitor cells, although several origins for these stem/progenitor cells have now 
been proposed including a local origin in the pulp mesenchyme and a remote one 
derived from the bone marrow. Pericytes in the pulp have also been proposed as 
candidate repair cells, although whether such cells originate from within the pulp or 
are transported there through the vasculature is unclear (Yamamura 1985; Shi and 
Gronthos 2003; Lovschall, Mitsiadis et al. 2007). 
Pluripotent cells have been described in the dental pulp (Gronthos, Mankani et al. 
2000; Gronthos, Brahim et al. 2002). These cells called DPSCs (Dental Pulp Stem 
Cells) are able to form dentine-like tissue after ectopic transplantation; they can also 
differentiate into adipocytes or neuronal cells. These DPSCs are probably progenitor 






To date, involvement of DPSCs in the pulp healing process has not been definitively 
demonstrated. The definitive characterisation of the origin of the cells responsible 
for the healing process in pulp would allow elucidation of their specific behaviour in 
the repair process, and help to inform the most appropriate treatment after pulp 
exposure. 
1.4.3.3 Pulp Healing and Growth factors: 
During dentine degradation, cytokines and growth factors are released from dentine. 
(Smith 2002b; McLachlan, Sloan et al. 2004; McLachlan, Smith et al. 2005; Smith, 
Lumley et al. 2008). These cytokines play a key role in the regulation of progenitor 
cell recruitment, cell proliferation and differentiation of new dentine secreting cells. 
The members of the TGF-β family have clearly been identified in dental tissue 
healing events (Rutherford, Wahle et al. 1993; Nakashima 1994; Rutherford, 
Spangberg et al. 1994; Cassidy, Fahey et al. 1997; Baker, Sugars et al. 2009). The 
differentiation of new odontoblast-like cells has also been reported after pulp 
capping with bFGF (Basic Fibroblast Growth Factor), TGF-β1 (Lovschall, Fejerskov et 
al. 2001) and BMP-7 (Jepsen, Albers et al. 1997).  
 Direct application of growth factors to pulp tissue offers an interesting therapeutic 
approach, however, it is important that we first derive a clear understanding of the 
biological and molecular processes involved in their action before attempting to 
develop a reliable, reproducible and efficacious new clinical therapy based on their 
use (Tziafas, Smith et al. 2000). 
1.4.3.4 Clinical Implication 
Reactionary and reparative dentinogenesis are two very different pathways for pulp 
repair. The description above of the two types of tertiary dentinogenesis highlights 
the need for different therapeutic strategies for pulp healing depending on which 






approaches will necessarily be based on the extent of pulpal disease and particularly, 
on odontoblast survival. 
Translation of biological knowledge into the clinical setting can be simply adoption of 
a more biological thought process during treatment planning, however it is not 
always that easy. For instance, the impact of tooth structure on biological events can 
be fairly readily appreciated, such as in the thickness of the residual dentine 
separating a cavity from the pulp, which can be an important factor in its protection. 
 
 
Figure 13 : The differing steps of the two pathways of tertiary 






 In deeper cavities, where the thickness of the cavity floor is less than 0.5 mm, the 
number and the length of the “opened” tubules is such that the communication with 
the pulp is possibly comparable to that of an actual cavity exposure (Smith, 2002). 
Also, clinically it can be very difficult, if not impossible, to know the inflammatory 
status of the pulp, and the cytological state of the odontoblasts since pulpal histology 
does not necessarily correlate well with clinical presentation; this makes it very 
difficult to effectively treatment plan in such situations and there is an urgent need 
for more reliable means of diagnosis of the activity of carious lesions and the level of 
pulpal inflammation. While thermal or electrical tests provide information on the 
innervation of the pulp, there is a need for tests which evaluate the vasculature and 
in particular, the effects thereon of any inflammation that may be present. 
Unfortunately, the hard tissue shell enclosing the pulp constrains use of techniques 
such as Laser Doppler scanning or scintography which provide valuable information in 
other medical specialities. 
1.5 MSX2 Homeobox Gene 
1.5.1 Msx2 
Msx2 or msh homeobox gene 2 encodes a member of the muscle segment homeobox 
gene family. The Msx2 gene is located on the long (q) arm of mouse chromosome 5 
between positions 34 and 35, from base pair 174,084,180 to base pair 174,090,507. 
 Msx genes (Muscle Homeobox Segment obstructs) are mammalian homologues of the 
Drosophila muscle segment homeobox gene; they encode for transcription factors. 
Msx-class homeobox genes are characterized by a distinct and highly conserved 
homeodomain and have been identified in a wide variety of metazoans from 
vertebrates to coelenterates (Davidson 1995). There is evidence that they participate 
in inductive tissue interactions that underlie vertebrate organogenesis, including 






mouse, Msx1, Msx2 and Msx3, but only two homeogenes (Msx1, Msx2) have been 
identified in humans and mutation of these genes has been related to dimorphism 
(Ivens, Flavin et al. 1990). 
Msx2 is known to be induced by BMPs and notably BMP4, which play critical roles in 
bone formation and osteoblast differentiation(Harada and Rodan 2003). Msx2-
deficient mice develop reduced bone formation, decreases in osteoblast numbers, 
impaired chondrogenesis, abnormal calvarial development, and defects in the 
ectodermal organs including the teeth, hair, and mammary glands (Satokata, Ma et 
al. 2000; Aioub, Lezot et al. 2007). In contrast, transgenic mice overexpressing Msx2 
show enhanced growth of calvariae (Liu, Kundu et al. 1995). Mutations in the MSX2 
gene in humans, which affects DNA binding activity, causes defects in skull 
ossification (Wilkie, Tang et al. 2000; Wuyts, Reardon et al. 2000). Furthermore, an 
autosomal dominant disorder, Boston-type craniosynostosis, results from a gain-of-
function mutation of MSX2 at proline 148 (Ma, Golden et al. 1996; Winograd, Reilly et 
al. 1997). These findings suggest a positive role for Msx2 in bone development and 
formation. In contrast to these genetic studies, in vitro studies have shown that Msx2 
negatively regulates the transcription of the osteoblast-specific genes such as 
osteocalcin (Towler, Rutledge et al. 1994; Ryoo, Hoffmann et al. 1997). In addition, 
Msx2 has been shown to bind to Runx2 and inhibit its transcriptional activity 
(Shirakabe, Terasawa et al. 2001). These studies suggest that Msx2 serves as a 
negative regulator for osteoblast differentiation. 
Msx2 is expressed in many craniofacial structures prior to embryonic day E14, but is 
expressed in a more restricted pattern at later stages, primarily in developing teeth. 
Msx2 and osteocalcin are expressed in reciprocal patterns during craniofacial 
development in vivo, and Msx2 expression in pre-odontoblasts clearly precedes 
osteocalcin expression in odontoblasts (Bidder, Latifi et al. 1998). In incisors, Msx2 is 






dental papilla cells. In appositional bell-stage molars, expression of Msx2 is observed 
in adjacent pre-odontoblast cells and odontoblasts within the same tooth. Msx2 is 
also expressed in adjacent immature ovoid pre-odontoblast cells. In less mature 
teeth populated only by immature ovoid pre-odontoblast cells, Msx2 is widely 
expressed (Maas and Bei 1997). 
Msx2 acts as a transcriptional repressor in dental cells (Zhou, Lei et al. 2000). Like 
Msx1, the Msx2 homeoprotein plays a key role in osteoblast differentiation and 
phenotypic expression, via the BMP osteoinductive pathways (Ryoo, Hoffmann et al. 
1997) and is involved in the regulation of diverse cell activities, including 
proliferation, differentiation and apoptosis. 
 
1.5.2 MSX2 and genetic disease 
More than 10 mutations in the MSX2 gene have been identified in people with 
enlarged parietal foramina type 1. These mutations include a change of one amino 
acid in the MSX2 protein and deletions of one or more nucleotides from the gene. 
These genetic changes result in the production of an unstable MSX2 protein that 
cannot bind to DNA. A non-functional MSX2 protein impairs the regulation of cell 
growth and division (proliferation), cell differentiation and the balance of cell 
survival and destruction in specific areas of the skull. These cell functional 
disturbances imply dysregulation of bone formation (ossification), resulting in 
formation of enlarged parietal foramina. 
A mutation in the MSX2 gene is associated with craniosynostosis type 2 disease (also 
known as Boston type) [(Ma, Golden et al. 1996) for review see (Mavrogiannis, Taylor 
et al. 2006)]. Craniosynostosis involves early bone closure in the skull, leading to a 
misshapen head. Skull malformations, including a protruding forehead (frontal 






cloverleaf-shaped skull (Kleeblattschaedel deformity) are commonly seen in patients 
suffering from craniosynostosis type 2.  
Only one mutation has been found to cause craniosynostosis type 2 and this occurs 
when the amino acid proline is replaced with the amino acid histidine at position 148. 
Craniosynostosis type 2 has been found to affect multiple members of a single multi-
generational family (Wilkie 1997). 
 
1.6 Aim of this research 
Overall this research aimed to investigate the molecular characterisation of 
odontoblasts during primary, secondary and tertiary (reactionary and reparative) 
dentinogenesis.  
The specific objectives of this project were four fold: 
1. To analyse and compare the transcriptome of bovine odontoblasts between early 
and late stage  of post-natal tooth development cells using gene microarrays with 
subsequent confirmation by sq-RT-PCR. 
2. Parallels between development and healing processes in teeth have been 
suggested. Based on this hypothesis, gene (particularly p38) regulation and protein 
activation were investigated using an in vitro model of tertiary dentinogenesis 
(involving young and mature cells). 
3. In vivo investigation is important for an understanding of the interplay of various 
cellular and molecular processes during wound healing. Currently the published in 
vivo models for pulp healing are limited in their ability to exploit transgenic 
technologies. In a third part of this work, we aimed to design a new laboratory model 
for pulp capping in the mouse. With such a validated model, transgenic animals could 
be used to investigate the role(s) of specific genes. 
4. In the final part of this research, we used a transgenic mouse model to analyse the 
possible role of Msx2 transcription factor in odontoblast differentiation. The precise 
description of the tooth phenotype in Msx2 null mutant animals was subsequently 
analysed.   
 





2 Materials and Methods 
2.1 Part one: Odontoblast maturity and dentinogenesis 
2.1.1 Aim of the project. 
So far there is no histological difference described between primary and secondary 
dentine except at the interface between both tissues delimited by a calciotraumatic line 
(Thewlis 1940); the two types of dentine are secreted by the same cells, albeit at 
different times and rates. Odontoblasts are actively secreting during primary 
dentinogenesis, but become largely less active during secondary dentinogenesis. 
 We therefore hypothesize that the changes in secretory activity of odontoblasts 
throughout their life cycle reflect differential transcriptional control and that regulatory 
processes involved in bone homeostasis may also occur in regulation of dentine secretion. 
The expression profiles of several genes (DSPP, DMP1, Collagen I) were used as well 
established markers of odontoblasts and their expression levels may reflect the cell 
secretory behaviour. So far, comparison of the gene profile of the odontoblast at 
different stages of its life cycle has not been described. Based on the hypothesis that 
differential dentine secretion is associated with changes in transcriptional activity within 
the cell, we have investigated the transcriptomes of odontoblasts involved in primary and 
secondary dentinogenesis and subsequently used this information to identify key 
regulatory intracellular pathways involved in this process.  
The aim of the first part of our work was therefore to search for the potential 
specificities between primary and secondary dentine odontoblast transcriptomes. 






2.1.2.1 Selective odontoblast isolation, RNA extraction and cDNA synthesis from 
cells during primary and secondary dentinogenesis stages. 
First permanent incisors, (erupted and with root formation completed), and fourth 
incisors (still impacted and at an early stage of development) were dissected from two 30 
month old cows immediately after slaughter. The root of each tooth was sectioned with a 
bone saw under cooling with DMEM culture medium (DEPCO, UK). Pulp tissue was 
subsequently removed, leaving the odontoblast layer remaining attached to the dentine 
(McLachlan, Smith et al. 2003). Odontoblasts were directly lysed in situ by the addition of 
SV RNA lysis buffer (Promega, UK) into the pulp chamber of the tooth and extracted 
pulpal tissue was immersed in the same buffer prior to homogenisation and RNA 
extraction. To support selective isolation of odontoblasts, histological analysis was 
performed. Four teeth (two after pulp removal and two after odontoblast lysis) were fixed 
for 24 hours with 10% (w/v) neutral buffered formalin, then demineralised in 10% formic 
acid for >7 days. Samples were dehydrated through a series of graded alcohols and 
xylene, and finally embedded in paraffin wax. Serial sections of 5μm thickness were cut 
and stained with Mayer’s haematoxylin and eosin. 
 Total RNA was extracted using the SV Total RNA Isolation kit (Promega, UK) and was 
eluted in a final volume of 30 μl of sterile water as recommended by the manufacturer. 
Subsequently, 1–2 μg of DNase-digested total RNA was used for oligo(dT) (Ambion, UK) 
reverse transcription to generate single-stranded cDNA using the Omniscript kit (Qiagen, 
UK). Both RNA and cDNA concentrations were determined from absorbance values at a 
wavelength of 260nm using a BioPhotometer (Eppendorf, UK). 
2.1.2.2 RT-PCR Analysis 
Semi-quantitative RT-PCR assays were performed using the RedTaq PCR system (Sigma, 
UK). For all analyses, 50 ng of single-stranded cDNA was used to seed 25 μl PCRs 





containing; 12.5 μl RedTaq ready reaction mix, 10.5 μl dH2O, 1 μl each of 25mM forward 
and reverse primers (Table 1). Notably, primers for the putative bovine DSPP transcript 
were derived from the bovine genome sequencing project contig (NW_001506143.1) not 
currently localized to a chromosome. This sequence had 78% identity over 431bp with the 
pig DSPP sequence (Acc. No. AY161863.1). To provide further evidence that this assay 
represented this key dental specific transcript, amplification was assayed from a range of 
bovine tissues and data indicated that products were only detected in cells derived from 
the dentine pulp-complex (Figure 14) . Reactions were amplified in a Thermal Cycler 
(Mastercycler Gradient, Eppendorf, UK) for between 20 and 30 cycles. Following an initial 
denaturation step of 5 min at 94 °C, a typical amplification cycle consisted of 94 °C for 20 
s, 61 °C for 20 s and 72 °C for 20 s ending with a 10-min extension at 72 °C. Following the 
designated number of cycles, 6 μl of the reaction was removed and the product was 
separated and visualised on a 1.5% agarose gel containing 0.5 mg/ml ethidium bromide 
after which gels were scanned and images captured using EDAS 120 software (Kodak, UK). 
Scanned gel images were imported into AIDA image analysis software (FUJI, UK) and the 
volume density of amplified products calculated and normalised against the GAPDH 
housekeeping gene control values. 
 
Figure 14: Sq-RT-PCR analysis showing differential expression of (GAPDH) (A) and DSPP genes in Early
stage (ES) and Late Stage (LS) Odontoblasts (od), pulp cells (P), skin, gingiva and muscle from bovine
tissues. This Sq-RT-PCR was performed to confirm the specificity of the bovine DSPP transcript assay
designed from the bovine genome sequencing project contig (NW_001506143.1). 





Gene Forward reverse Accession number Size
GAPDH GCCAAGAGGGTCATCATCTC CCCAGCATCGAAGGTAGAAG nm_001034034 316 bp
DMP-1 GCATCAGGTGGCCAAAGTAT GAAATCCCATGCAACGTTCT NM_174038 304 bp
Collagen 1 GGCTCTCCTGGTGAACAACGT GTAGTAGCGGCCACCATCCTG NM_074520 312 bp
DSPP TTTTCCTCCTTCCTTTATGCAA TTCATTGCCTGACCTAATGC NW_001506143.1 307 bp
TGF Beta1 TGAATCCTTCAAACGTGCTG CATTTTGATGCCTTCCTGCT m36271 320 bp
TGF Beta1 R TGAATCCTTCAAACGTGCTG CATTTTGATGCCTTCCTGCT nm_174621 331 bp
BMP4 TCGTTACCTCAAGGGAGTGG GTGGGAACACAACAGGCTTT NM_001045877 359 bp
PGAP1 CCATCTCCGCTTATCTTCCA GACAAAGCATGGAACCCTGT XM_580837 328 bp
OSTEOCALCIN TGACAGACACACCATGAGAACCC AGCTCTAGACTGGGCCGTAGAAG nm_174249 337 bp
ADM AGGGGAGGCAGTGTTCTCTT GGGGAGGGGAACAATACAAT NM_173888 385 bp
AMELOGENIN AGCAGACTCCCCAGAATCAC GAATATCGGAGGCAGAGGTG NM_001014984 338 bp
IBSP caccgaaatgaagacggttt gaaagggtggtgttctcagc NM_174084 349 bp
DECORIN aactcttttgcttgggctga tttgttgttttgcaggtcca NM_173906 340 bp
ALKALINE PHOSPHATASE TGAACCTCATCGACATCTGG AAAGACGTGGGAGTGGTCAG NM_176858 301 bp
CaSR ccaacatgaccctgggatac ttccagcggaagtactcgat NM_174002 345 bp
SOCSBOX PROTEIN tcagttcagtgccaggattg tcactgctctccttccaggt Nm001034209 327 bp
SPP-1 acagccaggacgtcaactct ggaaagctcgctactgttgg nM_174187 397 bp
PROTEIN S100 gggcaaagagggagacaagt aaagtaaggtgaggggaagca NM_001099042 325 bp
OSTF1 ggtggaaaggtacctgcaaa agcacctttttccagaagca NM_174409 348bp
PTPRR gcatttcctaaacccgcata cttcagatggcagagcatca NM_001015662 301 bp
NTRKK2 acgtgggactgaaaaacctg aaatttgctgatggcaaacc NM_001075225 334 bp
MAPK13 (p38) acaaagccccaaaaaggatt gtggtatcacgaggccattc NM_001014947 364 bp
MAP2K6 tccacttgcatgaagattgc gcttctgctcttggctgttt NM_001034045 400 bp
MKK3 catcaccattggagacagga ctccccgagaatgtcttctg Nm_001083693 358 bp  
Table 1: Primer details and conditions for sq-RT-PCR analysis. Primer sequences used in PCR
analysis and expected product sizes for each assay. Primers were designed using the Primer3
software (http://frodo.wi.mit.edu/cgi-bin/primer3/primer3_www.cgi) using sequences from the
Accession numbers provided.  
 






2.1.2.3 Microarray analysis 
Microarray analysis (Affymetrix, UK) was performed to compare the transcriptomes of 
the two odontoblast populations as previously described (McLachlan et al. 2005). 
100ng of total RNA were double amplified to generate cDNA and 25µg of cRNA 
synthesized using the in vitro transcription (IVT) reaction prior to fragmentation. 
15µg of each of the fragmented cRNAs were solubilized in a hybridization cocktail, 
which was subsequently incubated in duplicate with GeneChip Bovine Genome arrays 
(900561) for 16hrs at 45°C. All hybridisation control parameters were within 
Affymetrix recommended guidelines. Bioinformatics analysis was conducted with 
three software programmes (D-chip http://biosun1.harvard.edu/complab/dchip/, 
Onto-Express and Pathway express (http://vortex.cs.wayne.edu/projects.htm). 
 
2.1.2.4 Immunohistochemical analysis 
Immunohistochemistry was performed on 5 μm sections mounted on SuperFrost®Plus 
(Manzel Glase - Germany) slides. Deparaffined and rehydrated sections were 
incubated for 30 min in 3% H2O2/PBS to quench endogenous peroxidase activity, and 
then rinsed for 10 min in Phosphate Buffered Saline (PBS). Nonspecific protein binding 
was blocked by incubation for 30 min in 5% goat serum in PBS. Specimens were 
incubated for 1hour at room-temperature in a humidified chamber with a polyclonal 
rabbit anti-mouse DSPP (Dentin Sialophosphoprotein) antibody, (kindly provided by Dr 
Larry Fisher, National Institute of Health, Ref LF 153), a rabbit anti-mouse phospho-
p38 MAPK (T180/Y182) Antibody (R &D systems-USA) or anti-bovine DMP-1 Antibody 
(kindly provided by Dr Larry Fisher, National Institute of Health, Ref LF 148).  
Sections were washed three times in PBS at room-temperature prior to treatment for 
30 minutes at room temperature with the secondary biotin-labelled goat anti rabbit 





IgG antibody (Streptavigen Multilink Kit - Biogenex UK).  Subsequently, sections were 
incubated for 30 min at room temperature with peroxidase linked to avidin 
(Vectastain ABC kit, Vector Laboratories, Burlingame, CA, USA). After rinsing with 
three changes of PBS, the immunoreactivity was visualized by development for 2 to 5 
min with 0.1% 3,3-diaminobenzidine and 0.02% hydrogen peroxide (DAB substrate kit, 
Vector Laboratories). Sections were counterstained with Mayer’s haematoxylin, 
mounted with permanent mounting medium (XAM® - BDH Laboratory – England) and 
examined by light microscopy. A positive control was performed on untreated mouse 
teeth and a negative control on mouse oral mucosa. A further negative control 
involving omission of primary antibody was also performed on mouse or bovine tooth 
sections. 





2.2 Part Two: Tertiary dentinogenesis and p38 
MAPKinase pathway 
2.2.1 Aim of the project 
Understanding cell behaviour in dentine formation is critical to our future 
development of new regenerative therapies for teeth. During tooth repair and 
tertiary dentinogenesis, the healing process may recapitulate developmental events 
(Smith and Lesot 2001). In this situation, odontoblasts are “re-activated” to restore a 
greater rate of secretion of dentine (reactionary); they may also die and then pulpal 
progenitors can differentiate into odontoblast-like cells (reparative). It is therefore 
important to understand the cellular and molecular changes which occur in 
odontoblasts at different stages of their life-cycle to facilitate clinical exploitation of 
the reactivation of quiescent odontoblasts for dentine repair and exploit 
pharmacological tools to manage and control this healing process. 
The transcriptome of the odontoblast evolves as these cells mature. Among the 
several genes whose expression changed during odontoblast maturation, we found 
the p38 gene to be highly expressed in primary odontoblasts but completely silent in 
secondary odontoblasts.  
Based on these observations we hypothesized that p38 might be involved in 
regulating odontoblast activity, and initiated the present study to determine 
whether p38 is up-regulated and phophorylated when odontoblasts are stimulated 
(Figure 15). 







2.2.2.1 Isolation of Human dentine matrix proteins   
Dentine matrix proteins were isolated as previously described (Graham, Cooper et al. 
2006). Briefly, dentine matrix components were extracted from powdered dentine 
using 10% EDTA (pH 7.2) supplemented with the protease inhibitors n-
ethylmaleamide (10 mM) (Sigma, UK) and phenyl-methyl-sulphonyl fluoride (PMSF, 5 
mM) (Sigma, UK). Extractions were carried out with agitation over 14 days at 4ºC, 
and with the extraction solution changed daily. Extracts were transferred to dialysis 
tubing (Scientific Laboratory Supplies, UK) and dialyzed exhaustively for 10 days 
against repeated changes of distilled water. Dialyzed extracts were lyophilised using 
Figure 15: Hypothesis of gene regulation in odontoblasts during 
primary, secondary and tertiary dentinogenesis 





a Modulyo freeze-dryer (Edwards, UK). The lyophilised EDTA dentine matrix extracts 
were stored at -20ºC prior to use. 
2.2.2.2 Cell culture 
Mouse odontoblast-like cells (MDPC-23) (Hanks, Fang et al. 1998) were seeded and 
cultured  in 96-well plates (Appleton-Woods, UK) at a density of 25,000 cells per well 
in Dulbecco’s modified Eagle's medium (DMEM) supplemented with 10% fetal calf 
serum (FCS), 1% penicillin/streptomycin (Sigma, UK), and 200 mM glutamine (Sigma, 
UK). Cells were cultured in a humidified incubator in a 5% carbon dioxide atmosphere 
at 37ºC for 24 hours prior to stimulation. 
 
2.2.2.3 Cell stimulation 
Cells were stimulated for 15 min, 1 h, 3 h, and 24 h with TNF-α (100 ng/ml; 
Cellomics, UK), rh-TGFβ1 carrier-free (0.2 ng/ml; R&D systems, UK), EDTA-extracted 
dentine matrix proteins (DMPs) (1 μg/ml), or adrenomedullin  (10-11 M; Sigma, UK). As 
controls, cells were stimulated for 30 minutes before TGF-β1 stimulation with either: 
anti-TGF-β1 antibody (10 μg/ml; R&D systems, UK); anisomycin (40 ng/ml; Sigma, 
UK), which induces p38 phosphorylation; the p38 inhibitor SB203580 (0.6 μg/ml; 
Sigma, UK); or Streptococcus mutans (SM) (109 bacteria/ml based on chains of 10 
cocci). Alternatively, control cells were pre-stimulated with combinations of: TGFβ1 
+ TNFα, ADM + SM, TGFβ1 + SM, or DMPs + SM (all at concentrations previously 
described). 
 
2.2.2.4 P38 phosphorylation ELISA 
Phosphorylated p38 expression was measured using a cell-based, p38-MAPK ELISA kit 
(Raybiotech, Norcross, GA, USA). After stimulation, cells were fixed for 20 min in 10% 





formalin at room temperature (RT) with shaking, and then treated with a quenching 
buffer for 20 min at RT. After immersion in a blocking solution, cells were incubated 
with the primary anti-phospho-p38 antibody (Thr180/Tyr182) for 2 h at RT, and then 
with HRP-conjugated anti-mouse IgG antibody for 1h. TMP-One-Step reagent was 
then added to each well and the plates were incubated for 30 min at room 
temperature. After stopping the reaction, the absorbance of each well was read 
immediately at 450nm with a spectrophotometer (Universal Plate Reader ELx800, 
Bio-Tek Instruments Inc). All experiments were performed in triplicate. 
 
2.2.2.5 P38 phosphorylation and translocation analysis. 
To determine whether the various treatments activated p38, we examined both the 
phosphorylation and nuclear translocation of this protein using high-content analysis. 
After stimulation, cells were fixed in 1% formaldehyde in phosphate buffered saline 
(PBS) for 1 hour. The fixed plates were processed at Imagen Biotech (Manchester, 
UK) by permeabilisation and stained with anti-phospho-p38 antibody (Thermofisher, 
USA, Cat# K0100041). Plates were analyzed on an Arrayscan (Cellomics, 
Thermofisher, USA) using the compartmental analysis algorithm (Figure 16). 






Figure 16: Principles of the cell analysis performed using an Arrayscan (Cellomics, 
Thermofisher, USA) and the compartmental analysis algorithm. 





2.3 Part 3: Designing a new laboratory model for pulp 
repair: 
2.3.1 Aim of the project 
As pulp exposure results in odontoblast loss, the healing process is consequently more 
complex requiring the recruitment and subsequent differentiation of new dentine 
secreting cells. To date, the origin(s) of the recruited cells, the differentiation 
process, and the cellular and molecular reactions involved are not clearly defined. 
Similarities have been reported between the wound healing response and embryonic 
developmental events. It is therefore probable that the processes involved in pulp 
repair recapitulate those of initial odontogenesis, specifically during odontoblast 
differentiation (Tziafas, Smith et al. 2000; Smith and Lesot 2001). 
Despite significant study (Smith, Tobias et al. 1990; Decup, Six et al. 2000; Goldberg, 
Six et al. 2001; Smith, Tobias et al. 2001; Six, Lasfargues et al. 2002), the molecular 
signaling of cell differentiation during reparative dentinogenesis is not yet fully 
characterised. Several studies have characterized the effects of growth factors 
and/or matrix proteins on reparative dentinogenesis using animal models. Similarities 
in phenotype of primary odontoblasts and “odontoblast-like cells” differentiating 
during the healing process have been clearly demonstrated (D'Souza, Bachman et al. 
1995; About and Mitsiadis 2001). However, the markers used have so far not allowed 
the initial stages of cell recruitment to be followed, nor the presumptive precursors 
to be precisely defined, such as pulp fibroblasts, pericytes (Shi and Gronthos 2003), 
or pluripotent cells of bone marrow (Shi, Robey et al. 2001; Sloan and Smith 2007). 
Study of 3H-thymidine incorporation during reparative dentinogenesis has not allowed 
elucidation of the origin and the nature of these replacement cells (Fitzgerald, 
Chiego et al. 1990). 





To date, several animal models of reparative dentinogenesis, including the rat, dog, 
monkey and ferret, have been used, however, to our knowledge a mouse model has 
yet to be reported. The mouse represents an interesting and well characterized 
laboratory model, specifically with regards to transgenic manipulation. These models 
are predicted to be extremely informative in studies on the molecular signalling 
involved in pulp healing. The small size of the animal, however, complicates surgical 
procedures during pulp-capping, as traditional instrumentation is not suitable for use 
on molar teeth whose diameter is ~1.4mm. Miniaturization of these procedures is 
therefore necessary to exploit the mouse as a laboratory model for pulp-capping 
research. 
 The aim of our study was to demonstrate the utility of the mouse as a model for 
the study of reparative dentinogenesis. 
2.3.2 Methods 
2.3.2.1 Animal experimentation 
All animal experiments were conducted by an authorized person in accordance with 
French regulations. Nineteen young adult mice (3 months-old) were used (Table 1). 
Following anaesthesia by intra-peritoneal injection of 2,2,2 tribromoethanol 2-methyl 
2-butanol (Avertine® - Sigma Aldrich Germany) (0,017ml/g), a cavity was drilled with 
a carbide bur (Dia 0,04mm) (Komet- France) on the palatal aspect of the first upper 
left molar, in the centre of the tooth according to the mesio-distal plane until the 
pulp was visible through the transparency of the dentine floor of the cavity. A pulp 
exposure was subsequently mechanically created using an endodontic hand file of 
0.15mm diameter with a 4% taper (C+file®, Dentsply-Maillefer France); this approach 
enabled control of pulp exposure size to around 150μm (size of the tip of the file). 
Pulp capping was performed using Mineral Trioxide Aggregate (Pro-Root MTA®, 
Dentsply-Maillefer France) mixed with sterile water following the manufacturer’s 





recommendations.  MTA was placed in contact with the pulp using the tip of a probe, 
and slightly condensed with a sterile paper point (XX-Fine, Henry Schein, France), 
Subsequently, the cavity was sealed with light cured composite resin (Point4®, Kerr) 
associated with a one-step adhesive system (Prime and Bond ®NTTM, Denstply Caulk). 
Animals were placed in individual cages until they recovered from anaesthesia, and 
to aid recovery Paracetamol (0.06mg/g/day) was delivered in their drinking water for 
72 hours. As a control, the pulp capping procedure was performed in the absence of 
MTA on first upper molars of 2 animals i.e. the composite resin was placed directly in 
contact with the pulp. 
Prior to dental tissue extraction, animals were euthanized, after deep anaesthesia, 
by intracardiac perfusion with 4% paraformaldehyde (Sigma) (PFA) in Phosphate 
Buffered Saline PBS 0.1M (pH =7.4) through the left ventricle, using a monostaltic 
pump for 5 minutes (Touzart and Matignon, Vitry, France). Treated animals were 
euthanized at increasing time points following the clinical procedure, as follows : 
- Two treated animals at 3 days post operatively 
- Two animals at 1 week post operatively 
- Two animals at 2 weeks post operatively 
- Eight treated animals and the two “controls” at 5 weeks post operatively 
- And finally two animals at 11 weeks after treatment.  
Following removal of most of the soft tissues, heads of animals were immersed in 4% 
para-formaldehyde for 6 hours at 4°C.  
2.3.2.2 Histology: 
The whole maxillae of ten experimental animals and the two control animals were 
dissected, rinsed in PBS for 20 minutes, and decalcified for 7 weeks in a 4.17% 
Ethylene diamine tetra acetic Acid (EDTA) solution with 0.2% para-formaldehyde 





(pH=6.8) with agitation at 4°C. The solution was renewed every two days for the first 
week, and then every week until the decalcification was complete as confirmed by X-
ray analysis. Samples were dehydrated through increasing concentrations of ethanol 
and embedded in paraffin or Epon resin blocks according to standard procedures. The 
samples embedded in paraffin were cut with a microtome (Leica - Germany) in 
sections of 7µm, and then stained with haematoxylin and eosin (H&E). Samples 
embedded in Epon resin were cut in sections of 0.5µm  and stained using a solution 
of mixed Methyl Blue and Blue Azur II (50%:50%). Sections were mounted in Depex 
(Sigma, France) and observed by light microscopy. 
2.3.2.3 Immunohistochemistry 
Immunohistochemistry was performed on sections mounted on SuperFrost®Plus 
(Manzel Glase, Germany) slides. Deparaffinized and rehydrated sections were 
incubated for 30 min in 3% H2O2/PBS to quench endogenous peroxidase activity, and 
then rinsed for 10 min in PBS. Non-specific protein binding was blocked by incubation 
for 30 min in 5% goat serum in PBS. Specimens were incubated overnight at 4°C in a 
humidified chamber with the polyclonal rabbit anti-mouse DSPP (Dentin 
SialoPhosphoProtein) antibody, (kindly provided by Dr Larry Fisher, National Institute 
of Health, Ref LF 153).  Sections were washed three times in PBS at room 
temperature prior to treatment for 30 minutes at room temperature with the 
secondary biotin-labelled goat anti rabbit antibody (Streptavigen Multilink Kit, 
Biogenex, UK).  Subsequently, sections were incubated for 30 min at room 
temperature with peroxidase linked to avidin (Vectastain ABC kit, Vector 
Laboratories, Burlingame, CA, USA). After rinsing with three changes of PBS, the 
immunoreactivity was visualized by development for 2 to 5 min with 0.1% 3,3-
diaminobenzidine and 0.02% hydrogen peroxide (DAB substrate kit, Vector 
Laboratories). Sections were counterstained with Mayer’s haematoxylin, mounted in 
permanent mounting medium (XAM® - BDH Laboratory, England) and examined by 





light microscopy. A positive control was performed on untreated mouse teeth and a 
negative control on mouse oral mucosa. A further negative control involving omission 
of primary antibody was also performed on mouse teeth. 
 
2.3.2.4 Scanning Electron Microscopy: 
For scanning electron microscopy (SEM) examination, two specimens (five weeks post 
operative) were embedded in self-curing epoxy resin (Araldite; Ciba Geigy, Basel, 
Switzerland, Evanston, Ill). Specimens were prepared with a water-cooled low speed 
Isomet diamond saw (Buehler Ltd, Evanston, Ill) and polished with an automatic 
polishing device (Pedemax-2; Struers, Copenhagen, Denmark) with waterproof silicon 
carbide papers of decreasing abrasivity (600, 1200, 2400, and 4000 grit) and with soft 
tissue disks with fine diamond suspensions (3µm, 1µm, and 0.03µm) in combination 
with DL-lubricant cooling solution (Struers, Copenhagen, Denmark). On the two 
specimens, the three roots were removed and specimens ground and polished until 
the opening of the pulp chamber was reached.  
After polishing, specimens were immersed in 5% sodium hypochlorite solution for 5 
minutes, ultrasonicated in water for five minutes, etched with orthophosphoric acid 
(Bisico-France) for 15 seconds and washed with deionised water for 30 seconds. 
Specimens were rinsed with a solution of 0.2 M sodium cacodylate buffer at pH 7.4 
for 1 hour with 3 changes, and then dehydrated through increasing concentrations of 
ethanol (25% for 1hour, 50% for 1 hour, 75% for 1 hour, 95% 2x1hour, and 100% over 
night). Finally, the specimens were sputter-coated with gold palladium using a 
sputter coater (SC500; Biorad, Microscience Division, Elexience, France) at 20 mA. 
Specimens were observed under a field emission SEM (JSM-6400 F Scanning 
Microscope; JEOL, Ltd., Tokyo, Japan) at an accelerating voltage of 15 to 20 kV and a 
working distance from 6 to 10 mm. The SEM was equipped with an energy dispersive 
X-Ray spectrometer system (Tracor 5500). Signals in the energy region for phosphorus 





(P), and calcium (Ca) were recorded and compared between the primary dentine and 
the reparative dentine of the dentine bridge. The two samples were analysed, and 
reparative dentine composition was compared to orthodentine (in another area, but 
on the same sample). The energy scale of the X-Ray detector was calibrated using a 
cobalt standard. 
 
2.4 Part four: Msx2 and odontoblasts 
2.4.1 Aim of the project 
Studies of the dental and alveolar bone tissues from early postnatal stages up until 6 
month age in Msx2-/- animals  have shown that Msx2 has effects on many types of cells 
and stages and is not limited to the periodontal ligament (Aioub, Lezot et al. 2007). 
Because failure of eruption has been described in patients with an Msx2 mutation 
(Garcia-Minaur, Mavrogiannis et al. 2003) this gene may well be involved in the 
process of root formation, eruption and, indirectly, in odontoblast differentiation. 
The role of Msx2 in tooth development is important and Msx homeogenes studied 
seem to have different impacts during postnatal development and adulthood, 
whereas their expression patterns overlapped during early patterning (Berdal, Molla 
et al. 2009). 
Several cells, such as dental epithelial (Satokata, Ma et al. 2000; Zhou, Lei et al. 
2000; Bei, Stowell et al. 2004)and mesenchymal cells (Bidder, Latifi et al. 1998; 
Yamashiro, Tummers et al. 2003), appear to be potential targets for Msx2 and 
odontoblasts could also be a target of the Msx2 homeoprotein. A detailed analysis 
(morphological and histological) of Msx2 null mutant animals has highlighted defects 
in amelogenesis, dentinogenesis and bone including osteoporosis development (Aioub, 
Lezot et al. 2007).  





Implications of Msx2 in odontoblast differentiation at later stages of development 
and particularly during secondary dentinogenesis were explored to decipher its 
possible impact on odontoblast differentiation during root formation and/or 
dentine secretion and mineralisation. 
2.4.2 Methods 
2.4.2.1 Animal generation and sampling 
Msx2 gene knock-in (KI) mutants were generated by the insertion of the bacterial 
lacZ gene within the Msx2 gene coding sequences (Lallemand, Nicola et al. 2005). 
Heterozygous males and females were mated (on a CD1 Swiss genetic background). 
Their litters were used to compare wild-type, transgenic heterozygous and 
homozygous mice. The expression pattern of Msx2 in the dental pulp of the first 
upper molar was investigated in Msx2 homozygous and heterozygous KI mice at 7, 14, 
21, 28 post natal days, and at 4 months, and compared to Wild type teeth. Each 
experimental group comprised 5 mice, giving a total number of 115 animals.  
For genotyping, primers were selected for PCR analysis of genomic DNA extracted 
from the tails in order to determine the genotype. Amplification conditions were 95 
°C (10 s), 65 °C (30 s) and 72 °C (1 min) for 30 cycles. Amplification products were 
identified on 2% agarose gels. All experiments were performed in accordance with 
the French National Consultative Bioethics Committee for Health and Life Science, 
following the ethical guidelines for animal care. All experiments were performed by 
staff that had been trained and accredited to perform in vivo studies. 
2.4.2.2  Histology analysis 
Following anaesthesia by intra-peritoneal injection of 2,2,2 tribromoethanol 2-methyl 
2-butanol ( Avertine® - Sigma Aldrich Germany) (0,017ml/g), intra-cardiac perfusions 
were performed on animals with a fixative solution containing 4% paraformaldehyde 





(Sigma, la Verpillière, France) in phosphate-buffered saline (PBS) pH 7.4. Post-
fixation was ensured by immersion of dissected half-mandibles in the fixative 
solution overnight at 4°C. After rinsing in PBS, the half-maxillae were processed for 
histology by decalcification at 4°C for up to 60 days (depending on the anatomical 
size of the samples) in a pH 7.4 PBS solution containing 4.13% EDTA (Sigma, UK) and 
0.2% paraformaldehyde. After extensive washing in PBS, the samples were 
dehydrated in increasing concentrations of ethanol and toluene and were finally 
embedded in paraffin (Paraplast plus, Sigma, France). Serial longitudinal sections of 
the half-maxillae were cut with a microtome (RM 2145; Leica, Rueil-Malmaison, 
France). The 7-μm-thick sections were deparaffinised, rehydrated and stained by the 
Van Gieson protocol. Sections were mounted in Depex (Sigma – France) and observed 
by light microscopy. (Leica, France). 
2.4.2.3 Immunohistochemistry (anti-DSPP and anti-β-Gal): 
Immunohistochemistry was performed on 5 μm sections mounted on SuperFrost®Plus 
(Manzel Glase, Germany) slides. Deparaffinised and rehydrated sections were 
incubated for 30 min in 3% H2O2/PBS to quench endogenous peroxidase activity, and 
then rinsed for 10 min in Phosphate Buffered Saline (PBS). Non-specific protein 
binding was blocked by incubation for 30 min in 5% goat serum in PBS. Specimens 
were incubated for 1 hour at room-temperature in a humidified chamber with a 
polyclonal rabbit anti-mouse DSP (Dentin Sialoprotein) antibody, (kindly provided by 
Dr Larry Fisher, National Institute of Health, Ref LF 153), or polyclonal rabbit anti-
mouse BetaGalactosidase Antibody (ABCam, US) dilution 1/5000. Sections were 
washed three times in PBS at room-temperature prior to treatment for 30 minutes at 
room temperature with the secondary biotin-labelled goat anti rabbit IgG antibody 
(Streptavigen Multilink Kit - Biogenex UK).  Subsequently, sections were incubated 
for 30 min at room temperature with peroxidase linked to avidin (Vectastain ABC kit, 
Vector Laboratories, Burlingame, CA, USA). After rinsing with three changes of PBS, 





the immunoreactivity was visualized by development for 2 to 5 min with 0.1% 3,3-
diaminobenzidine and 0.02% hydrogen peroxide (DAB substrate kit, Vector 
Laboratories). Sections were counterstained with Mayer’s haematoxylin, mounted 
with permanent mounting medium (XAM® - BDH Laboratory – England) and examined 
by light microscopy. A positive control was performed on untreated mouse teeth and 
a negative control on mouse oral mucosa. A further negative control involving 
omission of primary antibody was also performed on mouse tooth sections. 
2.4.2.4  Analysis of cell division by BrdU incorporation 
Two post natal 14 days old Msx2 -/- mice were intraperitonealy injected with a 
60x10-3 mg/g BrdU (Sigma France) solution 24 hours before euthanasia. Maxillae were 
then fixed and processed as previously described (see part 2.3.2.2) and 
immunohistochemistry was performed on 7µm sections mounted on Superfrost+ slides 
with anti BrdU antibody (Sigma, France) diluted at 1/1000. 
Deparaffinised and rehydrated sections were incubated for 30 min in 3% H2O2/PBS to 
quench endogenous peroxidase activity, and then rinsed for 10 min in Phosphate 
Buffered Saline (PBS). Non-specific protein binding was blocked by incubation for 30 
min in 5% goat serum in diluent solution (PBS + 1% Bovine Serum Albumin + 0.05% 
Tween). Specimens were then treated with 0.1% Trypsin solution for 10 minutes, 
followed by immersion in 2N HCl solution for 30 minutes. After abundant washing, 
slides were incubated for 1hour at room-temperature in a humidified chamber with a 
mouse monoclonal anti-BrdU antibody (dilution 1/1000) (Sigma, France Ref8434). 
Sections were washed three times in PBS at room-temperature prior to treatment for 
30 minutes at room temperature with the biotinylated secondary antibody. 
Subsequently, sections were incubated for 30 min at room temperature with 1/20 
solution of extravidin peroxidase solution (Mouse Extravidin Peroxidase Staining Kit, 
SIGMA, France). After rinsing with three changes of PBS, the immunoreactivity was 





visualized by development for 2 to 5 min with 0.1% 3,3-diaminobenzidine and 0.02% 
hydrogen peroxide (DAB substrate kit, Vector Laboratories). A negative control was 
performed on sections of untreated (no BrdU injection) mouse teeth.  
2.4.2.5 In Situ Hybridization 
Collagen I sense and antisense RNA probes were prepared from full-length cDNA, 
subcloned into Bluescript plasmid and linearised with Xhol or Pstl endonucleases 
(Activity 0.405µg/µl). 
In summary, non-radioactive in situ hybridisation was performed on 7µm sections. 
Sections were deparaffinised, dehydrated and hybridised with 50µl of probe (3ng/µl) 
in a humidified chamber overnight. The reaction was revealed by reaction with anti-
digoxigenin alkaline phosphatase-conjugated Fab fragment. The sections were 
stained with haematoxylin and dehydrated before mounting under a coverslip and 
subsequent light microscopic examination.   
Protocol. 
Day1 : 
1-  Section preparation : 
• Xylene 2 x 5min 
• Ethanol 100% 5min 
• Ethanol 95% 5min 
• Ethanol 80% 5min 
• Ethanol 70% 5min 
• Rinse 3 times with DEPC water for 5min 
• Rinse in PBS 2 x 5min 
2- Immersion in para-formaldehyde solution (PFA)(4% in PBS) -10min 
3- Pretreatment with proteinase K for 5 min in RNase free TE buffer at 37ºC 
4- Rinse with DEPC water 3 times 
5- Immersion in PFA 4% in PBS solution for 10min 
6- Rinse with DEPC water 
7- PBS 1X 5min 
8- Pre-hybridisation with hybridisation buffer  
9- Denaturation of the probes at 80ºC for 10min 
10- Hybridisation of cuts with 50µl of diluted probe 
11- Hybridization overnight at 60 ºC  
 
Day 2 : 
12- First rinse with SSC4X + 50% formamide and 0.1% Tween for 15min at 60 ºC 
13- Rinse with SSC2X + 10mMDTT solution at 60 ºC for 15min (2 times) 





14- Rinse with SSC 1X + 10mMDTT solution at 60 ºC for 15min (2 times) 
15- Rinse with SSC 0.1X + 10mMDTT solution at 60 ºC for 15min (2 times) 
16-  Rinse in MABT at Room Temperature 30min (2 times) 
17- Rinse with NTE (10%NaCl 5M, 1% tris HCl 1M, 1% 0.5MEDTA) in DEPC water + 
2.5% RNase 
18- Incubation for 4hours with blocking solution (MABT 1x (20ml), blocking 
reagent (2g), inactivated goat serum (20ml), Tween 20 (100µl), made up 
with distilled water to 100ml) 
19- Incubation with anti-Digoxigenin antibody (1/200 in blocking solution) over 
night at room temperature in a humidified chamber 
 
Day 3: 
20- Rinse 2 times in MABT for 5min 
21- Rinse 10min in fresh NTMT at room temperature 
22- Revelation of Antibody activity in moist dark room with NBT/BCIP (30min) 
23- Rinse 10min at room temperature in NTMT 
24- Rinse with double-distilled water. 
25- Counterstained with haematoxylin and mounted in Depex(R) after 







DEPC: deionized, diethylpyrocarbonate treated water 
PBS: Phosphate buffered Saline 
TE Buffer: Tris-EDTA buffer 
PFA : 4% Paraformaldehyde in PBS 
SSC 20X: 0.3M trisodium citrate and 3.0M sodium chloride solution in high purity dH2O 
DTT: Dithiothreitol solution 
MAB5x : Maleic acid (23.22g) + NaCl (17.53g) + Water (up to 400ml) 
MABT : MAB solution + tween (0.1%) 
NTE: 100mM Tris; 2.0M NaCl; 10mM EDTA; pH 7.4 
NBT/BCIP: Solution of NBT Nitro blue tetrazolium chloride (18.75 mg/ml)+ BCIP (5-
Bromo-4-chloro-3-indolyl phosphate,toluidine salt) in 67% DMSO 
 





2.4.2.6  MSX2 over-expression in immortalised cells 
Molecular effects of over-expression of Msx2 were studied in MDPC23 (immortalised 
odontoblast-like cells) and OD21 (immortalised pulp-like cells) (Hanks, Fang et al. 




MDPC-23 cells were seeded and cultured  in 6-well plates (Appleton-Woods, UK) at a 
density of 25,000 cells per well in Dulbecco’s modified Eagle's medium (DMEM) 
supplemented with 10% fetal calf serum (FCS), 1% penicillin/streptomycin (Sigma, 
UK), and 200 mM glutamine (Sigma, UK). Cells were cultured in a humidified 
Figure 17 : Plasmid CMV-Msx2. Base plasmid pcB6. Cloning site: 5’-EcoRI  3’-HyndIII; 
Amino Acids Contained: 3-268. Plasmid designed for protein expression in eukaryotic 
cells. Cloning strategy: isolate/EcoRI/HindIII fragment from plasmid #129 and cloned
directly. Bacterial Strain: DH5α. Selectable marker AMP. 





incubator in a 5% carbon dioxide atmosphere at 37ºC for 24 hours prior to 
transfection. 
Plasmid pvB6 (concentration 1.01µg/µl) (see Figure 17 for plasmid construction and 
identification) was introduced into cells by lipofectamin transfection (EFFECTEN KIT- 
Qiagen – France). After medium removal, cells were incubated with 0.4µg of plasmid 
DNA, 3.2µl of Enhancer, Buffer (top up to 100µl), 10µl of Effectene Reagent, and 
1.6ml of culture medium for 6 or 48 hours. Cells were finally washed with DMEM 
medium, and lysed for further molecular biological analysis. 
2.4.2.7 Real Time quantitative PCR analysis 
Total RNA was extracted using the SV Total RNA Isolation kit (Promega, UK) and was 
eluted in a final volume of 30 μl of sterile water as recommended by the 
manufacturer. After total RNA quantification, equal amounts of RNA (1 µg) were 
transcribed into cDNA using a SuperScript II RNase H Reverse Transcriptase 
(Invitrogen) with oligo-dT and hexa-nucleotide random primers. Gene expression 
levels were determined by real-time PCR using primers (Table 2). Optimal conditions 
and cDNA dilutions were determined for each gene. q-PCR experiments were 
performed in a Roche light Cycler, in triplicate using FastStart DNA Master SYBR 
Green I (Roche, Neuilly-sur-Seine, France).  Amplification reactions were carried out 
in a total volume of 15 μl at 0.9µl of 300 nM (each- Forward and Reverse) primers), 5 
μl of cDNA, and 7.5µl of FastStart Universal SYBR Green Master buffer (Roche, 
Neuilly-sur-Seine, France) and 0.7µl of water. The PCR cycling programme consisted 
of one cycle at 95 degrees C, 20 s and 45 cycles at 95 degrees C, 3 s and 30 s at 60 
degrees C. A final cooling step of 3 min at 40°C was included for handling of the 
samples, because the LightCycler had no cooling block like many commercially 
available thermocyclers. Data collection was performed during the annealing phase 
of each amplification cycle, and the fluorescent signal was monitored through the F2 





channel. Data were analysed with LightCycler software by the Fit Point method to 
minimise noise and obtain the best correlation coefficient possible between 
standards. Positives were defined as samples having a Ct of less than 40 cycles and 
significant fluorescent gain when compared to the standard of GAPDH concentration. 
 
 



















Table 2: Primer details and conditions for q-RT-PCR analysis. Primer sequences used in
PCR analysis, and expected product size for each assay. Primers were designed using the






3.1 Microarray : 
3.1.1 Selective extraction of odontoblasts RNA. 
Histological examination of fixed teeth confirmed that only odontoblasts were retained 
following pulp tissue removal and that RNA extracted from these lysed cells was 
therefore preferentially derived from odontoblasts (Figure 18). 
3.1.2 Semi-quantitative RT-PCR analysis 
RT-PCR analysis was performed in triplicate on individual samples (i.e., technical 
replicates) and in duplicate for different samples (i.e., biological replicates). In initial 
RT-PCR analyses, gene expression analysis clearly indicated differential regulation of 
transcripts in cells at the two stages of dentinogenesis studied. DSPP and collagen Iα 
gene expression were down-regulated in the late stage odontoblast population 
compared to that of the early stage. The proteins encoded by these transcripts are key 
components of the dentine matrix and the down-regulation of the expression of these 
genes concurs with the less active deposition rate of the late stage cells. The expression 
of a further 6 genes (BMP4, DMP1, TGF-β1, TGF-β1R, PGAP1, (Post-
glycosylphosphatidylinositol attachment to proteins 1, Osteocalcin) was also analysed in 
extracted odontoblast and pulpal RNA samples. The differential gene expression data 
supported the purity of the isolated cell and tissue populations (McLachlan, Smith et al. 
2003). Confirmatory RT-PCR analysis of transcript levels for selected genes identified as 
being differentially expressed by microarray analysis between the late stage (LS) and 
early stage (ES) populations also supported the validity of our isolation technique 
(Figure 19). On a second stage, based on the results of microarray and analysis of the 





Amelogenin, IBSP, DCN, Alkaline phosphatase, CaSR, SOCSBOX, SPP1 (similar to OPN), 
PROTS100-A1, OSTF-1, p38-MAPK, NTRK2, MAP2K6, PTPRR (Figure 20). 
 
 
Figure 18 : Histological assessment of selective extraction of odontoblasts after lysis. 5μm 
thickness, haematoxylin and eosin staining. (A) Tooth after pulp parenchyma removal – only the 
odontoblast layer remains in place (black Arrow). (B) Tooth after pulp parenchyma removal and
in situ odontoblast lysis. These images support the selective lysis of odontoblasts for RNA 
extraction.  (D: Dentine, PD: Predentine, Od: Odontoblast Layer). 
Figure 19: Changes in DMP-1, Collagen I, DSPP, TGF β1, BMP4, TGFβ-1, PGAP-1 and Osteocalcin 
gene expression in ES (early stage odontoblasts), LS (Late stage odontoblasts), ES pulp (early
stage dental pulp) and LS pulp (late stage dental pulp). DMP-1 and Osteocalcin gene expression 
were up-regulated in the mature odontoblasts, whereas Collagen I, DSPP, TGF-β1 and TGF -β1-R 
gene expression were down-regulated. BMP4 and PGAP 1 gene expression were unchanged. In 








3.1.3 Microarray analysis. 
Microarray analysis supported the initial RT-PCR results obtained for Collagen I α 1 chain 
and DMP1 gene expression. Of the 24000 genes analyzed using microarrays, 1338 genes 
were differentially expressed in the two populations by >2 fold (574 genes with p<0.05) 
and among those, 216 genes by >5 fold, (paired analysis, p<0.05) (See Appendix 1 for 
the full list of regulated genes). The relatively large number of differentially expressed 
genes was unexpected. However, such a magnitude of differential changes concur with 
Figure 20: Post-array Sq-RT-PCR analysis showing differential expression in Early stage (ES) and
Late Stage (LS) odontoblasts. This sq-RT-PCR was performed to validate the microarray results 
and to characterize transcript levels of genes involved in the p38 MAP Kinase Pathway (PTPRR,





data previously reported for the proteomic analysis of bone cells (Cho, Lee et al. 2006). 
Transcripts were classified using a gene ontology classification (Figure 21). 
The data analysis highlighted differential expression of a significant number of genes, 
not previously associated with odontoblasts or dentinogenesis. These previously un-
associated genes also highlighted various regulatory mechanisms which may modulate ES 
and LS odontoblast activity including those of MAPKinase, apoptosis, TGF-β, and FGF 
pathways. Notably, a potentially important pathway identified from this analysis was 
that involving MAP Kinase (MAPK), with transcriptional changes identified in 6 
component genes, including PTPRR, NTRK2, MAP2K6, CD14, MAPK13 (p38)M and FGF1 
(Table 3 and Figure 22). Other pathways also appeared to be implicated as being 
differentially regulated with variable number of genes involved, such as TGF-β, GnRH 
and calcium signalling pathways.  
 
3.1.4 Post-array sq-RT- PCR analysis of differentially regulated genes 
As sq-RT- PCR screening of all differentially regulated genes was not feasible, 14 genes 
of interest were selected for further confirmatory analysis. Selection criteria were 
based on the level of differential regulation (high score with statistical significance), 
their known or alternatively previously uncharacterised role in dentinogenesis, their 
potential involvement in previously unexplored pathways (eg MAP Kinase pathway) or 






Figure 21: Ontological classification of genes up- and down-regulated between young and 






probe set GENE ID baseline mean (LS) experiment mean (ES) Change fold change lower bound o upper bound of FC Gene Title
Bt.1069.1.A1_aPTPRR 666,73 1757,93 ‐1091,2 2,64 2,36 2,98 protein tyrosine phosphatase, receptor type, R (PTP in the Pathway)
Bt.12217.1.S1_NTRK2 10,7 136,5 ‐125,8 12,76 6,2 100000000
Neurotrophic tyrosine kinase, receptor, type 2    (Tyr K A/B in 
Pathway)
Bt.561.1.S1_at MAP2K6 323,94 1233,75 ‐909,81 3,81 3,28 4,48 mitogen‐activated protein kinase kinase 6
Bt.13789.1.A1_CD14 154,8 12,37 142,43 ‐12,52 ‐8,45 ‐23,53 CD14 molecule
0
Bt.800.1.S1_at MAPK13 6,28 559,48 ‐553,2 89,06 40,69 100000000 mitogen‐activated protein kinase 13 (p38 MAPK)
Bt.5038.1.S1_aFGF1 1229,9 20,37 1209,53 ‐60,37 ‐37,88 ‐146,24 fibroblast growth factor 1 (acidic)
      
TGF Beta Pathway
probe set GENE ID baseline mean (LS) experiment mean (ES) Change fold change lower bound o upper bound of FC Gene Title
Bt.23178.1.S1_DCN 776,34 4372,5 ‐3596,16 5,63 4,96 6,51 decorin
Bt.405.1.S1_at FST 300,19 21,36 278,83 ‐14,05 ‐7,42 ‐125,3 follistatin
Bt.12760.1.S1_INHBA 28,24 932,21 ‐903,97 33,01 15,56 100000000 inhibin, beta A (Activin)
  Calcium Signaling Pathway
probe set GENE ID baseline mean (LS) experiment mean (ES) Change fold change lower bound o upper bound of FC Gene Title
Bt.1165.1.S1_aADCY7 345,04 1801,94 ‐1456,9 5,22 4,61 5,99 adenylate cyclase 7 (ADCY in pathway)
Bt.23606.1.S1_ITPR1 6647,25 2032,66 4614,59 ‐3,27 ‐2,48 ‐4,72 inositol 1,4,5‐triphosphate receptor, type 1 (IP3R in pathway)
GnRH Pathway
probe set GENE ID baseline mean (LS) experiment mean (ES) Change fold change lower bound o upper bound of FC Gene Title
Bt.1165.1.S1_aADCY7 345,04 1801,94 ‐1456,9 5,22 4,61 5,99 adenylate cyclase 7 (AC in pathway)
Bt.23606.1.S1_ITPR1 6647,25 2032,66 4614,59 ‐3,27 ‐2,48 ‐4,72 inositol 1,4,5‐triphosphate receptor, type 1 (IP3R in pathway)
Bt.561.1.S1_at MAP2K6 323,94 1233,75 ‐909,81 3,81 3,28 4,48 mitogen‐activated protein kinase kinase 6
Bt.800.1.S1_at MAPK13 6,28 559,48 ‐553,2 89,06 40,69 100000000 mitogen‐activated protein kinase 13 (p38 MAPK)  
Table 3: Data extracted from Microarray analysis data files, after transcriptome analysis Early Stage
cells (ES) versus Late Stage cells (LS). Negative fold change indicates that gene expression was 
down-regulated from ES to LS whilst a positive fold change indicates the gene expression was up-
regulated. These genes were selected from the list of 574 for which expression was up or down






Figure 22: The p38-MAPKinase pathway (Pathway-Express software
http://vortex.cs.wayne.edu). Differentially egulated genes as identified by microarray






Alkaline phosphatase and amelogenin transcripts were more abundant in early stage 
odontoblasts; these results concur with their previously described patterns of expression 
(Hotton, Mauro et al. 1999; Papagerakis, MacDougall et al. 2003). DMP1 RNA was 
detected in both cell samples, but was significantly more abundant in the late stage 
population. This observation was also in accordance with published results (Lu, Xie et 
al. 2007). ADM, IBSP (Bone Sialoprotein), SPP1 (Osteopontin), Osteocalcin and M1K3 
gene expression were also up-regulated in late stage cells as shown previously for 
osteocalcin (Papagerakis, Berdal et al. 2002), whereas in contrast TGF-β1 and SOCSBOX 
were down-regulated in these cells. Other genes investigated, including BMP4, TGF-βR1, 
PGAP 1, OSTF1, were not evidently differentially regulated. 
3.1.5 Immunohistochemical analysis 
3.1.5.1 DMP1 expression: 
DMP1 protein expression and localisation was examined by immunohistochemical 
staining using an anti-DMP1 antibody on unerupted bovine first molar histological 
sections. The differential staining of cells in the cuspal area compared to the apical 
area in this immature tooth clearly shows that odontoblasts are functioning differently 
in the coronal as compared to apical regions based on DMP1 immunoreactivity. To 
identify odontoblasts and confirm their activity in the secretory phase, Anti-DSP 
antibody staining was used as a positive control (Figure 23). 
3.1.5.2 Phosphorylated p38 MAPK analysis: 
As this pathway was highlighted as being potentially differentially regulated in LS 
compared to ES odontobalsts by both microarray and RT-PCR analyses, p38 protein 
expression and activity were investigated by performing immunohistochemical staining 
using an anti-phosphorylated p38 antibody on an erupted mouse maxillary incisor. The 






area clearly shows that phosphorylated-p38 is differentially expressed in young and old 
odontoblasts, further corroborating the gene expression findings previously identified 
(Figure 24).  
 
Figure 23: (A) Histology of a bovine unerupted first upper molar cusp, 5μm thickness 
section, haematoxylin and eosin staining, bar=500μm. (B-C) Immunohistochemistry with 
anti-DSP antibody on odontoblasts in the coronal area (B) and apical area (C). Expression 
of protein is visibly unchanged in both sections highlighting the secretory activity of the
cells. (D-E) Immunohistochemistry using the anti-DMP1 antibody in odontoblasts in the 
coronal (D) and apical areas (E). The differential expression of DMP1 protein between 









Figure 24: Mouse upper incisor (A) 5μm thickness, haematoxylin and eosin staining. (B) 
Immunohistochemical analysis using anti-mouse phosphorylated p38 antibody in apical area of the 
erupted mouse tooth. Nuclear staining of odontoblasts is evident, and phosphorylated-p38 is 
apparently also present in the cells of the pulpal parenchyma. (C) Immunohistochemistry using 
the same antibody performed on cells nearer the incisal tip, with mature odontoblasts. Staining is
enhanced in the apical area, indicating the higher concentration and activity of p38 protein in the
young cells compared to that of the mature ones. Cytoplasm of mature cells is free of staining, 
and nuclear staining is strong indicating that p38 is potentially acting as a transcription factor.  P=








3.2 Tertiary dentinogenesis and p38 MAPKinase pathway 
3.2.1   P38 Phosphorylation ELISA 
Anisomycin is known to stimulate the MAPKinase pathway by activating p38 (Geiger, 
Wright et al. 2005). In the present study, phosphorylated protein was expressed at a 
basal level in untreated MDPC-23 odontoblast-like cells and was further activated in 
cells following anisomycin stimulation, with a peak level reached at 15 min. Expression 
levels then progressively decreased, returning to basal levels by 24 hours. Exposure of 
cells to the p38 inhibitor SB203580 caused no detectable reduction in p38 protein 
expression (Figure 25). 
Similar expression profiles were observed after cells were stimulated with TGF-β1, ADM, 
or TNF-α. Incubation of cells with anti-TGF-β1-receptor alone reduced protein 
expression levels compared to the control. Pre-incubation of cells with antibody before 
incubation with rh-TGF-β1 led to no increase in protein activation, confirming previous 
findings that activation of the p38-MAPK pathway depends on TGF-β1 receptor binding. 
Significantly, use of extracted Dentine Matrix Proteins (DMPs) for stimulation also 
induced p38 phosphorylation, albeit with a different temporal profile. At 15 minutes, 
p38 protein was expressed at levels only two-fold above control, whereas expression 
was increased almost 5-fold with ADM or TNF-α, and nearly 6.5-fold with TGF-β1 
exposure. However, peak expression levels, which approached those achieved with 
other molecules, were reached only after 1 hour. At 3 hours, the protein expression 
level after DMP stimulation was higher than with other treatments, and at 24 hours 
phospho-p38 remained 25% over-expressed compared to that of the control, at which 









Figure 25: Phosphorylated p38 protein expression at a basal level in untreated MDPC-23 
cells and after cell treatment with anisomycin, SB203580 (p38 phosphorylation 
inhibitor), TGF-β1, TGF-β1+antiTGF-β1 antibody, ADM, TNF-α, Dentine Matrix Proteins 
for 15, 60, 180mins and 24hours. Bars are +/- S.E.M. y units:relative phosphorylated p38 






3.2.2 Segmental analysis of cytoplasmic and nuclear expression of 
phosphorylated-p38 
All molecules previously used induced an activation and translocation of the protein, 
albeit at different levels. With TNF-α, phospho-p38 protein appeared nearly completely 
translocated, however, following stimulation with Streptococcus Mutans, only half the 
activated protein was present in the nucleus. Notably, TGF-β1 was most effective for 
both p38 activation and protein translocation. Dentine Matrix Proteins and ADM 
exhibited similar effects, inducing activation of the protein resulting in 75% of the 
protein being translocated after one hour exposure. 
When the stimulatory molecules were applied in combination, to potentially better 
mimic the in vivo situation, protein activation was increased. TNF-α together with TGF-
β1 increased phospho-p38 expression by 55% compared to TNF-α exposure alone, and by 
15% compared to TGF-β1 exposure alone. Growth factors applied in combination with 
Streptococcus Mutans also led to a synergistic effect compared to Streptococcus 
Mutansor growth factors stimulation alone (Figure 26).  
 
Figure 26: Phoshorylated p38 protein expression in cytoplasmic and nuclear localisations of MDPC-23 
cells, after stimulation with TNF-α, Streptococcus mutans (SM), ADM, DMPs, TGF-β1, TNFα+TGF-
β1, ADM+SM, DMP+SM, TGF-β1+SM for 60 minutes. (DMP = dentine matrix protein preparation, SM 
= Streptococcus mutans). Y Axis units : Relative Phosphorylated p38 protein expression  / Non 







3.3 MSX2 proteins and dentinogenesis. 
3.3.1 Histology observations: 
No differences were observed for the first upper molar morphology of wild type and 
heterozygous transgenic mice. In contrast, tooth morphology was strongly disrupted in 
null mutant animals with crown morphology and root formation demonstrating clear 
alterations. Changes were also observed in the dentine thickness (Figure 27). 
3.3.1.1 At 7 days post-natally  
Dentine thickness was slightly increased in null mutant animals, and on the side of the 
cusp, a convex dome was observed instead of the concave shape seen in Wild Type (WT) 
teeth. 
In Msx2 -/- mouse teeth, a slight mineralization defect was noticeable on the top of the 
first molar cusp. The mantle dentine thickness was also noticed to be greater than in 
wild type animals. 
On Msx2 null mutant animals, the course of the coronal dentine tubules was more 
sinusoidal than those of Wild type (WT) animals; many lateral branches were clearly 
visible and in higher number than in WT, although it was difficult to see any true 
communication between them. The density of the lateral branching was greatest in 
between cuspal areas rather than on the cusps themselves (Figure 28). 
Root formation had already started in WT animals whereas it had not begun in -/- 
animals. 
The alterations in dentine morphology and tubular orientations confirm the disturbances 
in dentinogenesis in the absence of the MSX2 protein. In the odontoblast palisade layer, 
nuclear polarization was inverted in many cells. Such inversion of polarity was rarely 









Figure 27: Histology of the first upper molar in WT, +/- and -/- mice, at 7, 14 and 21 post-
natal days. 7μm thickness sections with haematoxylin and eosin staining. Bar=500µm 
Figure 28: First upper molar in Msx2 -/- 7 days post natal. 7μm thickness, haematoxylin and 







3.3.1.2  At 14 days post natal : 
Between 7 and 14 days post-natally, an obvious line of defective matrix secretion was 
readily seen in the dentine. Within this area of defective matrix secretion, some 
cellular inclusions were also observed. Subsequent matrix secretion on the pulpal aspect 
of the dentine appeared relatively normal at the histological level, although the 
dentinal tubule course appeared more disturbed after the defect area than before 
(Figure 30). 
This perturbation to matrix secretion was not specific to the first upper molar and was 
also seen in the second and third molars (Figure 31). This observation allowed us to 
hypothesize that the stimulus for this disturbance to dentinogenesis is probably time 
dependant, because the disturbance occurred at the same time of post natal 
development in the three molars.  
In Msx2 -/- animals, the odontoblast palisade layer appeared slightly disorganized 
compared to WT animals. Whereas root formation had begun in WT and +/- animals, this 
process was strongly disrupted in null mutant animals. On the mesial root, a 90° change 
in orientation occurred as soon as root formation started. At 14 days, this directional 
Figure 29: First upper molar in +/+ (A and D), +/- (B and E), -/- (C and F). 7 days post 
natal days. 7μm thickness, haematoxylin and eosin staining. (D, E and F) higher 
magnification of odontoblast layer. Note inverted polarisation of odontoblasts in -/-






change in root formation was noticeable, showing a ‘kinking’ of the root. Root length 
was shorter in -/- animals compared to WT or +/- ones. There was no predentine 
observed in the cuspal areas of the teeth in -/- animals. Inclusions were also detected 
in the thickness of dentine matrix. No nuclei were visible inside these inclusions, but 
the size and morphology of these inclusions led us to speculate that cells may have been 





Figure 30: Comparison of dentine structure on +/+ (A) and Msx2 -/- (B) first upper molar 
14 days post natal mice. 7μm thickness with haematoxylin and eosin staining. Bar = 
100µm 
Figure 31: Dentine structure in the coronal area of the second upper molar of 14 days post-
natal Msx2 -/- mice. A line is clearly visible in the thickness of the coronal dentine, which
may represent a landmark of an episode of dysregulation of odontoblast secretory activity.






3.3.1.3 At 21days post natal : 
The line of disturbed dentine matrix structure described above was still clearly visible 
at 21 days post-natally. Inclusions in the dentine were also noticeable and the 
odontoblast layer was highly disorganized. In Msx2 -/- animals, secondary 
dentinogenesis seemed to result in secretion of a combination of orthodentine, and 
reparative dentine with cellular inclusion (osteodentine). No predentine was present in 
the coronal area of the tooth.  
 
 
3.3.1.4     4 month old animals: 
The mesial cusp had been completely lost at 4 months, possibly due to abrasion of the 
enamel-free tooth. The line of disturbance of matrix secretion was still visible in the 
dentine and seemed to separate the two types of secreted (primary and secondary) 
dentine (Figure 33). In the apical area of the tooth, no true root formation was seen and 
Figure 32: Dentine structure of a first upper molar from a 21 days post natal Msx2 -/-
mouse showing different areas of the crown of the tooth. Abnormalities of dentine
structure were obvious, with the presence of vacuoles in the mineralized tissue
thickness, which may be a landmark of cellular inclusions. 7μm thickness,






only a mass of mineralized tissue with cellular inclusions (usually called osteodentine) 
had been secreted. A new predentine layer was noticed in few sections, leading us to 




3.3.2 Beta galactosidase immunohistochemistry: 
The n-lacZ gene encoding prokaryotic β-galactosidase (β-Gal) enzyme was used as a 
reporter gene for Msx2 screening. Hertwig Root Sheath cells were strongly stained, 
delimiting a pale zone, free of β-Gal staining in the apical papilla area (Figure 35). 
Expression of Msx2 protein in HERS cells confirmed Yamashiro’s previous data on RNA 
Figure 33: Dentine structure of first upper molar in a 4 month old Msx2 -
/- mouse.  (A) The line of disturbed matrix secretion in the dentine is 
still clearly visible (black arrow) (B and C) : dentine structure at higher
magnification. 7μm thickness, haematoxylin and eosin staining. A: Bar= 






expression, obtained using in situ hybridization in rat teeth.(Yamashiro, Tummers et al. 
2003) as β-Gal was highly expressed in central pulp parenchyma. A few odontoblasts 
also expressed the reporter protein, however, there were regional variations apparent 
(Figure 34). Higher expression was noticed in root odontoblasts compared to coronal 
cells. Interestingly, odontoblasts showing no polarization (nucleus in distal position) 
were systematically stained. Protein expression seemed to decrease with cell maturity 
(Figure 34: Immunohistochemical analysis using anti-mouse beta-galactosidase antibody 
on first upper molars of 7 days post natal Msx2 +/-mice. Nuclear staining of a few 
odontoblasts and pulp cells is evident. Counterstained with haematoxylin. A: 
Bar=150µm, B,C,D: Bar= 60µm.). Epthelial cell rests of Malassez cells also showed strong 
immunoreactivity for MSX2 (Figure 36 &Figure 37). 
 
Figure 34: Immunohistochemical analysis using anti-mouse beta-galactosidase
antibody on first upper molars of 7 days post natal Msx2 +/-mice. Nuclear
staining of a few odontoblasts and pulp cells is evident. Counterstained with








Figure 35: Immunohistochemical analysis using anti-mouse beta-galactosidase 
antibody on first upper molar of a 14 days post natal  Msx2 -/- mouse. Nuclear 
staining of a few odontoblasts  and pulp cells is evident and also in Hertwig’s 
Epithelial Root Sheath cells (B). Counterstained with haematoxylin. A: Bar=150µm,
B,C,D: Bar= 60µm. 
Figure 36: Immunohistochemical analysis using anti-mouse beta-galactosidase 
antibody on first upper molars of 21 days post natal Msx2 +/- mice. 








3.3.3 Dentine Sialoprotein (DSP) Immunohistochemistry 
DSP was normally expressed in odontoblasts of -/- mice. Whereas nuclei were not 
clearly visible inside the dentine inclusions observed in these animals, DSP 
immunoreactivity was strong in these vacuoles/disturbances of matrix secretion 
(Figure 38 , Figure 39). The immunoreactive areas co-localising with the inclusions 
described above were also evident in other areas, which appeared to be randomly 
localized in various regions of the dentine thickness. This was an important 
observation, indicating that even if these inclusions represented sites of cells which 
were no longer vital, they may have been entrapped during the dentinogenic 
process prior to death potentially by lack of nutritive supply (in contrast to 
Figure 37: Immunohistochemical analysis using anti-mouse beta-
galactosidase antibody on first upper molar of 21 days post natal Msx2 -/-







osteocytes). Interestingly, there appeared to be a true gradient of immunoreactivity 
observed between the dentine secreted “before the line of disturbed matrix 
secretion” and the dentine secreted “after” this point. 




Figure 38: Immunohistochemical analysis using anti-mouse DSP antibody on a first upper molar 
of 21 days post natal Msx2 -/- mouse. Counterstained with haematoxylin. A: Bar=150µm, B,C,D: 
Bar= 60µm, E: Bar=20µm. 
Figure 39: Coronal area of a first upper molar of a 21 days post natal Msx2 -/- mouse,. A: 7μm 
thickness, haematoxylin and eosin staining.  B: Immunohistochemical analysis using anti-
mouse DSP antibody. Counterstained with haematoxylin.  Bar 70µm.  DSP immunoreactivity is






3.3.4 BrdU IHC 
BrdU was injected 12 hours before euthanasia of the animals and subsequently IHC 
was performed on 7µm sections to identify the cells undergoing cell division. An 
appreciable number of proliferating cells were visible in the interradicular bone 
area, however, no odontoblast cell division was noticed (Figure 40). 
 
 
Figure 40: Immunohistochemical analysis using anti-mouse BrdU antibody on 14 days post 
natal Msx2 -/- animals, 12 hours after BrdU injection., no odontoblast cell division was 
noticeable. However, several cells mitoses were clearly highlighted in the bone area. A: 






3.3.5 In Situ Hybridization for Collagen I α1. 
In situ hybridization was performed to evaluate cell activity and vitality. All of the 
odontoblasts (even those not polarised) in the teeth of -/- animals were stained for 
Collagen I α1 RNA confirming their secretory activity (Figure 41).  
 
 
Figure 41: In Situ Hybridization of collagen Iα1 chain on first upper molar of a 14 days post 
natal Msx2 -/- mouse. Secretory activity of odontoblasts (even inverted polarity cells) was







3.3.6 Quantitative RT-PCR (Q-RT-PCR) 
Q-RT-PCR was initially undertaken on RNA of pulp mesenchyme extracted from +/+, 
+/- and -/- mice. Secondly, Q-RT-PCR were performed on MDPC-23 (immortalised 
mouse odontoblast-like cells) and OD21 (immortalised mouse pulp-like cells) before 
and after over-expression of MSX2 induced by lipofectamine transfection of CMV-
Msx2 plasmid. 
Data confirmed the absence of expression of MSX2 in the null mutant mesenchyme 
cells, and higher MSX2 expression after transfection in both cell types (Figure 42). 
DSPP was up regulated in +/- mesenchyme. A minimal down regulation was evident 
when comparing +/- and -/-. These results confirmed recent data (Molla et al. 
submitted; personal communication). No significant regulation of DSP RNA levels 
was noticed after Msx2 over-expression in MDPC-23 cells and OD21 (Figure 43). 
Osteocalcin was up-regulated in +/- and in -/- pulp mesenchyme compared to wild 
type. These results were in agreement with previous data (Molla et al. 
submitted). Interestingly, Osteocalcin seemed to be also over-expressed in cells 
after Msx2 over-expression. No significant change in regulation of  gene 
expression was noticed after Msx2 over-expression in immortalized pup cells 
(Figure 44).  
  
 
Figure 42: Quantitative RT-PCR analysis of Msx2 mRNA isolated from (A) incisor pulp 
mesenchymal cells of 3 months old Msx2 +/+, +/- and -/- mice, (B) MDPC23 cells (MDPC), MDPC 
23 after transfection with Msx2 probe (+++) or lipofectamin® vector only (MDPC vector), (C) 
OD21 (OD) and OD21 after transfection with Msx2(OD+++) probe or lipofectamin® vector only 












Figure 43: Quantitative RT-PCR analysis of DSPP mRNA isolated from (A) incisor pulp mesenchymal
cells of 3 months old  Msx2 +/+, +/- and -/- mice, (B) MDPC23 cells (MDPC), MDPC 23 after
transfection with Msx2 probe (+++) or lipofectamin® vector only (MDPC vector), (C) OD21 (OD) and
OD21 after transfection with Msx2(OD+++) probe or lipofectamin® vector only (OD vector). (**:
statistically significant) Y axis units: ratio DSPP/GAPDH (**: statistically significant (p<0,05)). 
Figure 44: Quantitative RT-PCR analysis of Osteocalcin (OC) mRNA isolated from (A) incisor pulp 
mesenchymal cells of 3 months old  Msx2 +/+, +/- and -/- mice, (B) MDPC23 cells (MDPC), MDPC 23 
after transfection with Msx2 probe (+++) or lipofectamin® vector only (MDPC vector), (C) OD21 (OD) 
and OD21 after transfection with Msx2(OD+++) probe or lipofectamin® vector only (OD vector). Y 







3.4 Design and use of a new laboratory model for pulp 
repair: 
3.4.1 Surgical procedure 
Following the surgical procedure, one animal did not recover from the anaesthesia 
and died 4 hours after treatment. The eighteen surviving mice recovered within 6 to 
10 hours, and were then housed individually, with food and water ad libitum. 
Paracetamol (0.06mg/g/day) was delivered in water for two days for analgesia. 
3.4.2 Light microscopy observations: 
All specimens were cut in a longitudinal plane with control of the positioning of 
specimens performed using the opposing first molar of the same maxilla as a 
landmark. Histological examination confirmed the successful completion of the 
procedure, the localisation of the cavity and the diameter of the pulp exposure at 
around 150µm.  
In the majority of the treated teeth (16/18), the perforation of the pulp was located 
in the mesial half of the tooth in front of the mesial root canal. The cavity was 
generally centred on the buccal-palatal aspect. In the two other specimens (5 weeks 
post operative), the floor of the pulp chamber was perforated during the surgical 
procedure and these specimens were considered failures. 
In the negative control in which no MTA was used for pulp capping, the histology of 
the pulp appeared normal, but neither a dentine bridge nor any signs of healing of 
the exposure were evident even 5 weeks after treatment. No histological signs of 










By two weeks post-operatively, a line with a high affinity for histological dyes was 
observed. This line precisely followed the contours of the capping material and this 
Junctional Extra-cellular Matrix (JEM) may represent an abrupt structural change in 
the extracellular matrix in contact with the capping material (Figure 46). This JEM 
appears as a structural reorganisation of the matrix in this area, and not a necrotic 
layer as described in many publications about pulp capping with calcium hydroxide. 
More investigations are needed to characterise this junctional area, which may 
reflect changes in cell secretory behaviour during dentine bridge formation at the 
material interface. 
Figure 45: (A) Histology of a mouse first upper molar capped with MTA, 11 weeks post
operatively. 0.5µm thickness sections were stained with Methyl Blue/Azur II blue (50%:50%). The
dentine bridge (db) was clearly visible, with inclusion of dentine chips. Dentine chips were
probably impacted into the pulp tissue during pulp exposure. (B) Mouse first upper molar treated
without MTA, 5weeks post operatively. No dentine bridge was visible. Histologically, the pulp 
tissue appears healthy with no inflammation evident. 7µm thickness cut sections stained with 







At five weeks post operatively, a dentine bridge was visible in all of the experimental 
specimens.  The dentine bridge was in close contact with the dentine walls and no 
gap was apparent between the two structures. The pulp cells were in close 
association with the new hard tissue, however, a polarised cell morphology was not 
apparent. In three specimens, dentinal tubules were visible in the matrix of the 
dentine bridge; these tubules were not linear and their course appeared interrupted 
(Figure 47 A). 
Figure 46: Histology at 2 weeks post-operatively. Haematoxylin and eosin (H&E) staining. The 
inflammation has already decreased, and few cells are present in contact with the material 
involved in tissue reorganisation. A specific line (→), with a high affinity for stain, demarcates 
the material and the pulp tissue. This line is in intimate contact with the material. At this 








In most of the specimens, several dentine chips were included within the dentine 
bridge, but did not appear to adversely affect the healing process. The embedding of 
this debris has previously been described in the literature as being part of the healing 
process. 
3.4.3 Immunohistochemical analysis 
The immunoreactivity for Dentin SialoPhosphoprotein (DSPP) associated with the 
dentine bridge was clearly evident (Figure 47). Cytoplasmic staining of the formative 
Figure 47: Mouse first upper molar, 5 weeks after pulp capping with MTA. (A) H&E staining. The
dentine bridge (db) appears very clearly between material (mat) and the pulp; there is no visible
gap between dentine bridge and dentine walls. In the thickness of the dentine bridge, a few 
tubules are evident; their course is not straight as in orthodentine (x 50). (B)
Immunohistochemistry with the DSPP antibody of untreated mouse molar pulp (positive control). 
Staining of odontoblasts is evident, and DSPP is apparently also present in the extracellular 
matrix of the pulp (x50). (C) Negative control staining with omission of primary antibody (DSPP).
(D) Immunohistochemistry with DSPP antibody of first upper molar tooth capped with MTA, 5
weeks post operatively (x50). Dentine bridge staining is very weak compared to orthodentine.
(E) At higher magnification, DSPP expression is clearly visible in the cells in close contact with






cells is also characteristic of dentine secreting odontoblast-like cells. Orthodentine 
was also stained as was the intratubular (peritubular) dentine. It was also noticeable 
that the dentine bridge was stained less intensely than the adjacent orthodentine. 
The negative controls demonstrated absence of staining. 
3.4.4 Scanning Electron Microscopy (SEM) analysis 
An inner view of the pulp chamber roof revealed the presence of the dentine bridge. 
Higher magnification observation showed an intimate contact between the dentine 
bridge and the dentinal wall of the tooth. The structure of the reparative dentine of 
the bridge had a globular morphology and appeared different from the tubular 
othodentine structure (Figure 48). 
 X-Ray spectrophotometeric analysis allowed comparison of phosphorus and calcium 
levels in different areas of the tooth (Figure 49). The calcium and phosphorus levels 
of both types of dentine (reparative and orthodentine) were analysed in the teeth 
and the Ca/P ratios of both tissues were similar confirming the calcification of the 
dentine constituting the bridge. The calcium levels were slightly lower for reparative 
dentine (62.52 % (Sample1) and 65.53 % (Sample 2)) than for orthodentine (73.64% 
(Sample 1) and 72.53% (Sample 2)), suggesting that the reparative dentine samples 








     
Figure 48: SEM observation of a mouse molar 5 weeks post operatively capped with MTA. Roots
and pulp chamber floor were removed and the the pulp chamber roof was observed under
different magnifications. (A) Magnification x60; dentine bridge appears clearly on the surface of 
the roof. (B) Observation of the dentine bridge at higher magnification (x200) (C) x4000
ultrastructure of the dentine bridge is different compared to orthodentine; it is more globular in
appareance. (D) SEM observation at magnification x2000 of the limit between dentine wall and
dentine bridge. No gap was visible. 
Figure 49: Results of X-ray spectrophotometeric analyses of orthodentine (left) and the 






4 Discussion  
4.1 Regulation of odontoblast secretion and clinical 
implications. 
Odontoblasts are actively secreting cells during primary dentinogenesis, but become 
largely quiescent during secondary dentinogenesis. Under physiological conditions, 
the reduction in size of the pulp chamber and canal size is gradual, and explains why 
teeth of elderly people show a diminution in the size of the root canal system 
compared to teeth from younger individuals. Under pathological conditions, 
odontoblasts can up-regulate their secretion again in response to an injurious 
challenge to secrete tertiary reactionary dentine at similar rates to primary dentine 
formation. This reactionary dentine is usually only secreted focally at sites of injury 
and therefore shows only limited distribution. 
It is probable that the processes involved in pulp repair (reactionary and reparative 
dentinogenesis) recapitulate those of physiological dentinogenesis, although 
regulation of odontoblast secretory behaviour may differ in tertiary dentinogenesis 
(Tziafas, Smith et al. 2000; Smith and Lesot 2001). 
Pulp exposure often occurs after trauma and as the pulp is generally free of 
inflammation, pulp capping in such situations represents a good approach for 
treatment. However, it is important to consider management of such cases in the 
context of the biological behaviour of the pulp, especially in immature teeth which 
are still developing. 
Luxation has been reported to result in pulp necrosis for 8% of immature permanent 
teeth (Andreasen and Pedersen 1985), although reduction in canal size occurs 
commonly when pulp vitality is preserved (Andreasen, Zhijie et al. 1987). Pulp canal 






more frequently in immature teeth after luxation or avulsion (Jacobsen and Kerekes 
1977). 
In one of our published case report (Simon, P.J et al. 2009) the pulp healing process 
was interesting due to the differential behaviour of two consecutive teeth (#21 and 
#11) where avulsion occurred in the former, but pulpal complications were more 
obvious in the latter and following pulp capping. The reduction in size of the root 
canal system in tooth #11 reflects dys-regulation in the control of odontoblast 
secretory activity, although it is not possible to identify the etiology or nature of this 
dysfunction. 
Traditionally, after completion of root formation secondary dentinogenesis is 
regarded as proceeding at a much slower rate than primary dentinogenesis gradually 
reducing the size of the pulp chamber and root canal system over many years. In the 
cited clinical case, the radiographic appearance suggested that two years after 
treatment dentinogenesis appeared to have slowed down in the luxated tooth while 
in tooth #11, dentinogenesis was still actively taking place implying dys-regulation of 
the normal physiological control of odontoblast secretory activity in this tooth. We 
still have limited understanding of how odontoblast behaviour changes from primary, 
through secondary to tertiary reactionary dentinogenesis, although dentinal tubule 
continuity strongly indicate that the same cells are responsible for all three of these 
stages. Morphological evidence also provides the basis of our understanding of the 
down-regulation of odontoblast secretion during secondary dentinogenesis and its up-
regulation again during reactionary tertiary dentinogenesis. 
In the present work, our data suggest that there is a change in gene expression 
profile from primary to secondary dentinogenesis, and that this change may be 
reversible as odontoblast secretion is up-regulated during reactionary dentinogenesis. 






odontoblast secretory behavior to understand what are the necessary cues for the 
down-regulation of the rate of dentine secretion during secondary dentinogenesis and 
its up-regulation during tertiary dentinogenesis. 
In the described case, pulp capping of tooth #11 with MTA might be expected to have 
led to a focal deposition of tertiary dentine around the site of application while 
radiographically there appeared to be active secretion of circumpulpal dentine 
throughout the root canal. Without extraction of the tooth and subsequent analysis, 
it is not possible to determine if this represents lack of transition from primary to 
secondary dentinogenesis in the tooth following the original trauma and pulp capping 
or whether widespread tertiary dentinogenesis has been induced by the treatment. It 
is tempting to speculate that the physiological cues for down-regulation of 
odontoblast secretion normally leading to secondary dentinogenesis were absent or 
overridden in this tooth. 
This case highlights why pulp capping is still a relatively controversial treatment in 
endodontics. Indication and prognosis are difficult to establish, and recommendations 
are often based on a rather limited scientific evidence base. Pulp capping is 
traditionally recommended on young teeth only, due to the greater reparative 
potential of younger pulp tissue, its better blood supply and cell density; 
retrospective studies, however, show clearly that age of the patient cannot be 
considered as a limiting factor (Haskell, Stanley et al. 1978; Barthel, Rosenkranz et 
al. 2000; Al-Hiyasat, Barrieshi-Nusair et al. 2006). 
Based on these observations, it appeared interesting to investigate the molecular 
changes in odontoblasts at different stage of maturity to better understand the 
behaviour of this population of cells during physiological and pathological 
dentinogenesis. Microarray and RT-PCR gene expression analysis in two populations of 






these secretory cells. To complement these gene expression studies, we highlighted 
the involvement of the MAPK pathway by regulation of p38 protein secretion and 
regulation. 
Based on these results and on the hypothesis that pulp healing could involve 
recapitulation of developmental processes, we secondly investigated regulation of 
the MAPK pathway in tertiary reactionary dentinogenesis using an in vitro model 
(stimulation of immortalised odontoblast-like cells with a preparation of isolated 
dentine matrix proteins). 
Thirdly, we were interested in reparative tertiary dentinogenesis, and we designed a 
pulp healing model using the mouse. Such a model was anticipated to provide a 
starting point for using transgenic animals in the future to investigate gene 
regulation with approaches such as use of gene reporters, conditional mutant or null 
mutant animals. 
Finally, we investigated the probable role of Msx2 transcription factor in the process 
of odontoblast differentiation or regulation of secretion. Working on null mutant and 
heterozygous animals, and based on previous observations already published in our 
laboratory, we investigated the phenotype of the first upper molar of Msx2 null 
mutant mice. The next stage of this work in the future would be to undertake pulp 
capping in null mutant or heterozygous animals to decipher the possible role of Msx2 
in odontoblast differentiation and/or the role of this protein in regulation of cell 
behaviour during tertiary dentinogenesis. 
The Msx2 transgenic model was used as a starting point for investigation of 
dentinogenesis. Others transgenic mice, such as the DMP1 null mutant, or p38 protein 
null mutant for example may provide further valuable models to increase our 
knowledge of pulp healing processes, and to facilitate development of new 







4.2 Molecular characterization of young vs mature 
odontoblasts 
4.2.1 Transcriptome comparison of young and mature odontoblasts 
Dentinogenesis is a continuous process of matrix deposition throughout the life of a 
tooth, albeit occurring at different rates. Odontoblasts, a monolayer of cells at the 
periphery of the pulp, firstly secrete the unmineralised dentine matrix (predentine) 
and then subsequently, are responsible for the mineralisation of this matrix (dentine). 
The presence of a permanent layer of predentine between the formative odontoblasts 
and mineralized dentine highlights the continuing activity of these cells. Three types 
of dentine are commonly described in the literature with the primary and secondary 
forms being physiologically secreted, whereas tertiary (reactionary or reparative) 
being synthesized in response to injury (Goldberg and Smith 2004). 
However, so far there is no histological difference described between primary and 
secondary dentine except at the interface between both tissues which is generally 
delimited by a calciotraumatic line (Thewlis 1940); In this area, dentine has a lower 
affinity for Periodic Acid-Schiff staining (Symons 1961; Symons 1962). Because of the 
post-mitotic nature of the odontoblast, the two types of dentine are secreted by the 
same cells, albeit at different times and rates. Although, both types of dentinogenesis 
are reported to differ in their rate of matrix deposition (4µm/day for primary and 
approximately 0.4µm/day for secondary) (Schour and Poncher 1937; Ziskin, 
Applebaum et al. 1949), this may reflect modulation in secretory activity of the 
odontoblasts rather than irreversible phenotypic change. Odontoblasts are actively 
secreting during primary dentinogenesis, but become largely less active during 
secondary dentinogenesis. They can up-regulate their secretory activity again in 
response to an injurious challenge to secrete tertiary reactionary dentine at similar 
rates to primary dentine (Wennberg, Mjor et al. 1982). Thus, odontoblasts are the 






forces, molecular products derived from microorganisms and inflammatory cells 
during patho-physiological responses to the environment of the tooth including the 
carious process. 
The interface between primary and secondary dentine remains controversial in the 
literature. To date the boundary between the two types of odontoblast behaviour has 
been based on anatomical landmarks. For some authors, the completion of root 
formation is the end point of primary dentinogenesis whereas for others, tooth 
eruption is the starting point of secondary secretion (Nanci 2003). So far, the absolute 
point of change in odontoblast activity reflecting the change from primary to 
secondary dentinogenesis is ill-defined. Without phenotypic landmarks, it is difficult 
to delineate the temporo-spatial pattern of the two types of dentinogenesis which 
may occur concomitantly in the same tooth, depending on its stage of development.  
In addition, understanding cell behaviour in dentine formation is critical to our future 
development of new regenerative therapies for teeth. During tooth repair and 
tertiary dentinogenesis, the healing process may recapitulate developmental events 
(Smith and Lesot 2001). In this situation, odontoblasts are “re-activated” to restore a 
greater rate of secretion of dentine (reactionary); they may also die and then pulpal 
progenitors can differentiate into odontoblast-like cells (reparative). It is therefore 
important to understand the cellular and molecular changes which occur in 
odontoblasts at different stages of their life-cycle to facilitate clinical exploitation of 
the reactivation of quiescent odontoblasts for dentine repair and exploit 
pharmacological tools to manage and control this healing process. 
The identification of the odontoblast phenotype has received much attention over the 
years, and has established at the molecular level, the different roles played by 
odontoblasts in dentine formation (Butler 1995; Linde 1995), their cell-cell 






al. 2004; Magloire, Couble et al. 2008) and their role in innate immunity (Staquet, 
Durand et al. 2008). We therefore hypothesize that the changes in secretory activity 
of odontoblasts throughout their life cycle reflect differential transcriptional control 
and that regulatory processes involved in bone homeostasis may also occur in 
regulation of dentine secretion. The expression profiles of several genes (DSPP, DMP1, 
Collagen I) were used as well established markers of odontoblasts and their 
expression levels may reflect the cell secretory behaviour. So far, comparison of the 
gene profile of the odontoblast at different stages of its life cycle has not been well 
characterized. Based on the hypothesis that differential dentine secretion is 
associated with changes in transcriptional activity within the cell, we have 
investigated the transcriptomes of odontoblasts involved in primary and secondary 
dentinogenesis and subsequently used this information to identify key regulatory 
intracellular pathways involved in this process.  
The differential gene expression that we observed in primary and secondary 
dentinogenesis highlights modifications in transcriptional control of the odontoblasts 
and the need to identify the nature of the underlying regulatory mechanisms, both to 
characterize cell phenotype and to better understand how cell secretory behaviour 
can be regulated during tertiary dentinogenesis for therapeutic purposes. Such a 
strategy has been applied to studies of bone cell lineage and has contributed to 
discrimination of the respective functions of osteoblasts and mature osteocytes. 
The relatively high number of genes differentially regulated between both 
populations of odontoblasts was an unexpected observation and therefore 
confirmation by RT-PCR of selected genes using experimental replicates was applied. 
Initially, DMP1 expression was demonstrated as this gene is commonly used as a 
phenotypic marker of odontoblasts differentiation (Butler 1995; Unterbrink, O'Sullivan 
et al. 2002). Notably, DMP1’s role in dentinogenesis has received considerable 






during dentinogenesis (Ye, MacDougall et al. 2004). Our analysis supported DMP1 as 
being a marker of maturity of odontoblasts, results which were also confirmed by 
immunohistochemistry on bovine teeth.  
The presently studied stages of odontoblasts potentially parallel the situation in bone 
where the osteoblast is the active-forming cell, while the osteocyte does not deposit 
bone. Both are secretory and mineralizing cells, and increasingly, it is difficult to 
characterise distinct or differential profiles of matrix components for either tissue. 
Differential expression of the same components in these two tissues implies their 
similarity rather than an absolute difference in composition. Such differences are also 
apparent between different skeletal sites, such as flat and long bones (Watahiki, 
Yamaguchi et al. 2008). A functional analogy between the odontoblast and 
osteoblast-life cycles has been recently highlighted by authors who interestingly, 
proposed a new nomenclature for odontoblasts sub-dividing them into three 
populations of pre-odontoblasts, odontoblasts and odontocytes (Kim and Simmer 
2007; Larmas 2008). 
In bone, preosteoblasts are differentiating cells. Osteoblasts secrete bone matrix and 
some of them subsequently become embedded in the mineralised matrix (Opperman 
2000). These osteocytes, are morphologically different, being much less active in 
matrix deposition and are characteristically dendritic cells. Despite much focus on 
the osteoblast, the osteocyte derived from it has received less interest until recently 
(Kubota, Wakabayashi et al. 2003; Stains and Civitelli 2003; Bonewald 2004; Cho, Lee 
et al. 2006). Osteocytes differ from osteoblasts in their respective functions and 
regulatory mechanisms, notably those related by the SOST gene and Wnt pathway for 
recruitment of osteoblast progenitors. A central role of osteocytes is to regulate bone 
mass by the transduction of biomechanical loading into molecular signals controlling 
osteoblast and osteoclast number (Bonewald 1999; Bonewald 2002; Bonewald 2004).  






differences. Bone cells are continuously renewed by reiterative cycles of proliferation 
and differentiation on bone surfaces while odontoblasts are post-mitotic cells. During 
physiological dentinogenesis, the odontoblast secretes dentine matrix and the cell 
moves pulpally leaving its process embedded in the matrix. The odontoblast cell body 
is never entrapped in its matrix, unlike osteocytes, except occasionally in the 
pathological situation of “osteodentine”. Finally, bone resorption is a physiological 
process under the control of osteoblast and osteocyte signals, while dentine 
resorption occurs in specific physio-pathological situations, such as root resorption 
and internal resorption. The present transcriptome data may provide a framework to 
underpin the analogy between, on the one hand, young odontoblasts and osteoblasts 
and, on the other hand, osteocytes and mature odontoblasts. Interestingly, DMP-1 is 
also a constitutive bone matrix protein and is differentially expressed in pre-
osteoblasts and mature osteoblasts (increased by 36.8 in mature cells) (Cho, Lee et 
al. 2006). In odontoblasts, expression was up-regulated by 3.21 fold in late stage 
cells. This protein therefore appeared to be a marker of maturity in both cell types. 
Similar observations were also  made for Bone Sialoprotein, which was increased by 
24.3 fold in mature bone cells (Cho, Lee et al. 2006), while by 800 fold in 
odontoblasts, Osteopontin (8.6 fold increase in bone (Gravallese 2003; Morinobu, 
Ishijima et al. 2003)), 4616 fold  in odontoblasts and Osteocalcin (8.0 fold in bone 
cells (Ducy, Desbois et al. 1996; Eghbali-Fatourechi, Lamsam et al. 2005), 715 fold in 
odontoblasts). Osteocalcin has previously been reported to be selectively localised in 
peritubular dentine produced by odontoblasts during secondary dentinogenesis 
(Papagerakis, Berdal et al. 2002). It appears that several markers of osteocytes are 
also up-regulated in mature odontoblasts compared to relatively younger cells. 
Nevertheless, not all the markers appear to be differentially regulated in the same 
way in bone and dentine forming cells. SOST gene (coding for Sclerostin protein) is 






is the product of the SOST gene and is expressed predominantly by osteocytes 
(Winkler, Sutherland et al. 2003; van Bezooijen, Roelen et al. 2004; Bellido, Ali et al. 
2005). Sclerostin stimulates the recruitment of osteoblast progenitors via the Wnt 
pathway and mutations in humans result in high bone mass disorders, such as Van 
Buchem’s disease (Balemans, Ebeling et al. 2001). In odontoblasts, the differential 
expression of the SOST gene appears to be the inverse to that in bone. SOST gene was 
highly expressed in young cells whilst it was strongly down-regulated in more mature 
cells (differential expression by 465 fold). This inverse SOST bone-dentine relationship 
may parallel divergence in odontoblast/osteoblast recruitment in a physiological 
context. Throughout growth and homeostasis, bone formation results from a 
continuous differentiation of new osteoblasts on the bone surface. In contrast, the 
odontoblast layer is composed of post-mitotic cells which contribute to the continuing 
deposition of dentine, without emergence of newly differentiated cells in a 
physiological context. In conclusion we have shown here that, as in bone cells, the 
transcriptome of odontoblasts evolves with the stage and the maturity of the cells. 
The temporal expression of all of these genes may correlate with a change in 
secretory activity of odontoblasts as their functional status changes (Lu, Xie et al. 
2007), as previously suggested by Larmas (Larmas 2008). In bone, osteocalcin and 
osteopontin are two well characterized markers of fully differentiated and mature 
osteoblasts and osteocytes (Park, Shin et al. 2001). We found the same differential 
expression between mature and young odontoblasts. It is interesting to compare the 
young odontoblast (primary dentinogenesis) to the osteoblast and the mature 
odontoblast (secondary dentinogenesis) to the osteocyte which may support the 
nomenclature for these cells as being pre-odontoblasts, odontoblasts and odontocytes 
(Larmas 2008).  
By comparison of the published data on dentine secretion rates (Schour and Poncher 






we can conclude that the functional status of the odontoblast evolves, and the less 
active deposition by the cell during secondary dentinogenesis is associated with 
important changes in its transcriptome. It should be noted, however, that the 
markers of osteocytes were not systematically regulated in the same way in 
odontoblasts. We still need to be cautious in suggesting new nomenclature for these 
cells and not to confuse the concept of two populations of cells with a continuum of 
changes in the transciptome, which appear to be associated with the secretory status 
of the cell and may have functional consequences. In future studies, it would  be 
interesting to compare the gene expression patterns reported here with those of 
odontoblasts or odontoblast-like cells taking part in tertiary dentinogenesis where 
secretory activity becomes up-regulated again (Wennberg, Mjor et al. 1982; Smith 
and Lesot 2001). However, such studies may be complex in view of the diversity of 
cellular responses during tertiary dentinogenesis (Smith, Cassidy et al. 1995; Smith, 
Lumley et al. 2008).  
Histological similarities between odontoblasts and bone cells are also apparent. 
Osteocytes communicate with other osteocytes and the bone surface via cytoplasmic 
processes that cross through the mineralised bone (Marotti 1996; Tatsumi, Ishii et al. 
2007). The presence of the processes in the canaliculi is clearly similar to the 
situation with the odontoblast, even though the odontoblast has only one main 
process with many lateral ramifications. The three dimensional structures of 
canalicular/tubular systems in odontoblasts and osteocytes are similar with a striking 
similarity between the morphological distribution of canaliculi/tubules in dentine and 
bone (Lu, Xie et al. 2007). Osteocytes and osteoblasts have been described as 
functional mechano-receptors, responsible for capturing information on the bone 
surface and controlling bone balance by transmitting the information to other 
osteoblasts and osteoclasts (Tatsumi, Ishii et al. 2007). The odontoblast has also been 






responses to mechanical stimuli by increasing dentine production and mineralisation. 
Although its potential role as a mechano-receptor is reported (Dhopatkar, Sloan et al. 
2005), the further molecular elucidation of its related mechano-transduction 
pathways could help to highlight its potential roles in pathological conditions such as 
internal dentinal resorption. If further similarities between odontoblasts and bone 
cells are identified, there is the possibility that the available data on bone research 
could be translated to new applications for dentine-pulp complex repair. 
Finally, the concept that primary dentine secretion occurs before tooth eruption 
whilst secondary dentine secretion occurs following eruption, may need revision 
based on our observations. Notably DMP1 immunohistochemistry indicated that during 
development, odontoblasts undergoing secondary dentinogenesis (in the cusp area) 
and odontoblasts secreting primary dentine (in the apical area) may coexist in the 
same tooth. Morphological appearance or anatomical localisation appear insufficient 
criteria to define the functional status of an odontoblast in regard to primary or 
secondary dentinogenesis.  
In bone, following injury, progenitor cells need to be recruited to differentiate into 
osteoblasts for bone repair. In contrast to the odontoblast, the osteocyte is unable to 
reverse its maturation state and change its status from a quiescent to an actively 
secreting cell. One of the unique features of the odontoblast is that it may be re-
activated after injury and secrete reactionary dentine at similar rates to primary 
dentine. As similarities have been described between development and the healing 
process (Tziafas, Smith et al. 2000; Smith and Lesot 2001), we sought to investigate 
the variation in protein secretory processes concomitant with the switch from early 
stage to late stage odontoblasts to examine whether key pathways could be 
identified, which might be targets for the switch from secondary to tertiary 
dentinogenesis.  The MAPK/ERK pathway is a signal transduction pathway that couples 






pathway is complex and includes many signalling mediators. It is also well established 
that the MAPK signalling pathway is involved in cellular differentiation. Microarray 
data identified 6 genes (PTPRR, NTRK2, MAP2K6, CD14, MAPK13 (p38) and FGF1) 
involved in the p38 pathway as being differentially regulated.  
Notably, the role of TGF-β1 is well established in odontoblast differentiation during 
primary development and in tertiary dentinogenesis (D'Souza, Flanders et al. 1992; 
D'Souza, Cavender et al. 1998; Smith and Lesot 2001; Unterbrink, O'Sullivan et al. 
2002) and significantly, recent publications indicate that TGF-β1 may regulate the 
MAPK pathway (Ning, Song et al. 2002; Zhao, Chen et al. 2004). The role of the MAPK 
pathway therefore warrants further investigation to try to better understand its role 
during the odontoblast maturation process and its possible involvement in the 
reactivation of odontoblast secretory activity during tertiary dentinogenesis. 
Characterization of such key pathways involved in odontoblast secretion may provide 
exciting targets for development of novel regenerative therapies.  Finally, the 
growing body of information suggesting similarities between pulp cells and bone cells 
may help us to better understand the physiology and pathology of the mineralised 
tissues of the body and allow greater comparison of data derived from bone and 
dental studies.  
4.2.2 Dentinogenesis definitions and the choice of our research 
model:  
An important outcome of this research has been re-evaluation of the limited 
evidence supporting the concept of the definitions for primary and secondary 
dentinogenesis. Initially, we tried to use the terms primary and secondary 
dentinogenesis widely to allow the reader to appreciate the context of the data we 






perhaps emphasise the paucity of reliable markers to distinguish the interface 
between what have become known as primary and secondary dentines in the 
literature. The presence of a calciotraumatic line may be more characteristic of 
human teeth than other species and even in the human, demarcation of this line can 
be quite subtle in some teeth. It is also important not to confuse this with the 
calciotraumatic line seen at the interface with reactionary tertiary dentine, which is 
sometimes confused with “secondary” dentine at sites, such as beneath worn incisal 
edges and occlusal surfaces. The “marriage” of traditional anatomical and 
histological knowledge with data derived from newer molecular technologies is 
sometimes not easy, but there is no doubt that we are moving into exciting times as 
we deepen our understanding of cell behaviour in the hard tissues and the functional 
significance of this knowledge. 
Indeed, the distinction between primary and secondary dentinogenesis was a starting 
point of our work and led us to re-evaluate the present established doctrine on the 
differences between primary and secondary dentinogenesis. Analysis of the published 
literature showed very limited data to support the definitions that have now become 
established in the textbooks. Much of the information is morphological in nature, eg, 
rate of dentine matrix secretion (based on thickness of dentine laid down in a certain 
period of time) suggesting secondary is slower than primary dentinogenesis (Smith 
2002a); continuity of dentinal tubules suggesting that the same cells are responsible 
for primary and secondary dentinogenesis. There appears to be a lack of data in the 
literature to underpin a robust definition of primary and secondary dentinogenesis, 
which may explain why some regard the change between the two as when the tooth 
erupts in the mouth and others define it as the completion of apexogenesis. The 
presence of a calciotraumatic line may not always provide a reliable marker to 
distinguish the two populations of odontoblasts in primary and secondary 






odontoblast physiological behaviour, e.g., neonatal line, at times of systemic 
disease, at the initiation of reactionary dentinogenesis etc.  
While a calciotraumatic line can be detected in the crown of the bovine tooth, its 
position represents a much earlier stage than might be anticipated for any 
primary/secondary dentine interface. We can only speculate about the cause of this 
line, but suspect it may represent an event such as weaning/lactation or other 
physio/patho-logical event. No such line was evident in the bovine incisor from a 
later stage perhaps emphasising a possible weaker relationship between the presence 
of such a line and a change in odontoblast secretory activity (i.e., as defined as 
primary and secondary dentinogenesis) in bovine teeth. Our experience generally 
with various bovine teeth is that although a gradual reduction in size of the pulp 
chamber with age is observed (equates to what has been termed secondary 
dentinogenesis), calciotraumatic lines are very variable features of these teeth and 
probably are not a reliable marker of the interface between primary and secondary 
dentines. 
Perhaps clearer evidence of altered secretory behaviour in the odontoblast with age 
is demonstrated by the ultrastructural changes reported in odontoblasts (Takuma and 
Nagai 1971; Couve 1986), which suggest a life cycle for these cells with secretory, 
transitional and aged stages although these stages have not been aligned to the 
presence of any calciotraumatic lines.  
Based on our observation, we feel that the presence of a calciotraumatic line is not 
necessarily strongly associated with a change in secretory activity of odontoblasts 
following crown and root formation, i.e., what has been defined as the interface 






In the present studies only crowns of the teeth were used for cell isolation. Most 
authors appear to consider that primary dentinogenesis stops when the tooth erupts, 
whereas others define this limit as the time of completion of apexogenesis. Based on 
this observation, we selected our tooth samples from two opposite points: erupted 
teeth with fully formed roots as a model for what has been termed secondary 
dentinogenesis, and a very early stage of development of the tooth (unerupted, no 
root formation, but calcified tissue formation in progress in the crown to ensure that 
differentiated and secreting odontoblasts were present. We sourced bovine teeth 
from 30 month old animals because both types of teeth are present in the same 
animal thereby minimising inter-species differences. 
4.2.3 DMP1 as a marker of odontoblast maturity 
In attempting to identify molecular markers to help to make a clear distinction 
between primary and secondary odontoblasts, we had the choice between several 
proteins for which the corresponding mRNAs were appreciably changed. Among 
those, BSP gene expression was increased by 714 fold and OPN by 968 fold in late 
stage cells. Nevertheless, we focussed on DMP1 which was only 3 fold increased and 
on DSP. 
There were two major reasons why we consider DMP1 to be a more reliable marker 
of cell maturity. Firstly, DMP-1 is one of the rare markers of mature odontoblasts 
that has already been identified (Larmas 2008), while neither OPN nor BSP have been 
previously highlighted in this context. 
DMP-1 immunohistochemistry on bovine molars was performed initially to investigate 
the expression of this gene in the crown tissues of unerupted teeth. Because the 
molar was unerupted and only crown formation was taking place, it is assumed that 






dentinogenesis. By performing immunohistochemistry on these tissues, we expected 
a basal expression of the protein, and not the observed gradient along the cells of 
the crown. Because of this unexpected result, we were concerned by the definitions 
of primary and secondary dentinogenesis and their putative markers.  
Secondly, the microarray data utilises fluorescence intensities of the probes in its 
expression level calculations. From the absolute data (fluorescence of the probe) for 
each sample (ES and LS), we calculated the relative data, based on the ratios 
between ES cell and LS cell values. 
‐ DMP 1: ES value : 5722   LS value: 18371    Ratio: 3.21 (Absolute value of 
variation: 12649) 
‐ IBSP (BSP): ES value 11.05   LS value: 7900   Ratio: 714 (Absolute value of 
variation: 7889)  
‐ SPP1 (OPN) : ES value: 4.77   LS Value: 4621 Ratio: 968.80 (Absolute value of 
variation: 4616) 
 
Based on these observations, DMP1 expression showed the greatest absolute change 
between young and mature cells and exhibited the highest basal level of expression. 
However, our data also indicated that BSP and OPN were appropriate markers of 
mature cells, because their expression was relatively low in young odontoblasts. The 
greater differential expression for DMP-1 may also be anticipated to be reflected in 
protein expression and hence DMP-1 was the favoured target for 
immunohistochemistry. Thus, for these two reasons it appeared to us that it was 
more appropriate at this stage to use DMP1 as it may be a more robust marker for 
mature cells and certainly highlights the need to reconsider our concepts of primary 






4.3 Phospho-p38 regulation and odontoblast 
stimulation  
Reactionary dentinogenesis is the secretion of a tertiary dentine matrix by surviving 
odontoblasts in response to an appropriate stimulus (Smith, Cassidy et al. 1995). The 
dentine matrix is permeable by virtue of its tubular structure and therefore following 
injury to the tooth and/or subsequent restorative procedures, this may allow 
molecules to diffuse and contact the pulp. Such substances may include bacteria, 
toxins and/or dentine matrix proteins (DMPs). Because the pulp is enclosed by a 
rigid, mineralised tissue shell, dentine matrix degradation by acid bacterial products 
begins before the disease process reaches the pulp. Notably, growth factors derived 
from the dentine have been shown to reach and stimulate the odontoblast layer, 
inducing new dentine secretion in those areas of the dentine-pulp complex that are 
in direct tubular connection with the traumatic agent (Mjor 1983).  
It has been suggested that, during tooth repair and tertiary reactionary 
dentinogenesis, the healing process recapitulates developmental events (Smith and 
Lesot 2001). TGF-β1 has been shown to play an important role in tooth development 
(Cam, Lesot et al. 1997; Lesot, Lisi et al. 2001), particularly in odontoblast 
differentiation (Begue-Kirn, Smith et al. 1992; Begue-Kirn, Smith et al. 1994). TGF-β1 
is also sequestrated within the dentine matrix (Cassidy, Fahey et al. 1997), and may 
be released during carious disease or by restorative agents commonly used in 
dentistry that dissolve mineralised components, such as ethylene diamine tetra-
acetic acid  (EDTA), calcium hydroxide (Graham, Cooper et al. 2006) or mineral 
trioxide aggregate (Tomson, Grover et al. 2007). Notably, TGF-β1 has also been 
demonstrated in vivo and in vitro to stimulate odontoblast mineralisation (Smith, 
Tobias et al. 1994; Sloan and Smith 1999; Duque, Hebling et al. 2006). 
It would be clinically valuable to be able to activate quiescent odontoblasts for 






cellular and molecular signalling in these cells. However, only limited information 
currently exists on these molecular events which occur during reactionary 
dentinogenesis. In a previous study, we provided evidence that changes in the 
secretory activity of odontoblasts reflect differential transcriptional control and that, 
therefore, the transcriptome of the odontoblast evolves as the cell matures (Simon, 
Smith et al. 2009). Among the dataset of genes whose expression changed during 
odontoblast maturation, we identified the p38 transcript to be abundantly expressed 
in odontoblasts during primary dentinogenesis whilst being significantly down-
regulated in secondary dentinogenesis. Based on these observations, we hypothesized 
that p38 signalling might be involved in regulating odontoblast activity, and the 
present study aimed to determine whether the p38 protein is up-regulated and 
phophorylated upon odontoblast stimulation. 
The MAPK/ERK pathway is a signal transduction pathway that couples intracellular 
responses to the binding of growth factors to cell surface receptors and has been 
implicated in odontoblast differentiation (Wang, Hu et al. 2006). The role of TGF-β1 
in odontoblast differentiation during primary development and in tertiary 
dentinogenesis is well established (D'Souza, Flanders et al. 1992; D'Souza, Cavender 
et al. 1998; Smith and Lesot 2001; Unterbrink, O'Sullivan et al. 2002; Baker, Sugars et 
al. 2009) with several recent publications indicating that TGF-β1 regulates the MAPK 
pathway (Ning, Song et al. 2002; Zhao, Chen et al. 2004). As similarities have been 
described between primary development and the healing process (Tziafas, Smith et 
al. 2000; Smith and Lesot 2001), we wished to investigate the role of the MAPK 
pathway in these processes and to determine whether odontoblasts might be 
stimulated in a model of reactivation of dentine secretion during reactionary 
dentinogenesis. 
Stimulation of odontoblast-like cells with several growth factors, as an in vitro model 






caries, caused an increase in p38 phosphorylation and its nuclear translocation. This 
enhancement of translocation is significant, as apart from the HSP27 pathway, most 
components of the p-38 MAPKinase pathway reside in the nucleus, where p38 acts as 
a transcription factor.  
TNF-α, ADM, and TGF-β1 showed similar patterns of p38 activation, whereas isolated 
dentine matrix proteins appeared to induce a different pattern of p38 activation. 
The cocktail of growth factors in the preparation of isolated dentine matrix proteins 
appeared to have a weaker, but a more enduring effect on cells than did the growth 
factors or bacterial stimulants alone. The effect of these dentine matrix proteins on 
p38 protein persisted past the point where the effect of growth factors alone had 
culminated. It is likely that this response profile better mirrors the events occurring 
in carious disease, in which dentine matrix components are released in combination. 
In view of the fact that tissue regeneration is a balance between inflammation and 
repair, the comparatively weaker effect of dentine matrix proteins may serve the 
biological role of protecting the dental pulp by preventing pulpal inflammation. 
Bacterial contamination of the pulp is usually described as the most important factor 
in pulp disease. In our experiments, when cells were stimulated with Streptococcus 
mutans, only half of the activated protein was translocated. Based on this 
observation, we hypothesize that bacteria might stimulate the cytoplasmic pathway 
better, whereas growth factors might directly induce transcription. It should be 
noted that bacteria alone were not able to induce odontoblast activation, but that 
they exhibit a synergistic effect when combined with growth factors. It is thus 
critical, when evaluating the healing and toxic effects of various agents, that they be 
tested both alone and in combination. Further study is needed to determine the 
effect of a range of concentrations of dentine matrix proteins and other agents, to 







Notably, our results are in agreement with the differential phospho-p38 expression 
that has been observed during tertiary dentinogenesis. As has been suggested by 
several authors, this finding may indicate that the behaviour of odontoblasts during 
tertiary dentinogenesis recapitulates the development of the primary cells (Tziafas, 
Smith et al. 2000; Smith and Lesot 2001). Understanding cellular behaviour in 
response to carious disease may allow the development of new approaches in 
regenerative dentistry that utilize biological and pharmacological control of cell 
behaviour, much as p38 phosphorylation is currently exploited as a target of anti-
inflammatory drugs. Better understanding of the regulation of the p38 pathway 
during tertiary dentinogenesis might also allow the development of new therapies, in 
particular for novel pharmaceuticals which facilitate bonding systems to better 
control the healing process and enhance the secretory activity of odontoblasts.  
4.4 The mouse as an experimental model for pulp 
capping. 
Several species of animal have been used for pulp-capping studies including the 
monkey (Pitt Ford, Torabinejad et al. 1996), dog (Tziafas, Kolokuris et al. 1992) 
ferret (Smith, Tobias et al. 1994), and rat (Decup, Six et al. 2000). The monkey and 
dog are large animals, and are therefore expensive, requiring special care facilities. 
Moreover, the rules concerning animal experimentation increasingly present 
difficulties for this kind of work, especially using non-human primate species.  For 
these reasons, the numbers of animals studied is often restricted, potentially 
influencing the experimental outcomes, reproducibility and subsequent 
interpretation of data.  
A pulp-capping protocol has been described in the rat model, using the mesial face of 
the first maxillary molar, after gingivectomy (Decup, Six et al. 2000) or on the 
occlusal face (Lovschall, Tummers et al. 2005). The molar of the rodent is 






counterpart: it has three roots, three cusps and thus shows analogous conditions of 
vascularisation and innervation. While the rat offers a number of advantages as an 
experimental model, the availability of genetically-altered models for this species is 
more restricted than for the mouse. 
Validation of the mouse as an experimental model now opens the way for use of 
transgenic studies in reparative dentinogenesis; such a model should enable more 
precise definition of the cellular and molecular mechanisms involved in the process 
of dentine-pulp repair. Potentially, animals with a modified genome (with reporter 
gene or gene deletion) could thus be used to: 
- characterise the phenotype of the replacement odontoblast-like cells and 
determine their origin through cell lineage-studies in transgenic mutated mice (Chai, 
Jiang et al. 2000) ; 
- decipher the cell differentiation process at the molecular level by using 
transgenic null mutant mice for potentially determinant factors (e.g. DSPP null 
mutant mice (Sreenath, Thyagarajan et al. 2003) Msx2 null mutant mice (Aioub, 
Lezot et al. 2007) to better understand the process of differentiation; and 
- evaluate effects of novel bioactive molecules.  
It is with this new knowledge and an understanding of these processes that new 
therapeutic strategies can be developed to promote pulp vitality and healing. Within 
the constraints of the regulations of animal experimentation, this model will also 
facilitate use of adequate numbers of sample for robust data collection.  
A limitation of the model presented is that it currently uses healthy teeth, whilst in 
the clinical situation pulp inflammation is generally present. However, future 
experiments could simulate caries-like situations by incorporating bacterial infection 
models using whole live bacteria or bacterial components. In addition, the presence 






contribute to reparative responses in the pulp. Although this may complicate data 
interpretation, it does reflect the clinical situation where dentine fragments 
(Tziafas, Kolokuris et al. 1992) and dissolution products (Smith 2002b) contribute to 
overall pulpal responses. Reproducibility of the pulp-capping procedure was regarded 
as an important element in the viability of the model especially in view of the small 
size of the mouse tooth. The histological observations confirmed the reproducibility 
of our surgical procedure. 
Contrary to many of the studies reported with calcium hydroxide (Schroder and 
Granath 1972; Horsted, El Attar et al. 1981; Fitzgerald, Chiego et al. 1990), neither a 
necrotic layer, nor a persistent inflammatory zone were noticed. The completion of 
the pulp-capping in a very short time, and adaptation of a clean procedure 
(sterilisation of the material) limited the duration of the pulp exposure to the oral 
cavity and thus, bacterial contamination. Moreover, the use of a light cured 
composite bonded with a one-step bonding system avoided any bacterial leakage 
post-restoration (Pradelle-Plasse, Besnault et al. 2003). Even at 11 weeks, the 
coronal filling was still intact and did not show any evidence of deterioration of the 
tooth-restoration interface. 
In our study, continuous bridge formation was observed, in good continuity with the 
dentine of the walls of the cavity and the discontinuity between the bridge and the 
dentinal wall, often described with the use of calcium hydroxide, was not apparent. 
This result confirms several published reports with other animal models after capping 
with MTA and also clinical reports (Holland, de Souza et al. 2001; Aeinehchi, Eslami 
et al. 2003; Dominguez, Witherspoon et al. 2003; Asgary, Parirokh et al. 2006; Nair, 
Duncan et al. 2007).  
Two weeks post-operatively, the first signs of the healing process were observed as 






zone followed the contours of the material precisely and was visible on all stained 
sections. The structural modification of the matrix at this level may play an 
important role in the process of differentiation of the second generation of 
odontoblast-like cells, as suggested by experiments using growth factors (Rutherford, 
Wahle et al. 1993). This could reflect recapitulation of developmental events in 
which signals from the inner dental epithelium mediated by the dental basement 
membrane are responsible for induction of odontoblast differentiation. In the mature 
tooth, epithelial cells and a basement membrane are absent, however, in the healing 
process of the pulp, similar signalling processes for odontoblast differentiation may 
exist but be of different derivation (Smith and Lesot 2001). The structural 
modification of the matrix in the area adjacent to the material at the exposure site 
might play a key role in the process of differentiation of the second generation of 
odontoblast-like cells. We speculate that the matrix in this area may substitute for 
the role of the basement membrane during odontoblast differentiation in tooth 
development. 
The modifications of the matrix at this level may include: 
- adsorption of dentinal matrix proteins (and predentine), produced by 
odontoblasts prior to cavity preparation 
- incorporation of serum components leaked into the pulpal parenchyma, at the 
time of surgery possibly resulting from inflammation 
- local cellular secretion either by various pulpal cell populations or newly 
differentiated odontoblast-like cells. 
This study has allowed the chronological monitoring of the healing process. The 
initial inflammatory phase was very short (the first two days) (data not shown), 






other species (Abedi, Torabinejad et al. 1996; Torabinejad and Chivian 1999). The 
subsequent dentine bridge formation showed evidence of a dentinogenic response. 
The staining of the new odontoblast-like cells with DSP antibody, confirmed the 
secretion of a matrix with at least some dentine characteristics, namely the 
secretion of Dentin Sialoprotein. However, further characterisation of the matrix 
with other markers (such as MEPE, nestin, alkaline phosphatase for example) may 
also be beneficial. 
The SEM and X-Ray spectrometric analyses allowed confirmation that the dentine 
bridge was calcified, although it appeared that the reparative dentine was probably 
less calcified than orthodentine. These observations are of interest and are 
potentially novel as most of our knowledge on reparative dentine is based on 
histological evidence that requires decalcification of the hard tissues and therefore 
may generate processing artefacts. The Ca/P ratios of the reparative dentine may be 
indicative of the presence of other forms of calcium phosphate rather than 
hydroxyapatite alone, emphasising the pathological nature of the process of 
reparative dentinogenesis. 
4.5 MSX2 homeoprotein and the dentine pulp complex: 
4.5.1 MSX2 repression and dental abnormalities 
The important role that Msx genes play in tooth development has already been 
described and is exemplified by mice lacking Msx gene function. Msx2-deficient mice 
exhibit late defects in tooth development (Maas and Bei 1997; Aioub, Lezot et al. 
2007). So far, the role of the Msx2 protein in odontoblast differentiation has only 
been investigated at the early stages of tooth development, as the role of homeobox 
transcription factor are predicted to affect the initial stages of tooth formation 






these studies were that Msx2 and Osteocalcin were expressed in reciprocal patterns 
during tooth development, and Msx2 expression in pre-odontoblasts clearly precedes 
Osteocalcin expression in odontoblasts. As a result, it has been suggested that Msx2 
suppresses Osteocalcin expression at stages immediately preceding odontoblast 
terminal differentiation (Bidder, Latifi et al. 1998). Our q-PCR results confirmed the 
reverse trascriptional regulation of Osteocalcin by Msx2, as Osteocalcin was highly 
over-expressed in null mutant pulp cells. Over-expression did not seem to induce any 
regulation of the presently analysed dentine protein secretion, except a slight 
change in osteocalcin. 
A transcriptional repression of Msx2 on matrix protein related gene expression is 
potentially instrumental for the regulation of odontoblast behaviour as established 
for the osteoblast (Cheng, Shao et al. 2008) 
Our histological observations, performed on post-natal tissues, appear to 
demonstrate that Msx2 protein is still expressed in pulp cells throughout the life of 
the tooth as suggested by the β-galactosidase data. Indeed, most of the cells of the 
pulpal parenchyma and a few odontoblasts, especially the ones showing reverse 
polarisation, (those which will probably be entrapped in the dentine matrix), still 
expressed Msx2 in adult animals. 
In regard to the putative cell inclusions, we wondered whether the cells were 
included in the matrix prior to or after their death. The high expression of DSP 
protein in these inclusions may be evidence that before being embedded inside the 
dentine matrix, cells were still vital and active.  
During odontoblast differentiation, after 15 mitoses (in the mouse), one cell aligns 
adjacent to the basal membrane and differentiates into an odontoblast, and the 
other becomes incorporated within the cell layer of Höhl (Ruch, Lesot et al. 1995). It 






dentinogenesis, some cells die thus avoiding the over population of the pulp with 
cells (Baume 1980). 
In MSX2 null mutant animals, the odontoblast layer appeared clearly disturbed with a 
probable over population of cells which may be explained by three hypotheses : 
- In the absence of MSX2 protein, the physiological cell death programme does 
not occur appropriately,  
- In the absence of MSX2 protein, odontoblast recruitment is still occurring from 
a progenitor pool, inducing an over population of cells, which finally become 
embedded in the secreted dentine matrix. 
- In the absence of MSX2 protein, the odontoblast is no longer a post-mitotic 
cell and division may occur. Nevertheless, with BrdU incorporation studies, we 
showed that no cell significant division occurred in the odontoblast layer. Whilst the 
time of BrdU injection (12 hours before animal death) is probably too short to be 
conclusive, this last hypothesis does not seem to be robust. 
 
Histologically, coronal dentinogenesis was clearly disturbed, except in the first layer 
of dentine secretion (before 7 days). The dentine thickness was altered in 
comparison to the wild type animals as was the thickness of enamel indicating a form 
of amelogenesis imperfecta (Aioub, Lezot et al. 2007); Mola et al., submitted). The 
moderate amount of circumpulpal dentine produced in such a context of extreme 
dental abrasion related to the quasi absence of enamel, suggested a reduced defence 
ability of the pulp in the null mutant animals. 
Root formation was also clearly altered; the roots were short, the pulp chamber was 
abnormally large, reflecting taurodontism. The dentinal walls were extremely thin, 
and the root surface presented many irregularities. Odontoblasts were not polarised 
at all in contrast to the gradient of odontoblast polarisation present along the root as 






generally less polarised than those in coronal third and cells on the pulp chamber 
floor are generally cuboidal showing a less obvious polarisation (Nanci 2003). The in 
situ hybridisation we performed in this study was on a 14 days post-natal mouse 
tooth. Root formation had not clearly started at this stage of development. 
Hybridization for collagen I performed on a later stage of tooth development could 
be helpful to characterise the nature of these cells. Indeed, secretion of collagen I 
by the apical cells may provide some evidence of the odontoblast phenotype, based 
on the known over expression of collagen Iα in odontoblasts and osteoblasts 
compared to fibroblasts (Leblond and Wright 1981; Leblond 1989; Heersche, Reimers 
et al. 1992). 
At this stage of our observations, we have not been able to identify if these changes 
are related to an absence of odontoblastic differentiation, or a defect in secretion 
and dentinogenesis in the root. Although no evident morphological abnormality was 
observed in heterozygous animals, histologically there were appreciable changes in 
the null mutant.  
Secondary dentinogenesis was significantly affected in the null mutant. Sinusoidal 
tubules, increased branching and morphological disturbances of the odontoblast layer 
provide evidence of disturbances in dentinogenesis. The most important observation 
was the line or zone of disturbed matrix secretion in the dentine. This line seemed to 
appear at seven days post-natally and might be compared to the calciotraumatic line 
described in mature teeth and generally considered as the limit between primary and 
secondary dentinogenesis. 
As stated earlier in this thesis (see Introduction), no established physiological 
understanding has still been given for the transition from primary to secondary 
dentinogenesis. From the present observations in Msx2 -/- animals, we speculate that 
Msx2 is involved (directly or indirectly) in the process of secondary dentinogenesis, as 






morphology. It was not possible, however, to identify the specific processes 
responsible for induction of these disturbances in dentinogenesis.  
In the microarray data we obtained from bovine odontoblasts, the MSX2 gene was not 
identified in the list of differentially regulated genes between young and mature 
odontoblasts however this may reflect species variation.  
 
4.5.2 MSX2 and pulp repair  
In further studies, it would be interesting to determine the influence of Msx2 on the 
pulp repair process. Our first hypothesis was that Msx2 should be a determinant 
factor for the differentiation of the progenitor cells whose niches lie within the 
radicular pulp, via intercellular interactions and regulation with growth factors such 
as BMP4 and/or TGFβ1. This hypothesis is based on the data obtained in our 
laboratory on the dental phenotype of Msx2, and the demonstration by Bei (Bei, 
Stowell et al. 2004) that abrogation of Msx2 inhibits the expression of BMP4. This is 
supported by the established role of the growth factors of the TGF-β superfamily in 
the process of osteo-odontoblastic differentiation in the context of development and 
repair. 
TGF-β1 could be directly involved in the regulation of cell proliferation, migration, 
and extracellular matrix production in the human dental pulp and eventually in the 
repair process occurring after tooth injury. It is clear that TGF-β plays a key role in 
dental repair (Smith, Matthews et al. 1998; Sloan, Couble et al. 2001; Baker, Sugars 
et al. 2009). This role is not well defined, and the members of the TGF-β family 
implicated in this process are not fully identified although TGF-β1 and TGF-β3 seem 
to provide the best candidates. In further studies, it would be interesting to 






the pulp healing process, as has been described in tooth development (Begue-Kirn, 
Smith et al. 1994). 
Indeed, many parallels have been shown between development and wound healing 
(Smith 2002b; Goldberg and Smith 2004). This hypothesis also applies to dentinal 
repair. The description of a possible role of Msx2 in the early stages of odontogenesis 
mainly at the level of the odontoblast (Begue-Kirn, Smith et al. 1994; Maas and Bei 
1997; Bidder, Latifi et al. 1998), encourages us to investigate whether this 
relationship persists during the differentiation of odontoblast-like cells after pulp 
capping of dental pulp. 
In a preliminary study, pulp capping with MTA was performed on the first upper 
molars of null mutant Msx2 mice. Histological procedures were implemented to 
investigate the presence or absence of dentinal bridge and the cytological aspect of 
pulpal responses. This preliminary study was curtailed by issues with animal 
experimentation during my stay in the UK, but in the few samples examined it 
appeared that no dentine bridge had been secreted 5 weeks after pulp capping, but 
the dental pulp was still vital, and reactionary dentinogenesis was visible on the pulp 
chamber floor opposite to the site of pulp exposure. More samples are needed to 
confirm these observations, but they may indicate a role for MSX2 in pulp repair 
(inflammation, progenitor recruitment and/or odontoblast differentiation) which will 







Research on pulp regeneration is growing and provides exciting possibilities for more 
biological approaches to endodontic therapy in the future. However, for significant 
progress to be made in translation to the clinic we need a much deeper 
understanding of the molecular control of odontoblast secretion and identification of 
the physiological cues responsible for regulation of odontoblast behaviour. 
Pulpectomy represents a radical treatment for the non-necrotic pulp, but pulpotomy 
or pulp capping are only likely to find broader use if we can extend our knowledge of 
pulp regenerative processes. Such developments will likely bring significant progress 
to the area of vital pulp therapy.   
Our work focussed on odontoblast behaviour during the three phases of 
dentinogenesis. These observations on molecular characterisation allowed us to 
clearly demonstrate transcriptional regulation of the dentinogenic cells at different 
stage of maturity. Based on the hypothesis of a parallel between development and 
healing process, we were secondly interested in investigating the reversibility of a 
molecular signalling process (p-38 MAPK pathway) which was shown to be absent in 
mature cells compared to younger cells. The phosphorylation of the protein and its 
translocation to the nucleus after cell stimulation allowed us to confirm this 
hypothesis. Based on these first results, it would be interesting to analyse in further 
studies the regulation of others genes that have been shown to be up- or down-
regulated during the maturation of the cells. 
Differentiation and transcriptional regulation of cells are also key processes during 
reparative dentnogenesis, since differentiation is one step of the complex system for 






Transcriptional regulation in odontoblasts has clearly been demonstrated in the 
present study. Neverthless, further data are needed to fully understand the complete 
healing process. In vitro models are ideally used for initial investigations, but in vivo 
models are also necessary for pulp repair research. The mouse as a laboratory model 
for pulp capping is a new tool now available for transgenic investigations offering the 
possibility to screen in vivo the role of a gene (or pathway) by using a reporter gene 
or a deletion construct in the genome. 
Msx2 transcription factor was the first gene we investigated in odontoblast 
differentiation. The analysis of the Msx2 null mutant tooth phenotype in post-natal 
animals confirmed the possible role of this protein in odontoblast differentiation 
and/or mineralisation. The next step will be to analyse the role of this protein during 
reparative dentinogenesis by undertaking pulp capping in Msx2 transgenic mice. Our 
preliminary findings were encouraging, although further studies are required to 
delineate the role of this molecule in the complex pulp repair process and to exploit 
it in new clinical therapies.  
A key point of the repair process is the balance between infection, inflammation and 
tissue healing. To complement of our understanding of the healing process, more 
data are also needed on pulp inflammation and its clinical quantification. With these 
new tools, new diagnostic models and devices may be designed and furthermore, 
true indications and contra-indications of such new procedures could then be 
robustly assessed. As a result, pulp capping or other clinical strategies, such as 
pulpotomy, may be considered as viable alternative treatments to root canal 








Figure 50: 14 months post operatively after endodontic treatment on tooth# 36. Necrotic pulp 
in the mesial root canal was treated endodontically and a conventional filling applied. Pulp 
vitality maintenance in the distal root allowed pulp capping of the tissue with a dedicated
material (Pro Root MTA®-Dentsply Mailelfer). More than 12 months later, tooth still responds to 
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Appendix 1:  
Full list of regulated genes between young and mature issued from Microarray data analysis










$Parenthesis E/B> or B/E> Use
$No 3,4 1,2 2.000 2.000 Lower Bound
[COMPARE_RESULT]
probe set GENE ID baseline mean (LSperiment mean (Efold change lower bound of F upper bound of Fdifference of meaGene Title
Bt.10029.2.S1_at LOC506032 979,14 340,99 ‐2,87 ‐2,5 ‐3,34 ‐638,15 similar to Chromosome 17 open reading frame 75
Bt.5879.1.S1_at ‐‐‐ 87,84 1358,46 15,47 13,79 17,61 1270,63 Transcribed locus
Bt.26387.1.A1_atLOC533760 885,52 12,25 ‐72,29 ‐43,88 ‐204,86 ‐873,27 Similar to glutamate receptor
Bt.22746.1.S1_at LOC505366 420,42 11273,33 26,81 20,6 38,39 10852,91 similar to prostate stromal protein ps20
Bt.29409.1.S1_at ‐‐‐ 635,21 18,72 ‐33,92 ‐25,55 ‐50,44 ‐616,48 Transcribed locus
Bt.9594.1.S1_at ‐‐‐ 2141,41 35,29 ‐60,69 ‐37,47 ‐159,32 ‐2106,13 Transcribed locus
Bt.22400.1.A1_atLOC615883 748,28 8022,51 10,72 9,36 12,54 7274,23 similar to SLIT3
Bt.12302.1.S1_atPLAT 16764,37 562,19 ‐29,82 ‐21,11 ‐50,75 ‐16202,18 plasminogen activator, tissue
Bt.26824.1.A1_a_MGC128625 703,41 2857,35 4,06 3,93 4,21 2153,93 similar to mitochondrial ribosomal protein L46
Bt.16188.2.S1_atCYYR1 18,23 279,37 15,32 12,37 20,12 261,14 cysteine/tyrosine‐rich 1
Bt.7349.1.S1_at ‐‐‐ 185,43 6992,42 37,71 28,6 55,31 6806,98 Transcribed locus
Bt.7870.1.S1_at PP 89,01 1877,59 21,09 15,97 31,04 1788,58 pyrophosphatase (inorganic)
Bt.4804.2.A1_at LOC510972 504,39 4212,72 8,35 7,38 9,61 3708,33 similar to Cyclin‐dependent kinase inhibitor 1C (Cyclin‐dependent kinase inhibitor p57) (p57KIP2)
Bt.6400.2.S1_a_a‐‐‐ 1756,52 132,86 ‐13,22 ‐10,7 ‐17,29 ‐1623,66 ‐‐‐
Bt.12769.1.S1_atPCK2 550,72 5647,44 10,25 8,71 12,46 5096,72 phosphoenolpyruvate carboxykinase 2 (mitochondrial)
Bt.16583.1.S1_atMGC126930 4585,1 299,34 ‐15,32 ‐11,98 ‐21,22 ‐4285,76 similar to Voltage‐dependent calcium channel gamma‐like subunit (Neuronal voltage‐gated calcium channel gamma‐like subunit)
Bt.28224.1.A1_at‐‐‐ 305,33 1410,35 4,62 4,29 5 1105,01 Transcribed locus
Bt.28171.1.S1_at LOC616560 451,95 4892,01 10,82 8,98 13,62 4440,06 hypothetical LOC616560
Bt.12498.1.A1_atLOC530657 57,71 3752,92 65,04 39,36 186,76 3695,21 similar to alpha 3 type VI collagen isoform 5 precursor
Bt.2025.1.A1_at ‐‐‐ 1318,9 7318,08 5,55 5,01 6,22 5999,18 Transcribed locus
Bt.5247.1.S1_at PTGIS 4705,94 410,34 ‐11,47 ‐9,18 ‐15,26 ‐4295,61 prostaglandin I2 (prostacyclin) synthase
Bt.4675.1.S1_a_aMX1 656,5 3229,73 4,92 4,5 5,42 2573,23 myxovirus (influenza virus) resistance 1, interferon‐inducible protein p78 (mouse)
Bt.5453.1.S1_at ‐‐‐ 663,4 4873,89 7,35 6,37 8,68 4210,5 Transcribed locus
Bt.9569.1.S1_at TACSTD1 117,79 1712,09 14,54 12,3 17,76 1594,31 tumor‐associated calcium signal transducer 1
Bt.18593.1.A1_at‐‐‐ 1,07 282,26 263,48 53,38 100000000 281,19 Transcribed locus
Bt.15822.1.S1_atMGC159776 378,6 2,78 ‐136,17 ‐33,5 ‐100000000 ‐375,82 similar to Proto‐oncogene tyrosine‐protein kinase FGR (P55‐FGR) (C‐FGR)
Bt.3100.1.A1_at IGFBP5 16824,86 1909,36 ‐8,81 ‐7,46 ‐10,77 ‐14915,5 insulin‐like growth factor binding protein 5
Bt.13853.1.S1_atMGC139227 1079,45 164,06 ‐6,58 ‐5,82 ‐7,56 ‐915,4 similar to cell adhesion kinase beta
Bt.1533.1.S1_at LOC444872 683,65 3373,36 4,93 4,67 5,23 2689,71 perlecan
Bt.20605.1.S1_at ‐‐‐ 247,14 5152,25 20,85 17,99 24,78 4905,11 Transcribed locus
Bt.15548.1.A1_at‐‐‐ 28,88 564,2 19,54 13,8 33,41 535,32 ‐‐‐
Bt.24618.1.S1_atDBP 1268,75 175,1 ‐7,25 ‐6,33 ‐8,47 ‐1093,65 D site of albumin promoter (albumin D‐box) binding protein
Bt.27332.1.A1_at‐‐‐ 227,96 1734,73 7,61 6,53 9,11 1506,77 ‐‐‐
Bt.4898.1.S1_at BASP1 137,09 2281,7 16,64 12,63 24,36 2144,61 brain abundant, membrane attached signal protein 1
Bt.29065.1.A1_at‐‐‐ 7824,15 951,48 ‐8,22 ‐6,87 ‐10,23 ‐6872,67 Transcribed locus
Bt.2359.1.A1_at FYN 755,24 4029,09 5,33 4,77 6,05 3273,85 FYN oncogene related to SRC, FGR, YES
Bt.12065.1.S1_at LOC618071 938,83 26,55 ‐35,35 ‐23,62 ‐70,14 ‐912,27 Hypothetical LOC618071
Bt.11662.1.A1_atLOC523311 391,15 6454,83 16,5 12,59 23,91 6063,68 hypothetical LOC523311
Bt.7133.1.S1_at LOC515547 /// LO 785,83 6903,98 8,79 7,18 11,3 6118,15 ornithine decarboxylase /// similar to Ornithine decarboxylase (ODC)
Bt.223.1.S1_at AMBN 1140,94 7936,22 6,96 5,93 8,4 6795,28 ameloblastin (enamel matrix protein)
Bt.11641.1.S1_atMGC129051 852,24 13383,38 15,7 12,49 21,12 12531,15 similar to thrombospondin 4 precursor
Bt.23178.1.S1_atDCN 776,34 4372,5 5,63 4,96 6,51 3596,16 decorin
Bt.16213.1.S1_atMGC148630 559,39 6986,8 12,49 11,21 14,1 6427,41 hypothetical protein LOC613320
Bt.27207.1.A1_at‐‐‐ 360,48 2685,81 7,45 6,73 8,34 2325,33 Transcribed locus
Bt.16972.1.A1_at‐‐‐ 5,5 1063,18 193,33 97,48 11333,66 1057,68 Transcribed locus
Bt.7393.1.S1_at LOC513362 263,64 3400,03 12,9 10,54 16,58 3136,39 Similar to nephronectin
Bt.16740.1.A1_atMGC143240 122,91 1600,01 13,02 9,62 20,1 1477,1 similar to laminin S B3 chain
Bt.22729.2.A1_atBoLA /// LOC507 133,4 3490,63 26,17 14,88 107,88 3357,23 MHC class I heavy chain /// major histocompatibility complex, class I, A
Bt.29415.1.A1_at‐‐‐ 6337,24 492,71 ‐12,86 ‐9,55 ‐19,64 ‐5844,53 Transcribed locus
Bt.5326.2.S1_at LOC539364 577,14 6284,79 10,89 9,42 12,88 5707,64 similar to TIS21
Bt.7128.1.S1_at ‐‐‐ 796,65 29,51 ‐26,99 ‐14,9 ‐142,22 ‐767,14 Transcribed locus
Bt.5163.1.A1_at ‐‐‐ 802,58 4287,41 5,34 4,75 6,1 3484,83 Transcribed locus, weakly similar to NP_001847.3  1 type XVI collagen precursor [Homo sapiens]
Combine Baseline and Experiment
probe set GENE ID baseline mean (LSperiment mean (Efold change lower bound of F upper bound of Fdifference of meaGene Title
Bt.2590.1.A1_at LOC520939 57 624,62 10,96 8,35 15,92 567,63 similar to Kruppel‐like zinc finger transcription factor
Bt.23770.1.A1_at‐‐‐ 182,43 1243,81 6,82 5,96 7,96 1061,38 Transcribed locus
Bt.984.1.S1_at ‐‐‐ 1344,11 7261,92 5,4 4,76 6,25 5917,81 Transcribed locus
Bt.24280.1.A1_atLOC616194 4258,75 1140,79 ‐3,73 ‐3,47 ‐4,04 ‐3117,96 similar to Placental protein 25 (PP25)
Bt.3251.1.S1_at LOC515749 1193,56 111,84 ‐10,67 ‐8,09 ‐15,64 ‐1081,71 similar to alpha‐catenin related protein
Bt.9760.1.S1_at CX26 286,29 3183,9 11,12 9,47 13,46 2897,61 connexin 26 protein
Bt.24305.1.A1_at‐‐‐ 2461,02 586,71 ‐4,19 ‐3,8 ‐4,67 ‐1874,31 Transcribed locus
Bt.14201.1.S1_atMGC134244 630,17 2644,69 4,2 3,81 4,66 2014,52 hypothetical protein MGC134244
Bt.22210.1.S1_atCGREF1 330,7 4945,3 14,95 11,43 21,57 4614,6 cell growth regulator with EF‐hand domain 1
Bt.25849.1.S1_atMGC148634 211,7 2743,48 12,96 9,66 19,64 2531,77 similar to C1q and tumor necrosis factor related protein 6
Bt.25918.1.A1_at‐‐‐ 5,8 4424,23 763,36 157,68 100000000 4418,44 Transcribed locus
Bt.20593.2.S1_atMGC140018 800,35 6489,43 8,11 7,07 9,48 5689,08 similar to Peptidyl‐prolyl cis‐trans isomerase C (PPIase) (Rotamase) (Cyclophilin C)
Bt.16109.1.S1_at ‐‐‐ 15,24 301,49 19,78 11,94 57,19 286,25 Transcribed locus
Bt.2592.1.A1_x_aBOLA 891,81 18,44 ‐48,37 ‐24,77 ‐984,29 ‐873,38 Classical MHC class I antigen
Bt.8802.1.S1_at MGC155170 390,15 2121,27 5,44 4,69 6,46 1731,12 hypothetical LOC508425
Bt.21589.1.S1_at LOC512019 1222,92 8217 6,72 5,64 8,28 6994,08 similar to angiopoietin‐related protein‐2
Bt.8909.1.S1_at LOC525869 109,82 986,85 8,99 7,03 12,4 877,03 similar to Ankycorbin (Ankyrin repeat and coiled‐coil structure‐containing protein) (Retinoic acid‐induced protein 14) (Novel retinal pigment
Bt.25703.1.A1_atMGC139970 3278,51 1013,97 ‐3,23 ‐2,98 ‐3,52 ‐2264,54 similar to plexin domain containing 2 precursor
Bt.5379.1.S1_at LOC512072 335,8 3107,87 9,26 7,85 11,26 2772,07 similar to protein tyrosine phosphatase, receptor type, F
Bt.26846.1.A1_atLOC507856 /// M 3308,93 361,82 ‐9,15 ‐7,74 ‐11,14 ‐2947,1 similar to La ribonucleoprotein domain family, member 6
Bt.23786.1.A1_atMGC165813 2195,99 710,01 ‐3,09 ‐2,86 ‐3,36 ‐1485,97 hypothetical LOC531552
Bt.7176.1.S1_at SPON1 31,45 633,45 20,14 12,01 62,06 602,01 spondin 1, extracellular matrix protein
Bt.24841.1.S1_at LOC790463 /// SP 520,07 3511,71 6,75 5,79 8,09 2991,64 splA/ryanodine receptor domain and SOCS box containing 1 /// similar to SPRY domain‐containing SOCS box protein SSB‐1
Bt.2096.2.S1_at LOC505206 24,25 680,2 28,05 17,4 71,89 655,95 similar to pincher
Bt.21369.1.S1_at ‐‐‐ 2923,44 666,39 ‐4,39 ‐3,94 ‐4,95 ‐2257,05 Transcribed locus
Bt.24383.1.S1_atMGC151582 1477,93 123,11 ‐12 ‐8,86 ‐18,54 ‐1354,81 similar to PSGC2903
Bt.13546.2.S1_at ‐‐‐ 124,98 13,28 ‐9,41 ‐7,18 ‐13,61 ‐111,71 Transcribed locus
Bt.21041.1.S1_at ‐‐‐ 1036,66 120,36 ‐8,61 ‐6,75 ‐11,88 ‐916,29 Transcribed locus
Bt.2801.1.S1_at LOC539976 589,04 4001,93 6,79 5,76 8,26 3412,88 hypothetical LOC539976
Bt.16941.1.A1_atMPZL1 3,16 172,81 54,72 18,4 100000000 169,65 myelin protein zero‐like 1
Bt.14853.1.A1_atMGC137223 1924,4 361,79 ‐5,32 ‐4,69 ‐6,13 ‐1562,6 similar to RAB3A interacting protein isoform alpha 1
Bt.231.1.S1_at TXN 1606,67 5163,98 3,21 2,99 3,47 3557,31 thioredoxin
Bt.26992.2.S1_at ‐‐‐ 452,5 1377,93 3,05 2,82 3,31 925,43 Transcribed locus
Bt.9559.2.S1_at APP 375,5 6719,52 17,89 14,66 22,93 6344,02 amyloid beta (A4) precursor protein
Bt.692.1.S1_at LOC539385 8455,65 1484,81 ‐5,69 ‐4,87 ‐6,84 ‐6970,84 hypothetical LOC539385
Bt.20542.1.S1_at LOC514246 3881,41 754,52 ‐5,14 ‐4,5 ‐5,99 ‐3126,89 similar to Transcription factor jun‐B
Bt.21071.2.A1_at‐‐‐ 5380,88 1137,66 ‐4,73 ‐4,15 ‐5,48 ‐4243,22 Transcribed locus
Bt.24157.1.A1_atMGC152175 325,05 10,21 ‐31,84 ‐20,38 ‐72,41 ‐314,84 similar to DKFZP564O0823 protein
Bt.22545.1.S1_a_MGC148755 976,13 5125,71 5,25 4,69 5,96 4149,58 similar to fibulin‐1 C
Bt.4461.1.S1_at CKMT1 15,16 2218,01 146,29 58,55 100000000 2202,85 creatine kinase, mitochondrial 1 (ubiquitous)
Bt.9914.1.S1_at MGC128163 253,65 1459,76 5,76 4,86 7,04 1206,11 similar to dolichyl‐phosphate mannosyltransferase polypeptide 3
Bt.7655.1.S1_at MGC148333 253,16 2007,56 7,93 6,62 9,88 1754,4 similar to Y‐box protein ZONAB‐B
Bt.24793.1.S1_at ‐‐‐ 128,87 658,59 5,11 4,46 5,97 529,72 Transcribed locus
Bt.28140.1.S1_atKCTD15 242,6 1423,71 5,87 5,12 6,88 1181,1 potassium channel tetramerisation domain containing 15
Bt.12649.1.S1_atMGC129108 531,76 2386,08 4,49 3,94 5,19 1854,32 similar to myo‐inositol monophosphatase A3
Bt.209.3.S1_at LYS 134,22 3,23 ‐41,52 ‐18,78 ‐100000000 ‐130,99 lysozyme C, non‐stomach isozyme
Bt.1818.1.S1_at LOC514360 14,8 846,24 57,19 25,4 100000000 831,44 similar to desmoplakin isoform II
Bt.16710.1.A1_at‐‐‐ 1439,68 4710,09 3,27 3 3,59 3270,41 Transcribed locus
Bt.350.1.S1_s_at BLA‐DQB 2806,75 31,84 ‐88,14 ‐29,58 ‐100000000 ‐2774,91 MHC class II antigen
Bt.22108.1.S1_at ‐‐‐ 527,26 1992,45 3,78 3,47 4,14 1465,2 Transcribed locus
Bt.13885.1.S1_at ‐‐‐ 2045,81 490,85 ‐4,17 ‐3,78 ‐4,63 ‐1554,96 Transcribed locus
Bt.9570.1.S1_at LOC786672 2300,31 549,44 ‐4,19 ‐3,84 ‐4,6 ‐1750,87 similar to tumor necrosis factor, alpha‐induced protein 2
Bt.4850.1.S1_at MGC140785 741,09 2368,3 3,2 2,94 3,5 1627,21 Similar to 5‐nucleotidase, cytosolic III
Bt.4952.2.S1_a_aLOC784507 91,28 344,11 3,77 3,38 4,25 252,83 similar to RPL22L1 protein
Bt.16445.1.A1_atLOC618444 1109,24 13,36 ‐83,02 ‐42,37 ‐1995,12 ‐1095,88 hypothetical LOC618444
Bt.5550.1.S1_at IMPG1 643,72 26,18 ‐24,59 ‐12,77 ‐319,89 ‐617,54 interphotoreceptor matrix proteoglycan 1
Bt.11826.1.S1_at LOC614589 1092,85 3302,37 3,02 2,8 3,28 2209,51 similar to Zinc finger CCCH type antiviral protein 1 (Zinc finger CCCH domain‐containing protein 2)
Bt.10076.1.S1_atRCSD1 336,26 2069,56 6,15 5,12 7,69 1733,3 RCSD domain containing 1
Bt.25616.1.S1_at LOC782069 18,09 287,27 15,88 10,12 36,64 269,18 hypothetical protein LOC782069
Bt.5021.1.S1_at FBN1 122,42 825,96 6,75 5,64 8,37 703,53 fibrillin 1
Bt.17317.1.S1_at LOC534505 26,24 1109,42 42,28 16,59 100000000 1083,18 similar to Carboxypeptidase X 2 (M14 family)
Bt.1646.1.S1_at EIF3S6IP 2242,53 5133,3 2,29 2,18 2,41 2890,77 eukaryotic translation initiation factor 3, subunit 6 interacting protein
Bt.21975.1.S1_atPRF1 554,98 35,06 ‐15,83 ‐9,96 ‐38,26 ‐519,92 perforin 1 (pore forming protein)
Bt.26011.1.A1_at‐‐‐ 1130,09 101 ‐11,19 ‐9,01 ‐14,72 ‐1029,09 Transcribed locus
probe set GENE ID baseline mean (LSperiment mean (Efold change lower bound of F upper bound of Fdifference of meaGene Title
Bt.28461.1.S1_at LOC408017 441,13 6374,19 14,45 9,44 30,63 5933,06 insulin receptor
Bt.9728.1.S1_at ATP1B3 6880,18 2173,3 ‐3,17 ‐2,91 ‐3,47 ‐4706,89 ATPase, Na+/K+ transporting, beta 3 polypeptide
Bt.19739.1.A1_at‐‐‐ 104,8 552,57 5,27 4,48 6,38 447,76 Transcribed locus
Bt.20354.1.S1_at ‐‐‐ 2472,34 5464,76 2,21 2,11 2,31 2992,42 CDNA clone MGC:166326 IMAGE:8229867
Bt.24456.1.S1_at ‐‐‐ 440,8 4205,68 9,54 8,09 11,61 3764,88 Transcribed locus
Bt.19120.1.A1_at‐‐‐ 224,5 17,55 ‐12,79 ‐8,59 ‐24,93 ‐206,95 Transcribed locus
Bt.2331.1.A1_at MGC148675 7193,16 1330,47 ‐5,41 ‐4,74 ‐6,28 ‐5862,69 similar to receptor activity‐modifying protein 1
Bt.9605.1.S1_at ms4A8B 59,78 756,84 12,66 8,64 23,58 697,06 membrane spanning 4‐domain subfamily A member 8B
Bt.21563.1.S1_at LOC520730 6,74 293,17 43,52 15,74 100000000 286,43 similar to KIAA0869 protein
Bt.24343.1.A1_atCLDN1 118,1 1759,94 14,9 11,19 22,24 1641,84 claudin 1
Bt.20531.1.A1_atMGC151713 3327,98 924,54 ‐3,6 ‐3,23 ‐4,05 ‐2403,44 similar to KIAA0668 protein
Bt.6954.1.S1_at LOC505149 5685,14 740,21 ‐7,68 ‐6,16 ‐10,18 ‐4944,93 similar to regulatory erythroid kinase long form
Bt.3797.1.S1_at FMOD 848,79 6834,58 8,05 6,72 10,02 5985,79 fibromodulin
Bt.21409.2.S1_atCOL11A1 44,7 681,75 15,25 9,58 37,14 637,05 collagen, type XI, alpha 1
Bt.2191.2.S1_at ‐‐‐ 81,3 810,93 9,97 8,94 11,26 729,63 ‐‐‐
Bt.24713.1.S1_at ‐‐‐ 1336,19 227,79 ‐5,87 ‐4,86 ‐7,38 ‐1108,4 Transcribed locus
Bt.2559.1.S1_at CETN2 5305,46 1132,08 ‐4,69 ‐4,28 ‐5,17 ‐4173,38 centrin, EF‐hand protein, 2
Bt.12510.2.S1_at LOC509824 32,81 473,63 14,43 10,85 21,47 440,82 Similar to Os08g0528700
Bt.1774.1.S1_at LOC513493 646,46 1979,54 3,06 2,8 3,37 1333,08 similar to myosin IXB
Bt.4078.1.S1_at RCN3 1409,85 4866,71 3,45 3,15 3,81 3456,85 reticulocalbin 3, EF‐hand calcium binding domain
Bt.5356.1.S1_s_aBoLA‐DRB3 622,2 44,55 ‐13,97 ‐8,85 ‐32,87 ‐577,65 major histocompatibility complex, class II, DRB3
Bt.27032.1.S1_at ‐‐‐ 931,83 34,3 ‐27,16 ‐13,12 ‐100000000 ‐897,53 ‐‐‐
Bt.4817.1.A1_at MGC128478 708,67 8924,06 12,59 9,44 18,88 8215,39 similar to claudin 11
Bt.5507.2.S1_at LOC506218 4277,41 965,75 ‐4,43 ‐3,85 ‐5,19 ‐3311,66 similar to Sorting nexin 9
Bt.22199.1.S1_atMGC155271 21,02 256,77 12,22 8,19 23,92 235,75 similar to RTP801‐like protein
Bt.27481.2.S1_atSPG3A 411,15 36,53 ‐11,25 ‐7,73 ‐20,6 ‐374,62 spastic paraplegia 3A (autosomal dominant)
Bt.7018.1.S1_at MGC159915 356,06 95,57 ‐3,73 ‐3,31 ‐4,25 ‐260,49 similar to OTTHUMP00000030232
Bt.7646.1.S1_at LOC613533 407,75 4598,48 11,28 8,7 16,01 4190,73 similar to filamin B, beta (actin binding protein 278)
Bt.21934.1.S1_a_MAP2 2569,99 455,21 ‐5,65 ‐4,76 ‐6,91 ‐2114,78 microtubule‐associated protein 2
Bt.21873.1.S1_atMGC152070 1930,62 440,71 ‐4,38 ‐3,82 ‐5,12 ‐1489,92 hypothetical LOC618177
Bt.488.1.S2_at PLA2R1 161,46 16,01 ‐10,09 ‐7,83 ‐14,1 ‐145,45 phospholipase A2 receptor 1, 180kDa
Bt.20958.1.A1_atMGC152553 30,72 892,53 29,06 14,61 1916,43 861,81 similar to ADP ribosylation factor‐like protein 7
Bt.4395.1.S1_at MGC140645 3643,2 1127,12 ‐3,23 ‐2,95 ‐3,57 ‐2516,08
similar to Phosphoribosyl pyrophosphate synthetase‐associated protein 1 (PRPP synthetase‐associated protein 1) (39 kDa 
phosphoribosypyrophosphate synthetase‐associated protein) (PAP39)
Bt.23559.1.S1_atMGC139725 685,65 1607,77 2,34 2,2 2,51 922,12 similar to thiamin pyrophosphokinase 1
Bt.23178.1.S2_atDCN 923,21 3736,58 4,05 3,54 4,71 2813,36 decorin
Bt.26764.1.A1_atLEC2 288,27 1998,47 6,93 5,5 9,35 1710,2 Lectomedin 2
Bt.27973.1.S1_atSLCO3A1 1308,23 3643,36 2,78 2,56 3,05 2335,13 solute carrier organic anion transporter family, member 3A1
Bt.4793.1.S1_at SLC12A2 1983,04 65,75 ‐30,16 ‐22,76 ‐44,64 ‐1917,29 solute carrier family 12 (sodium/potassium/chloride transporters), member 2
Bt.26812.1.S1_at ‐‐‐ 1744,68 698,11 ‐2,5 ‐2,36 ‐2,65 ‐1046,57 Transcribed locus
Bt.18049.1.A1_at‐‐‐ 532,15 1766,51 3,32 3,01 3,69 1234,36 Transcribed locus
Bt.2698.1.S1_at FKBP10 894,81 3307,87 3,7 3,27 4,24 2413,06 FK506 binding protein 10, 65 kDa
Bt.26635.2.S1_atFZD1 8923,15 3053,79 ‐2,92 ‐2,68 ‐3,21 ‐5869,35 frizzled homolog 1 (Drosophila)
Bt.23900.1.A1_at‐‐‐ 395,09 1651,09 4,18 3,71 4,77 1255,99 Transcribed locus
Bt.21765.1.S1_at LOC541106 1716,16 188,36 ‐9,11 ‐6,75 ‐13,94 ‐1527,8 similar to OTTHUMP00000016853
Bt.9773.1.A1_at ‐‐‐ 2995,09 894,34 ‐3,35 ‐3 ‐3,77 ‐2100,75 Transcribed locus
Bt.5301.2.S1_a_aTHBS 4,6 201,54 43,85 14,41 100000000 196,95 thrombospondin
Bt.17704.1.S1_atCHSY1 1066,56 5333,31 5 4,21 6,13 4266,76 carbohydrate (chondroitin) synthase 1
Bt.3513.1.A1_at ‐‐‐ 1457,64 146,84 ‐9,93 ‐7,49 ‐14,62 ‐1310,79 Transcribed locus
Bt.7220.1.S1_at BLA‐DQB 301,26 4,69 ‐64,28 ‐33,08 ‐1099,07 ‐296,58 MHC class II antigen
Bt.422.1.S2_at IGFBP3 3228,51 529,92 ‐6,09 ‐5,06 ‐7,63 ‐2698,59 insulin‐like growth factor binding protein 3
Bt.6933.1.S1_at LOC613449 204,52 1681,51 8,22 7,09 9,77 1476,99 similar to KIAA0369
Bt.9310.1.S1_at C16orf5 5317,71 790,14 ‐6,73 ‐5,33 ‐9,1 ‐4527,57 chromosome 16 open reading frame 5
Bt.12356.1.S1_atMGC157300 1663,63 6185,09 3,72 3,31 4,24 4521,46 hypothetical LOC534625
Bt.22036.1.S1_at ‐‐‐ 1114,67 202,7 ‐5,5 ‐4,62 ‐6,78 ‐911,97 Transcribed locus
Bt.1770.2.A1_at LOC515860 113,89 4140,91 36,36 28,2 51,11 4027,02 similar to peroxidasin homolog
Bt.4392.2.A1_at ‐‐‐ 104,42 543,81 5,21 4,29 6,59 439,39 Transcribed locus
Bt.21760.1.S1_at ‐‐‐ 36,92 518,83 14,05 9,02 31,48 481,91 Transcribed locus
Bt.4267.1.S1_at MIA 1918,77 8279,27 4,31 3,77 5,03 6360,5 melanoma inhibitory activity
Bt.25478.1.A1_atLOC529947 151,97 1400,25 9,21 7,62 11,62 1248,28 hypothetical LOC529947
Bt.1220.1.S1_at ‐‐‐ 577,76 31,44 ‐18,38 ‐11,38 ‐47,21 ‐546,32 Transcribed locus
Bt.20091.1.S1_at ‐‐‐ 438,08 1195,34 2,73 2,61 2,85 757,27 ‐‐‐
Bt.8879.2.S1_at ‐‐‐ 415,82 1725,81 4,15 3,57 4,94 1309,99 Transcribed locus
Bt.13490.1.S1_at LOC504408 2294,48 965,41 ‐2,38 ‐2,21 ‐2,56 ‐1329,07 similar to nuclear mitogen‐ and stress‐activated protein kinase‐1
probe set GENE ID baseline mean (LSperiment mean (Efold change lower bound of F upper bound of Fdifference of meaGene Title
Bt.20226.2.A1_at‐‐‐ 3437 1232,59 ‐2,79 ‐2,55 ‐3,08 ‐2204,41 Transcribed locus
Bt.9147.1.A1_at MEP50 1024,72 3087,59 3,01 2,74 3,34 2062,88 methylosome protein 50
Bt.19337.1.S1_at ‐‐‐ 1736,68 414,78 ‐4,19 ‐3,59 ‐5,01 ‐1321,9 Transcribed locus
Bt.19578.1.S1_at LOC618914 1776,85 477,75 ‐3,72 ‐3,26 ‐4,32 ‐1299,1 hypothetical LOC618914
Bt.16495.2.A1_atLOC511602 13,27 1760,95 132,7 59,24 100000000 1747,68 similar to alpha‐5 type IV collagen
Bt.27248.1.A1_atMMP16 539,62 2349,21 4,35 4,11 4,63 1809,59 matrix metallopeptidase 16 (membrane‐inserted)
Bt.5382.1.S1_at NT5C2 970,43 2298,67 2,37 2,2 2,56 1328,24 5'‐nucleotidase, cytosolic II
Bt.1720.1.S1_at LOC788823 2221,2 5919,58 2,67 2,46 2,9 3698,38 similar to nucleolar protein No55
Bt.5040.1.S1_at UQCR 1452,05 4997,42 3,44 3,07 3,9 3545,37 ubiquinol‐cytochrome c reductase (6.4kD) subunit
Bt.20793.1.A1_s_LOC532572 253,1 1822,54 7,2 6,21 8,54 1569,44 similar to Laminin gamma‐1 chain precursor (Laminin B2 chain)
Bt.3520.1.S1_at PYCR1 998,04 2370,13 2,37 2,25 2,51 1372,09 pyrroline‐5‐carboxylate reductase 1
Bt.22504.2.S1_atMGC140208 28,47 476,43 16,74 9,91 53,63 447,96 similar to G protein‐coupled receptor 56
Bt.22471.1.S1_atPHF5A 208,43 958,95 4,6 4,01 5,38 750,53 PHD finger protein 5A
Bt.10030.2.S1_a_TMEPAI 2476,82 565,62 ‐4,38 ‐3,76 ‐5,23 ‐1911,2 transmembrane, prostate androgen induced RNA
Bt.783.1.S1_at AOX1 53,13 655,77 12,34 7,83 28,93 602,63 aldehyde oxidase 1
Bt.9549.1.S1_at LAGY 3830,9 139,59 ‐27,44 ‐22,81 ‐34,42 ‐3691,31 homeodomain only protein
Bt.21096.1.S1_at ‐‐‐ 849,72 3000,83 3,53 3,13 4,04 2151,11 ‐‐‐
Bt.8904.1.S1_at ‐‐‐ 1717,13 378,38 ‐4,54 ‐4,04 ‐5,17 ‐1338,75 ‐‐‐
Bt.1403.1.S1_at NNT 265,76 1085,8 4,09 3,5 4,89 820,04 nicotinamide nucleotide transhydrogenase
Bt.11241.1.S1_atCDH1 145,72 1294,86 8,89 7,51 10,85 1149,14 Cadherin 1, type 1, E‐cadherin (epithelial)
Bt.15717.1.A1_atLOC512918 1248,1 419,18 ‐2,98 ‐2,69 ‐3,32 ‐828,92 similar to Sorting nexin‐7
Bt.7192.1.S1_at MRPL17 461,15 1812,71 3,93 3,41 4,63 1351,57 mitochondrial ribosomal protein L17
Bt.692.2.S1_at LOC539385 3542,88 533,14 ‐6,65 ‐5,35 ‐8,73 ‐3009,73 hypothetical LOC539385
Bt.25336.1.A1_at‐‐‐ 36,58 248,99 6,81 5,34 9,34 212,41 Transcribed locus
Bt.1613.1.S1_at PRSS11 9902,53 2159,57 ‐4,59 ‐4,01 ‐5,34 ‐7742,97 protease, serine, 11
Bt.2285.1.A1_at MGC142825 366,8 1565,2 4,27 3,63 5,15 1198,4 similar to Protein kinase C, delta binding protein
Bt.28780.1.A1_atLOC505234 582,22 1871,3 3,21 2,87 3,65 1289,07
similar to FYVE, RhoGEF and PH domain‐containing protein 4 (Actin filament‐binding protein frabin) (FGD1‐related F‐actin‐binding protein) (Zinc 
finger FYVE domain‐containing protein 6)
Bt.13347.1.S1_at LOC504458 964,24 2073,84 2,15 2,01 2,3 1109,6 similar to translocated to HRX in t(11;19) leukemia
Bt.6983.1.S1_at LOC790129 86,31 1792,8 20,77 17,6 25,32 1706,49 similar to SOX9
Bt.24563.1.S1_at LOC532952 694,42 103,06 ‐6,74 ‐5,17 ‐9,62 ‐591,36 similar to membrane‐associated guanylate kinase‐related 3 (MAGI‐3)
Bt.4056.1.S1_at CRIP2 2677,53 597,23 ‐4,48 ‐3,86 ‐5,34 ‐2080,31 cysteine‐rich protein 2
Bt.3577.1.S1_at GRAMD3 1694,89 501,85 ‐3,38 ‐3,05 ‐3,78 ‐1193,05 GRAM domain containing 3
Bt.18689.2.A1_atLOC538401 1141,41 5003,78 4,38 3,83 5,11 3862,37 similar to Arylsulfatase B precursor (ASB) (N‐acetylgalactosamine‐4‐sulfatase) (G4S)
Bt.27068.1.A1_atMGC137696 5947,9 1041,33 ‐5,71 ‐5,09 ‐6,49 ‐4906,58 similar to KIAA0517 protein
Bt.17876.1.A1_at‐‐‐ 3960,04 837,86 ‐4,73 ‐3,97 ‐5,82 ‐3122,18 Transcribed locus
Bt.27755.1.S1_at LOC788643 /// P 691,6 20,16 ‐34,31 ‐18,55 ‐223,58 ‐671,44 platelet‐derived growth factor B /// hypothetical protein LOC788643
Bt.15751.1.S1_at LOC514185 1167,3 3913,39 3,35 3,05 3,72 2746,1 similar to AMP deaminase
Bt.12552.1.S1_at LOC513148 2073,47 621,37 ‐3,34 ‐2,94 ‐3,84 ‐1452,1 similar to Probable ATP‐dependent RNA helicase DHX35 (DEAH box protein 35)
Bt.569.1.S1_at MAP2 1116,48 422 ‐2,65 ‐2,43 ‐2,89 ‐694,49 microtubule‐associated protein 2
Bt.2997.1.A1_at ‐‐‐ 6101,97 167,71 ‐36,38 ‐27,71 ‐52,9 ‐5934,26 Transcribed locus
Bt.422.1.S1_at IGFBP3 2453,8 314,33 ‐7,81 ‐6,25 ‐10,37 ‐2139,47 insulin‐like growth factor binding protein 3
Bt.4235.1.S1_at LOC505942 299,42 792,46 2,65 2,41 2,92 493,04 similar to Collagen alpha 2(IX) chain precursor
Bt.27886.1.S1_s_LOC783645 290,66 1030,08 3,54 3,11 4,1 739,42 similar to vinculin isoform meta‐VCL
Bt.22613.1.A1_at‐‐‐ 607,39 1791,52 2,95 2,69 3,26 1184,13 Transcribed locus
Bt.1670.1.A1_at ‐‐‐ 213,35 990,87 4,64 3,89 5,73 777,51 ‐‐‐
Bt.9201.1.A1_at MGC128839 785,03 3369,94 4,29 3,75 5 2584,91 similar to Tetraspanin‐14 (Tspan‐14) (Transmembrane 4 superfamily member 14) (DC‐TM4F2)
Bt.5605.3.S1_at MGC137530 90,71 389,79 4,3 3,7 5,11 299,07 Similar to Myristoylated alanine‐rich C‐kinase substrate (MARCKS)
Bt.7538.1.S1_at ‐‐‐ 1872,54 5793,89 3,09 2,75 3,52 3921,35 ‐‐‐
Bt.5084.1.S1_at CKB 368,33 2402,9 6,52 4,96 9,46 2034,57 creatine kinase, brain
Bt.22679.1.S1_atMGC137743 1912,86 325,86 ‐5,87 ‐4,72 ‐7,73 ‐1587 similar to Myosin Id
Bt.24819.1.S1_at LOC785433 818,18 2558,54 3,13 2,81 3,51 1740,36 similar to formin homology 2 domain containing 3
Bt.27347.1.A1_at‐‐‐ 178,25 401,43 2,25 2,1 2,43 223,19 Transcribed locus
Bt.9996.1.S1_at LOC533726 119,92 575,19 4,8 3,97 6,01 455,26 hypothetical LOC533726
Bt.21059.1.S1_at LOC509490 1141,8 335,3 ‐3,41 ‐3,05 ‐3,86 ‐806,5 similar to eIF4E‐binding protein 3
Bt.3546.1.S1_at LOC785924 23,1 1032,3 44,68 21,95 100000000 1009,2 similar to transmembrane receptor
Bt.12199.1.A1_at‐‐‐ 552,59 2091,07 3,78 3,3 4,43 1538,48 Transcribed locus
Bt.3313.1.A1_at ARHGAP24 2025,63 658,19 ‐3,08 ‐2,74 ‐3,5 ‐1367,44 Rho GTPase activating protein 24
Bt.6853.1.S1_at ‐‐‐ 999,13 4647,4 4,65 3,84 5,87 3648,27 Transcribed locus
Bt.6516.1.A1_at LOC540332 1214,69 156,86 ‐7,74 ‐5,65 ‐12,22 ‐1057,84 similar to Coiled‐coil domain containing 85B
Bt.20501.1.S1_at ‐‐‐ 2734,57 574,78 ‐4,76 ‐4,21 ‐5,45 ‐2159,79 Transcribed locus
Bt.12718.1.A1_atLOC613972 172,29 8,01 ‐21,51 ‐10,62 ‐100000000 ‐164,28 Similar to Apolipoprotein D precursor (Apo‐D) (ApoD)
Bt.24226.1.S1_atEEF1A1 1527,26 381,34 ‐4 ‐3,4 ‐4,86 ‐1145,92 Eukaryotic translation elongation factor 1 alpha 1
Bt.3750.1.S1_at S100A11 1736,95 4353,17 2,51 2,31 2,74 2616,23 S100 calcium binding protein A11 (calgizzarin)
probe set GENE ID baseline mean (LSperiment mean (Efold change lower bound of F upper bound of Fdifference of meaGene Title
Bt.15927.1.S1_atMGC159964 447,15 3360,09 7,51 6,21 9,48 2912,93 similar to WD repeat domain, phosphoinositide interacting 1
Bt.16326.2.S1_at LOC515475 226,46 19,04 ‐11,89 ‐7,84 ‐24,38 ‐207,41 hypothetical LOC515475
Bt.23994.1.A1_atMGC143207 6160,97 2499,55 ‐2,46 ‐2,36 ‐2,57 ‐3661,42 Similar to epsilon isoform of 61kDa regulatory subunit of PP2A
Bt.28502.1.S1_atMGC140374 1175,07 4020,02 3,42 3,08 3,83 2844,95 similar to FAM83D protein
Bt.13587.1.S1_at LOC521539 588,9 3138,87 5,33 4,35 6,83 2549,96 similar to mannosidase, alpha, class 2A, member 1
Bt.20234.1.S1_at LOC510926 111,7 6650,37 59,54 43,74 93,1 6538,67 hypothetical LOC510926
Bt.12220.1.S1_a_‐‐‐ 3199,81 894,6 ‐3,58 ‐3,15 ‐4,13 ‐2305,22 Transcribed locus
Bt.7431.1.S1_a_aLOC787862 870,72 155,26 ‐5,61 ‐4,43 ‐7,6 ‐715,46 similar to Formin homology 2 domain containing 1
Bt.12054.2.S1_at LOC511748 1346,38 288,04 ‐4,67 ‐3,84 ‐5,95 ‐1058,34 similar to Yip1 domain family, member 1
Bt.22090.1.S1_at ‐‐‐ 1124,84 2666,91 2,37 2,19 2,59 1542,07 Transcribed locus
Bt.799.1.S1_at ‐‐‐ 492 1339,34 2,72 2,47 3,03 847,34 Transcribed locus
Bt.25805.1.A1_at‐‐‐ 13,07 506,35 38,73 15,61 100000000 493,27 Transcribed locus
Bt.462.1.S1_at PRKAR2B 605,83 81,78 ‐7,41 ‐6,04 ‐9,53 ‐524,05 protein kinase, cAMP‐dependent, regulatory, type II, beta
Bt.6642.1.S1_at ‐‐‐ 751,07 122,69 ‐6,12 ‐4,74 ‐8,6 ‐628,39 Transcribed locus
Bt.21978.1.S1_atMGC160122 383,6 43,59 ‐8,8 ‐6,09 ‐15,77 ‐340,01 similar to KIAA1509 protein
Bt.15847.1.S1_atMGC128861 3953,77 1444,63 ‐2,74 ‐2,51 ‐3 ‐2509,14 similar to cerebellar degeneration‐related protein 2
Bt.20554.1.S1_at LOC527410 149,05 456,31 3,06 2,72 3,5 307,25 similar to P‐Rex1 protein
Bt.20090.1.S1_at LOC526006 583,81 70,6 ‐8,27 ‐5,82 ‐14,14 ‐513,21 similar to human gamma enolase
Bt.16951.1.A1_atLOC538507 68,67 647,54 9,43 6,7 15,78 578,87 similar to FZD2 protein
Bt.11156.1.S1_atMGC137074 535,48 3542,51 6,62 5,16 9,18 3007,03 similar to Hypothetical UPF0184 protein C9orf16 homolog
Bt.19643.2.S1_at LOC520448 338,85 1764,12 5,21 4,36 6,43 1425,27 similar to large‐conductance calcium‐activated potassium channel beta subunit
Bt.8948.1.S1_at LOX 1019,96 8283,38 8,12 6,42 11,05 7263,42 lysyl oxidase
Bt.10949.1.S1_at LOC782141 781,46 2701,48 3,46 3,07 3,95 1920,02 Hypothetical protein LOC782141
Bt.5121.1.S1_at CASR 25,88 6519,89 251,97 129,82 4234,78 6494,01 calcium‐sensing receptor
Bt.9989.1.S1_at ‐‐‐ 2657,85 1150,46 ‐2,31 ‐2,16 ‐2,47 ‐1507,39 ‐‐‐
Bt.20376.1.S1_at LOC521932 635,69 2175,33 3,42 3,1 3,81 1539,65 hypothetical LOC521932
Bt.4768.1.S2_at JAM1 690,29 2135,62 3,09 2,73 3,55 1445,33 junctional adhesion molecule 1
Bt.13734.2.S1_at ‐‐‐ 41,51 611,09 14,72 8,73 46,12 569,58 Transcribed locus
Bt.23494.1.S1_at LOC516399 587,45 1914,11 3,26 2,86 3,78 1326,65 similar to UDP‐glucose:glycoprotein glucosyltransferase 2
Bt.13771.2.S1_atMGC152529 1221,44 452,67 ‐2,7 ‐2,43 ‐3,02 ‐768,77 Similar to CD134 homologue
Bt.8327.1.S1_at LOC507622 2672,59 539,46 ‐4,95 ‐4,32 ‐5,81 ‐2133,13 similar to chromosome 13 open reading frame 14
Bt.12536.1.S1_atKCNK2 5028,34 1687,78 ‐2,98 ‐2,68 ‐3,34 ‐3340,55 potassium channel, subfamily K, member 2
Bt.27717.1.A1_at‐‐‐ 836,63 166,16 ‐5,04 ‐4,17 ‐6,33 ‐670,47 Transcribed locus
Bt.2047.1.S1_at ADM 40,06 1052,64 26,27 20,26 37,29 1012,57 adrenomedullin
Bt.9300.1.A1_at LOC519626 511,1 147,95 ‐3,45 ‐3 ‐4,06 ‐363,15 similar to opioid growth factor receptor‐like 1
Bt.3236.2.S1_at LOC782247 48,9 368,02 7,53 5,36 12,52 319,12 similar to RhoGEF protein
Bt.27471.1.S1_at LOC618415 1081,74 129,09 ‐8,38 ‐6,26 ‐12,64 ‐952,65 similar to synaptogyrin 3
Bt.5163.2.S1_at ‐‐‐ 110,26 506 4,59 3,74 5,9 395,74 Transcribed locus, weakly similar to NP_001847.3  1 type XVI collagen precursor [Homo sapiens]
Bt.17635.1.A1_atMGC152587 1460,74 278,85 ‐5,24 ‐4,18 ‐6,99 ‐1181,89 similar to ELOVL4
Bt.16053.1.S1_at LOC781625 312,7 55,64 ‐5,62 ‐4,44 ‐7,62 ‐257,06 similar to plexin D1
Bt.26715.1.S1_atST14 1843,41 378,86 ‐4,87 ‐3,97 ‐6,26 ‐1464,55 suppression of tumorigenicity 14
Bt.14106.1.A1_at‐‐‐ 184,85 1409,9 7,63 6,62 8,96 1225,05 Transcribed locus
Bt.15732.1.S1_atMGC157216 3512,82 7805,4 2,22 2,08 2,38 4292,58 similar to HMGIC fusion partner‐like 2
Bt.10124.1.S1_at LOC513129 12,11 581,07 47,97 25,53 388,09 568,96 hypothetical LOC513129
Bt.23555.2.S1_at ‐‐‐ 1371,56 3165,83 2,31 2,12 2,53 1794,27 ‐‐‐
Bt.2453.1.S1_at LOC505599 2409,93 5653,51 2,35 2,18 2,54 3243,58 similar to RNA polymerase II subunit hRPB17
Bt.4451.1.S1_at MGC137365 2825,41 1046,95 ‐2,7 ‐2,45 ‐3 ‐1778,46 similar to four and a half LIM domains 2
Bt.27386.1.A1_atLOC527956 263,76 805,11 3,05 2,71 3,49 541,34 similar to ankyrin repeat domain 50
Bt.19192.1.S1_at ‐‐‐ 786,83 18,13 ‐43,4 ‐23,65 ‐259,07 ‐768,7 Transcribed locus
Bt.25952.1.A1_at‐‐‐ 420,59 1004,37 2,39 2,19 2,62 583,78 ‐‐‐
Bt.12663.1.S1_at LOC514812 1881,92 7016,37 3,73 3,23 4,4 5134,45 cytokeratin 19
Bt.26708.1.A1_atLOC537314 2182,24 558,26 ‐3,91 ‐3,33 ‐4,72 ‐1623,99 similar to leucine rich repeat containing 16
Bt.21454.1.S1_atGPRC5C 3719,7 1136,15 ‐3,27 ‐2,93 ‐3,7 ‐2583,55 G protein‐coupled receptor, family C, group 5, member C
Bt.2508.1.S1_at ‐‐‐ 343,85 72,38 ‐4,75 ‐3,93 ‐5,99 ‐271,47 Transcribed locus
Bt.9723.1.S1_at ‐‐‐ 28,57 850,94 29,79 22,63 43,52 822,38 Transcribed locus
Bt.15561.1.S1_at LOC514259 1159,81 2623,86 2,26 2,11 2,43 1464,05 hypothetical LOC514259
Bt.4441.1.S1_at LOC509889 523,21 2661,9 5,09 4,04 6,83 2138,69 hypothetical LOC509889
Bt.26316.1.A1_at‐‐‐ 55,95 666,29 11,91 8,29 20,94 610,34 Transcribed locus
Bt.7288.1.S1_at SSR4 2171,09 8545,32 3,94 3,48 4,53 6374,23 signal sequence receptor, delta (translocon‐associated protein delta)
Bt.10967.1.S1_at LOC540924 1157,21 4245,25 3,67 3,33 4,08 3088,04 similar to cartilage‐associated protein (CASP)
Bt.5959.1.S1_at LOC526726 11,83 219,89 18,59 8,91 100000000 208,06 similar to Retinal short chain dehydrogenase reductase
Bt.21083.1.S1_at LOC504658 369,73 2493,92 6,75 5,71 8,2 2124,18 hypothetical LOC504658
Bt.24716.1.S1_at ‐‐‐ 1986,11 8638,22 4,35 3,82 5,05 6652,1 Transcribed locus
Bt.16467.2.A1_atLOC532960 962,04 244,62 ‐3,93 ‐3,34 ‐4,77 ‐717,41 similar to KIAA1378 protein
probe set GENE ID baseline mean (LSperiment mean (Efold change lower bound of F upper bound of Fdifference of meaGene Title
Bt.25761.1.S1_at LOC780994 /// TH 801,95 2076,41 2,59 2,34 2,89 1274,45 THO complex 7 homolog (Drosophila) /// hypothetical protein LOC780994
Bt.16051.1.S1_at LOC513279 281,87 720,15 2,55 2,31 2,85 438,28 similar to KIAA0595 protein
Bt.15732.1.S1_a_MGC157216 1193,06 3141,64 2,63 2,38 2,94 1948,58 similar to HMGIC fusion partner‐like 2
Bt.7500.1.S1_at RAB8B 2454,15 1126,48 ‐2,18 ‐2,01 ‐2,37 ‐1327,66 RAB8B, member RAS oncogene family
Bt.20193.1.S1_atGARS 2824,8 6231,42 2,21 2,03 2,4 3406,62 glycyl‐tRNA synthetase
Bt.2289.1.S1_at ‐‐‐ 464,66 1022,64 2,2 2,04 2,39 557,98 ‐‐‐
Bt.11192.1.S1_atMGC139030 2020,75 5216,7 2,58 2,36 2,85 3195,95 similar to inducible poly(A)‐binding protein
Bt.1701.2.A1_a_aLOC616222 1445,99 4557,02 3,15 2,98 3,34 3111,03 similar to nonclathrin coat protein zeta‐COP
Bt.23779.1.A1_at‐‐‐ 16,95 1498,1 88,37 47,67 599,56 1481,15 Transcribed locus
Bt.12966.1.S1_atNOLA2 930,32 5433,35 5,84 5,02 6,98 4503,02 nucleolar protein family A, member 2
Bt.16719.1.A1_at‐‐‐ 891,03 2155,9 2,42 2,21 2,66 1264,88 ‐‐‐
Bt.23285.1.S1_at LOC616719 597,98 1451 2,43 2,21 2,68 853,02 hypothetical LOC616719
Bt.26673.1.S1_at LOC535280 4470,98 131,87 ‐33,91 ‐22,38 ‐69,65 ‐4339,11 similar to neuroblastoma, suppression of tumorigenicity 1 1
Bt.9288.3.A1_at LOC510738 17,59 1004,3 57,09 34,52 164,12 986,71 similar to FLJ00258 protein
Bt.2949.1.S1_at MGC138032 483,77 37,25 ‐12,99 ‐8,34 ‐28,96 ‐446,51 similar to Growth factor receptor‐bound protein 7 (GRB7 adapter protein) (Epidermal growth factor receptor GRB‐7) (B47)
Bt.9708.2.S1_at CUTC 2019,38 604,17 ‐3,34 ‐2,9 ‐3,92 ‐1415,21 cutC copper transporter homolog (E. coli)
Bt.11259.1.S1_at ISG12(A) 11418,3 1870,74 ‐6,1 ‐5,41 ‐6,98 ‐9547,57 similar to putative ISG12(a) protein
Bt.1645.1.S1_at PTGDS 4636,71 932,24 ‐4,97 ‐4,14 ‐6,19 ‐3704,47 prostaglandin D2 synthase 21kDa (brain)
Bt.2520.1.S1_at LOC523846 151,26 726,99 4,81 4,17 5,65 575,73 similar to testican‐2
Bt.9248.1.A1_at TNFRSF19L 132,49 2490,54 18,8 13,37 31,47 2358,05 tumor necrosis factor receptor superfamily, member 19‐like
Bt.1954.1.S1_at ‐‐‐ 2250,07 942,61 ‐2,39 ‐2,2 ‐2,61 ‐1307,46 Transcribed locus
Bt.22079.1.A1_at‐‐‐ 223,16 947,19 4,24 3,62 5,11 724,04 Transcribed locus
Bt.1336.1.S1_at LOC617340 567,85 37,94 ‐14,97 ‐7,84 ‐153,79 ‐529,91 similar to putative emu2 protein
Bt.8874.1.S1_at LOC514296 682,94 2468,91 3,62 3,07 4,37 1785,98 hypothetical LOC514296
Bt.12811.1.S1_a_UACA 4748,53 1778,46 ‐2,67 ‐2,46 ‐2,91 ‐2970,07 uveal autoantigen with coiled‐coil domains and ankyrin repeats
Bt.14272.1.A1_at‐‐‐ 1412,58 5121,27 3,63 3,33 3,97 3708,69 Transcribed locus
Bt.17605.1.A1_at‐‐‐ 146,63 737,58 5,03 4,09 6,49 590,95 Transcribed locus
Bt.15667.1.S1_at LOC539361 5920,43 1872,7 ‐3,16 ‐2,88 ‐3,49 ‐4047,73 similar to adipocyte determination and differentiation‐dependent factor 1
Bt.18748.1.A1_atLOC505696 59 11022,4 186,83 135,92 298,63 10963,41 similar to Protein tyrosine phosphatase, receptor type, B
Bt.4137.1.A1_at LOC507436 798,5 2734,2 3,42 3,14 3,76 1935,7 similar to Putative lymphocyte G0/G1 switch protein 2
Bt.23318.1.S1_at LOC510833 1743,47 7524,01 4,32 3,7 5,16 5780,54 similar to Collagen alpha 1(III) chain precursor
Bt.6651.1.S1_at LOC781063 6730,01 1398,24 ‐4,81 ‐4,04 ‐5,93 ‐5331,77 similar to T‐box 3 (ulnar mammary syndrome)
Bt.20430.1.A1_atLOC537521 333,29 47,4 ‐7,03 ‐5,12 ‐11,14 ‐285,89 similar to KIAA1622 protein
Bt.3732.1.A1_at ‐‐‐ 2419,35 5269,13 2,18 2,07 2,3 2849,78 Transcribed locus
Bt.12510.3.S1_at LOC509824 /// LO 41,1 312,42 7,6 5,34 13,06 271,32
similar to Os08g0528700 /// similar to Mucoepidermoid carcinoma translocated protein 1 (Transducer of regulated cAMP response element‐binding 
protein 1) (Transducer of CREB protein 1)
Bt.10161.1.A1_at‐‐‐ 529,99 21,11 ‐25,11 ‐14,66 ‐87,26 ‐508,88 Transcribed locus
Bt.9179.1.A1_at LOC509283 585,42 1490,55 2,55 2,31 2,83 905,13 similar to chromosome 17 open reading frame 27
Bt.13443.1.S1_at LOC531208 472,79 70,45 ‐6,71 ‐5,07 ‐9,82 ‐402,34 similar to KIAA0363
Bt.12263.1.S1_atDLL4 2129,59 264,6 ‐8,05 ‐6,23 ‐11,35 ‐1864,99 delta‐like 4 protein
Bt.16710.2.S1_at ‐‐‐ 578,61 1694,8 2,93 2,63 3,3 1116,19 Transcribed locus
Bt.24717.2.S1_a_MED6 705,02 247,04 ‐2,85 ‐2,55 ‐3,23 ‐457,98 mediator complex subunit 6
Bt.2824.1.S1_at MGC137062 996,53 2559,56 2,57 2,35 2,83 1563,03 similar to Biogenesis of lysosome‐related organelles complex‐1, subunit 1 (BLOC‐1 subunit 1) (GCN5‐like protein 1) (RT14 protein)
Bt.28173.2.S1_at LOC512700 308,93 11,53 ‐26,78 ‐12,16 ‐100000000 ‐297,39 similar to Flt3
Bt.12404.1.S1_atCLPTM1L 3036,58 6569,22 2,16 2,01 2,34 3532,64 CLPTM1‐like
Bt.13975.2.A1_atLOC613972 9494,11 175,42 ‐54,12 ‐40,29 ‐82,34 ‐9318,69 Similar to Apolipoprotein D precursor (Apo‐D) (ApoD)
Bt.22665.1.S1_atGART 975,23 2353,7 2,41 2,19 2,68 1378,47 phosphoribosylglycinamide formyltransferase
Bt.11465.1.S1_athmg‐coa‐r 627,8 2222,01 3,54 3,06 4,18 1594,21 3‐hydroxy‐3‐methylglutaryl CoA reductase
Bt.18578.1.A1_at‐‐‐ 575,1 64,11 ‐8,97 ‐5,98 ‐17,73 ‐510,99 ‐‐‐
Bt.20581.2.S1_at ‐‐‐ 58,1 336,4 5,79 4,37 8,5 278,31 Transcribed locus
Bt.18169.1.A1_at‐‐‐ 123,07 16,04 ‐7,67 ‐5,44 ‐12,93 ‐107,03 ‐‐‐
Bt.13986.1.S1_at LOC404110 13071,65 5618,84 ‐2,33 ‐2,14 ‐2,55 ‐7452,81 EST00848 homolog
Bt.24907.1.A1_atADSS 5871 1128,65 ‐5,2 ‐4,34 ‐6,49 ‐4742,35 adenylosuccinate synthase
Bt.21102.1.S1_at ‐‐‐ 321,07 12,29 ‐26,13 ‐16,69 ‐59,75 ‐308,78 ‐‐‐
Bt.28173.3.A1_a_LOC512700 1737,37 10,77 ‐161,29 ‐66,41 ‐100000000 ‐1726,6 similar to Flt3
Bt.2638.1.S1_at SERPINF1 260,55 14013,7 53,78 40,15 81,34 13753,15 serpin peptidase inhibitor, clade F (alpha‐2 antiplasmin, pigment epithelium derived factor), member 1
Bt.12864.1.S1_atMGC133682 1072,66 2361,96 2,2 2,02 2,41 1289,3 similar to 14 kDa phosphohistidine phosphatase (Phosphohistidine phosphatase 1)
Bt.18166.1.A1_atLOC540709 1905,85 391,79 ‐4,86 ‐4,17 ‐5,81 ‐1514,06 similar to KIAA0941 protein
Bt.3026.1.A1_at MGC137536 759,81 1844,55 2,43 2,21 2,68 1084,73 similar to Transcription elongation factor A protein 3 (Transcription elongation factor S‐II protein 3) (Transcription elongation factor TFIIS.h)
Bt.26960.1.S1_at ‐‐‐ 931,79 2889,23 3,1 2,8 3,47 1957,43 CDNA clone MGC:165765 IMAGE:8011844
Bt.19334.3.S1_at LOC517192 385,04 67,66 ‐5,69 ‐4,31 ‐8,31 ‐317,38 similar to jun D proto‐oncogene
Bt.26755.3.S1_a_LOC783009 744,66 214,55 ‐3,47 ‐2,99 ‐4,12 ‐530,11 similar to KIAA0674 protein
Bt.29029.1.S1_atMGC151590 1005,71 2471,53 2,46 2,25 2,7 1465,82 similar to transforming, acidic coiled‐coil containing protein 2
Bt.15298.1.A1_at‐‐‐ 205,17 8,91 ‐23,02 ‐9,58 ‐100000000 ‐196,26 Transcribed locus
probe set GENE ID baseline mean (LSperiment mean (Efold change lower bound of F upper bound of Fdifference of meaGene Title
Bt.18577.2.A1_at‐‐‐ 287,6 763,95 2,66 2,38 2,99 476,35 Transcribed locus
Bt.17000.1.A1_atLOC510272 720,22 2589,48 3,6 3,04 4,37 1869,26 hypothetical LOC510272
Bt.12366.1.S1_atMGC128891 889,66 2007,73 2,26 2,07 2,47 1118,07 similar to cyclin L2
Bt.10859.1.A1_atMGC139506 2742,15 762,25 ‐3,6 ‐3,18 ‐4,13 ‐1979,9 similar to cAMP responsive element binding protein‐like 2
Bt.9711.1.S1_at LOC510065 2477,92 941,55 ‐2,63 ‐2,36 ‐2,96 ‐1536,37 hypothetical LOC510065
Bt.4688.1.S1_a_aLOC510830 552,2 2288,81 4,14 3,49 5,08 1736,61 similar to KIAA1169 protein
Bt.22413.1.A1_atMGC155172 151,27 846,95 5,6 4,45 7,54 695,68 Similar to TLE4 protein
Bt.19656.3.A1_atBCL10 203,54 1,69 ‐120,47 ‐32,67 ‐100000000 ‐201,85 B‐cell CLL/lymphoma 10
Bt.405.1.S1_at FST 300,19 21,36 ‐14,05 ‐7,42 ‐125,3 ‐278,82 follistatin
Bt.15722.1.S1_atFBL 5404,37 2322,02 ‐2,33 ‐2,12 ‐2,58 ‐3082,36 fibrillarin
Bt.5484.1.S1_at vldlr 270,64 4058,25 15 12,78 18,12 3787,61 very low density lipoprotein receptor
Bt.3211.1.S2_at GABARAPL1 7942,4 3551,16 ‐2,24 ‐2,06 ‐2,44 ‐4391,24 GABA(A) receptor‐associated protein like 1
Bt.648.2.S1_at MGC151609 1571,72 269,28 ‐5,84 ‐5,24 ‐6,57 ‐1302,44 similar to TRIP protein
Bt.27089.1.S1_at ‐‐‐ 2523,93 602,5 ‐4,19 ‐3,8 ‐4,65 ‐1921,42 Transcribed locus
Bt.22589.1.S1_atMGC155183 320,18 1256,06 3,92 3,34 4,72 935,88 similar to group XIIA secreted phospholipase A2
Bt.1798.1.S1_at MANBA 435,64 1170,81 2,69 2,4 3,05 735,18 mannosidase, beta A, lysosomal
Bt.9169.1.A1_at LOC513730 7220,03 2671,01 ‐2,7 ‐2,47 ‐2,98 ‐4549,02 similar to notch 2 preproprotein
Bt.25475.1.A1_at‐‐‐ 17,17 5243,9 305,44 190,16 775,1 5226,73 Transcribed locus
Bt.1452.2.A1_at ‐‐‐ 1561 469,49 ‐3,32 ‐2,86 ‐3,96 ‐1091,51 Transcribed locus
Bt.8879.1.A1_at ‐‐‐ 82,2 713,82 8,68 6,13 14,68 631,61 Transcribed locus
Bt.4336.1.S1_at DF 1831,72 357,65 ‐5,12 ‐3,96 ‐7,2 ‐1474,07 D component of complement (adipsin)
Bt.17496.1.S1_at LOC511508 3202,87 1198,28 ‐2,67 ‐2,4 ‐3,01 ‐2004,6 similar to KIAA0438
Bt.20359.1.S1_atMGC148465 325,23 32,89 ‐9,89 ‐6,74 ‐18,3 ‐292,34 similar to IKAROS family zinc finger 3 (Aiolos)
Bt.14398.1.S1_atMGC127772 138,62 8274,31 59,69 44,6 90,13 8135,7 similar to phosphatidylethanolamine‐binding protein 4
Bt.4108.1.S1_at MGC151609 6511,33 663,69 ‐9,81 ‐8,19 ‐12,19 ‐5847,64 similar to TRIP protein
Bt.4831.1.S1_at NDP52 2379,61 966,85 ‐2,46 ‐2,22 ‐2,75 ‐1412,76 nuclear domain 10 protein
Bt.2257.1.S1_at ‐‐‐ 1561,84 4089,56 2,62 2,4 2,87 2527,71 Transcribed locus
Bt.7346.1.S1_at LOC507464 105,65 1095,38 10,37 8,12 14,26 989,72 similar to keratin 15
Bt.16861.1.A1_atLOC515128 282,76 1381,79 4,89 3,96 6,35 1099,03 hypothetical LOC515128
Bt.4203.1.S1_at LOC506492 1014,49 3288,94 3,24 2,82 3,79 2274,46 F1Fo‐ATP synthase complex Fo membrane domain f subunit
Bt.11179.1.S1_at ITFG3 452,84 2519,07 5,56 4,58 7,09 2066,23 integrin alpha FG‐GAP repeat containing 3
Bt.17939.1.S1_at LOC540643 28,56 156,85 5,49 4,28 7,58 128,28 similar to Lamin‐B1
Bt.9958.1.S1_at IGFBP6 13807,12 1270,08 ‐10,87 ‐7,74 ‐18,25 ‐12537,04 insulin‐like growth factor binding protein 6
Bt.5302.1.S1_a_aMRVI1 142,67 411,32 2,88 2,53 3,34 268,64 murine retrovirus integration site 1 homolog
Bt.28975.1.S1_at LOC538841 300,57 2547,91 8,48 7,57 9,6 2247,34 similar to Zinc finger SWIM domain‐containing protein 6
Bt.5395.1.S1_a_aCSPG2 13,26 159,71 12,04 6,78 52,12 146,44 chondroitin sulfate proteoglycan 2 (versican)
Bt.26030.1.A1_atLOC789674 613,5 8349,51 13,61 12,77 14,56 7736 similar to Calpain 10
Bt.7142.1.S1_at LOC617914 811,35 213,18 ‐3,81 ‐3,16 ‐4,76 ‐598,17 similar to OTTHUMP00000028701
Bt.27939.2.A1_a_LOC525346 1396,91 315,86 ‐4,42 ‐3,69 ‐5,5 ‐1081,05 similar to nuclear receptor coactivator‐1
Bt.13324.1.S1_a_IDH1 336,47 31,2 ‐10,79 ‐8,2 ‐15,64 ‐305,28 isocitrate dehydrogenase 1 (NADP+), soluble
Bt.26692.1.S1_a_LOC615342 653 186,15 ‐3,51 ‐2,97 ‐4,27 ‐466,85 similar to BCL2/adenovirus E1B 19‐kDa protein‐interacting protein 3
Bt.8121.1.S1_x_aBOLA 3888,25 37,27 ‐104,33 ‐59,36 ‐428,89 ‐3850,98 Classical MHC class I antigen
Bt.16738.1.A1_atLOC540417 7372,64 1556,97 ‐4,74 ‐4 ‐5,79 ‐5815,67 similar to Iroquois related homeobox 3 (Drosophila)
Bt.7815.1.A1_at ‐‐‐ 543,28 120,16 ‐4,52 ‐3,71 ‐5,76 ‐423,12 Transcribed locus
Bt.7773.1.S1_x_aBOLA 5435,34 116,43 ‐46,68 ‐27,67 ‐148,22 ‐5318,91 MHC class I heavy chain
Bt.27403.1.S1_at LOC540987 4818,55 1863,2 ‐2,59 ‐2,41 ‐2,79 ‐2955,36 similar to Chromosome 5 open reading frame 5
Bt.16092.1.S1_at ‐‐‐ 860,19 2788,22 3,24 2,99 3,53 1928,03 Transcribed locus
Bt.18639.2.S1_atFBXO32 252,41 43,67 ‐5,78 ‐4,45 ‐8,18 ‐208,74 F‐box protein 32
Bt.29025.1.A1_atLOC523809 7,02 127,55 18,18 8,21 100000000 120,53 similar to KIAA1959 protein
Bt.24501.1.A1_atLOC539689 525,17 1539,45 2,93 2,62 3,31 1014,28 similar to Cartilage paired‐class homeoprotein 1
Bt.17928.2.A1_atLOC532126 3417,95 854,51 ‐4 ‐3,28 ‐5,09 ‐2563,44 similar to transmembrane protein 16A
Bt.2147.1.S1_at ‐‐‐ 166,84 1609 9,64 8,17 11,73 1442,16 Transcribed locus
Bt.24794.1.A1_atC6orf106 2100,35 915,09 ‐2,3 ‐2,12 ‐2,49 ‐1185,26 Hypothetical protein LOC617655
Bt.1573.2.S1_a_aFDX1 816,32 2396,68 2,94 2,66 3,28 1580,36 ferredoxin 1
Bt.5495.1.S1_at BZW2 453,87 1231,38 2,71 2,4 3,11 777,51 basic leucine zipper and W2 domains 2
Bt.21662.1.S1_atATP6V0E2 641,73 89,68 ‐7,16 ‐4,97 ‐12,61 ‐552,05 ATPase, H+ transporting V0 subunit e2
Bt.27288.1.S1_at ‐‐‐ 65,43 424,41 6,49 4,84 9,74 358,99 Transcribed locus
Bt.3284.1.A1_a_aMGC142824 207,29 1221,7 5,89 4,56 8,26 1014,4 similar to Not56‐like protein
Bt.20296.1.S1_atSFXN2 94,93 590,61 6,22 5,39 7,33 495,67 sideroflexin 2
Bt.20991.1.S1_atPOLR3D 357,06 775,36 2,17 2,05 2,3 418,3 polymerase (RNA) III (DNA directed) polypeptide D, 44kDa
Bt.1707.1.S1_at VKORC1 3055,78 7698,62 2,52 2,28 2,81 4642,84 vitamin K epoxide reductase complex, subunit 1
Bt.18721.1.A1_at‐‐‐ 290,95 57,43 ‐5,07 ‐3,89 ‐7,19 ‐233,52 Transcribed locus
Bt.5993.1.S1_at KPNA2 1066,8 2856,88 2,68 2,4 3,03 1790,09 karyopherin alpha 2 (RAG cohort 1, importin alpha 1)
Bt.18639.1.A1_atFBXO32 2140,76 563,98 ‐3,8 ‐3,29 ‐4,49 ‐1576,78 F‐box protein 32
probe set GENE ID baseline mean (LSperiment mean (Efold change lower bound of F upper bound of Fdifference of meaGene Title
Bt.9086.1.S1_at AP1S1 9328,8 1477,88 ‐6,31 ‐5,65 ‐7,13 ‐7850,93 adaptor‐related protein complex 1, sigma 1 subunit
Bt.22647.3.A1_atLOC532952 147,61 18,74 ‐7,88 ‐5,43 ‐14,28 ‐128,87 similar to membrane‐associated guanylate kinase‐related 3 (MAGI‐3)
Bt.27101.1.S1_at ‐‐‐ 915,82 175,87 ‐5,21 ‐4,02 ‐7,35 ‐739,95 Transcribed locus
Bt.8694.1.S1_at LOC512110 7136 1862,62 ‐3,83 ‐3,27 ‐4,6 ‐5273,39 similar to Protein KIAA0195 (Transmembrane protein 94)
Bt.596.1.S1_at PHYH 4454,61 1499,91 ‐2,97 ‐2,58 ‐3,49 ‐2954,7 phytanoyl‐CoA 2‐hydroxylase
Bt.8601.1.S1_at LOC617280 145,18 729,96 5,03 3,9 7,03 584,78 similar to Rho guanine nucleotide exchange factor (GEF) 19
Bt.22373.1.A1_at‐‐‐ 781,5 2068,17 2,65 2,38 2,98 1286,67 CDNA clone MGC:160111 IMAGE:8518814
Bt.4310.1.A1_at MGC152252 250,54 21,83 ‐11,47 ‐7,39 ‐25,24 ‐228,71 similar to regulator of G‐protein signalling 1
Bt.20989.1.S1_at ‐‐‐ 498,87 1625,29 3,26 2,82 3,85 1126,41 Transcribed locus
Bt.21044.1.A1_at‐‐‐ 3277,47 1411,91 ‐2,32 ‐2,1 ‐2,58 ‐1865,56 Transcribed locus, moderately similar to XP_001092337.1  retinoic acid receptor, beta isoform 1 [Macaca mulatta]
Bt.16976.1.S1_at ‐‐‐ 294,19 71,37 ‐4,12 ‐3,35 ‐5,32 ‐222,82 Transcribed locus
Bt.269.1.S1_at ATP2C1 2433,01 1028,74 ‐2,37 ‐2,13 ‐2,65 ‐1404,27 ATPase, Ca++ transporting, type 2C, member 1
Bt.13489.1.S1_at ‐‐‐ 1057,43 2524,51 2,39 2,17 2,64 1467,08 Transcribed locus
Bt.22458.1.S1_at LOC512543 496,93 1945,13 3,91 3,52 4,39 1448,2 Hypothetical LOC512543
Bt.28780.2.A1_atLOC505234 461,17 1718,87 3,73 3,32 4,23 1257,7
similar to FYVE, RhoGEF and PH domain‐containing protein 4 (Actin filament‐binding protein frabin) (FGD1‐related F‐actin‐binding protein) (Zinc 
finger FYVE domain‐containing protein 6)
Bt.27019.1.S1_at ‐‐‐ 31,21 506,93 16,24 9,74 47,73 475,71 Transcribed locus
Bt.12294.2.A1_atAMIGO2 1232,77 98,83 ‐12,47 ‐10,43 ‐15,47 ‐1133,93 amphoterin induced gene 2
Bt.20014.1.S1_at ‐‐‐ 456,94 80,86 ‐5,65 ‐4,4 ‐7,89 ‐376,09 Transcribed locus
Bt.15808.1.S1_atMGC142541 1383,51 235,93 ‐5,86 ‐4,7 ‐7,72 ‐1147,57 similar to membrane‐associated RING‐CH protein III
Bt.28390.1.S1_at ‐‐‐ 1417,7 576,51 ‐2,46 ‐2,2 ‐2,77 ‐841,19 CDNA clone MGC:139363 IMAGE:8278811
Bt.18965.1.A1_atLOC537901 501,59 132,07 ‐3,8 ‐3,19 ‐4,68 ‐369,52 Similar to Na+‐driven Cl‐HCO3 exchanger
Bt.22465.1.S1_at LOC615055 72,66 401,44 5,53 4,13 8,28 328,78 similar to EF‐hand calcium binding domain 4A
Bt.8166.3.A1_s_aCXXC5 94,7 1603,08 16,93 13,43 22,81 1508,37 CXXC finger 5
Bt.11030.1.S1_at LOC514557 815,03 3195,79 3,92 3,3 4,82 2380,76 similar to OAF homolog (Drosophila)
Bt.3706.1.S1_at MGC152079 253,37 783,07 3,09 2,72 3,55 529,7 similar to TSC22 domain family 4
Bt.7058.1.S1_at LOC508088 888,09 2856,21 3,22 2,84 3,68 1968,12 similar to Nuclear distribution protein nudE homolog 1 (NudE)
Bt.23317.1.S1_at LOC508221 3708,43 8494,43 2,29 2,11 2,5 4786 RPL13 protein‐like
Bt.28362.1.S1_at LOC613810 174,72 589,94 3,38 2,87 4,09 415,22 similar to serine/threonine protein kinase
Bt.1287.1.S1_at PMM2 451,88 1575,94 3,49 3,04 4,07 1124,06 phosphomannomutase 2
Bt.28311.1.A1_atLOC507708 1530,34 407,04 ‐3,76 ‐3,41 ‐4,17 ‐1123,29 similar to oxysterol‐binding protein‐like protein OSBPL10
Bt.18986.1.S1_at LOC511682 1053,41 3849,9 3,65 3,26 4,16 2796,49 membrane‐bound transcription factor site 1 protease‐like
Bt.4597.1.S1_at GPR68 34,5 294,64 8,54 5,43 19,7 260,14 G protein‐coupled receptor 68
Bt.10541.1.S1_at LOC535643 1174,25 3577,89 3,05 2,64 3,59 2403,64 similar to microtubule associated serine/threonine kinase 2
Bt.28481.1.A1_at‐‐‐ 84,87 401,09 4,73 3,84 6,1 316,22 Transcribed locus
Bt.11413.1.S1_atRAB7B 116,29 460,33 3,96 3,24 5,05 344,04 RAB7B, member RAS oncogene family
Bt.29280.1.S1_at ‐‐‐ 135,37 1906,06 14,08 8,53 39,35 1770,69 Transcribed locus
Bt.28082.1.S1_atMGC139253 932,3 2810,64 3,01 2,6 3,57 1878,34 hypothetical LOC533562
Bt.7327.2.S1_a_aMGC133692 3403,72 7982,69 2,35 2,12 2,62 4578,97 hypothetical LOC506714
Bt.10620.1.S1_at LOC537203 1069,81 3808,92 3,56 2,97 4,43 2739,1 similar to DOCK180 protein
Bt.15358.1.S1_at ‐‐‐ 1516,96 525,82 ‐2,88 ‐2,5 ‐3,38 ‐991,15 Transcribed locus
Bt.15788.3.S1_at LOC507402 41,12 228,56 5,56 4,11 8,51 187,44 Similar to Bone marrow stromal cell antigen 2
Bt.9078.2.S1_a_aLOC505916 78,73 421,54 5,35 4,21 7,29 342,81 similar to spermidine synthase
Bt.10911.1.S1_at LOC506495 /// LO 446,05 1027,57 2,3 2,08 2,57 581,53 hypothetical LOC506495 /// similar to zinc finger protein 665 /// hypothetical LOC619052 /// similar to Zinc finger protein Kr18 (HKr18)
Bt.23007.1.A1_atMGC151906 751,54 297,85 ‐2,52 ‐2,24 ‐2,87 ‐453,69 Similar to Sorcin (22 kDa protein) (CP‐22) (V19)
Bt.21957.1.S1_at ‐‐‐ 3350,26 1036,2 ‐3,23 ‐2,86 ‐3,7 ‐2314,07 Transcribed locus
Bt.22857.1.S2_atTRB2 407,82 1687,56 4,14 3,52 5,01 1279,74 TRB‐2 protein
Bt.2749.1.S1_at LOC513497 525 2387,3 4,55 3,82 5,61 1862,31 similar to p21/WAF1
Bt.19625.1.A1_at‐‐‐ 1172,68 260,64 ‐4,5 ‐3,81 ‐5,48 ‐912,04 Transcribed locus, weakly similar to NP_055525.3  protein‐coupled receptor associated sorting protein 1 [Homo sapiens]
Bt.2367.1.A1_at NT5E 37,65 6631,99 176,17 81,96 100000000 6594,34 5'‐nucleotidase, ecto (CD73)
Bt.27984.1.S1_x_IgCgamma 242,19 17,66 ‐13,71 ‐7,67 ‐62,03 ‐224,53 IgG2a heavy chain constant region
Bt.26227.1.A1_at‐‐‐ 4738,96 1785,3 ‐2,65 ‐2,36 ‐3,02 ‐2953,66 Transcribed locus
Bt.5598.1.S1_at C8ORF4 14400,93 4398,91 ‐3,27 ‐2,78 ‐3,96 ‐10002,02 chromosome 8 open reading frame 4
Bt.2506.1.S1_at LOC506627 212,58 2697,21 12,69 10,55 15,87 2484,63 similar to dickkopf homolog 3
Bt.10105.1.S1_at LOC523277 306,09 5,57 ‐54,98 ‐11,95 ‐100000000 ‐300,52 similar to membrane glycoprotein
Bt.16808.2.A1_atMGC139757 507,98 23,54 ‐21,58 ‐12,61 ‐73,37 ‐484,44 similar to RAS‐like, family 12 protein
Bt.4078.2.S1_a_aRCN3 242,55 705,71 2,91 2,58 3,32 463,17 reticulocalbin 3, EF‐hand calcium binding domain
Bt.6127.1.S1_at GLB1 1114,09 2925,59 2,63 2,32 3,02 1811,5 galactosidase, beta 1
Bt.9925.1.S1_at ‐‐‐ 295,35 1548,53 5,24 4,57 6,16 1253,18 ‐‐‐
Bt.6354.1.S1_at LOC539337 2575,37 604,44 ‐4,26 ‐3,91 ‐4,66 ‐1970,93 similar to wingless‐type MMTV integration site family, member 10B
Bt.1422.1.S1_at ‐‐‐ 283,15 2067,54 7,3 5,53 10,74 1784,39 Transcribed locus
Bt.29102.1.S1_at ‐‐‐ 36,09 275,33 7,63 5,08 15,02 239,24 Transcribed locus
Bt.16326.1.S1_at LOC515475 666,91 107,6 ‐6,2 ‐4,48 ‐9,97 ‐559,32 hypothetical LOC515475
Bt.28186.1.S1_at ‐‐‐ 973,55 324,12 ‐3 ‐2,69 ‐3,38 ‐649,43 Transcribed locus, strongly similar to XP_001106588.1  similar to angiogenic factor VG5Q isoform 1 [Macaca mulatta]
probe set GENE ID baseline mean (LSperiment mean (Efold change lower bound of F upper bound of Fdifference of meaGene Title
Bt.5365.1.S1_at LOC508208 424,39 128,11 ‐3,31 ‐2,79 ‐4,05 ‐296,28 similar to LATS, large tumor suppressor, homolog 2 (Drosophila)
Bt.27719.1.A1_atSH3BP4 245,18 62,34 ‐3,93 ‐3,25 ‐4,95 ‐182,83 SH3‐domain binding protein 4
Bt.22803.1.S2_at LOC533307 1429,44 4162,83 2,91 2,54 3,4 2733,39 hypothetical LOC533307
Bt.10543.1.S1_at LOC784675 1146,86 2926,94 2,55 2,31 2,83 1780,08 Similar to KIAA1462 protein
Bt.12588.1.S1_at ‐‐‐ 6979,05 2937,05 ‐2,38 ‐2,15 ‐2,66 ‐4042,01 Transcribed locus
Bt.24478.1.S1_at LOC540132 796,7 226,82 ‐3,51 ‐2,93 ‐4,36 ‐569,88 Similar to TNE5
Bt.20968.1.S1_atVSNL1 20,67 156,93 7,59 5,05 15,04 136,26 visinin‐like 1
Bt.22046.1.S1_at LOC540376 528,26 1358,51 2,57 2,28 2,94 830,25 similar to Alpha‐methylacyl‐CoA racemase (2‐methylacyl‐CoA racemase)
Bt.16770.1.A1_at‐‐‐ 167,01 43,44 ‐3,84 ‐3,19 ‐4,8 ‐123,56 ‐‐‐
Bt.15905.1.S1_at ‐‐‐ 1616,51 687,61 ‐2,35 ‐2,12 ‐2,63 ‐928,91 Transcribed locus
Bt.9698.1.S1_at MGC142910 1896,78 844,6 ‐2,25 ‐2,05 ‐2,48 ‐1052,18 similar to CSaids binding protein
Bt.8251.1.A1_at LOC514192 317,1 976,96 3,08 2,63 3,69 659,86 similar to YEATS domain containing 2
Bt.13336.2.S1_atSMC4L1 71,78 182,23 2,54 2,26 2,89 110,45 SMC4 structural maintenance of chromosomes 4‐like 1 (yeast)
Bt.19227.2.A1_at‐‐‐ 332,44 900,57 2,71 2,4 3,09 568,14 ‐‐‐
Bt.24660.1.S1_at LRRC59 1745,76 4686,54 2,68 2,44 2,98 2940,78 leucine rich repeat containing 59
Bt.13383.1.S1_at ‐‐‐ 47,95 578,07 12,06 7,92 25,16 530,12 Transcribed locus
Bt.9556.1.S1_at MEST 609,05 2204,93 3,62 3,3 3,99 1595,88 mesoderm specific transcript homolog (mouse)
Bt.20286.1.S1_at ‐‐‐ 1982,19 540,95 ‐3,66 ‐3,12 ‐4,43 ‐1441,25 CDNA clone MGC:154987 IMAGE:8563345
Bt.4850.2.S1_at MGC140785 443,05 1932,08 4,36 3,86 4,98 1489,02 similar to 5‐nucleotidase, cytosolic III
Bt.24459.1.A1_atDCP1B 1285,88 537,71 ‐2,39 ‐2,16 ‐2,67 ‐748,17 DCP1 decapping enzyme homolog B (S. cerevisiae)
Bt.15952.1.A1_atLOC512176 /// LO 673 134,01 ‐5,02 ‐4,11 ‐6,41 ‐538,99 similar to SEC14 and spectrin domains 1
Bt.19508.1.A1_atLOC540179 292,67 1354,22 4,63 3,67 6,18 1061,55 similar to glypican 4
Bt.13313.2.S1_at LOC525346 1294,19 273,45 ‐4,73 ‐3,73 ‐6,45 ‐1020,73 similar to nuclear receptor coactivator‐1
Bt.11462.1.S1_atSDC2 1432,46 514,48 ‐2,78 ‐2,45 ‐3,22 ‐917,98 syndecan 2
Bt.5888.1.S1_at LOC782900 1169,22 3144,98 2,69 2,53 2,86 1975,76 similar to SNHG8 protein
Bt.27030.1.S1_at LOC538640 14,73 1036,25 70,37 31,96 100000000 1021,53 similar to RBM35A protein
Bt.2871.2.A1_at ‐‐‐ 3404,94 1244,04 ‐2,74 ‐2,41 ‐3,17 ‐2160,9 Transcribed locus
Bt.10515.1.S1_atMGC151821 1027,6 4574 4,45 3,98 5,03 3546,4 similar to NXN protein
Bt.9067.1.S1_at ‐‐‐ 668,65 1512,55 2,26 2,04 2,53 843,9 Transcribed locus
Bt.5237.1.S1_at IGFBP4 1873,8 740,74 ‐2,53 ‐2,27 ‐2,84 ‐1133,06 insulin‐like growth factor binding protein 4
Bt.27321.1.S1_at ‐‐‐ 285,06 720,66 2,53 2,23 2,9 435,6 Transcribed locus
Bt.11932.1.S1_at ‐‐‐ 2784,06 6441,93 2,31 2,15 2,5 3657,87 Transcribed locus
Bt.26635.1.S1_atFZD1 2308,11 550,1 ‐4,2 ‐3,44 ‐5,35 ‐1758,01 frizzled homolog 1 (Drosophila)
Bt.13465.1.S1_atMGC137215 376,85 962,11 2,55 2,25 2,93 585,26 similar to COMM domain containing 6
Bt.3714.2.S1_at ‐‐‐ 804,75 259,08 ‐3,11 ‐2,64 ‐3,75 ‐545,67 ‐‐‐
Bt.5455.3.S1_a_aLOC513782 180,89 35,29 ‐5,13 ‐3,84 ‐7,61 ‐145,6 similar to PRPF40B protein
Bt.11212.1.S1_at LOC781759 /// V 718,53 41,98 ‐17,12 ‐11,57 ‐32,56 ‐676,55 vasoactive intestinal peptide /// similar to vasoactive intestinal polypeptide
Bt.22111.1.S1_at ‐‐‐ 659,54 183,17 ‐3,6 ‐3,18 ‐4,12 ‐476,38 Transcribed locus
Bt.23659.1.S1_at ‐‐‐ 210,69 76,99 ‐2,74 ‐2,38 ‐3,2 ‐133,7 Transcribed locus
Bt.6817.1.S1_at ‐‐‐ 2819,98 197,46 ‐14,28 ‐10,83 ‐20,84 ‐2622,53 Transcribed locus
Bt.471.1.S1_at THBD 3301,06 10,49 ‐314,84 ‐87,25 ‐100000000 ‐3290,57 thrombomodulin
Bt.7873.1.S1_at LU 611,9 1655,17 2,7 2,37 3,14 1043,26 Lutheran blood group (Auberger b antigen included)
Bt.26602.1.S1_atMGC139115 155,38 442,78 2,85 2,47 3,36 287,39 hypothetical LOC509157
Bt.21721.1.A1_atMGC137635 48,31 195,17 4,04 3,23 5,35 146,87 similar to ubiquitin specific protease 2
Bt.8275.1.S1_at ‐‐‐ 131,4 2605,97 19,83 15,33 28 2474,57 Transcribed locus
Bt.27114.1.A1_at‐‐‐ 1213,25 4045,38 3,33 3,11 3,58 2832,13 Transcribed locus
Bt.23619.1.S1_a_LOC540101 266,44 44,63 ‐5,97 ‐4,22 ‐10,09 ‐221,81 similar to MGC52980 protein
Bt.20113.1.S1_atCASP6 368,27 982,87 2,67 2,41 2,98 614,6 caspase 6, apoptosis‐related cysteine peptidase
Bt.9740.1.S1_at ‐‐‐ 483,92 1369,35 2,83 2,44 3,35 885,43 Transcribed locus
Bt.26218.1.A1_at‐‐‐ 84,83 252,64 2,98 2,57 3,52 167,81 Transcribed locus
Bt.28209.1.S1_at LOC540954 809,64 295,14 ‐2,74 ‐2,38 ‐3,22 ‐514,5 similar to RGM domain family, member B
Bt.2612.1.S1_at TCTEL1 600,28 1525,38 2,54 2,29 2,84 925,1 TCTEL1 protein
Bt.27452.1.A1_at‐‐‐ 113,02 7,94 ‐14,23 ‐7,97 ‐65,77 ‐105,08 Transcribed locus
Bt.3278.1.A1_at LOC616742 610,59 1761,16 2,88 2,57 3,27 1150,57 similar to Ephrin‐A5 precursor (EPH‐related receptor tyrosine kinase ligand 7) (LERK‐7) (AL‐1)
Bt.19884.1.A1_atPLA1A 1375,93 28,67 ‐47,99 ‐21,18 ‐100000000 ‐1347,26 phospholipase A1 member A
Bt.14572.1.A1_at‐‐‐ 38,94 310,94 7,99 5,06 18,64 272 Transcribed locus
Bt.5847.1.S1_at LOC504948 1386,8 307,26 ‐4,51 ‐3,58 ‐6,08 ‐1079,54 Similar to glycerol‐3‐phosphate dehydrogenase
Bt.13296.2.A1_atMGC179470 644,68 2690,57 4,17 3,46 5,26 2045,89 hypothetical LOC534290
Bt.9791.1.S1_at LOC414346 152,82 430,36 2,82 2,47 3,25 277,54 cyclophilin F
Bt.21409.1.A1_atCOL11A1 11,91 3147,83 264,29 142,27 1848,61 3135,91 collagen, type XI, alpha 1
Bt.7676.3.S1_at IGF2 7783,07 1279,02 ‐6,09 ‐4,92 ‐7,89 ‐6504,05 insulin‐like growth factor 2
Bt.17810.1.S1_a_RBP1 3667,44 243,99 ‐15,03 ‐12,33 ‐19,2 ‐3423,45 retinol binding protein 1, cellular
Bt.21014.1.S1_at LOC529905 126,26 1361,69 10,78 8,08 16,09 1235,43 hypothetical LOC529905
Bt.11832.2.A1_at‐‐‐ 409,57 91,52 ‐4,48 ‐3,45 ‐6,33 ‐318,05 Transcribed locus
probe set GENE ID baseline mean (LSperiment mean (Efold change lower bound of F upper bound of Fdifference of meaGene Title
Bt.27058.1.A1_atLOC511976 465,08 11,44 ‐40,66 ‐17,11 ‐100000000 ‐453,65 similar to integrin, alpha 8
Bt.9286.1.S1_at MGC137407 473,85 1172,54 2,47 2,23 2,77 698,7 similar to LPS‐induced TN factor
Bt.27803.1.A1_atLOC522810 759,27 130,27 ‐5,83 ‐4,55 ‐8,09 ‐629,01 similar to testis expressed sequence 14
Bt.6612.1.S1_at LOC507418 207,99 591,82 2,85 2,52 3,25 383,82 hypothetical LOC507418
Bt.18637.1.A1_atLOC506860 975,12 2192,69 2,25 2,08 2,44 1217,57 similar to 6‐pyruvoyl tetrahydrobiopterin synthase precursor (PTPS) (PTP synthase)
Bt.3715.1.S1_at LOC789063 1743,69 4850,26 2,78 2,48 3,16 3106,57 similar to chromosome 6 open reading frame 86
Bt.23171.2.S1_atPCBD1 5357,47 2186,4 ‐2,45 ‐2,17 ‐2,8 ‐3171,06 pterin‐4 alpha‐carbinolamine dehydratase/dimerization cofactor of hepatocyte nuclear factor 1 alpha (TCF1)
Bt.29481.1.A1_atMGC139804 471,15 1282,06 2,72 2,4 3,12 810,91 hypothetical LOC509583
Bt.12414.1.S1_at LOC508633 1677,53 31,6 ‐53,08 ‐27,73 ‐596,34 ‐1645,92 similar to CD8 beta antigen
Bt.3724.1.S1_at ‐‐‐ 3471,37 837,44 ‐4,15 ‐3,76 ‐4,6 ‐2633,93 Transcribed locus
Bt.15667.2.S1_at LOC539361 1019,2 235,5 ‐4,33 ‐3,67 ‐5,27 ‐783,7 similar to adipocyte determination and differentiation‐dependent factor 1
Bt.26769.1.S1_at LOC531516 556,24 11,85 ‐46,95 ‐23,48 ‐11604,31 ‐544,39 similar to GTPase, IMAP family member 8
Bt.16441.1.A1_atLOC508151 1241,34 2875,95 2,32 2,09 2,59 1634,61 similar to Desmoglein 2
Bt.5964.3.S1_at ‐‐‐ 344,62 63,19 ‐5,45 ‐4,2 ‐7,75 ‐281,43 Transcribed locus
Bt.19978.1.A1_at‐‐‐ 2231,25 758,94 ‐2,94 ‐2,52 ‐3,52 ‐1472,31 Transcribed locus
Bt.11386.1.S1_at LOC510844 1938,81 248,33 ‐7,81 ‐5,91 ‐11,36 ‐1690,48 similar to Alpha‐fetoprotein enhancer‐binding protein (AT motif‐binding factor) (AT‐binding transcription factor 1)
Bt.18822.1.A1_atTRB2 1385,72 5957,36 4,3 3,67 5,18 4571,64 TRB‐2 protein
Bt.22174.1.S1_at LOC523661 1644,82 447,42 ‐3,68 ‐3,17 ‐4,34 ‐1197,4 similar to neural plakophilin‐related arm‐repeat protein (NPRAP)
Bt.21770.1.S1_atSLC29A1 3941,9 400,45 ‐9,84 ‐7,25 ‐15,31 ‐3541,45 solute carrier family 29 (nucleoside transporters), member 1
Bt.28910.1.A1_at‐‐‐ 236,68 27,23 ‐8,69 ‐5,9 ‐16,17 ‐209,45 ‐‐‐
Bt.27339.2.S1_at LOC536741 18,7 289,68 15,49 9,04 52,55 270,98 similar to Mme protein
Bt.22234.1.S1_at LOC505901 499,56 53,49 ‐9,34 ‐6,3 ‐17,72 ‐446,07 similar to protein kinase C‐theta
Bt.8798.2.S1_at LOC507093 /// LO 360,52 52,54 ‐6,86 ‐5,1 ‐10,33 ‐307,97 similar to retinaldehyde dehydrogenase 3 /// similar to aldehyde dehydrogenase 6
Bt.8888.1.A1_at LOC523408 5151,19 1248,06 ‐4,13 ‐3,71 ‐4,63 ‐3903,13 similar to importin 8
Bt.6407.1.S1_at LOC782137 /// M 139,65 706,11 5,06 4,52 5,71 566,46 hypothetical protein LOC613986 /// hypothetical protein LOC782137
Bt.10340.1.S1_at ‐‐‐ 2599,12 497,2 ‐5,23 ‐4,27 ‐6,68 ‐2101,92 Transcribed locus
Bt.1760.1.S1_at MGC148716 450,23 3493,62 7,76 7,16 8,46 3043,38 similar to CGI‐114 protein
Bt.6404.1.S1_at LOC407241 1162,36 155,21 ‐7,49 ‐5,28 ‐12,82 ‐1007,16 Kruppel‐like factor 15
Bt.4065.1.S1_at ‐‐‐ 609,83 242,74 ‐2,51 ‐2,22 ‐2,88 ‐367,09 Transcribed locus
Bt.13324.4.S1_at IDH1 4856,95 1981,52 ‐2,45 ‐2,28 ‐2,64 ‐2875,44 isocitrate dehydrogenase 1 (NADP+), soluble
Bt.27918.1.S1_at LOC505059 639,29 175,02 ‐3,65 ‐3,02 ‐4,57 ‐464,27 similar to Wtip protein
Bt.5098.1.S1_at PTPN13 2446,88 800,06 ‐3,06 ‐2,65 ‐3,62 ‐1646,82 protein tyrosine phosphatase, non‐receptor type 13
Bt.8337.1.S1_at ‐‐‐ 1427,99 356,86 ‐4 ‐3,56 ‐4,54 ‐1071,14 Transcribed locus
Bt.20226.1.A1_at‐‐‐ 4913,22 2102,39 ‐2,34 ‐2,14 ‐2,57 ‐2810,83 Transcribed locus
Bt.2846.1.A1_at MGC154996 179,1 627,1 3,5 2,86 4,48 448 similar to ras homolog gene family, member U
Bt.22982.1.A1_atRTN1 309,63 1149,27 3,71 2,98 4,88 839,64 reticulon 1
Bt.21741.2.A1_atLOC530184 1830,36 209 ‐8,76 ‐7,47 ‐10,54 ‐1621,36 similar to Ssbp3 protein
Bt.20519.1.A1_atLOC507076 /// LO 11,37 599,7 52,73 27,87 473,84 588,33 similar to dopamine‐oxygenase /// hypothetical protein LOC784321
Bt.28641.1.S1_at ‐‐‐ 138,88 24,18 ‐5,74 ‐4,69 ‐7,35 ‐114,7 Transcribed locus, moderately similar to XP_235326.4  similar to two AAA domain containing protein [Rattus norvegicus]
Bt.13413.2.A1_at‐‐‐ 174,93 583,07 3,33 2,74 4,21 408,13 Transcribed locus
Bt.6661.1.S1_at MGC128636 1737,33 5165,93 2,97 2,54 3,55 3428,6 similar to transcription elongation factor B (SIII), polypeptide 2
Bt.14204.1.A1_atLOC538880 1640,33 5024,43 3,06 2,7 3,54 3384,1 similar to cytoplasmic polyadenylation element binding protein CPEB2b
Bt.2091.1.S1_at MGC139459 603,94 4273,63 7,08 5,86 8,86 3669,69 similar to RTP801
Bt.19884.2.S1_atPLA1A 402,24 6,27 ‐64,16 ‐24,32 ‐100000000 ‐395,97 phospholipase A1 member A
Bt.9786.1.S1_at MGC139669 603,88 44,91 ‐13,45 ‐9,03 ‐25,94 ‐558,97 similar to Alpha‐N‐acetylgalactosaminide alpha‐2,6‐sialyltransferase 2 (GalNAc alpha‐2,6‐sialyltransferase II) (ST6GalNAc II) (Sialyltransferase 7B) 
Bt.24266.2.S1_at LOC534869 616,58 78,15 ‐7,89 ‐4,96 ‐18,73 ‐538,43 similar to KIAA0172
Bt.19598.1.A1_at‐‐‐ 367,11 10,22 ‐35,91 ‐15,91 ‐100000000 ‐356,89 ‐‐‐
Bt.21939.1.S1_at ‐‐‐ 887,08 99,88 ‐8,88 ‐5,78 ‐19,09 ‐787,21 Transcribed locus
Bt.11260.2.S1_at LOC511904 514,12 1195,68 2,33 2,06 2,65 681,56 similar to TGOLN2 protein
Bt.19329.2.S1_atMGC139784 995,86 66,23 ‐15,04 ‐10,82 ‐24,45 ‐929,62 similar to EF‐hand domain‐containing protein 1 (Swiprosin‐2)
Bt.6509.3.S1_a_aLOC511043 34,57 199,95 5,78 4,08 9,84 165,38 similar to laminin 5 gamma 2 subunit
Bt.13028.1.S1_atPOSTN 59,15 315,87 5,34 4,66 6,22 256,72 periostin, osteoblast specific factor
Bt.13604.1.S1_at ‐‐‐ 306,29 691,95 2,26 2,04 2,51 385,65 Transcribed locus
Bt.5531.3.S1_at BACE1 2302,43 829,55 ‐2,78 ‐2,38 ‐3,31 ‐1472,87 beta‐site APP‐cleaving enzyme 1
Bt.4750.1.S1_at TKT 2020,1 5351,13 2,65 2,31 3,09 3331,04 transketolase
BtAffx.1.2.S1_at ATP8A1 72,78 206,12 2,83 2,42 3,39 133,33 ATPase, aminophospholipid transporter (APLT), Class I, type 8A, member 1
Bt.28395.1.S1_atMGC137245 690,37 149,51 ‐4,62 ‐3,52 ‐6,62 ‐540,86 similar to WD repeat domain 54
Bt.4937.1.S1_at LOC505941 4157,56 9529,14 2,29 2,09 2,54 5371,59 similar to ribosome binding protein 1
Bt.13588.1.A1_atMGC166278 240,77 986,79 4,1 3,23 5,56 746,02 similar to Phosphoserine aminotransferase 1
Bt.28145.1.S1_at ‐‐‐ 70,31 368,73 5,24 4,21 6,89 298,42 Polymorphic microsatellite locus (AFZ1)
Bt.8823.2.S1_a_aMGC126999 329,75 1041,96 3,16 2,74 3,73 712,21 similar to Protein C9orf46
Bt.14054.1.A1_atMGC127247 2369,42 715,63 ‐3,31 ‐2,92 ‐3,8 ‐1653,8 similar to interferon‐related developmental regulator 1
Bt.11408.1.A1_at‐‐‐ 148,3 1609,21 10,85 9,65 12,37 1460,9 Transcribed locus
Bt.13723.1.S1_atMGC127182 54,19 311,92 5,76 4,13 9,42 257,73 Similar to sulfotransferase family, cytosolic, 1B, member 1
probe set GENE ID baseline mean (LSperiment mean (Efold change lower bound of F upper bound of Fdifference of meaGene Title
Bt.11362.1.A1_at‐‐‐ 292,55 12,39 ‐23,61 ‐11,61 ‐100000000 ‐280,16 Transcribed locus, strongly similar to XP_001100845.1  similar to cyclic AMP‐regulated phosphoprotein, 21 kD isoform 1 isoform 1 [Macaca mulatta]
Bt.28617.1.S1_at ‐‐‐ 3114,54 233,13 ‐13,36 ‐10,98 ‐17 ‐2881,41 Transcribed locus, weakly similar to NP_001018155.1  [Danio rerio]
Bt.22304.1.S1_at LOC614557 542,96 225,67 ‐2,41 ‐2,19 ‐2,65 ‐317,29 hypothetical LOC614557
Bt.28305.1.S1_at LOC515280 3916,67 76,5 ‐51,2 ‐34,35 ‐100,15 ‐3840,17 similar to hepatocellular carcinoma antigen gene 520
Bt.18674.1.A1_at‐‐‐ 8,81 550,96 62,56 31,43 5015,46 542,16 Transcribed locus
Bt.4775.1.S1_at LOC525716 3383,71 1326,92 ‐2,55 ‐2,27 ‐2,9 ‐2056,79 S100B
Bt.2933.1.S1_at LOC788205 325,79 1227,04 3,77 3,08 4,8 901,25 hypothetical protein LOC788205
Bt.21547.1.A1_atMGC140246 181,66 885,44 4,87 3,91 6,39 703,78 similar to plakophilin 2a
Bt.6509.1.S1_at LOC511043 16,78 289,29 17,24 10,12 56,48 272,51 similar to laminin 5 gamma 2 subunit
Bt.17954.1.A1_at‐‐‐ 205,48 533,42 2,6 2,3 2,97 327,95 Transcribed locus
Bt.12058.1.A1_at‐‐‐ 2665,65 1023,26 ‐2,61 ‐2,26 ‐3,05 ‐1642,39 Transcribed locus
Bt.3778.1.S1_at LOC526461 499,97 7296,3 14,59 12,36 17,76 6796,33 similar to interferon induced transmembrane protein 5
Bt.11058.1.A1_atPDP 1737,32 704,32 ‐2,47 ‐2,16 ‐2,86 ‐1033 pyruvate dehydrogenase phosphatase
Bt.20236.1.S1_atADAMTSL4 639,6 1557,21 2,43 2,14 2,81 917,61 thrombospondin repeat containing 1
Bt.21685.1.A1_at‐‐‐ 342,87 61,72 ‐5,56 ‐4,6 ‐6,95 ‐281,15 Transcribed locus
Bt.12294.1.S1_atAMIGO2 165,69 30,51 ‐5,43 ‐3,85 ‐9,05 ‐135,18 amphoterin induced gene 2
Bt.25921.1.A1_at‐‐‐ 16,89 183,39 10,86 6,16 43,57 166,51 Transcribed locus
Bt.27800.1.A1_atMGC152029 520,45 1187,51 2,28 2,04 2,57 667,06 similar to source of immunodominant MHC‐associated peptides
Bt.24919.1.S1_at ‐‐‐ 58,55 323,1 5,52 3,98 8,91 264,54 Transcribed locus
Bt.21944.1.S1_atMGC139976 88,03 383,1 4,35 3,63 5,37 295,07 similar to Syndecan‐1 precursor (SYND1) (CD138 antigen)
Bt.17963.1.A1_atARL1 829,23 2114,83 2,55 2,3 2,86 1285,6 ADP‐ribosylation factor‐like 1
Bt.13162.1.S1_atKRT5 78,2 9754,99 124,74 73,65 405,88 9676,79 keratin 5 (epidermolysis bullosa simplex, Dowling‐Meara/Kobner/Weber‐Cockayne types)
Bt.1521.1.S1_at RDX 2268,71 5450,04 2,4 2,25 2,58 3181,33 radixin
Bt.10341.1.S1_at ‐‐‐ 222,23 611,01 2,75 2,36 3,28 388,77 Transcribed locus
Bt.4956.1.S1_at COL11A1 52,55 496,54 9,45 5,56 31,03 443,99 collagen, type XI, alpha 1
Bt.29371.1.A1_at‐‐‐ 7,03 138,62 19,72 8,65 100000000 131,59 Transcribed locus
Bt.13546.1.A1_at‐‐‐ 267,74 37,05 ‐7,23 ‐4,63 ‐16,22 ‐230,69 Transcribed locus
Bt.8531.1.A1_at MGC140202 1491,88 4608,54 3,09 2,83 3,38 3116,65 hypothetical LOC512206
Bt.13757.1.S1_at ‐‐‐ 2149,45 286,24 ‐7,51 ‐6,1 ‐9,7 ‐1863,22 Transcribed locus
Bt.126.1.S2_at KCNJ2 11,09 116,92 10,54 5,59 84,89 105,83 potassium inwardly‐rectifying channel, subfamily J, member 2
Bt.7541.1.S1_at LOC789324 /// N 178,79 420,21 2,35 2,08 2,68 241,42 non‐metastatic cells 4, protein expressed in /// similar to nucleoside‐diphosphate kinase
Bt.21215.1.A1_atLOC506721 77,39 5356 69,21 58,35 84,96 5278,61 similar to ALL1 responsive protein ARP1c
Bt.17982.1.S1_at ‐‐‐ 204,15 485,6 2,38 2,09 2,75 281,45 Transcribed locus
Bt.26942.1.S1_at LOC530164 569,02 1485,04 2,61 2,26 3,07 916,02 similar to membrane glycoprotein SP55
Bt.13495.1.S1_at ‐‐‐ 102,99 6065,15 58,89 42,67 94,83 5962,16 Transcribed locus
Bt.16749.1.S1_at LOC782382 101,02 525,42 5,2 3,8 8,17 424,4 similar to plexin A3
Bt.16925.1.A1_atLOC515156 /// LO 40,89 203,23 4,97 4,16 6,11 162,34 similar to six transmembrane endothelial antigen of PAEC /// hypothetical protein LOC784147
Bt.10870.1.S1_at ‐‐‐ 159,18 17,79 ‐8,95 ‐5,62 ‐21,74 ‐141,38 Transcribed locus
Bt.11696.2.S1_at ‐‐‐ 301,69 678,51 2,25 2 2,56 376,82 Transcribed locus
Bt.21539.1.S1_atMGC127316 459,85 1533,65 3,34 2,9 3,91 1073,81 similar to CG32066‐PB
Bt.21115.1.A1_atMGC143381 657,28 2334,47 3,55 2,88 4,61 1677,19 similar to SEC23A (S. cerevisiae)
Bt.2798.1.S1_a_aTMSB10 1883,14 14080,93 7,48 5,71 10,81 12197,79 thymosin, beta 10
Bt.28143.1.S1_at ‐‐‐ 4680,34 1953,54 ‐2,4 ‐2,19 ‐2,64 ‐2726,8 ‐‐‐
Bt.27968.1.S1_atMGC155048 11,31 2236,07 197,76 96,93 100000000 2224,76 similar to autoantigen
Bt.25966.1.A1_atCBX6 6585,59 2644,41 ‐2,49 ‐2,3 ‐2,71 ‐3941,17 Chromobox homolog 6
Bt.28201.1.S1_atMGC148280 26,77 193,45 7,23 4,54 17,15 166,68 similar to SQAW5801
Bt.26703.1.S1_at ‐‐‐ 1500,38 571,29 ‐2,63 ‐2,26 ‐3,11 ‐929,08 Transcribed locus
Bt.16063.1.A1_at‐‐‐ 492,67 2323,04 4,72 4,02 5,65 1830,37 Transcribed locus
Bt.6351.1.S1_at ‐‐‐ 80,94 384,79 4,75 3,85 6,14 303,86 Transcribed locus, weakly similar to NP_001847.3  1 type XVI collagen precursor [Homo sapiens]
Bt.2582.1.S1_at GALNT1 183,48 719,58 3,92 3,32 4,75 536,09 UDP‐N‐acetyl‐alpha‐D‐galactosamine:polypeptide N‐acetylgalactosaminyltransferase 1 (GalNAc‐T1)
Bt.2129.1.S1_at LOC786175 /// LO 24,95 205,18 8,22 5,55 15,78 180,22 similar to versican V0 splice‐variant
Bt.8669.1.S1_at ‐‐‐ 263,4 906,83 3,44 2,85 4,3 643,43 Transcribed locus
Bt.2369.1.S1_at MGC142882 1863,69 352,12 ‐5,29 ‐4,37 ‐6,65 ‐1511,57 similar to Ubiquitin specific peptidase 3
Bt.16056.1.A1_atLOC525906 87,19 521,5 5,98 4,96 7,47 434,31 similar to Cas‐Br‐M (murine) ecotropic retroviral transforming sequence b
Bt.5451.1.S1_at RAB5B 79,25 270,15 3,41 2,77 4,4 190,9 RAB5B, member RAS oncogene family
Bt.22869.1.S1_atFABP5 43,13 1490,83 34,57 23,09 68,35 1447,71 fatty acid binding protein 5
Bt.21956.2.A1_at‐‐‐ 392,19 871,75 2,22 2,04 2,43 479,57 ‐‐‐
Bt.20930.1.A1_atLOC782162 /// LO 537,33 85,61 ‐6,28 ‐4,16 ‐12,53 ‐451,72 hypothetical protein LOC782162 /// similar to folate transporter/carrier
Bt.18945.1.A1_atLOC525772 712,47 1650,76 2,32 2,12 2,55 938,29 similar to pleckstrin homology domain containing, family G (with RhoGef domain) member 1
Bt.30.1.S1_at CRTL1 192 2320,12 12,08 10,91 13,52 2128,12 cartilage linking protein 1
Bt.24547.1.S1_at ‐‐‐ 402,18 40,11 ‐10,03 ‐6,16 ‐25,95 ‐362,07 Transcribed locus
Bt.17497.1.S1_at ‐‐‐ 352,41 857,01 2,43 2,12 2,83 504,6 Transcribed locus
Bt.13484.1.A1_atPPP1R3C 918,49 342,67 ‐2,68 ‐2,34 ‐3,11 ‐575,82 protein phosphatase 1, regulatory (inhibitor) subunit 3C
Bt.22013.1.S1_atPRKCH 713,3 64,01 ‐11,14 ‐8,39 ‐16,42 ‐649,29 protein kinase C, eta
probe set GENE ID baseline mean (LSperiment mean (Efold change lower bound of F upper bound of Fdifference of meaGene Title
Bt.5911.1.S1_at ‐‐‐ 2115,53 790,11 ‐2,68 ‐2,38 ‐3,05 ‐1325,42 Transcribed locus
Bt.4551.1.S1_at CTPS 315,39 4966,06 15,75 13,28 19,27 4650,67 CTP synthase
Bt.27343.1.A1_atLOC534114 260,64 66,5 ‐3,92 ‐3,24 ‐4,91 ‐194,14 similar to Rab3A‐interacting molecule
Bt.21473.1.A1_atMPZL1 425,35 1847,2 4,34 3,42 5,93 1421,85 myelin protein zero‐like 1
Bt.3560.1.S1_at LOC786606 437,09 138,81 ‐3,15 ‐2,62 ‐3,91 ‐298,28 similar to SH3 domain binding protein
Bt.9449.1.S1_at LOC510175 504,82 8,1 ‐62,34 ‐28,71 ‐100000000 ‐496,72 similar to Proline‐rich cyclin A1‐interacting protein
Bt.12444.2.S1_atTEX261 549,94 196,03 ‐2,81 ‐2,39 ‐3,37 ‐353,91 testis expressed 261
Bt.16220.1.S1_at LOC538491 8617,5 2385,81 ‐3,61 ‐3,2 ‐4,12 ‐6231,69 hypothetical LOC538491
Bt.4080.1.S1_at LOC512530 2091,89 5846,02 2,79 2,36 3,4 3754,12 similar to SEC13‐like 1
Bt.20510.1.S1_atMGC127681 2530,48 1044,87 ‐2,42 ‐2,11 ‐2,81 ‐1485,6 similar to phospholemman precursor
Bt.21119.1.A1_atLOC525346 579,78 93,45 ‐6,2 ‐4,22 ‐11,6 ‐486,32 similar to nuclear receptor coactivator‐1
Bt.22600.1.A1_at‐‐‐ 217,43 57,98 ‐3,75 ‐2,94 ‐5,13 ‐159,44 Transcribed locus
Bt.17162.1.A1_at‐‐‐ 223,18 33,13 ‐6,74 ‐5,51 ‐8,59 ‐190,05 Transcribed locus
Bt.28583.1.S1_s_COL1A1 /// LOC4 2592,43 15824,73 6,1 5,16 7,42 13232,3 collagen, type I, alpha 1 /// similar to pro alpha 1(I) collagen
Bt.11380.1.A1_at‐‐‐ 5,1 139,84 27,4 11,46 100000000 134,73 Transcribed locus
Bt.21015.1.S1_atMGC142781 289,86 859,03 2,96 2,49 3,65 569,16 carnitine acetyltransferase
Bt.719.1.A1_at ‐‐‐ 925,76 2249,51 2,43 2,22 2,68 1323,75 Transcribed locus
Bt.20511.1.S1_at LOC783943 /// M 451,26 52,8 ‐8,55 ‐5,29 ‐21,43 ‐398,46 similar to Ral guanine nucleotide dissociation stimulator A
Bt.28687.1.A1_atLOC618247 35,76 340,01 9,51 7,19 13,87 304,25 similar to ZMYM6 protein
Bt.10245.1.S1_atMGC154964 4724,74 1864,15 ‐2,53 ‐2,25 ‐2,9 ‐2860,59 similar to p130
Bt.14228.1.S1_atRPL35 2934,09 8285,91 2,82 2,59 3,11 5351,82 ribosomal protein L35
Bt.2888.1.S1_at OSTF1 1271,07 5123,44 4,03 3,69 4,43 3852,37 osteoclast stimulating factor 1
Bt.15667.1.S1_a_‐‐‐ 9446,04 3816,6 ‐2,47 ‐2,22 ‐2,8 ‐5629,44 ‐‐‐
Bt.15400.1.A1_at‐‐‐ 1639,24 328,24 ‐4,99 ‐4,32 ‐5,87 ‐1311 ‐‐‐
Bt.6728.1.A1_at Ndn 701,65 1584,71 2,26 2,01 2,57 883,06 necdin
Bt.11704.1.S1_at ‐‐‐ 184,19 1201,47 6,52 4,93 9,62 1017,28 Transcribed locus
Bt.28105.1.S1_at LOC615534 3985,13 8900,44 2,23 2,04 2,46 4915,32 similar to Fibronectin type III domain containing 3B
Bt.4929.1.S2_at GAA 307,07 967,27 3,15 2,68 3,79 660,2 glucosidase, alpha; acid
Bt.28741.1.A1_atMGC152526 96,77 401,47 4,15 3,54 4,97 304,7 similar to hepatocellular carcinoma antigen 519
Bt.6002.1.S1_at LOC505787 1152,51 378,31 ‐3,05 ‐2,59 ‐3,68 ‐774,2 similar to ABC‐C transporter
Bt.1756.2.S1_at ‐‐‐ 7473,92 3223,49 ‐2,32 ‐2,03 ‐2,69 ‐4250,43 Transcribed locus
Bt.25063.1.A1_at‐‐‐ 1793,2 426,04 ‐4,21 ‐3,49 ‐5,25 ‐1367,16 Transcribed locus
Bt.20596.1.S1_atEVA1 10,57 641,75 60,7 22,94 100000000 631,18 epithelial V‐like antigen 1
Bt.9217.1.A1_at MGC151529 546,11 185,79 ‐2,94 ‐2,44 ‐3,66 ‐360,32 Similar to RT1‐149 protein
Bt.21284.1.A1_at‐‐‐ 3530,16 1455,61 ‐2,43 ‐2,25 ‐2,62 ‐2074,55 Transcribed locus
Bt.3371.1.S1_at LOC510120 37,55 313,81 8,36 5,72 15,15 276,27 similar to MCM2 minichromosome maintenance deficient 2, mitotin (S. cerevisiae)
Bt.28189.1.S1_at ‐‐‐ 1163,24 2742,26 2,36 2,12 2,65 1579,02 Transcribed locus
Bt.6592.1.S1_at CDH13 2721,52 6562,9 2,41 2,18 2,69 3841,38 cadherin 13, H‐cadherin (heart)
Bt.29143.1.S1_atMGC139389 36,67 213,94 5,83 4,1 9,86 177,27 similar to B‐cell CLL/lymphoma 11A
Bt.24984.1.A1_at‐‐‐ 252,31 39,87 ‐6,33 ‐4,1 ‐13,57 ‐212,44 Transcribed locus
Bt.23576.1.A1_atLOC539655 2685,4 6043,53 2,25 2,02 2,53 3358,13 similar to PCTAIRE protein kinase 2
Bt.23654.1.S1_at LOC614589 2050,19 4694,6 2,29 2,1 2,51 2644,41 similar to Zinc finger CCCH type antiviral protein 1 (Zinc finger CCCH domain‐containing protein 2)
Bt.4404.1.A1_at TRYP8 19,75 333,98 16,91 10,23 47,39 314,22 pancreatic anionic trypsinogen
Bt.26048.1.A1_atMGC133508 564,14 4209,94 7,46 6,54 8,65 3645,8 similar to Small EDRK‐rich factor 1 (4F5) (m4F5)
Bt.24314.1.A1_atFBP2 1982,42 499,63 ‐3,97 ‐3,38 ‐4,75 ‐1482,78 Fructose‐1,6‐bisphosphatase 2
Bt.22165.1.S1_atMGC137948 55,31 948,62 17,15 14,43 21,07 893,3 similar to KIAA1914 protein
Bt.5679.1.S1_at MGC137616 1809,27 693,31 ‐2,61 ‐2,3 ‐3,02 ‐1115,96 similar to Dynein light intermediate chain 1, cytosolic (Dynein light chain A) (DLC‐A)
Bt.16663.1.A1_at‐‐‐ 3563,49 9,04 ‐394,33 ‐200,36 ‐12061,16 ‐3554,45 Transcribed locus
Bt.4596.2.S1_at MGC139878 505,43 130,18 ‐3,88 ‐3,08 ‐5,17 ‐375,26 similar to Epidermal Langerhans cell protein LCP1
Bt.16385.1.A1_atMGC127926 2225,74 76,49 ‐29,1 ‐20,58 ‐49,41 ‐2149,25 similar to 3‐hydroxysteroid epimerase
Bt.4817.2.S1_at MGC128478 70,08 674,1 9,62 5,49 38,21 604,01 similar to claudin 11
Bt.4407.1.S1_at MGC137732 192,84 685,31 3,55 2,88 4,61 492,46 similar to CG7289‐PA
Bt.15909.1.S1_atMGC142520 2510,01 5973,49 2,38 2,18 2,62 3463,49 similar to Family with sequence similarity 98, member A
Bt.26594.1.S1_at ‐‐‐ 293,31 1671,92 5,7 4,38 8,03 1378,61 Transcribed locus
Bt.20118.1.S1_atSAR1A 263,77 1291,73 4,9 4,01 6,21 1027,96 SAR1 gene homolog A (S. cerevisiae)
Bt.23129.3.S1_a_LOC532572 3015,87 7573,92 2,51 2,21 2,91 4558,05 similar to Laminin gamma‐1 chain precursor (Laminin B2 chain)
Bt.27645.1.A1_atLOC506902 745,9 5905,72 7,92 6,72 9,59 5159,82 Similar to C20orf82
Bt.19862.2.S1_at LOC518458 15,72 1060,38 67,45 39,37 233,12 1044,66 similar to semaphorin 6D
Bt.2964.1.S1_at LOC787714 /// ZN 674,3 2567,59 3,81 3,1 4,91 1893,29 zinc finger protein 330 /// similar to Zinc finger protein 330
Bt.9268.1.S1_at LOC537028 341,64 37,59 ‐9,09 ‐5,06 ‐41,25 ‐304,05 hypothetical LOC537028
Bt.4470.1.S1_at RGS7 366,19 75,68 ‐4,84 ‐3,57 ‐7,47 ‐290,51 regulator of G‐protein signaling 7
Bt.12688.1.A1_atLOC785152 70,78 238,85 3,37 2,69 4,45 168,06 hypothetical protein LOC785152
Bt.27283.1.S1_x_BOLA 4276,24 72,64 ‐58,87 ‐50,48 ‐70,51 ‐4203,6 Classical MHC class I antigen
Bt.2222.2.S1_at LOC537096 813,85 279,41 ‐2,91 ‐2,4 ‐3,66 ‐534,44 similar to WD repeat and FYVE domain containing 3
probe set GENE ID baseline mean (LSperiment mean (Efold change lower bound of F upper bound of Fdifference of meaGene Title
Bt.23733.1.A1_at‐‐‐ 7,59 177,94 23,45 12,68 146,66 170,35 ‐‐‐
Bt.5083.1.S1_at LOC781099 /// M 37,22 160,02 4,3 3,34 6,02 122,8 similar to solute carrier family 27 (fatty acid transporter), member 4 /// hypothetical protein LOC781099
Bt.19784.1.A1_at‐‐‐ 979,28 402,03 ‐2,44 ‐2,11 ‐2,86 ‐577,24 Transcribed locus
Bt.27206.1.A1_at‐‐‐ 6,8 129,79 19,09 9,27 100000000 122,99 Transcribed locus, moderately similar to XP_001149128.1  hypothetical protein [Pan troglodytes]
Bt.23493.1.S1_atTHBS 118,56 2031,08 17,13 13,6 23,04 1912,52 thrombospondin
Bt.29874.1.S1_atEIF2C3 651,95 1609,23 2,47 2,15 2,88 957,28 eukaryotic translation initiation factor 2C, 3
Bt.7490.1.A1_at MGC140483 2050,42 782,61 ‐2,62 ‐2,36 ‐2,92 ‐1267,81 similar to methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 1‐like
Bt.5692.2.S1_at ‐‐‐ 795,15 189,33 ‐4,2 ‐3,23 ‐5,97 ‐605,83 Transcribed locus
Bt.2587.2.S1_a_aMGC140701 186,85 19,55 ‐9,56 ‐5,55 ‐33,81 ‐167,3 similar to Fumarate hydratase, mitochondrial precursor (Fumarase)
Bt.5970.1.S1_a_aMGC127936 7986,24 3350,01 ‐2,38 ‐2,17 ‐2,64 ‐4636,23 similar to S100 calcium‐binding protein A2 (S‐100L protein) (CAN19)
Bt.15188.1.S1_at ‐‐‐ 37,63 868,63 23,08 11,85 368,51 831 ‐‐‐
Bt.11176.2.S1_atMGC127803 727,56 208,39 ‐3,49 ‐2,83 ‐4,48 ‐519,17 similar to transmembrane protein 14A
Bt.24247.1.S1_at ‐‐‐ 424,28 127,21 ‐3,34 ‐2,73 ‐4,26 ‐297,07 Transcribed locus
Bt.25783.1.A1_atSP2 613,3 200,71 ‐3,06 ‐2,59 ‐3,69 ‐412,6 Sp2 transcription factor
Bt.18203.1.A1_atMGC151720 345,13 89,11 ‐3,87 ‐2,98 ‐5,48 ‐256,02 similar to C21ORF43
Bt.21405.1.S1_at ‐‐‐ 118,41 796,67 6,73 5,99 7,65 678,26 Transcribed locus
Bt.20129.1.S1_atCUTL1 758,65 1766,6 2,33 2,1 2,6 1007,95 cut‐like 1, CCAAT displacement protein (Drosophila)
Bt.5281.2.S1_a_a‐‐‐ 399,58 912,35 2,28 2,03 2,59 512,77 CDNA clone MGC:139634 IMAGE:8280525
Bt.28642.1.A1_at‐‐‐ 25,87 126,89 4,9 3,45 8,36 101,02 Transcribed locus
Bt.22534.1.S1_at LOC534497 364,43 5379,66 14,76 13,06 16,94 5015,22 similar to peripheral myelin protein 22
Bt.4845.1.S1_at WBSCR22 3406,7 1320,7 ‐2,58 ‐2,29 ‐2,95 ‐2085,99 Williams Beuren syndrome chromosome region 22 protein
Bt.3253.1.A1_at LOC617871 1881,98 598,98 ‐3,14 ‐2,68 ‐3,78 ‐1283,01 hypothetical LOC617871
Bt.28632.2.S1_at LOC540826 418,67 135,29 ‐3,09 ‐2,61 ‐3,78 ‐283,39 similar to ubiquitin E3 ligase SMURF2
Bt.26971.1.S1_at ‐‐‐ 82,21 1935,93 23,55 16,42 41,32 1853,72 Transcribed locus, moderately similar to XP_001088883.1  similar to NUAK family, SNF1‐like kinase, 2 [Macaca mulatta]
Bt.5376.1.S1_at YIF1A 1781,7 4038,11 2,27 2,08 2,47 2256,41 Yip1 interacting factor homolog A (S. cerevisiae)
Bt.24973.1.A1_atLOC505941 2267,04 5440,7 2,4 2,2 2,64 3173,66 similar to ribosome binding protein 1
Bt.2039.1.S1_at LOC514971 247,87 26,63 ‐9,31 ‐5,18 ‐44,48 ‐221,24 similar to cytochrome P450 2S1
Bt.13725.2.S1_at ‐‐‐ 1199,97 479,78 ‐2,5 ‐2,29 ‐2,74 ‐720,2 Transcribed locus, strongly similar to XP_001112553.1  similar to hyperparathyroidism 2 homolog isoform 2 [Macaca mulatta]
Bt.26461.1.A1_atLOC511800 14768,65 826,17 ‐17,88 ‐14,46 ‐23,31 ‐13942,48 similar to KIAA1581 protein
Bt.22283.1.S1_at ‐‐‐ 1435,82 174,67 ‐8,22 ‐5,78 ‐13,95 ‐1261,15 Transcribed locus
Bt.16188.1.S1_atCYYR1 11,05 1575,08 142,54 81,21 578,93 1564,03 Cysteine/tyrosine‐rich 1
Bt.2886.1.S1_at DKKL1 30,46 172,03 5,65 4,33 8 141,57 dickkopf‐like 1 (soggy)
Bt.14000.1.S1_at LOC789594 41,58 181,23 4,36 3,55 5,57 139,65 Hypothetical protein LOC789594
Bt.9068.1.S1_at LOC404108 1106,46 2840,91 2,57 2,17 3,11 1734,44 non‐muscle myosin heavy chain
Bt.18533.1.S1_atMGC137608 497,98 35,33 ‐14,1 ‐7,37 ‐156,35 ‐462,66 similar to Cyclic‐AMP‐dependent transcription factor ATF‐3 (Activating transcription factor 3) (Liver regeneration factor 1) (LRF‐1)
Bt.15989.1.S1_at IRF2 239,11 88,94 ‐2,69 ‐2,3 ‐3,23 ‐150,17 interferon regulatory factor 2
Bt.6898.2.S1_a_aMGC138118 2,59 5254,92 2030,71 54,65 100000000 5252,33 similar to SPRY domain‐containing SOCS box protein SSB‐2
Bt.22576.3.S1_at LOC782160 280,51 69,52 ‐4,04 ‐3,01 ‐6,02 ‐210,99 similar to Protein phosphatase 1, regulatory subunit 3D
Bt.29153.1.S1_at ‐‐‐ 1327,34 64,29 ‐20,65 ‐15,97 ‐29,08 ‐1263,06 ‐‐‐
Bt.9521.1.S1_at LOC512924 399,58 26,21 ‐15,24 ‐9,57 ‐36,61 ‐373,37 similar to rhoHP1
Bt.19423.1.S1_atABCA1 534,45 1595,49 2,99 2,57 3,53 1061,03 ATP‐binding cassette, sub‐family A (ABC1), member 1
Bt.3196.1.S1_at STRA6 345,85 20,99 ‐16,48 ‐7,57 ‐100000000 ‐324,87 stimulated by retinoic acid gene 6 homolog
Bt.13930.2.S1_at LOC539979 261,96 56,45 ‐4,64 ‐3,6 ‐6,41 ‐205,51 similar to protein kinase
Bt.3276.1.A1_at MGC137490 375,6 120,47 ‐3,12 ‐2,57 ‐3,93 ‐255,14 similar to rTS beta protein
Bt.15861.1.S1_at ‐‐‐ 58,68 174,75 2,98 2,57 3,5 116,07 Transcribed locus
Bt.3975.1.S1_at LOC506522 864,2 2090,75 2,42 2,09 2,86 1226,55 similar to WD repeat domain 85
Bt.8724.1.S1_at ‐‐‐ 65,78 313,52 4,77 3,74 6,45 247,74 CDNA clone IMAGE:8473920
Bt.24206.1.A1_atMGC157166 152,91 583,56 3,82 3,22 4,62 430,65 hypothetical LOC525916
Bt.17765.2.A1_at‐‐‐ 353,14 40,19 ‐8,79 ‐5,22 ‐27,41 ‐312,95 Transcribed locus
Bt.9511.1.S1_at ‐‐‐ 564,59 196,93 ‐2,87 ‐2,39 ‐3,57 ‐367,66 Transcribed locus
Bt.10999.2.S1_atMGC159894 843,72 294,21 ‐2,87 ‐2,38 ‐3,57 ‐549,51 similar to NCK adaptor protein 2
Bt.29257.1.A1_at‐‐‐ 66,53 2628,55 39,51 27,11 72,45 2562,02 Transcribed locus
Bt.5788.1.S1_at MGC155084 1662,09 377,64 ‐4,4 ‐3,74 ‐5,3 ‐1284,45 Similar to SAP‐2=ERP/NET homolog
Bt.14201.1.S1_a_LOC784840 /// M 226,1 1026,04 4,54 4,16 4,98 799,94 hypothetical protein MGC134244 /// hypothetical protein LOC784840
Bt.23521.1.S1_atMGC139846 1997,34 303,88 ‐6,57 ‐4,99 ‐9,63 ‐1693,46 similar to dual specificity phosphatase 26
Bt.4130.1.S1_at F5 478,93 11,55 ‐41,47 ‐22,79 ‐224,18 ‐467,38 coagulation factor V (proaccelerin, labile factor)
Bt.21943.1.S1_at LOC524460 1468,63 530,63 ‐2,77 ‐2,59 ‐2,96 ‐938 similar to UDP‐Gal:glucosylceramide beta‐1,4‐galactosyltransferase
Bt.22200.1.S1_at ‐‐‐ 167,97 5210,47 31,02 25,31 39,97 5042,51 Transcribed locus
Bt.6113.1.S1_at LOC524274 2628,37 878,13 ‐2,99 ‐2,69 ‐3,35 ‐1750,24 similar to Xeroderma pigmentosum, complementation group C
Bt.29796.1.S1_at ‐‐‐ 639,19 11716,52 18,33 13,45 28,54 11077,33 B4 cell‐line anti‐respiratory syncytial virus Ig lambda chain V region (IgL)
Bt.20293.1.S1_atMGC127598 580,24 240,9 ‐2,41 ‐2,13 ‐2,77 ‐339,34 hypothetical protein MGC127598
Bt.4877.1.S1_at LOC790012 /// P 628,24 1870,32 2,98 2,44 3,79 1242,08
phospholipase C, delta 1 /// similar to 1‐phosphatidylinositol‐4,5‐bisphosphate phosphodiesterase delta 1 (Phosphoinositide phospholipase C) (PLC‐
delta‐1) (Phospholipase C‐delta‐1) (PLC‐III)
Bt.1694.1.S1_at LOC539853 19,75 506,19 25,62 18,55 41,19 486,43 similar to gp50/Trop‐2
probe set GENE ID baseline mean (LSperiment mean (Efold change lower bound of F upper bound of Fdifference of meaGene Title
Bt.26713.1.S1_atSLC38A5 88 1004,83 11,42 7,59 22,53 916,83 solute carrier family 38, member 5
Bt.5775.1.S1_at MGC155110 922,96 4710,73 5,1 4,39 6,06 3787,77 similar to biliverdin‐IX alpha reductase
Bt.21246.1.A1_at‐‐‐ 15,51 2786,45 179,65 60,19 100000000 2770,94 Transcribed locus
Bt.17465.1.S1_atMGC148990 919,33 2720,35 2,96 2,58 3,46 1801,02 similar to rhomboid‐related protein
Bt.20947.1.S1_at ‐‐‐ 18,56 685,32 36,93 24,18 77,62 666,77 ‐‐‐
Bt.27104.1.A1_at‐‐‐ 80,52 2737,32 33,99 19,66 122,92 2656,8 Transcribed locus
Bt.18995.1.A1_a_LOC514174 434,03 21,43 ‐20,26 ‐13,51 ‐39,98 ‐412,6 similar to cytoplasmic polyadenylation element‐binding protein long form
Bt.15738.1.A1_at‐‐‐ 1692,17 654,29 ‐2,59 ‐2,23 ‐3,07 ‐1037,88 Transcribed locus, strongly similar to XP_001113528.1  hypothetical protein LOC9728 isoform 2 [Macaca mulatta]
Bt.2349.1.S1_at LOC512732 582,84 52,7 ‐11,06 ‐7,1 ‐24,3 ‐530,14 similar to stathmin‐like‐protein RB3
Bt.21113.1.S1_a_CPT1B 18,74 708,34 37,8 23,9 89,51 689,61 carnitine palmitoyltransferase 1B
Bt.656.1.S1_at MGC143403 10440,05 3993,41 ‐2,61 ‐2,4 ‐2,85 ‐6446,64 similar to coronin, actin binding protein, 1C
Bt.3701.1.S1_at LOC618459 679,18 1911,35 2,81 2,53 3,15 1232,17 hypothetical LOC618459
Bt.7196.1.S1_at LOC404111 52,76 5740,32 108,8 76,31 188,99 5687,55 epidermal keratin VII
Bt.4394.1.S1_at GUCY1B3 2374,73 878,58 ‐2,7 ‐2,24 ‐3,37 ‐1496,15 guanylate cyclase 1, soluble, beta 3
Bt.2904.1.S1_at MGC126974 6101,91 2667,38 ‐2,29 ‐2,07 ‐2,54 ‐3434,54 hypothetical LOC507725
Bt.3823.1.S1_at AVPI1 256,89 81,76 ‐3,14 ‐2,7 ‐3,71 ‐175,13 arginine vasopressin‐induced 1
Bt.27481.1.A1_atSPG3A 377,04 25,16 ‐14,99 ‐9,37 ‐36,44 ‐351,89 spastic paraplegia 3A (autosomal dominant)
Bt.8881.1.A1_at LOC525946 11,76 121,7 10,35 6,68 22,19 109,94 similar to Ephrin type‐A receptor 1 precursor (Tyrosine‐protein kinase receptor EPH)
Bt.28084.1.S1_at LOC517496 261,43 4766,45 18,23 13,76 26,83 4505,02 similar to KIAA1285 protein
Bt.14444.1.A1_atLOC533295 69,35 314,72 4,54 3,48 6,48 245,37 Similar to Y53F4B.4a
Bt.10088.1.A1_at‐‐‐ 676 146,64 ‐4,61 ‐3,59 ‐6,43 ‐529,36 Transcribed locus
Bt.2046.1.S1_at ext1 38,6 1033,84 26,78 18,09 51,12 995,23 sushi repeat‐containing protein
Bt.8552.1.S1_at BOLA‐DRA 1118,68 89,44 ‐12,51 ‐9,07 ‐19,9 ‐1029,24 major histocompatibility complex, class II, DR alpha
Bt.29921.1.S1_at LOC614583 430,54 1592,69 3,7 3,16 4,47 1162,16 similar to SERTA domain containing 4
Bt.10214.1.S1_atMGC140096 187,83 1648,82 8,78 7,7 10,17 1460,99 similar to DRAK1
Bt.24380.1.A1_atMGC166193 729,53 1783,96 2,45 2,08 2,94 1054,42 similar to BTB (POZ) domain containing 5
Bt.9003.1.S1_at KIAA1797 533,02 1406,55 2,64 2,27 3,13 873,53 hypothetical protein LOC506199
Bt.6033.1.S1_at ST7 64,29 507,79 7,9 5,69 12,66 443,51 suppression of tumorigenicity 7
Bt.4793.1.S2_at SLC12A2 3610,67 178,18 ‐20,26 ‐16,71 ‐25,65 ‐3432,49 solute carrier family 12 (sodium/potassium/chloride transporters), member 2
Bt.18894.1.A1_atLOC785123 194,57 617,85 3,18 2,7 3,81 423,28 similar to putative RIN zinc finger protein
Bt.23135.1.S1_atTAGLN2 5700,47 656,43 ‐8,68 ‐7,17 ‐10,92 ‐5044,04 transgelin 2
Bt.5141.1.S2_at B4GALT1 716,99 3633,9 5,07 4,46 5,84 2916,91 UDP‐Gal:betaGlcNAc beta 1,4‐ galactosyltransferase, polypeptide 1
Bt.4105.1.S1_at MGC143272 417,27 2403,18 5,76 4,97 6,79 1985,91 similar to putative GPCR interacting protein GIP
Bt.21053.2.S1_atMGC128630 1157,66 474,43 ‐2,44 ‐2,09 ‐2,92 ‐683,23 similar to synaptogyrin 1 isoform 1b
Bt.9840.1.S1_at ‐‐‐ 276,48 816,59 2,95 2,53 3,51 540,11 Transcribed locus
Bt.15788.1.S1_a_LOC507402 170,17 1538,06 9,04 7,45 11,42 1367,89 Similar to Bone marrow stromal cell antigen 2
Bt.6771.1.S1_at LOC533149 248,57 896,22 3,61 2,93 4,68 647,65 hypothetical LOC533149
Bt.13422.1.A1_atMGC152585 2711,38 783,85 ‐3,46 ‐2,8 ‐4,49 ‐1927,53 Hypothetical LOC507035
Bt.20936.1.S1_at ‐‐‐ 901,32 2940,89 3,26 2,83 3,82 2039,57 Transcribed locus
Bt.23.2.S1_at SLC6A2 2527,53 10,77 ‐234,66 ‐112,24 ‐100000000 ‐2516,76 solute carrier family 6 (neurotransmitter transporter, noradrenalin), member 2
Bt.22435.1.S1_atMGC133535 809,79 3193,65 3,94 3,1 5,31 2383,86 similar to FN5 protein
Bt.10813.1.S1_atPDLIM4 1370 3324,34 2,43 2,06 2,93 1954,33 PDZ and LIM domain 4
Bt.22797.1.A1_at‐‐‐ 981,22 45,46 ‐21,58 ‐13,4 ‐54,32 ‐935,76 Transcribed locus
Bt.1055.1.S1_at LOC518563 706,11 1689,79 2,39 2,13 2,72 983,68 similar to HS6ST1 protein
Bt.2452.1.S1_at LUM 415,21 2049,47 4,94 4,29 5,77 1634,26 lumican
Bt.24923.1.S1_at LOC535060 29,44 1406,86 47,78 28,18 154,87 1377,41 hypothetical LOC535060
Bt.20035.2.A1_atCXXC5 85,15 512,27 6,02 4,61 8,51 427,12 CXXC finger 5
Bt.26656.1.S1_at LOC537631 299,13 22,95 ‐13,03 ‐8,84 ‐24,32 ‐276,18 similar to JNK3 beta2 protein kinase
Bt.26770.1.S1_atMGC140759 310,32 918,76 2,96 2,61 3,39 608,44 similar to Transducin beta‐like 2 protein (WS beta‐transducin repeats protein) (WS‐betaTRP) (Williams‐Beuren syndrome chromosome region 13 
Bt.28686.1.S1_atMGC151721 702,82 27,68 ‐25,39 ‐15,12 ‐77,5 ‐675,14 similar to MAL2 proteolipid
Bt.15758.1.S1_atPTGS2 2158,19 141,02 ‐15,3 ‐13,25 ‐18,05 ‐2017,17 prostaglandin‐endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase)
Bt.9108.1.S1_at ‐‐‐ 576,05 118,61 ‐4,86 ‐3,92 ‐6,28 ‐457,45 Transcribed locus
Bt.23502.1.S1_atMGC159420 194,69 1048,97 5,39 4,42 6,81 854,28 similar to receptor activity‐modifying protein 2
Bt.29907.1.S1_atKLHDC8B 697,8 81,57 ‐8,56 ‐6,39 ‐12,75 ‐616,24 kelch domain containing 8B
Bt.9373.1.S1_at ‐‐‐ 123,55 402,82 3,26 2,58 4,36 279,27 Transcribed locus
Bt.5732.2.A1_at ‐‐‐ 3273,88 925,29 ‐3,54 ‐3,14 ‐4,02 ‐2348,59 Transcribed locus
Bt.3071.1.S1_at LOC515784 3942,05 10196,63 2,59 2,23 3,07 6254,58 similar to P63 protein
Bt.18305.1.A1_at‐‐‐ 37,29 3179,13 85,26 57,38 165,16 3141,84 ‐‐‐
Bt.19733.1.A1_at‐‐‐ 377,79 99,14 ‐3,81 ‐3,1 ‐4,94 ‐278,65 Transcribed locus
Bt.26444.1.A1_at‐‐‐ 611,07 47,02 ‐12,99 ‐8,9 ‐23,63 ‐564,05 Transcribed locus
Bt.20402.1.S1_atPKD2 621,31 153,91 ‐4,04 ‐3,1 ‐5,66 ‐467,4 polycystic kidney disease 2 membrane protein
Bt.27400.1.S1_at LOC523226 185,38 1086,18 5,86 5,14 6,78 900,8 similar to Protocadherin alpha subfamily C, 2
Bt.8867.1.S1_at LOC536213 551,71 1626,51 2,95 2,53 3,53 1074,81 similar to CHKB protein
Bt.22573.1.A1_at‐‐‐ 116,85 378,62 3,24 2,69 4,01 261,78 ‐‐‐
probe set GENE ID baseline mean (LSperiment mean (Efold change lower bound of F upper bound of Fdifference of meaGene Title
Bt.8894.1.S1_at ‐‐‐ 631,31 199 ‐3,17 ‐2,49 ‐4,3 ‐432,3 Transcribed locus
Bt.4837.1.A1_at ALDOC 4849,69 1642,59 ‐2,95 ‐2,63 ‐3,34 ‐3207,1 aldolase C, fructose‐bisphosphate
Bt.21615.1.A1_atMGC140693 518,85 19,54 ‐26,56 ‐15,2 ‐101,73 ‐499,31 similar to transmembrane protein 22
Bt.19332.2.A1_at‐‐‐ 72,43 289,09 3,99 3,01 5,79 216,66 Transcribed locus
Bt.11481.1.A1_at‐‐‐ 285,59 110,12 ‐2,59 ‐2,2 ‐3,14 ‐175,47 Transcribed locus
Bt.3391.1.S1_at LOC781397 639,45 1640,08 2,56 2,28 2,93 1000,63 hypothetical protein LOC781397
Bt.20111.1.S1_at LOC617439 1074,5 51,95 ‐20,68 ‐13,47 ‐43,8 ‐1022,55 similar to type I transmenmbrane protein
Bt.1165.1.S1_at ADCY7 345,04 1801,94 5,22 4,61 5,99 1456,91 adenylate cyclase 7
Bt.4635.2.S1_a_aCNN2 108,12 700,58 6,48 5,13 8,69 592,46 calponin 2
Bt.3948.1.S1_at CDH3 148,75 788,44 5,3 4,42 6,55 639,69 cadherin 3, type 1, P‐cadherin (placental)
Bt.25259.1.A1_atLOC541187 29,71 420,03 14,14 11,83 17,48 390,31 similar to FIC1
Bt.22803.1.S1_atTUBB 1877,75 4930,5 2,63 2,34 2,98 3052,75 tubulin, beta
Bt.23548.2.S1_atMGC138006 66,77 920,73 13,79 10,34 20,48 853,96 hypothetical LOC513445
Bt.26637.2.S1_atMGC138046 1324,76 117,38 ‐11,29 ‐9,56 ‐13,71 ‐1207,37 similar to chromatin modifying protein 4C
Bt.11770.1.S1_a_SLC25A20 1067,37 2707,73 2,54 2,16 3,07 1640,36 solute carrier family 25 (carnitine/acylcarnitine translocase), member 20
Bt.12927.1.S1_atHAS2 5,74 449,09 78,2 38,79 100000000 443,35 hyaluronan synthase 2
Bt.20979.1.S1_at ‐‐‐ 5494,85 1293,75 ‐4,25 ‐3,59 ‐5,13 ‐4201,1 Transcribed locus
Bt.21473.1.A1_a_MPZL1 619,76 2258,07 3,64 3,26 4,1 1638,3 myelin protein zero‐like 1
Bt.5548.1.S1_at SLC1A5 122,37 865,88 7,08 4,89 12,44 743,51 solute carrier family 1 (neutral amino acid transporter), member 5
Bt.29954.1.S1_atGKAP1 890,65 294,8 ‐3,02 ‐2,5 ‐3,79 ‐595,85 G kinase anchoring protein 1
Bt.19329.1.A1_atMGC139784 6198,13 335,14 ‐18,49 ‐15,3 ‐23,28 ‐5862,99 similar to EF‐hand domain‐containing protein 1 (Swiprosin‐2)
Bt.27178.1.S1_at LOC506539 311,84 688,4 2,21 2,02 2,42 376,56 similar to KIAA0999 protein
Bt.6362.1.A1_at LOC785088 931,31 22,73 ‐40,97 ‐25,92 ‐96,84 ‐908,59 similar to hormone‐sensitive lipase
Bt.24635.2.A1_atIGFALS 682,22 2508,52 3,68 2,94 4,88 1826,31 insulin‐like growth factor binding protein, acid labile subunit
Bt.5684.1.S1_at LOC508877 222,78 613,99 2,76 2,3 3,39 391,21 hypothetical LOC508877
Bt.22498.1.A1_at‐‐‐ 211,14 639,9 3,03 2,4 4,05 428,76 Transcribed locus
Bt.2849.1.S1_at ‐‐‐ 5,54 425,95 76,83 32,26 100000000 420,41 Transcribed locus
Bt.11178.1.S1_atMGC128119 12576,38 2953,39 ‐4,26 ‐3,17 ‐6,42 ‐9622,98 similar to Glypican‐3 precursor (Intestinal protein OCI‐5) (GTR2‐2) (MXR7)
Bt.10458.1.A1_at‐‐‐ 8442,47 889,92 ‐9,49 ‐7,63 ‐12,42 ‐7552,54 Transcribed locus
Bt.7849.1.S1_at MGC127504 2184,12 5029,41 2,3 2,04 2,63 2845,29 similar to Lysyl‐tRNA synthetase (Lysine‐‐tRNA ligase) (LysRS)
Bt.16976.2.A1_at‐‐‐ 1420,22 454,12 ‐3,13 ‐2,6 ‐3,91 ‐966,1 Transcribed locus
Bt.13985.1.S1_at ‐‐‐ 677,69 135,75 ‐4,99 ‐3,87 ‐7,01 ‐541,95 Transcribed locus
Bt.29053.1.A1_at‐‐‐ 2953,3 954,23 ‐3,09 ‐2,69 ‐3,64 ‐1999,07 Transcribed locus
Bt.9966.2.S1_a_aLOC782818 4541,29 11193,84 2,46 2,12 2,93 6652,55 similar to procollagen alpha 2(V)
Bt.21362.1.S1_at ‐‐‐ 1639,71 635,67 ‐2,58 ‐2,25 ‐3,01 ‐1004,04 Transcribed locus
Bt.4357.1.S1_at MGC139832 191,38 975,44 5,1 3,94 7,19 784,06
similar to Tetraspanin‐7 (Tspan‐7) (Transmembrane 4 superfamily member 2) (Cell surface glycoprotein A15) (T‐cell acute lymphoblastic leukemia 
associated antigen 1) (TALLA‐1) (Membrane component, X chromosome, surface marker 1) (CD231 antigen)...
Bt.23830.1.A1_at‐‐‐ 568,63 170,45 ‐3,34 ‐2,69 ‐4,36 ‐398,18 Transcribed locus, moderately similar to XP_001104510.1  similar to gluconokinase‐like protein isoform 1 [Macaca mulatta]
Bt.20330.1.S1_atMGC139156 99,21 1383,73 13,95 11,42 17,82 1284,51 hypothetical LOC538575
Bt.14061.1.A1_atMGC143209 150,99 19,96 ‐7,56 ‐4,78 ‐17,24 ‐131,03 hypothetical LOC534389
Bt.20402.2.A1_atPKD2 1355,14 493,09 ‐2,75 ‐2,34 ‐3,32 ‐862,05 polycystic kidney disease 2 membrane protein
Bt.29922.1.S1_at ‐‐‐ 538,16 1244,34 2,31 2,02 2,69 706,18 Transcribed locus
Bt.12811.1.S1_atUACA 4456,89 1558,09 ‐2,86 ‐2,72 ‐3,01 ‐2898,8 uveal autoantigen with coiled‐coil domains and ankyrin repeats
Bt.199.1.S1_at PNOC 6,09 1770,75 290,89 66,86 100000000 1764,67 prepronociceptin
Bt.25105.2.A1_atLOC524375 374,03 87,97 ‐4,25 ‐3,62 ‐5,09 ‐286,06 similar to lymphocyte alpha‐kinase
Bt.20436.1.S1_at ‐‐‐ 664,96 250,1 ‐2,66 ‐2,29 ‐3,15 ‐414,86 Transcribed locus
Bt.4544.1.S1_at LOC535043 301,49 1576,54 5,23 4,16 7,04 1275,05 hypothetical LOC535043
Bt.7348.1.S1_at ‐‐‐ 831,24 200,72 ‐4,14 ‐3,16 ‐5,85 ‐630,52 Transcribed locus
Bt.599.1.S1_at DSPG3 34,81 341,29 9,8 6,25 21,87 306,48 dermatan sulfate proteoglycan 3
Bt.22545.2.S1_atMGC148755 2397,54 9050,1 3,77 3,13 4,75 6652,56 similar to fibulin‐1 C
Bt.5528.1.S1_at SLC7A5 43,46 495,88 11,41 5,76 452,32 452,42 solute carrier family 7 (cationic amino acid transporter, y+ system), member 5
Bt.2632.1.S1_at SPP1 4621,17 4,77 ‐969,03 ‐395,13 ‐100000000 ‐4616,4 secreted phosphoprotein 1
Bt.20694.1.A1_atLOC515749 167,32 17,96 ‐9,32 ‐6,18 ‐18,3 ‐149,36 similar to alpha‐catenin related protein
Bt.22389.1.S1_at LOC617336 4,6 2500,25 542,96 273,24 37438,69 2495,65 similar to WGAR9166
Bt.24801.1.A1_at‐‐‐ 6409,23 21,39 ‐299,6 ‐172,83 ‐1117 ‐6387,84 Transcribed locus
Bt.28651.1.S1_at LOC538697 350,91 888,86 2,53 2,23 2,9 537,95 similar to deleted in liver cancer 2 alpha
Bt.5160.1.S1_at LOC513577 154,1 35,1 ‐4,39 ‐3,26 ‐6,66 ‐119 similar to U4/U6 snRNP‐associated 61 kDa protein
Bt.16329.1.A1_atLOC510050 158,45 564,17 3,56 3,14 4,08 405,72 similar to TG‐interacting factor
Bt.1402.2.S1_at GNAO1 773,63 20,14 ‐38,41 ‐22,06 ‐145,27 ‐753,49 guanine nucleotide binding protein (G protein), alpha activating activity polypeptide O
Bt.23174.1.S1_atMGC127643 399,36 28,76 ‐13,89 ‐8,24 ‐42,18 ‐370,6 similar to CD74 antigen
Bt.1069.1.A1_at PTPRR 666,73 1757,93 2,64 2,36 2,98 1091,2 protein tyrosine phosphatase, receptor type, R
Bt.24915.1.A1_atCNTNAP3 252,43 62,07 ‐4,07 ‐3,05 ‐6,07 ‐190,36 cell recognition molecule CASPR3
Bt.17405.1.S1_at ‐‐‐ 285,51 84,29 ‐3,39 ‐2,68 ‐4,58 ‐201,21 Transcribed locus
Bt.22614.2.S1_at ‐‐‐ 2889,49 1069,6 ‐2,7 ‐2,27 ‐3,33 ‐1819,9 Transcribed locus
probe set GENE ID baseline mean (LSperiment mean (Efold change lower bound of F upper bound of Fdifference of meaGene Title
Bt.14083.2.S1_atMASP1 93,72 300,17 3,2 2,73 3,86 206,45 mannan‐binding lectin serine peptidase 1 (C4/C2 activating component of Ra‐reactive factor)
Bt.9399.1.S1_at ‐‐‐ 781,22 231,95 ‐3,37 ‐2,99 ‐3,82 ‐549,28 Transcribed locus
Bt.26122.2.S1_atUXT 194,63 656,48 3,37 3,08 3,7 461,85 ubiquitously‐expressed transcript
Bt.8319.3.S1_a_aLOC515016 436,65 174,37 ‐2,5 ‐2,18 ‐2,91 ‐262,28 similar to mitochondrial tumor suppressor 1
Bt.19937.2.S1_at LOC532189 541,18 1306,05 2,41 2,06 2,9 764,87 similar to carboxypeptidase D
Bt.20955.1.A1_at‐‐‐ 1876,08 545,18 ‐3,44 ‐2,91 ‐4,16 ‐1330,9 Transcribed locus
Bt.1775.1.A1_at ‐‐‐ 1714,36 641,6 ‐2,67 ‐2,31 ‐3,15 ‐1072,76 Transcribed locus
Bt.29417.1.S1_atTMEM30A 593,34 1777,96 3 2,79 3,22 1184,62 transmembrane protein 30A
Bt.4417.1.S1_at CDH2 349,88 4736,05 13,54 11,41 16,55 4386,17 cadherin 2
Bt.22078.1.S1_at LOC513520 2062,91 822,45 ‐2,51 ‐2,09 ‐3,08 ‐1240,46 similar to ATPase, H+ transporting, lysosomal accessory protein 2
Bt.6276.2.S1_at LOC616537 281,17 90,24 ‐3,12 ‐2,48 ‐4,16 ‐190,92 similar to Rab6 protein
Bt.7337.2.S1_at LOC781512 7,48 153,87 20,57 9,32 100000000 146,39 similar to ARAP2
Bt.24405.2.A1_atLOC783765 275,08 46,65 ‐5,9 ‐4,12 ‐10,34 ‐228,43 tetraspanin similiar to uroplakin 1
Bt.16831.1.A1_atLOC615978 2829,52 687,42 ‐4,12 ‐3,6 ‐4,75 ‐2142,1 similar to Chst2 protein
Bt.979.1.A1_at MGC160128 138,81 7380,13 53,17 38,96 83,32 7241,32 similar to Myosin IB
Bt.8496.1.S1_at MGC134517 823,2 1909,15 2,32 2,08 2,62 1085,96 similar to GDP‐mannose pyrophosphorylase B
Bt.25109.1.S1_at LOC533642 2680,75 7077,74 2,64 2,31 3,08 4396,98 Similar to Procollagen‐lysine, 2‐oxoglutarate 5‐dioxygenase 2
Bt.4844.1.S1_at PTN 103,93 1243,83 11,97 9,49 16,05 1139,91 pleiotrophin
Bt.23318.1.S2_at LOC510833 675,36 5154,81 7,63 6,43 9,32 4479,45 similar to Collagen alpha 1(III) chain precursor
Bt.19254.1.A1_atLOC506738 175,47 21,11 ‐8,31 ‐5,08 ‐22,76 ‐154,36 Similar to nucleoporin 155
Bt.15290.1.A1_at‐‐‐ 888,68 21,31 ‐41,7 ‐29,7 ‐69,54 ‐867,37 Transcribed locus
Bt.23664.1.S1_at LOC527211 455,14 1298,2 2,85 2,55 3,21 843,06 similar to polyamine oxidase
Bt.26501.1.S1_at ‐‐‐ 114,93 2504,75 21,79 18,41 26,61 2389,82 Transcribed locus
Bt.8617.1.S1_at MGC139773 2170,63 537,15 ‐4,04 ‐3,53 ‐4,69 ‐1633,48 similar to chromosome 2 open reading frame 32
Bt.6619.1.S1_at LOC614661 37,84 598,95 15,83 9,33 49,91 561,12 similar to coronin 6
Bt.26895.2.S1_at LOC521099 6,8 428,29 63,02 23,39 100000000 421,5 hypothetical LOC521099
Bt.9930.1.S1_at ‐‐‐ 1543,8 496,51 ‐3,11 ‐2,64 ‐3,77 ‐1047,29 Transcribed locus
Bt.24373.1.S1_at LOC618638 312,72 68,45 ‐4,57 ‐3,12 ‐8,38 ‐244,27 similar to tripartite motif‐containing 47
Bt.14054.2.S1_atMGC127247 256,91 36,77 ‐6,99 ‐4,83 ‐12,2 ‐220,14 similar to interferon‐related developmental regulator 1
Bt.18434.1.A1_at‐‐‐ 1244,58 271,53 ‐4,58 ‐4,11 ‐5,14 ‐973,04 Transcribed locus
Bt.8335.1.S1_at ‐‐‐ 804,19 2104,47 2,62 2,3 3,03 1300,28 Transcribed locus
Bt.4585.1.S1_at ACAT2 425,06 1195,78 2,81 2,37 3,44 770,73 acetyl‐Coenzyme A acetyltransferase 2
Bt.4107.1.S1_at DSC2 1739,88 3772,8 2,17 2,02 2,33 2032,92 desmocollin 2
Bt.20076.1.S1_atUBTF 427,31 1473,44 3,45 2,88 4,28 1046,13 upstream binding transcription factor, RNA polymerase I
Bt.19018.1.A1_at‐‐‐ 256,39 7,72 ‐33,22 ‐16,5 ‐100000000 ‐248,67 Transcribed locus
Bt.28073.1.S1_at LOC523223 419,71 1595,82 3,8 3,35 4,36 1176,11 similar to macrophage actin‐associated‐tyrosine‐phosphorylated protein
Bt.28385.1.A1_atLOC782489 /// M 25,1 1846,27 73,57 49,45 142,88 1821,18 similar to Cholinesterase precursor (Acylcholine acylhydrolase) (Choline esterase II) (Butyrylcholine esterase) (Pseudocholinesterase) /// hypothetical
Bt.12054.1.S1_at ‐‐‐ 5701,93 1208,02 ‐4,72 ‐4,3 ‐5,21 ‐4493,91 ‐‐‐
Bt.19409.1.A1_s_‐‐‐ 1731,43 7283,91 4,21 3,55 5,15 5552,48 Transcribed locus
Bt.24364.1.A1_atPRSS35 24,24 433,48 17,88 10,89 48,45 409,24 protease, serine, 35
Bt.13315.1.S1_at LOC768237 1790,66 4938,96 2,76 2,44 3,17 3148,3 hypothetical protein LOC768237
Bt.20820.1.A1_atLOC781032 3849,71 52,15 ‐73,83 ‐44,7 ‐209,78 ‐3797,56 similar to latent transforming growth factor beta binding protein 1 isoform LTBP‐1L
Bt.13152.1.S1_s_APP 91,91 1128,62 12,28 8,26 23,36 1036,71 amyloid beta (A4) precursor protein
Bt.373.3.S1_a_at AMELX /// AMELY 373,47 2598,66 6,96 4,44 15,96 2225,19 amelogenin (amelogenesis imperfecta 1, X‐linked) /// amelogenin, Y‐linked
Bt.24694.1.A1_atLOC511689 80,37 232,1 2,89 2,46 3,45 151,73 Similar to KIAA1237 protein
Bt.10458.2.S1_at LOC513774 1587,54 175,79 ‐9,03 ‐6,72 ‐13,51 ‐1411,75 Similar to myasthenia gravis autoantigen gravin
Bt.13975.1.S1_a_LOC613972 16284,08 983,58 ‐16,56 ‐12,8 ‐23,26 ‐15300,5 similar to Apolipoprotein D precursor (Apo‐D) (ApoD)
Bt.23606.1.S1_at ITPR1 6647,25 2032,66 ‐3,27 ‐2,48 ‐4,72 ‐4614,6 inositol 1,4,5‐triphosphate receptor, type 1
Bt.27040.1.A1_at‐‐‐ 306,23 64,28 ‐4,76 ‐3,13 ‐9,59 ‐241,94 Transcribed locus, moderately similar to XP_001067582.1  similar to BTB (POZ) domain containing 7 isoform 2 [Rattus norvegicus]
Bt.24810.1.S1_atADC 2455,1 195,85 ‐12,54 ‐10,03 ‐16,57 ‐2259,25 arginine decarboxylase
Bt.1976.1.S1_at MGC139033 1495,9 601,14 ‐2,49 ‐2,07 ‐3,07 ‐894,76 similar to suppression of tumorigenicity 5
Bt.3551.1.S1_at LOC518062 441,93 1594,92 3,61 3,07 4,31 1152,99 similar to Putative transporter C20orf59
Bt.21071.1.S1_at ‐‐‐ 2201,82 276,22 ‐7,97 ‐6,95 ‐9,28 ‐1925,6 Transcribed locus
Bt.25472.1.A1_atLOC512714 115,5 11,85 ‐9,75 ‐6,19 ‐21,89 ‐103,65 similar to Lrrc34 protein
Bt.12217.1.S1_atNTRK2 10,7 136,5 12,76 6,2 100000000 125,8 Neurotrophic tyrosine kinase, receptor, type 2
Bt.287.1.S1_at RNASE6 129,95 8,67 ‐14,98 ‐7,44 ‐1496,53 ‐121,27 ribonuclease, RNase A family, k6
Bt.3410.1.S1_at SYNGR2 728,56 2208,2 3,03 2,51 3,76 1479,64 synaptogyrin 2
Bt.20605.2.S1_at ‐‐‐ 24,84 438,04 17,64 10,98 43,55 413,2 Transcribed locus
Bt.9699.1.S1_at CYP26 39,14 8398,32 214,57 87,99 100000000 8359,18 cytochrome P450 retinoic acid hydroxylase
Bt.12361.1.S1_at LOC541100 1058,23 178,57 ‐5,93 ‐4,53 ‐8,56 ‐879,66 similar to Pleckstrin homology domain containing, family H (with MyTH4 domain) member 3
Bt.25578.1.A1_at‐‐‐ 21,15 236,17 11,17 6,68 31,99 215,03 Transcribed locus
Bt.27655.1.S1_at LOC534112 2664,87 313,28 ‐8,51 ‐7,36 ‐10,01 ‐2351,59 similar to connector enhancer of KSR2A
Bt.568.1.S1_at IBSP 7900 11,05 ‐715,21 ‐311,66 ‐100000000 ‐7888,95 integrin‐binding sialoprotein (bone sialoprotein, bone sialoprotein II)
Bt.13930.1.A1_atLOC539979 501,93 118,45 ‐4,24 ‐3,05 ‐6,68 ‐383,49 Similar to protein kinase
probe set GENE ID baseline mean (LSperiment mean (Efold change lower bound of F upper bound of Fdifference of meaGene Title
Bt.26992.1.A1_at‐‐‐ 1433,18 3554,96 2,48 2,13 2,96 2121,78 Transcribed locus
Bt.9948.1.S1_at NOTCH1 185,91 1396,59 7,51 5,93 10,09 1210,68 Notch homolog 1, translocation‐associated (Drosophila)
Bt.20227.1.S1_at ‐‐‐ 149,67 1716,03 11,47 9,98 13,41 1566,36 Transcribed locus, moderately similar to XP_001092357.1  similar to solute carrier family 25 member 2 [Macaca mulatta]
Bt.4758.1.S1_at FABP 42,56 2187,82 51,41 36,54 86,17 2145,26 fatty acid binding protein ( heart ) like
Bt.26404.1.S1_at ‐‐‐ 463,44 29,84 ‐15,53 ‐6,57 ‐100000000 ‐433,6 Transcribed locus
Bt.29420.1.S1_at ‐‐‐ 11,58 118,82 10,26 5,13 1743,88 107,24 Transcribed locus
Bt.5656.1.S1_at FEZ1 1543,33 583,91 ‐2,64 ‐2,33 ‐3,02 ‐959,42 fasciculation and elongation protein zeta 1 (zygin I)
Bt.4038.1.S1_at LOC524352 4235,08 1735,94 ‐2,44 ‐2,12 ‐2,87 ‐2499,14 similar to betaPix‐bL
Bt.20393.1.S1_atPDIA5 548,86 1985,19 3,62 3,07 4,34 1436,33 protein disulfide isomerase family A, member 5
Bt.13789.1.A1_atCD14 154,8 12,37 ‐12,52 ‐8,45 ‐23,53 ‐142,44 CD14 molecule
Bt.1199.1.S1_at LOC509687 2242,95 10861,73 4,84 3,98 6,19 8618,78 similar to OTTHUMP00000028924
Bt.8888.2.S1_at LOC523408 632,4 109,12 ‐5,8 ‐4,78 ‐7,27 ‐523,28 similar to importin 8
Bt.20557.1.S1_at ‐‐‐ 1999,8 783,17 ‐2,55 ‐2,24 ‐2,97 ‐1216,63 Transcribed locus
Bt.7715.1.S1_at LOC526884 602,37 1587,91 2,64 2,24 3,2 985,54 similar to WD‐repeat protein 6
Bt.4854.1.A1_at ‐‐‐ 321,78 71,37 ‐4,51 ‐3,63 ‐5,84 ‐250,41 Transcribed locus
Bt.7576.1.S1_at ‐‐‐ 49,14 343,95 7 5,84 8,64 294,81 Transcribed locus
Bt.1178.1.S1_a_aMGC159706 10984,16 173,39 ‐63,35 ‐45,72 ‐102,62 ‐10810,76 similar to Protein S100‐A1 (S100 calcium‐binding protein A1) (S‐100 protein alpha subunit) (S‐100 protein alpha chain)
Bt.2737.1.S1_at MGC127744 15997,5 4366,29 ‐3,66 ‐2,91 ‐4,94 ‐11631,21 similar to Carbonic anhydrase III (Carbonate dehydratase III) (CA‐III)
Bt.20725.1.A1_at‐‐‐ 785,66 133,6 ‐5,88 ‐4,89 ‐7,29 ‐652,06 Transcribed locus
Bt.21504.1.A1_atLOC540351 336,45 113,82 ‐2,96 ‐2,29 ‐4,1 ‐222,63 similar to Zyg‐11 homolog B (C. elegans)‐like
Bt.370.1.S1_at AMD1 965,63 343,98 ‐2,81 ‐2,31 ‐3,56 ‐621,66 adenosylmethionine decarboxylase 1
Bt.21047.1.A1_at‐‐‐ 173,62 21,95 ‐7,91 ‐4,75 ‐21,99 ‐151,67 Transcribed locus
Bt.4747.1.S1_at NUP88 409,82 164,45 ‐2,49 ‐2,16 ‐2,9 ‐245,37 nucleoporin 88kDa
Bt.22770.1.S1_at LOC511229 289,94 1002,7 3,46 2,95 4,12 712,76 similar to CARD8 protein
Bt.1178.1.S1_at MGC159706 4036,33 65,64 ‐61,49 ‐34,63 ‐268,13 ‐3970,69 similar to Protein S100‐A1 (S100 calcium‐binding protein A1) (S‐100 protein alpha subunit) (S‐100 protein alpha chain)
Bt.17121.1.S1_at ‐‐‐ 2234,88 934,17 ‐2,39 ‐2,08 ‐2,78 ‐1300,71 ‐‐‐
Bt.28429.1.S1_at ‐‐‐ 3215,34 7476,86 2,33 2,06 2,66 4261,53 Transcribed locus
Bt.15784.1.S1_at LOC521424 /// LO 427,03 4323,44 10,12 8,27 12,93 3896,41 similar to squamous cell‐specific protein
Bt.24258.2.S1_at LOC528150 /// LO 33,79 525,8 15,56 9,66 38,66 492,02 similar to Man9‐mannosidase
Bt.4827.1.S1_at ‐‐‐ 800,59 2331,4 2,91 2,68 3,17 1530,8 ‐‐‐
Bt.25881.1.A1_atMGC134325 960,33 380,66 ‐2,52 ‐2,21 ‐2,93 ‐579,67 Similar to transmembrane protein 53
Bt.17188.1.A1_at‐‐‐ 221,46 10,94 ‐20,24 ‐11,11 ‐104,98 ‐210,53 Transcribed locus
Bt.13141.1.S1_atBCL2 3824,23 331,77 ‐11,53 ‐9,27 ‐15,1 ‐3492,46 B‐cell CLL/lymphoma 2
Bt.19491.1.S1_at LOC787736 473,25 2031,67 4,29 3,81 4,87 1558,42 similar to selenoprotein SelM
Bt.16795.1.A1_atSPAG6 204,6 5,67 ‐36,11 ‐15,25 ‐100000000 ‐198,93 sperm associated antigen 6
Bt.15939.1.A1_at‐‐‐ 127,74 3736,6 29,25 26,04 33,26 3608,86 Transcribed locus
Bt.28035.1.S1_at LOC518159 447,8 2352,76 5,25 4,65 5,99 1904,95 similar to Uncharacterized protein C20orf142
Bt.7760.1.S1_at MGC139859 1184,48 3678,62 3,11 2,66 3,73 2494,14 similar to Glyoxylase 1
Bt.19850.2.S1_at ‐‐‐ 4867,89 1400,23 ‐3,48 ‐3,07 ‐3,96 ‐3467,65 Transcribed locus, weakly similar to XP_001084069.1  similar to acyl‐CoA synthetase long‐chain family member 1 isoform 4 [Macaca mulatta]
Bt.23401.1.S1_atMGC127148 6141,01 255,36 ‐24,05 ‐20,06 ‐29,88 ‐5885,65 similar to Four and a half LIM domains protein 1 (FHL‐1) (Skeletal muscle LIM‐protein 1) (SLIM 1) (SLIM)
Bt.3362.1.S1_at LOC522886 32,81 1625,51 49,54 20,33 100000000 1592,7 similar to periplakin
Bt.21923.1.A1_at‐‐‐ 49,8 5037,8 101,16 72,73 165,24 4988 Transcribed locus
Bt.13336.1.A1_atSMC4L1 146,46 382,86 2,61 2,23 3,16 236,4 SMC4 structural maintenance of chromosomes 4‐like 1 (yeast)
Bt.12760.1.S1_at INHBA 28,24 932,21 33,01 15,56 100000000 903,97 inhibin, beta A
Bt.29931.1.S1_at LOC514928 722,21 1686,05 2,33 2,06 2,68 963,84 similar to Kinesin family member 1C
Bt.561.1.S1_at MAP2K6 323,94 1233,75 3,81 3,28 4,48 909,81 mitogen‐activated protein kinase kinase 6
Bt.12304.1.S1_at ISG15 159,61 1455,79 9,12 5,68 21,8 1296,18 ISG15 ubiquitin‐like modifier
Bt.3367.1.S1_at NR1H2 1014,97 415,5 ‐2,44 ‐2,1 ‐2,92 ‐599,47 nuclear receptor subfamily 1, group H, member 2
Bt.11044.1.S1_atARPP‐21 340,8 9,36 ‐36,4 ‐19,86 ‐206,44 ‐331,44 cyclic AMP‐regulated phosphoprotein, 21 kDa
Bt.4797.1.S1_at FKBP4 1862,58 700,38 ‐2,66 ‐2,26 ‐3,22 ‐1162,2 FK506‐binding protein 4
Bt.7670.1.A1_at LOC539020 5068,89 905,67 ‐5,6 ‐4,7 ‐6,82 ‐4163,23 similar to zinc finger protein
Bt.612.1.S1_at LOC506406 248,83 735,36 2,96 2,62 3,35 486,54 similar to mitochondrial glutathione reductase
Bt.9781.1.S1_at ‐‐‐ 333,1 1526,74 4,58 3,95 5,4 1193,64 Transcribed locus, strongly similar to XP_001090650.1  hypothetical protein [Macaca mulatta]
Bt.4138.2.S1_at ‐‐‐ 697,64 1794,92 2,57 2,05 3,39 1097,28 ‐‐‐
Bt.24345.1.S1_atC2 73,18 247,01 3,38 2,47 5,2 173,82 complement component 2
Bt.10107.1.S1_atCBARA1 1820,77 529,83 ‐3,44 ‐2,96 ‐4,04 ‐1290,94 calcium binding atopy‐related autoantigen 1
Bt.26895.1.S1_at LOC521099 5,91 7042,62 1192,39 283,46 100000000 7036,71 hypothetical LOC521099
Bt.2750.1.S1_at TFAP2A 40,16 415,45 10,34 7,67 15,61 375,28 transcription factor AP‐2 alpha (activating enhancer binding protein 2 alpha)
Bt.9919.1.S1_at MGC134370 11,85 667,31 56,31 26,1 100000000 655,46 similar to CG14120‐PA
Bt.9672.1.S1_at LOC514577 8,12 518,86 63,88 23,34 100000000 510,74 hypothetical LOC514577
Bt.22303.1.S1_at ‐‐‐ 391,83 1263,89 3,23 2,91 3,59 872,06 Transcribed locus
Bt.27634.1.A1_a_LOC534112 774,13 64,86 ‐11,93 ‐8,93 ‐17,72 ‐709,27 similar to connector enhancer of KSR2A
Bt.20316.1.S1_at LOC525365 23,42 177,18 7,56 6,12 9,77 153,76 similar to diabetes related ankyrin repeat protein
Bt.18626.2.A1_at‐‐‐ 1010,88 243,43 ‐4,15 ‐3,3 ‐5,47 ‐767,44 Transcribed locus
probe set GENE ID baseline mean (LSperiment mean (Efold change lower bound of F upper bound of Fdifference of meaGene Title
Bt.27281.1.S1_at ‐‐‐ 2748,45 1001,34 ‐2,74 ‐2,4 ‐3,16 ‐1747,1 Transcribed locus
Bt.5301.1.S1_at THBS 612,17 7469,23 12,2 10,04 15,43 6857,06 thrombospondin
Bt.15927.2.S1_atMGC159964 46,84 270,31 5,77 4,03 9,76 223,47 similar to WD repeat domain, phosphoinositide interacting 1
Bt.13330.2.A1_atMGC166250 3729,79 1360,25 ‐2,74 ‐2,42 ‐3,12 ‐2369,55 similar to pyruvate dehydrogenase kinase
Bt.1577.1.S1_at C1QA 564,8 22,17 ‐25,47 ‐15,78 ‐64,38 ‐542,62 complement component 1, q subcomponent, A chain
Bt.1701.1.S1_at LOC616222 382,58 1416,12 3,7 3,05 4,62 1033,55 similar to nonclathrin coat protein zeta‐COP
Bt.27138.1.S1_at ‐‐‐ 1481,51 439,14 ‐3,37 ‐2,88 ‐4,01 ‐1042,37 ‐‐‐
Bt.2494.2.S1_a_aSDC2 3536,03 537,06 ‐6,58 ‐5,63 ‐7,85 ‐2998,97 Syndecan 2
Bt.13853.2.S1_a_MGC139227 420,42 141,3 ‐2,98 ‐2,46 ‐3,76 ‐279,12 similar to cell adhesion kinase beta
Bt.15953.1.S1_atMGC138975 295,92 965,02 3,26 2,42 4,9 669,11 similar to mitochondrial ribosomal protein L14
Bt.24033.1.A1_atLOC504760 624,58 1661,66 2,66 2,4 2,96 1037,08 similar to DEAD/H (Asp‐Glu‐Ala‐Asp/His) box polypeptide RIG‐I
Bt.25916.1.A1_atHSF2BP 562,64 3349,3 5,95 4,71 7,93 2786,65 heat shock transcription factor 2 binding protein
Bt.5520.1.S1_at IDH2 230,88 1755,11 7,6 5,87 10,57 1524,23 isocitrate dehydrogenase 2 (NADP+), mitochondrial
Bt.8053.1.S1_at LOC506045 7406,59 3151,1 ‐2,35 ‐2,04 ‐2,76 ‐4255,49 hypothetical LOC506045
Bt.20774.1.A1_at‐‐‐ 729,75 147,97 ‐4,93 ‐4,1 ‐6,08 ‐581,79 Transcribed locus
Bt.633.1.S1_at SFXN1 2,9 425,79 146,78 45,73 100000000 422,89 sideroflexin 1
Bt.15939.2.S1_at ‐‐‐ 17,38 880,79 50,69 28,06 252,07 863,41 Transcribed locus
Bt.20891.1.S1_atOAS1 1858,71 5360,77 2,88 2,67 3,12 3502,06 2',5'‐oligoadenylate synthetase 1, 40/46kDa
Bt.18233.1.A1_s_BCL2 3859,33 388,46 ‐9,93 ‐7,84 ‐13,36 ‐3470,87 B‐cell CLL/lymphoma 2
Bt.2159.1.S1_at MGC140063 215,3 6939,36 32,23 23,07 52,95 6724,06 similar to Transmembrane protein 45a (Dermal papilla derived protein 7)
Bt.25823.1.A1_at‐‐‐ 246,83 71,75 ‐3,44 ‐2,46 ‐5,58 ‐175,08 Transcribed locus
Bt.3651.2.A1_at LOC784977 281,36 4887,84 17,37 15,81 19,19 4606,48 similar to LOC387763 protein
Bt.13670.1.S2_atALPL 320,37 2405,92 7,51 6,41 8,98 2085,54 alkaline phosphatase, liver/bone/kidney
Bt.25090.1.A1_atMGC143187 7,84 139,61 17,82 12,09 33,13 131,77 similar to Dimethylaniline monooxygenase [N‐oxide‐forming] 2 (Pulmonary flavin‐containing monooxygenase 2) (FMO 2) (Dimethylaniline oxidase 2) 
Bt.5392.1.S1_at CD36 3424,3 316 ‐10,84 ‐9,57 ‐12,41 ‐3108,3 CD36 molecule (thrombospondin receptor)
Bt.17081.1.A1_atMGC139114 17,09 2258,57 132,14 82,84 322,94 2241,48 similar to Rhombotin‐2 (Cysteine‐rich protein TTG‐2) (T‐cell translocation protein 2) (LIM‐only protein 2)
Bt.19330.1.A1_s_LOC616665 745,09 1858,84 2,49 2,25 2,77 1113,75 similar to Cdc42 effector, long
Bt.27339.1.A1_atLOC536741 15,3 698,22 45,65 26,66 154,68 682,93 similar to Mme protein
Bt.347.1.S1_at CHAD 9,7 221,81 22,86 13,44 73,22 212,1 chondroadherin
Bt.27401.1.A1_atRNF128 45,74 237,56 5,19 4,13 6,85 191,83 ring finger protein 128
Bt.1742.1.S1_at ‐‐‐ 104,1 524,58 5,04 4,05 6,54 420,48 ‐‐‐
Bt.20418.1.A1_atLOC534488 206,46 77,06 ‐2,68 ‐2,38 ‐3,02 ‐129,39 similar to solute carrier family 35, member A5
Bt.1424.1.S1_at LOC520842 2041,74 5027,77 2,46 2,22 2,74 2986,03 similar to kruppel‐like factor 4
Bt.20342.2.S1_a_LOC533595 72,2 732,05 10,14 7,88 14,01 659,85 similar to Transducin‐like enhancer of split 2 (E(sp1) homolog, Drosophila)
Bt.10135.2.S1_at LOC534488 985,05 428,32 ‐2,3 ‐2,03 ‐2,61 ‐556,73 similar to solute carrier family 35, member A5
Bt.27621.1.A1_atMGC155048 60,66 1196,84 19,73 12,54 44,94 1136,18 similar to autoantigen
Bt.2577.1.S1_at LOC783506 /// LO 6,28 1445,15 230,12 76,68 100000000 1438,87 similar to MGC127538 protein
Bt.19485.1.A1_at‐‐‐ 613,11 2144,73 3,5 2,87 4,37 1531,62 Transcribed locus
Bt.21492.1.S1_at LOC613647 696,07 231,55 ‐3,01 ‐2,64 ‐3,45 ‐464,52 similar to CDA04
Bt.2331.2.S1_at MGC148675 337,01 15,99 ‐21,07 ‐12,78 ‐57,92 ‐321,02 similar to receptor activity‐modifying protein 1
Bt.9140.1.S1_at LOC526377 423,41 124,79 ‐3,39 ‐2,89 ‐4,04 ‐298,62 geminin‐like
Bt.7478.1.S1_at MGC140541 737,09 25,87 ‐28,5 ‐18,35 ‐62,51 ‐711,23 similar to heat shock protein, alpha‐crystallin‐related, B6
Bt.19601.1.S1_atMGC142353 3512,41 1321,07 ‐2,66 ‐2,39 ‐3 ‐2191,34 similar to centrin 3
Bt.19805.1.A1_atLOC786885 /// SL 666,6 2550,61 3,83 3,43 4,28 1884,01 solute carrier family 2 (facilitated glucose/fructose transporter), member 5 /// similar to glucose transporter 5
Bt.26784.2.S1_at LOC538685 165,15 4,3 ‐38,36 ‐11,24 ‐100000000 ‐160,85 similar to KIAA1754 protein
Bt.5850.1.S1_at ‐‐‐ 934,08 345,65 ‐2,7 ‐2,24 ‐3,39 ‐588,44 Transcribed locus
Bt.6865.1.S1_at LOC516598 10793,72 864,08 ‐12,49 ‐9,84 ‐16,88 ‐9929,64 similar to AXL receptor tyrosine kinase
Bt.28152.1.S1_at ‐‐‐ 233,78 12,71 ‐18,39 ‐10,37 ‐75,22 ‐221,07 Transcribed locus
Bt.21954.1.S1_at ‐‐‐ 6641,82 2786,4 ‐2,38 ‐2,13 ‐2,68 ‐3855,42 Transcribed locus, strongly similar to XP_001097236.1  hypothetical protein [Macaca mulatta]
Bt.6172.1.A1_at LOC524109 8,66 258,82 29,89 15,75 258,5 250,17 similar to Protocadherin‐19
Bt.17849.2.S1_at LOC533166 303,01 106,84 ‐2,84 ‐2,22 ‐3,89 ‐196,17 similar to mosaic protein LR11
Bt.24725.1.S1_atPOLR2K 1143,57 469,64 ‐2,44 ‐2,03 ‐3,03 ‐673,93 polymerase (RNA) II (DNA directed) polypeptide K, 7.0kDa
Bt.12440.1.A1_atIGFBP5 8657,49 542,65 ‐15,95 ‐13,99 ‐18,46 ‐8114,84 insulin‐like growth factor binding protein 5
Bt.16391.1.A1_atLOC782315 17,32 121,63 7,02 5,75 8,88 104,31 similar to IQ motif containing GTPase activating protein 2
Bt.16495.1.A1_atLOC511602 7,68 1749,05 227,72 122,41 1578,3 1741,36 similar to alpha‐5 type IV collagen
Bt.2096.1.S1_at LOC505206 122,04 1530,09 12,54 9,7 17,47 1408,05 similar to pincher
Bt.24475.1.S1_at LOC515758 49,94 483,12 9,67 6,94 15,54 433,18 hypothetical LOC515758
Bt.16094.1.S1_at LOC509106 27,35 275,9 10,09 6,59 20,59 248,54 similar to enhancer of zeste homolog 2
Bt.3554.1.S1_at LOC529049 8,11 154,46 19,03 9,08 100000000 146,35 similar to mannose receptor, C type 2
Bt.22586.1.A1_atMGC129108 163,98 807,78 4,93 4,27 5,76 643,79 Similar to myo‐inositol monophosphatase A3
Bt.3722.1.S1_at ‐‐‐ 71,84 401,32 5,59 3,85 9,67 329,48 CDNA clone IMAGE:8067330
Bt.20170.1.S1_atEHD2 28,49 308,88 10,84 6,37 33,23 280,38 EH‐domain containing 2
Bt.26797.1.S1_atDENND2D 50,71 669,1 13,19 9,32 22,09 618,39 DENN/MADD domain containing 2D
Bt.18321.1.A1_atMGC152413 270,75 1255,27 4,64 4,11 5,27 984,52 similar to guanine nucleotide binding protein beta subunit 4
probe set GENE ID baseline mean (LSperiment mean (Efold change lower bound of F upper bound of Fdifference of meaGene Title
Bt.378.1.S1_at ATP5I 2039,39 5246,99 2,57 2,13 3,24 3207,6 ATP synthase, H+ transporting, mitochondrial F0 complex, subunit e
Bt.1366.1.S1_at CLEC3B 3466 11015,85 3,18 2,67 3,92 7549,85 C‐type lectin domain family 3, member B
Bt.24260.2.S1_at ‐‐‐ 533,43 216,89 ‐2,46 ‐2,03 ‐3,04 ‐316,54 Transcribed locus
Bt.29185.1.S1_at ‐‐‐ 490,22 196,59 ‐2,49 ‐2,15 ‐2,96 ‐293,63 Transcribed locus
Bt.6244.1.S1_at LOC505839 705,05 246,72 ‐2,86 ‐2,17 ‐4,12 ‐458,33 similar to ubiquitin specific protease 20
Bt.19937.1.S1_at LOC532189 1228,14 3654,39 2,98 2,63 3,38 2426,25 similar to carboxypeptidase D
Bt.5401.1.S1_at TGM2 12,84 1286,42 100,19 40,6 100000000 1273,58 transglutaminase 2 (C polypeptide, protein‐glutamine‐gamma‐glutamyltransferase)
Bt.161.1.S2_at DSG1 16,84 2541,01 150,89 93,95 378,18 2524,17 desmoglein 1
Bt.15740.1.A1_atLOC534629 19,93 1064,79 53,43 30,97 189,21 1044,86 similar to tumor protein D52‐like 1
Bt.25614.1.A1_atTPP1 1086,79 2325,03 2,14 2,01 2,28 1238,25 Tripeptidyl‐peptidase I
Bt.22568.1.S1_atRPL29 2564,56 6650,24 2,59 2,26 3,04 4085,68 ribosomal protein L29
Bt.6133.2.A1_at ‐‐‐ 566,7 19,32 ‐29,34 ‐19,88 ‐55,02 ‐547,38 Transcribed locus, weakly similar to XP_001097766.1  glypican 3 isoform 4 [Macaca mulatta]
Bt.1491.1.S1_at C1S 634,66 196,4 ‐3,23 ‐2,44 ‐4,74 ‐438,26 complement component 1, s subcomponent
Bt.3435.1.A1_at LOC507975 22,44 7513,69 334,8 108,86 100000000 7491,24 hypothetical protein LOC507975
Bt.22760.1.S1_at ‐‐‐ 5000,47 1468,53 ‐3,41 ‐3,01 ‐3,87 ‐3531,95 Transcribed locus
Bt.25661.1.A1_atLOC537027 /// LO 1460,48 377,6 ‐3,87 ‐3,25 ‐4,69 ‐1082,89 similar to Mitotic checkpoint serine/threonine‐protein kinase BUB1 beta /// similar to BUB1 budding uninhibited by benzimidazoles 1 homolog beta 
Bt.24607.2.S1_atMGC128683 591,77 222,86 ‐2,66 ‐2,23 ‐3,28 ‐368,91 similar to Nucleolar protein 11
Bt.4106.1.S1_at F3 /// LOC784008 159,48 1475,11 9,25 7,82 11,2 1315,64 coagulation factor III (thromboplastin, tissue factor) /// similar to F3 protein
Bt.648.3.S1_at MGC151609 3911,1 685,19 ‐5,71 ‐4,55 ‐7,5 ‐3225,91 similar to TRIP protein
Bt.25228.1.A1_at‐‐‐ 2420,78 963,51 ‐2,51 ‐2,01 ‐3,32 ‐1457,26 Transcribed locus
Bt.1404.1.S1_at LOC514631 1794,03 381,2 ‐4,71 ‐3,93 ‐5,77 ‐1412,83 Similar to Cell division cycle associated 7‐like
Bt.26901.2.S1_a_JPH2 114,47 356,16 3,11 2,39 4,31 241,69 junctophilin 2
Bt.8513.1.A1_at LOC509610 1062,22 2568,76 2,42 2,26 2,58 1506,54 similar to N‐acetylglucosamine‐1‐phosphate transferase
Bt.27243.1.A1_s_LOC533414 277,22 69,91 ‐3,97 ‐2,92 ‐6,13 ‐207,31 similar to RAD54B protein
Bt.14198.2.S1_at LOC783295 536,03 133,64 ‐4,01 ‐3,16 ‐5,47 ‐402,39 hypothetical protein LOC783295
Bt.20822.1.A1_at‐‐‐ 1341,68 588,45 ‐2,28 ‐2,01 ‐2,63 ‐753,23 Transcribed locus
Bt.5038.1.S1_at FGF1 1229,9 20,37 ‐60,37 ‐37,88 ‐146,24 ‐1209,53 fibroblast growth factor 1 (acidic)
Bt.18325.2.A1_atMGC151537 938,9 381,31 ‐2,46 ‐2,14 ‐2,89 ‐557,59 microtubule‐associated protein 7
Bt.8330.1.S1_at ‐‐‐ 407,12 1321,16 3,25 2,86 3,71 914,04 Transcribed locus
Bt.5494.1.S1_at CD44 276,94 2475,76 8,94 7,5 10,94 2198,82 CD44 molecule (Indian blood group)
Bt.10688.1.S1_at LOC529661 67,43 932,12 13,82 9,85 22,66 864,7 similar to E2IG4
Bt.5334.1.S1_at LAMR1 4241,73 12919,8 3,05 2,52 3,85 8678,07 laminin receptor 1 (ribosomal protein SA, 67 kDA)
Bt.8798.1.S1_at LOC507093 /// LO 2329,95 333,42 ‐6,99 ‐6,12 ‐8,07 ‐1996,53 similar to retinaldehyde dehydrogenase 3 /// similar to aldehyde dehydrogenase 6
Bt.10283.1.S1_at LOC537938 157,98 1645,75 10,42 8,35 13,65 1487,77 hypothetical protein LOC537938
Bt.3809.1.S1_at LDHA 9185,4 3391,5 ‐2,71 ‐2,49 ‐2,95 ‐5793,89 lactate dehydrogenase A
Bt.28490.1.S1_at ‐‐‐ 319,13 65,57 ‐4,87 ‐3,3 ‐9,2 ‐253,57 ‐‐‐
Bt.27376.1.S1_atBAG4 368,07 122,87 ‐3 ‐2,21 ‐4,47 ‐245,2 BCL2‐associated athanogene 4
Bt.17447.1.A1_atLOC541122 237,96 2719,48 11,43 10,43 12,56 2481,52 similar to chromosome 6 open reading frame 60
Bt.18229.1.A1_atLOC507620 593,72 130,2 ‐4,56 ‐3,8 ‐5,6 ‐463,51 similar to partner and localizer of BRCA2
Bt.24112.1.A1_atLOC511907 59,41 293,54 4,94 3,89 6,6 234,12 hypothetical LOC511907
Bt.19274.1.A1_atMGC142642 10,59 241,08 22,76 11,3 2975,65 230,48 similar to C1q and tumor necrosis factor related protein 7
Bt.24124.1.A1_at‐‐‐ 5,32 616,66 115,94 61,05 1076,16 611,34 Transcribed locus
Bt.27924.1.S1_atRAP80 1256,18 408,25 ‐3,08 ‐2,48 ‐4,05 ‐847,92 receptor associated protein 80
Bt.981.3.S1_at ‐‐‐ 1396,35 402,61 ‐3,47 ‐3,06 ‐3,94 ‐993,74 Transcribed locus
Bt.16114.1.S1_at ‐‐‐ 293,2 77,05 ‐3,81 ‐2,72 ‐6,27 ‐216,15 Transcribed locus
Bt.18689.1.S1_at LOC538401 194,11 1592,11 8,2 6,59 10,66 1397,99 similar to Arylsulfatase B precursor (ASB) (N‐acetylgalactosamine‐4‐sulfatase) (G4S)
Bt.20518.1.A1_at‐‐‐ 13,05 131,62 10,09 6,63 20,05 118,57 Transcribed locus
Bt.26606.1.S1_atCHST1 675,17 1764,32 2,61 2,42 2,82 1089,14 carbohydrate (keratan sulfate Gal‐6) sulfotransferase 1
BtAffx.1.13.S1_atTAC3 61,45 2555,96 41,59 28,64 74,87 2494,51 tachykinin 3 (neuromedin K, neurokinin beta)
Bt.7347.1.S1_at ‐‐‐ 949,11 2218,79 2,34 2,05 2,72 1269,68 Transcribed locus
Bt.6154.1.S1_at FHL3 904,77 284,9 ‐3,18 ‐2,53 ‐4,25 ‐619,87 four and a half LIM domains 3
Bt.11001.1.S1_at ‐‐‐ 1937,47 364,95 ‐5,31 ‐4,64 ‐6,13 ‐1572,52 Transcribed locus
Bt.15739.1.S1_atMGC137017 316,03 895,33 2,83 2,45 3,3 579,3 similar to stimulated by retinoic acid 13
Bt.24351.1.A1_atMGC142689 4,91 1338,09 272,67 114,82 100000000 1333,18 similar to limb expression 1
Bt.9211.1.S1_at APBB1IP 1043,45 434,31 ‐2,4 ‐2,11 ‐2,75 ‐609,14 amyloid beta (A4) precursor protein‐binding, family B, member 1 interacting protein
Bt.13235.1.S1_atMGC148992 9,63 2153,59 223,56 99,8 100000000 2143,96 similar to RGC‐32
Bt.13899.1.A1_atLOC615535 6,58 656,28 99,68 43,95 100000000 649,69 similar to PDNP1
Bt.22741.2.A1_at‐‐‐ 11,23 1347,53 119,96 67,77 506,14 1336,29 Transcribed locus
Bt.28388.1.S1_at LOC514572 699,07 2353,86 3,37 2,76 4,31 1654,79 similar to Anaphase promoting complex subunit 4
Bt.20435.1.S1_at LOC613935 220,19 2800,34 12,72 5,41 100000000 2580,15 similar to tumor suppressing subtransferable candidate 1
Bt.13734.1.A1_at‐‐‐ 138,79 816,93 5,89 3,99 11,15 678,15 Transcribed locus
Bt.2039.2.S1_at LOC514971 1712,15 21,92 ‐78,1 ‐30,24 ‐100000000 ‐1690,22 Similar to cytochrome P450 2S1
Bt.26423.1.A1_at‐‐‐ 255,56 49,43 ‐5,17 ‐3,35 ‐11,16 ‐206,13 Transcribed locus
Bt.26107.1.A1_atLOC540563 523,37 212,53 ‐2,46 ‐2,05 ‐3,01 ‐310,84 similar to ash1 (absent, small, or homeotic)‐like
probe set GENE ID baseline mean (LSperiment mean (Efold change lower bound of F upper bound of Fdifference of meaGene Title
Bt.16087.1.S1_atMGC159943 22,09 836,94 37,88 27,67 59,28 814,85 similar to nidogen‐2
Bt.5856.1.S1_at ‐‐‐ 460,91 94,54 ‐4,88 ‐3,57 ‐7,34 ‐366,37 Transcribed locus
Bt.18840.1.S1_at LOC510708 62,78 1114,38 17,75 14,48 22,67 1051,59 similar to adenylate cyclase 2
Bt.12600.1.S1_at ‐‐‐ 953,59 161,63 ‐5,9 ‐4,86 ‐7,37 ‐791,96 Transcribed locus
Bt.23608.1.S1_s_KRT8 2,16 1719,19 794,94 188,47 100000000 1717,03 keratin 8
Bt.8433.1.S1_at LOC526045 1215,05 3199,1 2,63 2,17 3,33 1984,05 similar to SURF‐4
Bt.23354.1.S1_atMGC126963 3609,38 194,17 ‐18,59 ‐14,74 ‐24,86 ‐3415,21 similar to epoxide hydrolase 1
Bt.27140.1.S1_at LOC535166 1080,42 92,6 ‐11,67 ‐9,88 ‐14,09 ‐987,82 similar to sulfatase 1
Bt.24460.1.S1_atMGC143376 330,75 16,08 ‐20,57 ‐12,97 ‐47,9 ‐314,67 similar to zinc finger, CCHC domain containing 12
Bt.12360.1.S1_at ‐‐‐ 472,38 1242,3 2,63 2,31 3,01 769,92 Transcribed locus
Bt.20157.1.S1_at LOC539561 3392,32 137,74 ‐24,63 ‐18,69 ‐35,62 ‐3254,58 similar to glutaminase liver
Bt.3227.1.S1_at ASCC2 418,91 1247,59 2,98 2,5 3,6 828,69 activating signal cointegrator 1 complex subunit 2
Bt.14121.1.S1_at ‐‐‐ 5,96 757,51 127,18 66,82 1216,25 751,55 Transcribed locus
Bt.10343.1.A1_atPALMD 2893,15 240,71 ‐12,02 ‐9,23 ‐16,89 ‐2652,44 palmdelphin
Bt.25077.1.S1_at ‐‐‐ 111,57 897,14 8,04 6,69 9,93 785,57 ‐‐‐
Bt.3989.1.S1_at ‐‐‐ 1265,02 2870,94 2,27 2,06 2,53 1605,92 Transcribed locus
Bt.16176.1.A1_at‐‐‐ 51,25 2454,79 47,9 31,5 98,02 2403,54 Transcribed locus
Bt.22279.1.S1_at LOC614739 3,31 1394,91 421,78 54,99 100000000 1391,61 hypothetical LOC614739
Bt.15623.1.S1_at ‐‐‐ 45,97 705,67 15,35 12,11 20,66 659,7 Transcribed locus, weakly similar to XP_001085012.1  similar to desmoplakin isoform I isoform 2 [Macaca mulatta]
Bt.12054.3.S1_at LOC511748 1877,25 449,24 ‐4,18 ‐3,66 ‐4,79 ‐1428,02 similar to Yip1 domain family, member 1
Bt.16243.1.S1_atMGC140079 11,62 3269,3 281,46 150,43 2066,06 3257,68 similar to chemokine‐like factor superfamily 8
Bt.6591.1.S1_at ‐‐‐ 895,07 2351,13 2,63 2,19 3,27 1456,06 Transcribed locus
Bt.7130.1.S1_at LOC534774 14,5 355,49 24,51 12,69 275,01 340,98 similar to aspartic‐like protease
Bt.16415.1.S1_at ‐‐‐ 4,34 266,87 61,49 31,03 2104,73 262,53 Transcribed locus
Bt.9750.2.S1_a_aSNRPG 1469,21 3513,63 2,39 2,17 2,63 2044,42 small nuclear ribonucleoprotein polypeptide G
Bt.21177.1.A1_s_LOC511229 333,31 1347,22 4,04 3,64 4,5 1013,9 similar to CARD8 protein
Bt.6261.1.S1_at LOC614323 32,89 463,54 14,09 10,68 20,33 430,65 similar to carbonic anhydrase
Bt.16063.2.S1_at ‐‐‐ 141,21 914,52 6,48 5,33 8,09 773,31 Transcribed locus
Bt.1819.1.S1_at MGC127828 1133,17 2852,69 2,52 2,11 3,12 1719,52 similar to ubiquinol‐cytochrome c reductase complex 7.2kDa protein
Bt.8829.1.S1_at IFT122 929,69 323,92 ‐2,87 ‐2,49 ‐3,33 ‐605,77 WD repeat domain 10
Bt.13880.1.S1_at LOC504445 155,26 3653,33 23,53 20,11 28,08 3498,07 similar to Dickkopf‐1 (hdkk‐1)
Bt.5026.1.S1_at ANXA8 42,63 930,69 21,83 13,55 53,88 888,06 annexin A8
Bt.5324.1.S1_s_aJSP.1 999,85 4106,16 4,11 3,74 4,51 3106,3 MHC Class I JSP.1
Bt.16815.1.S1_at LOC513526 749,17 2673,98 3,57 3,13 4,1 1924,81 similar to U11/U12 snRNP 25K protein
Bt.12295.1.S1_atPDPN 302,49 2788,44 9,22 7,47 11,83 2485,95 Podoplanin
Bt.20295.1.A1_at‐‐‐ 572,56 22,75 ‐25,17 ‐16,48 ‐51,79 ‐549,81 Transcribed locus
Bt.14001.1.A1_at‐‐‐ 345,69 20,75 ‐16,66 ‐10,51 ‐38,36 ‐324,94 Transcribed locus
Bt.23360.1.S1_at LOC399559 1277,47 416,65 ‐3,07 ‐2,56 ‐3,82 ‐860,83 nicotinate phosphoribosyltransferase‐like
Bt.21641.1.S1_atMGC139340 9,11 1495,23 164,09 80,08 100000000 1486,12 similar to Ectoderm‐neural cortex‐1 protein (ENC‐1) (p53‐induced protein 10) (Nuclear matrix protein NRP/B)
Bt.10859.2.S1_atMGC139506 737,15 131,3 ‐5,61 ‐4,46 ‐7,38 ‐605,85 similar to cAMP responsive element binding protein‐like 2
Bt.2282.1.S1_a_aLOC530071 186,27 31,45 ‐5,92 ‐4,57 ‐8,16 ‐154,82 similar to OTTHUMP00000016433
Bt.6552.1.S1_at ‐‐‐ 318,68 47,18 ‐6,75 ‐4,09 ‐19,35 ‐271,51 Transcribed locus
Bt.8191.1.S1_at SLC9A3R1 472,82 1783,13 3,77 3,32 4,31 1310,31 solute carrier family 9 (sodium/hydrogen exchanger), member 3 regulator 1
Bt.17702.1.A1_at‐‐‐ 2,89 414,19 143,55 49,74 100000000 411,31 Transcribed locus
Bt.800.1.S1_at MAPK13 6,28 559,48 89,06 40,69 100000000 553,2 mitogen‐activated protein kinase 13
Bt.21191.2.A1_atMGC143198 1111,07 406,68 ‐2,73 ‐2,28 ‐3,39 ‐704,39 similar to phosphodiesterase 4D interacting protein (myomegalin)
Bt.21853.1.S1_atAP1S1 1853,34 249,59 ‐7,43 ‐6,21 ‐9,07 ‐1603,74 Adaptor‐related protein complex 1, sigma 1 subunit
Bt.554.1.S1_at DMP1 18371,4 5722,07 ‐3,21 ‐2,58 ‐4,23 ‐12649,33 dentin matrix acidic phosphoprotein
Bt.166.1.S1_at PENK 941,96 23,21 ‐40,58 ‐21,69 ‐282,87 ‐918,74 proenkephalin
Bt.11710.1.S1_atMGC140046 606,28 1602,84 2,64 2,08 3,6 996,56 similar to phosducin‐like 3
Bt.27202.1.A1_atSOSTDC1 5,61 2612,75 465,39 218,04 100000000 2607,14 sclerostin domain containing 1
Bt.16874.1.A1_atLOC617120 574,82 199,81 ‐2,88 ‐2,5 ‐3,32 ‐375,01 Hypothetical LOC617120
Bt.22194.1.S1_at IER2 1634,47 497,12 ‐3,29 ‐2,57 ‐4,38 ‐1137,35 immediate early response 2
Bt.19862.1.A1_atLOC518458 97,63 3245,35 33,24 28,13 40,18 3147,71 similar to semaphorin 6D
Bt.28423.1.S1_at LOC541051 1831,73 24,16 ‐75,83 ‐39,25 ‐953,64 ‐1807,57 similar to KIAA0984 protein
Bt.6642.1.S1_a_a‐‐‐ 901,21 239,42 ‐3,76 ‐3,14 ‐4,59 ‐661,79 Transcribed locus
Bt.13203.1.S1_at ‐‐‐ 2350,07 9,02 ‐260,42 ‐115,99 ‐100000000 ‐2341,04 Transcribed locus
Bt.2812.1.A1_at MGC142413 43,67 156,29 3,58 3,14 4,1 112,62 similar to Zinc‐finger protein neuro‐d4 (D4, zinc and double PHD fingers family 1)
Bt.22757.1.S1_at ‐‐‐ 4813,13 1654,48 ‐2,91 ‐2,61 ‐3,25 ‐3158,65 Transcribed locus
Bt.25303.1.A1_at‐‐‐ 107,65 565,93 5,26 3,98 7,44 458,28 Transcribed locus
Bt.373.2.S1_a_at AMELX /// AMELY 4,49 3617,34 806,31 358,49 100000000 3612,85 amelogenin (amelogenesis imperfecta 1, X‐linked) /// amelogenin, Y‐linked
Bt.28295.1.S1_atMGC159392 18,71 195,17 10,43 5,41 89,1 176,46 hypothetical LOC617670
Bt.1580.1.S1_at LOC508224 35,99 428,08 11,9 8,42 19,61 392,1 similar to secretory granule, neuroendocrine protein 1 (7B2 protein)
Bt.26505.1.S1_at ‐‐‐ 12,59 422,03 33,51 22,55 63,73 409,44 Transcribed locus
probe set GENE ID baseline mean (LSperiment mean (Efold change lower bound of F upper bound of Fdifference of meaGene Title
Bt.25257.1.A1_at‐‐‐ 133,95 30,37 ‐4,41 ‐2,62 ‐12,12 ‐103,58 Transcribed locus
Bt.1976.2.S1_at MGC139033 191,35 31,68 ‐6,04 ‐3,14 ‐45,1 ‐159,66 similar to suppression of tumorigenicity 5
Bt.24258.1.S1_at LOC528150 /// LO 174,61 2352,23 13,47 11,98 15,22 2177,62 similar to Man9‐mannosidase
Bt.9599.1.A1_at MGC128671 489,09 1782,39 3,64 3,15 4,24 1293,29 Similar to Inositol hexakisphosphate kinase 2 (InsP6 kinase 2) (Inositol hexakisphosphate kinase 2) (P(i)‐uptake stimulator) (PiUS)
Bt.21319.1.A1_at‐‐‐ 71,05 2522,42 35,5 25,46 57,52 2451,37 Transcribed locus, weakly similar to NP_001036812.1  repeat domain 5 [Xenopus tropicalis]
Bt.13911.1.S1_s_‐‐‐ 13,07 214,64 16,42 9,57 53,07 201,57 ‐‐‐
Bt.21475.3.S1_a_LOC786013 536,44 1357,32 2,53 2,21 2,96 820,88 similar to Ded protein
Bt.9640.1.A1_at SPON1 26,85 900,23 33,52 23,25 58,78 873,38 Spondin 1, extracellular matrix protein
Bt.28168.1.A1_atMGC166050 8,18 146,18 17,88 9,18 210,22 138 similar to insulin gene enhancer binding protein Isl‐1
Bt.13030.2.S1_atCOL2A1 248,85 709,45 2,85 2,44 3,43 460,6 collagen, type II, alpha 1
Bt.16639.1.A1_at‐‐‐ 6030,1 709,15 ‐8,5 ‐6,86 ‐10,95 ‐5320,95 Transcribed locus
Bt.18204.2.A1_atSGLT5 9,43 311,36 33,02 17,45 259,93 301,93 Na+/glucose cotransporter‐related protein
Bt.26637.1.A1_at‐‐‐ 991,64 67,63 ‐14,66 ‐9,69 ‐28,85 ‐924,01 Transcribed locus
Bt.18955.2.A1_at‐‐‐ 150,25 2,81 ‐53,38 ‐23,28 ‐100000000 ‐147,44 Transcribed locus
Bt.7728.1.A1_at ‐‐‐ 2187,67 343,23 ‐6,37 ‐5,52 ‐7,42 ‐1844,44 Transcribed locus
Bt.21215.2.S1_at LOC506721 21,78 458,53 21,05 13,44 46,48 436,75 similar to ALL1 responsive protein ARP1c
Bt.13587.2.S1_a_LOC521539 220,94 1626,83 7,36 6,09 9,12 1405,89 Similar to mannosidase, alpha, class 2A, member 1
Bt.28430.1.S1_at ‐‐‐ 10 313,64 31,36 17,03 176,09 303,64 ‐‐‐
Bt.19936.1.A1_at‐‐‐ 187,88 916,49 4,88 4,21 5,7 728,61 Transcribed locus
Bt.115.1.S1_at DDC 130,14 3090,29 23,75 19,63 29,61 2960,15 dopa decarboxylase (aromatic L‐amino acid decarboxylase)
Bt.7418.1.S1_at LOC511800 5972,5 262,34 ‐22,77 ‐17 ‐33,73 ‐5710,16 similar to KIAA1581 protein
Bt.18969.1.S1_at ‐‐‐ 1767,1 295,64 ‐5,98 ‐4,84 ‐7,62 ‐1471,46 Transcribed locus
Bt.4438.1.S1_at PRKAR1B 198,48 29,11 ‐6,82 ‐4,29 ‐16,56 ‐169,37 protein kinase, cAMP‐dependent, regulatory, type I, beta
Bt.8712.1.S1_at STIM1 3117,53 1197,32 ‐2,6 ‐2,16 ‐3,27 ‐1920,21 stromal interaction molecule 1
Bt.9288.1.S1_at LOC510738 18,08 1001,4 55,4 36,92 108,13 983,33 similar to FLJ00258 protein
Bt.14209.1.A1_at‐‐‐ 13,29 1329,13 99,98 46,11 100000000 1315,84 Transcribed locus
Bt.18203.2.S1_atMGC151720 277,9 60,84 ‐4,57 ‐2,74 ‐13,14 ‐217,06 similar to C21ORF43
Bt.24925.1.A1_at‐‐‐ 9,44 530,46 56,18 18,45 100000000 521,02 ‐‐‐
Bt.7700.1.S1_at ACTN1 133,9 1097,56 8,2 6,7 10,33 963,67 actinin, alpha 1
Bt.16187.1.A1_atLOC538461 290,66 86,7 ‐3,35 ‐2,95 ‐3,81 ‐203,96 similar to Kelch repeat and BTB (POZ) domain containing 6
Bt.29801.1.S1_at ‐‐‐ 42,92 3666,75 85,44 48,03 362,53 3623,83 B4 cell‐line anti‐respiratory syncytial virus Ig lambda chain V region (IgL)
Bt.25009.1.S1_at ‐‐‐ 76,63 837,96 10,94 4,9 100000000 761,33 Clone NG010006A21G10 mRNA, complete sequence
Bt.19181.1.A1_atLOC532572 92,45 805,21 8,71 7,21 10,76 712,76 similar to Laminin gamma‐1 chain precursor (Laminin B2 chain)
Bt.5515.1.S1_at NT5E 17,05 5539,93 324,99 215,31 644,04 5522,88 5'‐nucleotidase, ecto (CD73)
Bt.4882.1.S1_at FKBP9 2249,41 5906,32 2,63 2,11 3,47 3656,92 FK506 binding protein 9
Bt.2725.1.S1_at UBE2C 11,16 251,88 22,56 11,54 297,31 240,71 ubiquitin‐conjugating enzyme E2C
Bt.16036.1.S1_atMGC139020 102,5 2018,52 19,69 15,92 25,31 1916,01 similar to SH3BGRL2 protein
Bt.11454.1.A1_at‐‐‐ 372,99 6,47 ‐57,67 ‐29,78 ‐705,04 ‐366,53 Transcribed locus
Bt.7980.1.S1_at LASP1 /// LOC787 3374,97 8385,24 2,48 2,12 2,99 5010,27 LIM and SH3 protein 1 /// similar to LIM and SH3 protein 1
Bt.12179.1.S1_at LOC518469 41,53 1141,05 27,48 19,58 44,75 1099,52 similar to RP5‐1022P6.2
Bt.7808.1.A1_at ‐‐‐ 93,74 1594,98 17,02 12,99 24,01 1501,24 Transcribed locus
Bt.543.1.S1_at NR2F1 1855,45 100,05 ‐18,55 ‐12,55 ‐34,03 ‐1755,4 nuclear receptor subfamily 2, group F, member 1
Bt.3139.1.A1_at ‐‐‐ 6694,83 78 ‐85,83 ‐56,13 ‐176,26 ‐6616,83 Transcribed locus
Bt.11017.1.S1_at LOC540504 126,9 915,35 7,21 5,95 8,92 788,45
similar to Nesprin‐2 (Nuclear envelope spectrin repeat protein 2) (Syne‐2) (Synaptic nuclear envelope protein 2) (Nucleus and actin connecting 
element protein) (Protein NUANCE)
Bt.3236.1.A1_at LOC782247 6,36 386,5 60,74 34,03 260,32 380,14 similar to RhoGEF protein
Bt.26081.1.A1_atLOC514646 343,59 25,34 ‐13,56 ‐9,5 ‐22,66 ‐318,25 similar to Acyltransferase like 1
Bt.21203.1.S1_at ‐‐‐ 173,52 952,97 5,49 4,72 6,44 779,45 Transcribed locus
Bt.13702.1.S1_at ‐‐‐ 287,24 2496,17 8,69 7,52 10,1 2208,92 Transcribed locus
Bt.11013.1.S1_at ‐‐‐ 43,22 399,55 9,24 6,85 13,64 356,33 Transcribed locus
Bt.11476.1.S1_atMGC128664 3194,04 67,19 ‐47,53 ‐34,2 ‐75,8 ‐3126,84 similar to Beta‐1,3‐N‐acetylglucosaminyltransferase lunatic fringe (O‐fucosylpeptide 3‐beta‐N‐acetylglucosaminyltransferase)
Bt.22596.1.A1_at‐‐‐ 41,92 409,21 9,76 8,1 12,01 367,29 Transcribed locus
Bt.14239.1.A1_atMGC155329 52,56 953,37 18,14 13,9 25,39 900,82 similar to enhancer of filmentation 1
Bt.64.1.S1_at NDUFB7 276,35 3003,19 10,87 5,47 765,54 2726,84 NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 7, 18kDa
Bt.20853.1.S1_a_LOC506769 715,87 36,61 ‐19,56 ‐12,9 ‐38,47 ‐679,27 similar to src kinase associated phosphoprotein 1
Bt.648.1.A1_at MGC151609 3657,57 734,45 ‐4,98 ‐4,23 ‐5,91 ‐2923,12 similar to TRIP protein
Bt.227.1.A1_at GSTA2 41,66 579,2 13,9 10,48 20,01 537,54 glutathione S‐transferase A2
Bt.25236.1.A1_atLOC786844 25,48 974,56 38,25 25,28 75,55 949,08 similar to adlican
Bt.4277.1.A1_at ‐‐‐ 53,42 1154,52 21,61 16,84 29,38 1101,1 Transcribed locus
Bt.20905.1.S1_at LOC504509 439,85 27,82 ‐15,81 ‐11,39 ‐24,9 ‐412,03 similar to Zeta‐chain (TCR) associated protein kinase
Bt.8436.1.S1_at IFI6 399,34 4064,3 10,18 8,66 12,07 3664,95 interferon, alpha‐inducible protein 6
Bt.21958.1.A1_atLOC508963 794,62 289,15 ‐2,75 ‐2,07 ‐4,04 ‐505,46 hypothetical LOC508963
Bt.18132.1.A1_atLOC516290 6,8 320,49 47,12 21,98 100000000 313,69 similar to FLJ00261 protein
Bt.13435.1.A1_atLOC539445 132,51 718,1 5,42 4,59 6,45 585,59 similar to serine/threonine protein kinase MASK
probe set GENE ID baseline mean (LSperiment mean (Efold change lower bound of F upper bound of Fdifference of meaGene Title
Bt.4912.1.S1_at PI16 175,1 65,41 ‐2,68 ‐2,21 ‐3,38 ‐109,69 peptidase inhibitor 16
Bt.3399.2.S1_at ‐‐‐ 20,47 935,86 45,72 31,12 82,9 915,39 Transcribed locus
Bt.12625.1.S1_at LOC615883 79,78 1309,37 16,41 13,31 20,86 1229,59 similar to SLIT3
Bt.2410.1.A1_at ‐‐‐ 23,48 209,43 8,92 6,08 15,65 185,95 Transcribed locus
Bt.22459.1.S1_at LOC785319 70,67 2219,79 31,41 24,2 43,42 2149,12 similar to Neural cell adhesion molecule 1, 180 kDa isoform precursor (N‐CAM 180) (NCAM‐180)
Bt.25989.1.A1_atGJB6 4,52 758,74 167,78 63,84 100000000 754,21 gap junction protein, beta 6
Bt.5046.2.A1_a_aLOC506670 275,97 17,93 ‐15,39 ‐9,53 ‐36,67 ‐258,04 similar to Solute carrier family 7, (cationic amino acid transporter, y+ system) member 13
Bt.10144.1.A1_s_MGC142564 23,14 508,88 21,99 16,39 32,28 485,74 similar to T‐lymphoma invasion and metastasis inducing protein 1 (TIAM1 protein)
Bt.16415.3.A1_at‐‐‐ 2,83 416,95 147,18 57,14 100000000 414,12 Transcribed locus
Bt.4670.1.S1_at LOC539596 60,94 1014,59 16,65 11,95 26,08 953,65 similar to Transforming growth factor‐beta induced protein IG‐H3 precursor (Beta IG‐H3) (Kerato‐epithelin) (RGD‐containing collagen associated 
Bt.25187.1.A1_atLOC615535 15,34 383,57 25 18,46 37,07 368,22 Similar to PDNP1
Bt.13184.1.S1_at ‐‐‐ 4,59 521,4 113,51 62,04 565,94 516,81 Transcribed locus
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Aim: To review the latest developments in the field of pulp biology, particularly those 
elements of specific interest to clinical dentists, whilst highlighting the importance of 
maintaining pulp vitality for conservative dentistry. Pulp biology is crucial to everyday 
practice in dentistry and the knowledge acquired, especially in the last five years on the 
pulp healing process, has highlighted simple but effective applications. However, 
difficulties in communication between biologists and clinicians, mostly due to the 
complexity of biology as a discipline, are a significant obstacle to therapeutic 
developments and their application on a larger scale. 
Methods: A literature review was undertaken on the current understanding of the biology 
of the dentine- 
pulp complex, especially in the context of conservative dentistry. 
Results: Novel biotechnological insights have recently been discovered, including the 
presence of stem cell-like cells within the tooth and their potential roles in reparative and 
regenerative processes. A greater understanding is also developing regarding the structure 
of the dentine-pulp complex, both macroscopically and microscopically, which may have 
important consequences for therapeutic choices. 
Conclusions: The emergence of new adhesive systems, together with disinfecting 
molecules, represents a first step towards the application of new biological approaches to 
the treatment of pulpal disease. Improved understanding of the many pathophysiological 
processes of the dentine-pulp complex and the development of new materials, which are 
being adapted to clinical conditions, has led to significant advances for the therapeutic 
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The odontoblast is the secretory cell responsible for primary, secondary and tertiary 
reactionary dentinogenesis. We provide evidence that the changes in secretory activity of 
odontoblasts reflect differential transcriptional control and that common regulatory 
processes may exist between dentine and bone. 
Introduction: Based on the hypothesis that differential dentine secretion (primary and 
secondary dentinogenesis) is associated with changes in the transcriptional control within 
the cell, we have investigated the transcriptome of odontoblasts at young and mature 
stages and subsequently used this information to identify key regulatory intracellular 
pathways involved in this process. 
Materials and Methods: We used microarray analysis to compare the transcriptome of 
early stage (primary dentinogenesis) and late stage (secondary dentinogenesis) 
odontoblasts from 30 month old bovine teeth. Secondarily, we used post-array sqRT-PCR 
to confirm the differential expression of 23 genes in both populations of odontoblasts. 
Finally, immunohistochemistry was performed on bovine and murine tissues with 
antibodies to DMP1 and anti-phospho p38 proteins. 
Results: DMP-1 and osteocalcin gene expression were up-regulated in the mature 
odontoblasts, whereas collagen I, DSPP, TGF-beta1 and TGF-beta1R gene expression were 
down-regulated. Microarray analysis highlighted 574 differentially regulated genes (fold 
change>2 - p<0.05). This study supports further existing similarities between pulp cells 
and bone cells. Using post-array Sq-RT-PCR we characterized transcript levels of genes 
involved in the p38 MAP kinase pathway (PTPRR, NTRKK2, MAPK13, MAP2K6,MKK3). 
Differential p38 gene activation was confirmed by immunohistochemistry for p38 protein 
in murine teeth. Finally, immunohistochemistry for DMP1 indicated that odontoblasts 
involved in primary and secondary dentinogenesis may coexist in the same tooth.  
Conclusion: As established in bone cells, the transcriptome of the odontoblast was shown 
here to evolve with their stage and functional maturity. Identification of the involved 
signalling pathways, as highlighted for p38, will enable the deciphering of physiology and 
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We have previously shown that the p38 gene is highly expressed in odontoblasts during active 
primary dentinogenesis, but is drastically down-regulated as cells become quiescent in 
secondary dentinogenesis. Based on these observations, we hypothesized that p38 expression 
might be upregulated, and the protein activated by phosphorylation, when odontoblasts are 
stimulated such as during tertiary reactionary dentinogenesis. We stimulated immortalized, 
odontoblast-like MDPC-23 cells, alone or in combination, with heat-inactivated Streptococcus 
mutans, EDTA-extracted dentine matrix proteins (DMPs), or growth factors, including 
transforming growth factor (TGF)-β1, tumor necrosis factor-α (TNF-α), and adrenomedullin 
(ADM). We used ELISA to measure the resulting phosphorylation of the p38 protein, as well as 
its degree of nuclear translocation. Our results suggest that the p38-MAPKinase pathway is 
activated during odontoblast stimulation in tertiary dentinogenesis by both p38 phosphorylation 
and enhanced nuclear translocation. Data indicate that odontoblast behaviour therefore 
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Aim: To assess the feasibility of using the mouse as an in vivo model for studying pulpal 
healing in response to restorative procedures.  
Methodology: Direct pulp capping on maxillary first molar teeth with mineral trioxide 
aggregate (MTA), overlaid with light-cured composite resin, was performed on nineteen 3-
month-old mice. For control teeth, the composite resin was placed in direct contact with 
the pulp. Animals were killed at 3 days, 1 week, 2 weeks, 5 weeks and 11 weeks 
postoperatively. Extracted dental tissues were subsequently analysed by haematoxylin and 
eosin staining, immunohistochemistry for dentine sialophosphoprotein (DSPP) expression, 
scanning electronic microscopy and X-ray analysis to determine both pulpal response and 
dentine bridge formation.  
Results: Of the 19 mice initially used, 16 were subsequently studied. Histological analyses 
of pulps directly exposed to MTA for up to 2 weeks demonstrated a distinct structural 
change in the extracellular matrix. By weeks 5 and 11, a dentine bridge was present in all 
MTA-treated specimens in which DSPP immunoreactivity was clearly apparent. Scanning 
electronic microscopy and X-ray analysis enabled confirmation of calcification of the 
dentine bridge, and demonstrated that it had a globular surface morphology as opposed to 
the tubular appearance associated with orthodentine. 
Conclusions: This is the first description of the utilization of a murine model for study of 
in vivo pulpal repair. This approach provides a novel opportunity to enable the use of 
genetically modified animals to explore cellular and molecular processes during reparative 
events. 
